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Abstract  
Age-related hearing impairment (ARHI) is the most common sensory impairment in 
the ageing population. Disabling hearing loss affects a third of people aged 65 and is a 
major risk factor for dementia. Little is currently known about genetic risk factors and 
the underlying pathology of ARHI, making it a challenge to develop accurate diagnoses 
and treatment strategies. ARHI is a thought to be a polygenic, heterogeneous trait and so 
under the common trait common variant hypothesis, large studies are required to 
achieve the necessary statistical power to identify multiple genetic variants with small 
effect sizes. Previous studies have been limited by reduced sample sizes and the absence 
of a comprehensive, consistent definition of ARHI. 
In this thesis, the UK Biobank (UKBB) resource was used to perform two genome-wide 
association studies (GWAS) that were a magnitude larger than previous ARHI GWAS 
(n>250,000) and various methods were used to validate and investigate the subsequent 
associations. The results support the use of GWAS to uncover putative ARHI genetic risk 
variants. Forty-four independent genome-wide significant loci (p < 5E-08) were 
identified from the two GWAS studies, a 9-fold increase in the number of 
loci previously associated with common adult hearing impairment. A quarter of 
the identified loci contain genes that are implicated in other forms of hearing loss, while 
the remaining are novel gene candidates. The work demonstrates the viability of using 
self-report measures of adult hearing impairment for genetic discovery in large 
samples for the first time. Further, genetic correlation analysis revealed strong positive 
correlations with multiple personality and psychological traits for the first time. Multiple 
associations were validated via a replication meta-analysis, and tissue-specific 
expression was observed with immunohistochemistry for three candidate genes at 
significantly associated loci. All associated loci were evaluated for use in functional 
analysis, providing a framework for future studies. 
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Chapter 1 - Introduction 
1.1 Auditory function  
The auditory system spans multiple organs, tissues and cell types between and including 
the outer ear and the auditory cortex as depicted in Figure 1.1. The outer, middle and 
inner ear make up the peripheral auditory system, which is largely encased in the 
temporal bone; a hard bone that constitutes part of the side and base of the skull. The 
central auditory system comprises of structures from the cochlear nucleus to the 
primary auditory cortex and is largely located in the brain. In a fully functioning auditory 
system, the peripheral and central systems work independently and in conjunction with 
one another. During sound processing, the afferent system (Figure 1.1,(b)) runs in the 
direction from the outer ear to the primary auditory cortex, while the efferent system 
runs from the primary auditory cortex to the cochlea along a similar route. 
 
 
 
 
 
 
Figure 1.1. (a) Ascending auditory pathway. (b) Key structures of the auditory pathway. 
(a)This diagram illustrates the path of the ascending auditory pathway. All auditory structures are coloured. 
Those which are not labelled can be identified by these colours on the left-hand side of the diagram: beige, 
outer ear; green yellow and brown, middle ear; blue, inner ear. Figure from Purves, Dale et al., 20011.  
(b)The structures are presented in the order of the afferent pathway. The peripheral and central systems 
and ascending and descending pathways are discussed in detail later in the introduction. The colours do 
not correspond to the colours in Figure 1.1. 
(a) 
(b) 
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The peripheral auditory system: The outer and middle ear  
The peripheral auditory system consists of the outer and middle ear, the cochlea and the 
auditory nerve. Three separate organs make up the ear itself; the outer ear, middle ear 
and inner ear, which work in combination to enable balance (vestibular system) and 
noise perception (peripheral auditory system). The outer ear comprises of the pinna 
(visible ear), the external auditory meatus (the ear canal) and the lateral portion of the 
tympanic membrane (the eardrum)2, as displayed in Figure 1.2. The outer ear functions 
to channel acoustic stimuli toward the middle ear, via specialised crests and depressions 
and through the external auditory meatus (Figure 1.2). Skin covers the cartilage and the 
bone of the outer ear, and is partially covered with hair follicles and a wax that is 
produced by the sebaceous glands2.  
 
The outer ear funnels the sound stimuli toward the tympanic membrane (ear drum), 
where it is converted into kinetic energy. The middle ear lies behind this tympanic 
membrane and contains three bones, the malleus, incus and stapes, that are collectively 
known as the ossicles. The medial wall of the inner ear comprises of the temporal bone 
and two membrane-covered openings; the oval window and the round window (Figure 
1.2).  When the sound stimuli reach the tympanic membrane, both the tympanic 
membrane and in turn the ossicles, vibrate precisely in response to the frequency and 
intensity of the received acoustic signal. The ossicles here work to amplify the acoustic 
signal received by the middle ear as the energy reaches the interface between the middle 
 
Figure 1.2. Anatomy summary of the outer, middle and inner ear.    
https://www.pacificneuroscienceinstitute.org/eye-ear/hearing/overview/ 
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and inner ears. Here the stapes connects to the oval window, the membrane between the 
air-filled middle ear and the fluid-filled inner ear. 
Malformations of the outer ear may be inherited, result from a spontaneous genetic 
alternation or be acquired from environmental exposures in utero or later in life such as 
physical trauma, and are collectively termed ‘conductive’ hearing loss. For example, 
microtia is a condition that occurs when defects arise during the development of the 
pinna affecting its size, orientation, position and/or relief pattern3. These defects are 
graded on a scale from I to III based on the severity of the malformation and are generally 
treated with corrective surgeries. Structural malformations can also occur at the external 
auditory canal, rendering it narrowed or partially developed. These cases are graded on 
a scale from A-C based on the extent of the obstruction3. Conductive hearing loss can also 
be caused by malformations that affect the conformation of structures within the middle 
ear, such as deformations or fixation of the ossicles (including otosclerosis4), a narrowing 
of the tympanic cavity and, or the conformation of the round or oval windows.  Mutations 
in the POU3F4 gene transcript for example, result in a form of X-linked HL, causing 
morphological malformations of the temporal bone including either the internal auditory 
canal, vestibular aqueduct, modiolus and, or vestibule5. 
The peripheral auditory system: The inner ear  
The inner ear (or the ‘labyrinth’) contains the cochlea and the peripheral vestibular 
system. The vestibular system functions to maintain balance and spatial orientation6. 
The cochlea receives and relays acoustic stimuli from the middle ear to the auditory 
nerve. The membranous oval window acts as a barrier between the air-filled middle ear 
and fluid-filled cochlea of the inner ear. As the membrane of the oval window vibrates, 
the fluid of the cochlea takes on the amplified energy of the acoustic stimuli from the 
middle ear. 
The cochlea is a spiral structure that holds the organ of Corti, as depicted in Figure 1.3. 
The organ of Corti is the site of mechanotransduction; where kinetic energy is 
transformed to electrochemical activity via specialised mechanoreceptor sensory hair 
cells (HCs) 7. The resulting stimuli is received by higher auditory structures via spiral 
ganglion neurons and the auditory nerve (Figure 1.3, A). Dysregulation of or damage to 
the structures of the inner ear therefore leads to forms of ‘sensorineural’ hearing loss 
such as ARHI.  
The cochlea consists of three fluid filled chambers; the Scala Tympani, Scala Vestibuli and 
Scala Media. The Scala Tympani and Scala Vestibuli contain perilymph (0 mV, low K+ 
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concentration) and the middle chamber, the Scala Media, contains endolymph (80 mV, 
the endocochlear potential, high K+ concentration) 7. Figure 1.3, A and Figure 1.4 
illustrate the configuration of these three chambers. The ionic potential of these fluids is 
termed the ‘endocochlear potential’ and is predominantly generated and maintained by 
the stria vascularis. The stria vascularis is a structure that lines part of the Scala Media 
chamber, Figure 1.4, and recycles K+ ions in the endolymph via strial marginal cells8. 
Maintenance of this potential is critical for successful mechanotransduction via 
mechanoelectrical transduction (MET) channels near the tips of HC stereocilia (Figure 
1.5).    
 
 
The stria vascularis maintains the endolymph via a network of ion channels, gap 
junctions and tight junctions, which either permit or restrict the flow of ions into and out 
of the scala media. Key gap junction proteins are encoded by GBJ2 and GBJ6, and aid 
communication between the intermediate and basal cells of the stria vascularis via ion 
transport. Mutations in GJB2 are the most common cause of non-syndromic hearing loss 
in a number of populations9,10, as discussed in section 1.2. The passive movement of ions 
between the marginal and basal cell layers of the stria vascularis is prohibited by tight 
junctions such as those encoded by CLDN14 and MARVELD2. These tight junctions can 
also be a site of pathology; forms of autosomal recessive non-syndromic hearing loss are 
caused by mutations within these two genes11,12.  
 
Figure 1.3. Structure of the cochlea and the organ of Corti.  
(A) Cross-section of the cochlea (top inset shows diagram of the whole cochlea and sectioning scheme). The 
three compartments composing the cochlea are indicated (scala tympani, scala vestibuli and scala media). 
The organ of Corti is located in the scala media. The spiral ganglion comprises the somas of auditory nerve 
neurons innervating hair cells. (B) Structure of the organ of Corti. Inner (1) and outer (2) hair cells are 
indicated. Afferent dendrites belonging to auditory nerve neurons are indicated in purple, and medial olivary 
complex neurons in light blue. Some efferent fibers (light blue) also make axo-dendritic contacts with afferent 
boutons. Some afferent fibers represent a small proportion (type II) of afferent contacts on OHC. Image by 
Alan Larsen. Figure composition and legend from Goutman et al., 2015.7.  
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The HCs are the sensory cells of the organ of Corti. The inner hair cells (IHCs) relay the 
primary stimuli via mechanotransduction. The outer hair cells (OHCs) primarily amplify 
and fine-tune the stimuli by electromechanical feedback13 and electromotility, a unique 
property of OHCs. IHCs spiral around the structure in single a row of ~3,500 cells while 
the OHCs spiral around the structure in three rows of ~12,00 cells. ‘Supporting’ cells 
surround the sensory cells in the organ of Corti. Phalangeal cells support the IHCs and 
the Deiters’ cells support the OHCs, along with supporting cells such as the Hensen and 
Claudian cells (Figure 1.4). Between the rows of IHCs and OHCs lie the Pillar cells, that 
form a structure termed the ‘tunnel of Corti’.  
Sensory HCs are organised tonotopically along the length of the cochlea; higher 
frequencies are transduced at the basal end of the cochlea and lower frequencies at the 
apical end of the cochlea. The basilar membrane, upon which the organ of Corti sits 
(Figure 1.3, B &, Figure 1.4), is specialised in function such that it vibrates according to 
specific fluid movement, resulting in frequency tuning. The membrane is wider and more 
flexible toward the apical end of the cochlea that responds to lower frequency acoustic 
stimuli, and narrower and stiffer at the basal end of the cochlea that responds specifically 
to high frequency acoustic stimuli14. 
 At the apical end of the sensory HCs, lie 20-500 mechanosensing stereocilia13 that are 
anchored to the apex of the HC by a structure called the cuticular plate. Actin filaments 
at the base of the stereocilia form rootlets in the cuticular plate, organised into dense 
 
Figure 1.4. Schematic of the organ of Corti. Davis and Silverman, 197015.  
 
17 
 
bundles by TRIO and F-actin binding protein, encoded by TRIOBP. Deleterious mutations 
in TRIOBP can therefore prevent the correct organisation of these anchoring bundles, 
resulting in a form of non-syndromic recessive HL16.  
The stereocilia are physically connected to adjacent stereocilia via cross links, made up 
of proteins such as espin, which provide strength and rigidity to the links. Deleterious 
mutations in the ESPN transcript, that codes for espin, are implicated in multiple types 
of non-syndromic hearing loss and can present in conjunction with balance problems, 
indicative of vestibular dysfunction11. The stereocilia are also connected via tip links 
(Figure 1.5A) which create synchronised movement of the stereocilia of a HC in response 
to the movement of the surrounding endolymph. Cadherin-23, together with 
protocadherin-15, forms the tip-links and is crucial for the maintenance of the hair 
bundle structure11; mutations in CDH23 are a common cause of pre-lingual forms of 
sensorineural HL such as Usher Syndrome type 1, and have more recently been found to 
cause forms of post-lingual HL17.  
Mutations in the MYO7A transcript, which codes for Myosin VIIA, also impair stereocilia 
function and also result in a form of Usher Syndrome type 15,  (these forms of HL are 
discussed further in Syndromic hearing loss (SHL), on page 30). The physical deflection 
of the hair bundle, due to the displacement of endolymph fluid, occurs toward the tallest 
row of stereocilia and the tip links create a force causing the MET channels to open, 
inducing an influx of K+ and Ca2+ ions into the HC body (Figure 1.5B). The exact 
mechanism of how this force causes the MET channels to open is still to be determined.  
Upon the influx of K+ and Ca2+ ions into IHC cell bodies, a temporary cell depolarization 
occurs which increases the cell membrane potential. This in turn induces afferent ribbon 
synapses at the cell base to release glutamate-filled vesicles into a synaptic cleft.  The 
vesicles are met by glutamate receptors on afferent terminals of type I spiral ganglion 
neurons (SGNs) at the synaptic cleft. The main component of the ribbon synapse is the 
Ribeye protein, encoded by CTBP2. The protein otoferlin, encoded by OTOF, also plays a 
key role in the excitation process, by interacting with SNARE proteins at the pre-ribbon 
synapse. Deleterious mutations in OTOF can result in a disruption to this mechanism, 
causing cases of auditory neuropathy spectrum disorder and, or sensorineural HL18,19. 
Each IHC is innervated by 10-20 unmyelinated type I nerve fibres via these afferent 
synapses. The type 1 nerve fibres are unmyelinated until they reach the habenula 
perforata, where the nerve fibres align together to form the modiolus. Also at the 
basolateral surface of the sensory hair cells, are channels that release K+ following the 
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influx at the apex. Structural defects of these potassium channels can lead to impaired 
function; deleterious mutations in KCNQ4 (the transcript of which codes for KCNQ4, a 
protein component of potassium channels in the inner ear) can result in a type of 
autosomal dominant non-syndromic hearing loss11.  
 
 
90-95% of these auditory nerve fibres are type I20. The remaining population of auditory 
nerve fibres are type II20, which innervate the OHCs. Similar to the IHCs, the membrane 
potential of OHCs increases due to the influx of K+ and Ca2+ ions. This also induces release 
of glutamate-filled vesicles at the synaptic cleft to meet afferent terminals of myelinated 
type II SGNs. This afferent signal is much reduced in comparison to the IHC afferent 
signal and may be involved in the medial olivocochlear reflex (an efferent feedback loop) 
and other functions, hypothesised elsewhere21. The OHCs have another, unique, 
physiological response to the increase in membrane potential, termed ‘electromotility’ 
 
Figure 1.5. Cochlear inner hair cell anatomy. 
At the apex of the IHC, lies the cuticular plate which anchors actin-rich stereocilia. The 
stereocilia are connected by tip links and cross links. Mechanoelectrical transduction (MET) 
channels are at the top of the stereocilia, and open in response to the force generated by the 
movement of stereocilia and connecting tip links. Ca2+ and K+ enter the cell via the MET 
channels, from the surrounding endolymph. Upon this influx of ions, neurotransmitter vesicles, 
attached to ribbons, reach the synaptic cleft. Glutamate neurotransmitters are released and 
met by receptors on afferent type I nerve fibres 
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whereby the cells elongate and contract in response to the ion influx22. This physiological 
property enables the OHCs to amplify and fine-tune signals received by the cochlea, in 
essence extending the function of the basilar membrane.  
In addition to afferent synapses, efferent synapses are present at the base of IHCs and 
OHCs and are components of two systems. The function the first of these systems has 
largely been established, it originates at the medial superior olivary complex and is thus 
termed the MOC system. Its role is to transmit inhibitory currents to OHCs when it is 
activated23. These currents work to reduce OHC amplifier mechanisms7. in response to 
such currents, a reduction in the motion of the basilar membrane can be observed, along 
with a temporary reduction in the auditory nerve sensitivity to sound23. 
The function of the second system, the lateral superior olivary (LOC) complex system, is 
yet to be established24. The system comprises of unmyelinated axons that originate at 
the lateral superior olivary complex and terminate as dendrites at IHC synapses23. Figure 
1.6 is a diagram of the ascending and descending auditory pathways from the cochlea to 
the primary auditory cortex, including the LOC and MOC efferent systems (green arrow 
between the olivary nuclei and the cochlea(b)).  
Figure 1.6. Ascending and descending auditory pathways. 
 (a). Ascending auditory pathway. (b). Ascending (blue/black), descending (cortical: orange; brainstem: green), 
and crossed (blue) auditory circuits, and crossed (green) auditory circuits. Sequential processing of acoustic 
stimuli takes place across the entire auditory system while parallel processing occurs mainly in the neural 
system.  Diagram based on schematics displayed in Peterson & Renee 2019.  
   
 
Returning to the afferent pathway, the auditory nerve fibres, (type I and type II) 
travelling from IHCs and OHCs to the modiolus, reach the central auditory processing 
pathway at the spiral ganglion and travel down the modiolus toward the cochlear nuclear 
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complex (CNC). The composition of the modiolus is also organised tonotopically. Nerve 
fibres that transmit signals of high frequency stimuli are located on the outside of the 
modiolus, while the fibres transmitting electrical stimuli from low frequency acoustic 
stimuli are located towards the core of the modiolus structure. 
The CNC is the site where all primary auditory fibres terminate. Figure 1.7 displays the 
route of both the high and low frequency nerve fibres upon reaching the CNC. The low 
frequency fibres (originating from the apex of the cochlea) fork upon entry to the CNC. 
The ascending branch travels to the anterior ventral cochlear nucleus (AVCN) and the 
descending branch travels to the posterior ventral nucleus (PVCN) followed by the dorsal 
cochlear nucleus (DCN).  
 
Figure 1.7. Schematic diagram of a dorsolateral view of the human cochlear nuclear 
complex. 
Schematic diagram of a dorsolateral view of the human cochlear nuclear complex with its three divisions, 
anterior ventral cochlear nucleus(AVCN), posterior central cochlear nucleus (PBCN), and dorsal cochlear 
nucleus (DCN). Two spiral ganglion nerve fibres (VIIIN) are shown bifurcating into ascending branches (ab) 
and descending branches (db). Note that high-frequency (basal) fibres course in the dorsomedial portion 
and low-frequency (apical) fibres course in the centrolateral portion of the cochlear nuclear complex. A single 
spherical bushy cell of AVCN is shown in A with its axon (a) and an endbulb of Held (e) synapsing on it. A 
single cell of DCN is shown in B with its axon (a). A single octopus cell of PVCN is shown in C with its axon 
(a). Figure and legend adapted from Webster, 200525 
 
From the CNC, nerve fibres reach the superior olivary complex (SOC), primarily from the 
AVCN. In the SOC are three major nuclei, that are the site of the first binaural processing. 
The localisation and intensity differential of stimuli perceived by each ear is processed 
by the Medial superior olivary complex (MSO) and lateral superior olivary complex (LSO) 
respectively25. The stimuli then reach the major midbrain auditory complex; the inferior 
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colliculus. The cells of the inferior colliculus are organised tonotopically and have a role 
in the integration of multiple sound stimuli.  
Sites of pathology in ARHI 
Forms of hearing loss that are caused by defects or damage to structures within the inner 
ear or the eighth cranial nerve are termed ‘sensorineural hearing loss’ (SNHL). SNHL is 
a common condition, and the most prevalent form is age-related hearing impairment 
(ARHI), the focus of this thesis. The first comprehensive theory of ARHI pathology was 
proposed by Schuknecht in the 1960s26. Based on histological analysis of human 
temporal bone samples, he proposed that there are four subtypes of ARHI; sensory 
(loss/damage of hair cells in the inner ear), strial (metabolic, imbalance of the 
endocochlear potential), neuronal (loss of spiral ganglion cells) and mechanical 
(stiffening of the basal membrane in the organ of Corti). It was further theorised that 
each of the four subtypes would result in a distinct audiogram shape (audiogram shapes 
are discussed in section 1.2). 
 
Figure 1.8. Diagram of the organ of Corti, shaded according to sites of Schuknecht's 
four ARHI subtypes.  
Sensory, HCs shaded in blue; strial, stria vascularis shaded in pink; neuronal, neurons and spiral ganglion 
shaded in green; mechanical, basilar membrane shaded in orange. The original black and white diagram 
is from Davis and Silverman, 197015 and has been adapted for use here.  
 
In 2016, the temporal bone samples were re-examined (with improved 
cytocochleograms) and were again compared to the audiogram measures. The work 
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established that the four subtypes did not significantly correlate with distinct audiogram 
shapes27 and that most cases of ARHI actually present with a mixed pathology. 
Schuknecht’s pathology subtypes described in the 1960s are therefore not commonly 
used in the diagnosis of ARHI, and patients’ ARHI subtypes are generally not assigned 
based on their audiogram shapes. The subtypes do however highlight the range of 
distinct auditory components that contribute to the mixed pathologies of ARHI and can 
therefore be used as a framework for ARHI pathology.  
Firstly, the sensory and neuronal subtypes do describe common physiological hallmarks 
of sensorineural hearing loss; the loss or damage of both sensory cells and auditory nerve 
fibres(ANFs),28 Figure 1.9, and results from early research indicated that HC damage is a 
key contributor to sensorineural hearing loss29,30 (as detected by a PTA). A theory was 
therefore proposed that HC degradation was primary to cochlear nerve degeneration31.  
According to this model of progression, the subsequent sensorineural HL is irreversible 
as mammalian sensory hair cells and neurons do not regenerate32. 
Subsequent studies however, have challenged this order of degeneration in the auditory 
tissues. A recent examination of human temporal bone specimens in a “normal-hearing” 
sample reported outer hair cell loss of >30% at all frequencies when comparing young 
(<60) and old (>60) individuals. It was also observed that in 7/11 of the subjects aged 
>60 years, there was a 60% loss of periphery axons compared to the ‘young’ group28. The 
study reports a loss of auditory nerve fibres that outweighs the observed loss of IHCs. 
This disputes previous findings33,34 as it suggests that ANFs loss may be primary to or 
even independent of HC loss, rather than a secondary event. 
Further research has supported this order of degradation, by showing that in cases of 
sensorineural hearing loss, damage to and the loss of synapses between cochlear 
neurons can occur before HC damage and long before subsequent HC degeneration35. 
This synaptic loss was not detectable on audiograms or in histological material (such as 
the samples used in relation to Schuknecht’s work). Authors propose that this ‘hidden 
hearing loss’ may be the root cause of issues such as the inability to hear clearly in the 
presence of background noise; a key symptom of both ARHI and noise-induced hearing 
loss35,36. As auditory thresholds and histological studies had been the primary method of 
data collection in these early studies, this order would have been impossible to observe.  
Repair or replacement of these neuronal synapses and a subsequent recovery of function 
has also recently been achieved with neurotrophin treatment in animal models37. This is 
a progression from the theory that HC degeneration was the primary pathology and that 
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sensorineural HL is therefore irreversible as sensory cells cannot regenerate. In addition, 
these recent findings demonstrate that ARHI subtypes are not as distinct as initially 
proposed and that the order of sensory and neuronal cell degeneration is not as straight 
forward as originally predicted.  
 
 
Figure 1.9. Cochlear cell survival over time.  
The age-related loss of (auditory nerve fibres) ANF peripheral axons is steeper than that for SGCs or 
IHCs. For ANF and IHC data, each point is the cell-survival in each case averaged over all sample points 
within the audiometric frequencies (0.25–8.0 kHz inclusive). The SGC data are from a prior study of 
normal ageing individuals (n= 10 per decade of life, normalized to % survival using the y-intercept of the 
best-fit straight line. The ANF data are averaged over all points from 0.25 to 8.0 kHz, and also normalized 
using the best-fit straight line. Red arrow points to the one case exposed to a known ototoxin (cisplatin). 
IHC data are averaged over all points from0.25 to 8.0 kHz. IHC data were obtained as % survival and do 
not require normalization. The 95% confidence limits are shown for the IHC and ANF regressions. Figure 
and legend (legend adapted) from Wu et al., 2019.28 
 
 
The third of Schuknecht’s subtypes, ‘strial’, concerns dysregulation of the metabolic 
equilibrium of the cochlea26. As described, the mechanotransduction properties of the 
HCs and the electromotility of the OHCs is heavily dependent on precise fluctuations of 
the endocochlear potential. The stria vascularis is a structure that has a key role in 
generating and maintaining this potential via the recycling of ions in the scala media8. 
Therefore, damage to this structure, as observed in ageing mouse models of ARHI and in 
Schuknecht’s histological samples, likely disrupts the precise transmission of the 
acoustic signal at the organ of Corti. As described earlier in this section, organic ions, 
mainly K+ and Ca2+ ions, are key drivers of the endocochlear potential.   
Alongside damage to the stria, metabolic function can be dependent on ion receptors and 
transporters elsewhere in the auditory system, such as those involved in calcium 
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signalling. Ca2+ is involved in multiple auditory mechanisms and its disruption is an 
established contributor to neuronal death during ageing. Null and heterozygous mice of 
a subunit of t-type calcium channels display a reduction in age-related cochlea 
dysfunction and preservation of spiral ganglion neurones. Moreover, calcium signalling 
could be involved in cell survival mechanisms; profoundly deaf C57 mice have been 
shown to exhibit an upregulation of calcium binding proteins in cochlear nucleus 
neurons. A putative link between ARHI and calcium signalling has also been suggested in 
a human population; a genome-wide association (GWAS) study highlighted a putative 
link (P=3.5e−7) between a genetic variant in the Collagen and Calcium Binding EGF 
Domains 1 gene (CCBE1) transcript and an ARHI phenotype38.  
There is comparatively little evidence that the fourth subtype proposed by Schuchnekt, 
termed ‘mechanical’, has a significant role in ARHI phenotypes. The subtype is based on 
the stiffening of the basal membrane, hindering its precise movement in response to the 
displacement of cochlear fluid. However, it is not unlikely that genetic variation within 
the population, or even individual environmental insults could result in variable function 
and maintenance in this structure, which could thus contribute to a sensorineural HL. A 
primary aim of this thesis will be to develop the understanding of these multiple 
pathologies which lead to sensorineural HL, specifically focusing on the aetiology of 
ARHI. 
1.2 Hearing loss 
In the population, hearing impairments and hearing loss present in many forms. In the 
clinic, hearing ability is generally measured by a pure tone audiometry test (PTA). PTA 
is considered the ‘gold standard’ measure for hearing assessment. A PTA provides 
detailed analysis of an individual’s hearing thresholds independently for each ear, 
presented as an audiogram. The test is presented as a set of pure-tone pulses at different 
frequencies and intensities, the individual is asked to signal when the sound can be 
heard, with an overall aim to determine their ability to hear at a range of frequencies and 
decibels.  
Diagnoses are usually given to individuals based on their PTA test results, according to 
thresholds determined by the World Health Organisation39. Normal hearing is defined as 
having hearing thresholds of 25dB in both ears. Those with a hearing threshold greater 
than 25dB in one or both ears, have a ‘hearing loss’ which can be classified as mild (26-
40 dB), moderate (41-60 dB), severe (61-80 dB) or profound (>81 dB). A disabling HL in 
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adults is defined as a hearing loss greater than 40dB in the better hearing ear 
(https://www.who.int/pbd/deafness/hearing_impairment_grades/en/).  
 
Figure 1.10. An audiogram displaying a typical pattern for someone with ‘normal 
hearing’.  
The right and left ear are tested separately at each frequency and intensity and plotted on the same 
audiogram. The range for ‘normal’ hearing is between -10 and 10 dB for both ears, at all frequencies 
displayed. Annotations on the right-hand side of the audiogram depict levels at which hearing abilities are 
described as normal, mild, moderate, severe and profound. The number of frequency thresholds that are 
tested can also differ between clinics. 
 
1.2.1 Forms of hearing loss 
Hearing loss can be a congenital condition (such as the pathologies caused by genes 
described in the previous section), a late-onset genetic condition, have an environmental 
cause such as acoustic trauma, or show a progressive decline in function with increasing 
age (such as ARHI). The various forms of HL can be characterised using different criteria 
as demonstrated in Figure 1.11 and Figure 1.12. Firstly, hearing loss can be divided into 
syndromic and non-syndromic based on how it presents clinically (Figure 1.11). 
Syndromic hearing loss occurs in conjunction with other symptoms representing a 
particular disorder. Non-syndromic hearing loss is diagnosed when hearing loss in 
confirmed in the absence of additional symptoms. Per 1000 newborns, 1-3 present a 
hearing impairment, about 20% of which are in conjunction with other symptoms 
(syndromic hearing impairment)25, half of which are caused by genetic abnormalities 
such as those described in section 1.1. 
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Figure 1.11. Classification of hearing loss based on clinical presentation 
 
Alternatively, forms of hearing loss can be determined based on the location of pathology 
within the auditory system (Figure 1.12), also introduced in section 1.1. Conductive 
hearing loss, as introduced previously, describes pathologies of the outer and middle ear; 
the impairment affects the conduction of sound to the cochlea. These forms of hearing 
loss include problems with either the structure of the outer ear, the tympanic membrane 
or the ossicles which function to channel and amplify acoustic stimuli into the inner ear. 
Often the cause of these issues is either developmental (including genetic conditions that 
affect the formation of auditory structures) or a trauma such as a rupture of the tympanic 
membrane. Surgical or pharmacological are the most common types of treatment for 
conductive hearing loss.  
Sensorineural hearing loss, also introduced earlier, consists of pathologies of the inner 
ear and the eighth cranial nerve. The aetiology of sensorineural hearing loss also differs 
between individual cases. The pathology of this form of hearing loss is due to either the 
development and maintenance of, or damage to and loss of the sensory cells of the 
cochlea, the supporting structures including the stria vascularis or the auditory nerve. It 
is understood that most patients present a mixed pathology of these causes such as 
multiple visible defects as described by Schuknecht. ARHI is generally understood to be 
non-syndromic, sensory neural hearing loss.  
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Figure 1.12. Classification of hearing loss based on the site of pathology 
 
Non-syndromic hearing loss (NSHL) 
Newborn hearing screening takes place in the majority of developed countries, which 
signifies the high prevalence of congenital hearing loss in the general population. 
Congenital forms of NSHL usually follows a pattern of Mendelian inheritance, with the 
majority being autosomal recessive (75-80%), presenting as a severe or profound, 
prelingual hearing loss. The remaining ~20% of cases are mainly autosomal dominant 
and resemble a post-lingual, progressive hearing loss39. The remaining ~5% of cases are 
x-linked or caused by mitochondrial mutations39. The most prevalent form of non-
congenital NSHL is ARHI. 
Forms of non-syndromic HL are highly heterogeneous (with over 100 genomic sites 
harbouring causal genetic variants, (https://hereditaryhearingloss.org/)). The first NSHL 
locus was mapped in 198840 via linkage analysis (Figure 1.13). Whole genome 
sequencing in large, clinically characterised family pedigrees has recently enabled a 
number of NSHL-causing genes to be identified. Genes and gene regions found to cause 
NSHL have a specific nomenclature. Dominant inheritance patterns are represented by 
DFNA*, where * denotes a HUGO gene nomenclature characterisation41. Similarly, 
recessive inheritance patterns are named DFNB*. Two identified modifier loci are named 
DFNM1 and DFNM2, while X-linked and Y-linked inheritance are denoted DFNX* and 
DFNY* respectively.  
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Figure 1.13.  Timeline of NSHL genes identified according to method of discovery. 
The timeline also detailed the major achievements in the development of NGS technologies per year39, 
1995-2015. Abbreviations: D, dominant form of HL; R, recessive form of HL; WES, whole exome 
sequencing; WGS, whole genome sequencing. Figure and legend adapted from Vona et al. 201542.  
 
The focus of this thesis is on the genetic risk of ARHI, which is comprehensively 
introduced later, in section 1.3.4, yet the genetic risk loci that are involved in other forms 
of HL can reveal key mechanisms in hearing function, specifically those that are affected 
by genetic mutations. These genes can therefore be used as primary gene candidates for 
ARHI risk, and, or to hypothesise mechanisms involved in ARHI pathologies. Figure 1.13 
demonstrates the heterogeneity of NSHL gene defects, yet a small subset of these genes 
cause a high proportion of known NSHL cases, specifically GJB2 and SLC26A4.  
Genetic defects in the GJB2 gene (DFNA3A, which codes for Connexin 26)43 have been 
identified to cause cases of NSHL around the world, and make up 50% of NSHL cases in 
populations of northern European ancestry, where different mutations and allele 
dosages result in a range of phenotypes10,44,45. Disparities between phenotypes are also 
observed in groups of patients that display the same GJB2 mutations, indicative of 
possible dosage or epigenetic effects. 
The molecular consequences of specific GJB2 mutations have been and are currently 
being studied extensively. GJB2 (Cx26), in addition to Cx30, Cx29 and Cx43, are all gap 
junction proteins that make up the connexin channel gap junctions and, when mutated, 
have been found to cause various forms of HL. A hypothesised pathology of GJB2- related 
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forms of HL, is the disruption of homeostasis in the cochlea. As a component of gap 
junctions that line the scala media, it was theorised that GJB2 may have a crucial role in 
the efficient cycling of K+ ions and Ca2+ signalling, and thus maintenance of the 
endocochlear potential and function of HC mechanoelectrical transduction. Over 100 
different mutations have been identified in GJB2 that result in a range of pathological 
changes. These changes predominantly affect channel formation and permeability, and 
are discussed elsewhere46. While these have been described, as of yet, no clear 
relationship has been observed between mutation, channel function, and hearing 
phenotype46. Of connexin proteins expressed in the inner ear, is thought that mutations 
in GJB2 in particular lead to a high incidence of HL because Cx26 channels, unlike 
connexin channels such as Cx30, are permeable to anions and thus may have a 
substantial role in intracellular signalling46,47.  
Animal models have been used to further understand the pathophysiology of GJB2 
(Cx26) mutations. In one study, three strains of conditional null connexin 26 mice were 
generated, and all displayed NSHL48. Histologically, the development of structures in the 
cochlea of the three strains are indistinguishable from the development observed in wild 
type strains; HCs, supporting cells, the stria vascularis and tectorial membrane all 
displayed normal development. A deterioration of structures was first observed at ~P8, 
in the supporting cells, and at P9, the tunnel of Corti did not form in the mutant lines 
while full formation was observed in the wild type. By P13, wide-spread cell death had 
occurred at the OHCs and surrounding supporting cells and SGNs. The deterioration was 
first observed in the middle section of the cochlea, followed by the basal section and later 
the apical section48. 
A later study induced GJB2 expression to GJB2-mutant mice via viral delivery44. A full 
recovery of gap junction function was observed in the scala media and a partial recovery 
of SGNs was observed. ABR thresholds of GJB2-mutant mice were not however 
significantly improved when compared to the wild type thresholds, possibly indicating 
that the viral injection occurred after the critical window for rescue44.  
Genetic alterations in SLC26A4 are also a common cause of non-syndromic autosomal 
sensorineural hearing loss (DFNB4)49.  The SLC26A4 gene codes for pendrin, an ion 
transporter, and so SLC26A4-related hearing pathologies are therefore thought to 
manifest due to an ion imbalance in the inner ear, which disrupts the development and 
function of multiple cochlear structures49. While a number of causal genes have been 
identified in forms of NSHL (Figure 1.13), phenotypic variability is observed within 
family members that display NSHL. It is thought that modifier gene regions such as 
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DFNM1 (1q24)50 and DFNM2 (8p23)50 or digenic configurations51,52 are responsible for 
variation seen within some families, along with polygenic variants or genome 
rearrangements42.   
There is a vast range of auditory structures that are affected by the >100 genes that, 
when mutated, can lead to forms of HL. Examples of these were highlighted in section 
1.1, Auditory function, particularly in the inner ear structures. For example, mutations in 
TRIOBP can cause a form of NSHL as TRIOBP has a role in anchoring of HC stereocilia 
rootlets, which provide the necessary rigidity for efficient mechanotransduction16,53,54. 
Mutations in MYO7A impair stereocilia function and so can cause HL, including forms of 
Usher Syndrome (see the section below)55,56. A further structure, the stria vascularis, can 
also be impaired by mutations that lead to NSHL; mutations in CLDN14 and MARVELD2, 
which code for proteins that make up tight junctions between stria cell layers, impair the 
movement of ions and thus the function of the structure11,12. Another example, further 
along the auditory pathway at the pre-ribbon synapse, is OTOF which interacts with 
SNARE proteins at the synaptic cleft; mutations in  OTOF are also known to cause 
NSHL18,19.  
Syndromic hearing loss (SHL) 
Alternatively, hearing loss can present as one of a number of symptoms of a particular 
syndrome. Over 400 forms of syndromic hearing loss have been identified to date. The 
most common being Usher syndrome, Waardenburg syndrome and Pendred syndrome. 
Usher syndrome is the most common cause of combined hearing and vision loss and is 
classified into three subtypes as the condition is highly heterogeneous both clinically and 
genetically. The three subtypes are based on the severity of symptoms and age of onset. 
Type I and II patients display severe to profound, and mild to severe congenital hearing 
loss respectively, in addition to vision impairments. The age of onset and progression of 
hearing loss for Type III patients is varied49. Nine genes have been identified as causal 
for USH cases.  Two further genes were previously reported to cause forms of USH 
syndrome; HARS57 and CIB258, and PDZD7 was  identified as an USH modifier gene, 59 but 
these findings have since been questioned, see Table 1.1. The protein products of the 
nine genes are understood to be involved in the formation, maintenance and functioning 
of inner ear hair bundles49.  USH genes listed in Table 1.1 that are expressed in HCs, are 
those specifically expressed in HC cytoplasm, stereocilia, tip links and cross links60.  
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USH 
subtype 
Hearing loss Vestibular 
function 
Retinitis 
pigmentosa 
Identified genes 
USH1 Congenital, 
severe to 
profound  
Vestibular 
areflexia  
Onset before 
10 years of age  
MYO7A61, USH1C62,63, 
CDH2364, PCDH1565, 
USH1G66,   
USH2 Congenital, 
moderate to 
severe 
Normal Onset between 
10 and 20 
years of age 
USH2A67, GPR9867, 
DFNB3167  
USH3 Progressive  Sporadic 
dysfunction 
Variable onset  CLRN168  
Table 1.1 Summary table of the three subtypes of Usher Syndrome.  
Information in the table and legend is summarised from Mathur & Yang 201460 and 
https://hereditaryhearingloss.org/usher      CIB258 and HARS57 have been reported to cause Usher Syndromes 
Type 1J and 3B respectively, but these findings have since been called in to question. It has since been shown 
that mutations in CIB2 cause NSHL only69, and the homozygous mutation identified in HARS is yet to be 
replicated and supported by functional analysis. Mutations in PDZD7 were originally found to cause 
digenic USH2 with ADGRV159 but it has since been reported that mutations in PDZD7 cause NSHL only69. 
 
Similarly, Waardenburg syndrome is categorised into subtypes named I-4, based on the 
genetic alternation that is present. Collectively, 9 genes are known currently to be 
involved in the development of the condition, and the majority of patients exhibit 
bilateral, sensorineural hearing loss70. The most common form, Type I, is caused by 
genetic alternations in the PAX3 gene which are thought to affect the formation of a 
number of cochlear structures70. 
The third most prevalent form of syndromic hearing loss is Pendred syndrome. Similar 
to common forms of non-syndromic hearing loss, Pendred syndrome is caused by 
biallelic mutations in the SLC26A4 gene71,72. SLC26A4 codes for pendrin, the anion 
exchanger protein that works to maintain the composition and the potential of the 
endolymph73. Patients exhibit inner ear abnormalities that result in sensorineural 
hearing loss, and commonly an enlarged vestibular aqueduct74. Another gene common 
to both syndromic and non-syndromic forms of hearing loss is GJB2 which, as noted, 
codes for Connexin 26.  Mutations in this gene transcript have been linked to multiple 
syndromes, and, based on the nature of the mutation, can even cause multiple subtypes 
of the same syndrome such as seen in cases of Keratitis-Ichthyosis-Deafness syndrome75. 
While these forms of hearing loss are largely beyond the scope of this thesis, it can be 
hypothesised that ARHI risk loci may be common to those underlying NSHL or SHL. 
Therefore, genes that are known to be implicated in congenital forms of deafness are 
potential candidates for ARHI-risk loci and ought to be considered when evaluating 
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findings. Furthermore, these genetic alterations and resulting phenotypes can provide 
hypotheses for ARHI pathologies. While many of the genes already identified to cause 
NSHL and SHL cause an early-onset and severe phenotype, ARHI differs in that it is a late-
onset, progressive condition. The following section discusses this form of HL in more 
detail and outlines the current limitations in the identification of genetic risk loci.   
1.3 Age-related hearing impairment  
1.3.1 Epidemiology  
The focus of this thesis is on ARHI (also termed presbycusis) which, as previously 
introduced, is a form of sensorineural hearing impairment. It has been established that 
it is the most common sensory impairment in the elderly population, with the World 
Health Organisation (WHO) had estimated that a third of the population aged over 65 
are affected by disabling hearing loss (www.who.int/pbd/deafness/estimates/en/). The 
true population prevalence of ARHI is challenging to determine however, because there 
is little standardisation across population samples, mainly with regards to which tonal 
frequencies are used to classify a hearing loss.  
The main symptoms of ARHI are a hearing loss originating in the higher frequencies that 
can progress to an impairment at all frequencies76, and impaired speech intelligibility. 
ARHI is clinically defined as a hearing impairment that gradually declines with increasing 
age and that is of a bilateral nature. As noted in section 1.2, the WHO asserted a definition 
of hearing loss summarised below in Table 1.2. The definition of ARHI differs between 
epidemiological studies, however. Studies are inconsistent in (i) the PTA thresholds 
tested and used to classify HL (ii) whether cases are defined by mono-or-binaural HL, 
and (iii) the age ranges of different study samples differ.  Collectively, these factors mean 
that that prevalence estimates are not always comparable or even applicable to the wider 
population.  
Pure tone threshold Hearing ability 
25dB in both ears  Normal 
26-40dB in one or both ears  Mild 
41-60dB in one or both ears  Moderate  
61-80dB in one or both ears  Severe  
>81dB in one or both ears  Profound  
Table 1.2. World Health Organisation of hearing loss based on pure 
tone thresholds.  
A disabling HL in adults is defined as a hearing loss greater than 40dB in the better 
hearing ear. https://www.who.int/pbd/deafness/hearing_impairment_grades/en/ 
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In the NHANES study sample, using the WHO definition of HL, it was reported that 63% 
of the study sample aged >70 years had a HL77. In the Framingham study, the prevalence 
of ARHI was estimated to be 29% but was based on a hearing loss of >26dB for 
frequencies 0.5-2 kHz in the better ear, in subjects aged >60 years78. This definition 
further differs to that used in the Health ABC study classified a HL as 26dB, in the worse 
ear but which likewise assessed frequencies of 0.5-2 kHz79. The prevalence was 
estimated at 60%, but in a sample of 73-84-year-olds. Similarly, the Beaver Dam study 
used a sample of older age; 73% of the >70-year-olds in the sample had a hearing loss 
classified by a 25dB threshold loss at 0.5-2 kHz frequencies80.  
These prevalence estimates are collectively higher than in a European systematic review 
of multiple samples, which reported 30% of males and 20% of females to have a HL by 
the age of 70, and 55% of males and 45% of females to have a HL by the age of 8081. These 
slightly lower estimates may in part be due to the HL definition of a threshold increase 
of at least 30dB, the most conservative threshold of the studies noted.  The authors of 
this review drew attention to the heterogeneity of the data rendering them ‘unable to 
establish an integrative quantitative overview of prevalence rates over age and hearing 
loss’81. 
While there is heterogeneity in estimates based on varied pure tone thresholds, there is 
an additional argument for the use of alternative methods to assess the prevalence of 
ARHI in the population. These alternative measures may result in a more ‘real life’ 
definition of ARHI because, unlike PTA thresholds, these measures can assess an 
individual’s speech intelligibility, (a debilitating symptom of ARHI). These alternative 
methods are introduced in further detail in section 1.3.4 and are comprehensively 
investigated in Chapter 3. 
ARHI is widely understood to be a common complex trait; the condition is caused by 
genetic and environmental factors. These factors lead to a sensorineural HL which, as 
described in section 1.1, is due to either cochlear dysfunction, a type of auditory brain 
neuropathy, or a combination of both. The pathology is therefore highly heterogenous 
within the population and the condition varies between individuals with regard to age of 
onset, underlying pathology and rate of progression. There is currently relatively little 
knowledge of the specific genetic and environmental factors that impact ARHI. This 
limited knowledge has resulted in few treatment or prevention strategies. Despite being 
such a common and often debilitating condition, hearing aids are the main treatment 
option available, though multiple studies report less than 50% rate of uptake of hearing 
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aids by those with HL82.  The following sections review the current knowledge and 
theories regarding ARHI development and progression. 
1.3.2 ARHI risk factors  
ARHI is associated with a broad range of risk factors including genetic variants, 
environmental exposures and health co-morbidities83,84. Age is the single biggest risk 
factor for ARHI; the risk of developing ARHI increases with increasing age. It is thought 
that in most cases, symptoms begin around middle age, but the age of onset varies 
between individuals and is not comprehensively documented at a population level. Males 
are also understood to have an elevated risk of developing ARHI; in a number of 
population samples male subjects show a higher prevalence, a faster rate of decline and 
an earlier age of onset than female subjects77,85–88.  
Although not all studies report these trends between male and female subjects89, the 
observed differences could aid in our understanding of how the pathology manifests in 
different individuals90. One theory is that stereotypically ‘male’ professions have a higher 
risk of daily noise exposure, leading to a greater prevalence of HL and faster decline in 
hearing ability in male subjects.  However, doubt has been cast on this theory as the 
observation of a higher prevalence and faster rate of decline, remains after adjusting for 
factors such as noise exposure85,86,91. Furthermore, cohorts with low or no evidence of 
noise exposure have reported a difference in male female prevalence87.  
An alternative theory is that sex hormone exposure may be a risk factor for ARHI. A 
population study found an association between hearing and a genetic variant in the 
oestrogen related receptor gamma gene (ESRRG), to be significant in females only92. In 
addition, hearing deterioration has been observed earlier in ESRRG KO mice compared 
to controls, and the deterioration was more severe in female mice92. Effects of 
progesterone have also been linked with ARHI; women taking progesterone as a 
component of hormone replacement therapy  were observed to have poorer speech 
perception than controls93. Mice treated with different forms of HRT supported this 
finding; outer hair cell and overall auditory function was impaired in the progesterone + 
oestrogen group compared to the oestrogen only group94. These findings are important 
firstly because they indicate that hormone levels are an ARHI risk factor, and secondly 
that hormone therapies could potentially mediate this risk.  
The risk of developing ARHI also varies between different ethnic groups. Initial 
observations attributed this to the environmental exposures experienced by different 
study samples such as industrialised vs. rural settings. More recent work however 
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suggests that the production of melanin may be a protective factor against ARHI95. 
Observational studies have reported that African Americans have a decreased risk of 
ARHI compared with White or Hispanic Americans96. Another study estimated that black 
participants had an up to 70% lower prevalence of ARHI than white participants97,98.  A 
further study, in mice, indicated that melanin may be protective against SNHL following 
noise exposure99. It is important to understand why prevalence differs in different 
samples, as it could reveal sample-specific pathological mechanisms and direct ethnicity-
specific diagnostics and treatments, promoting health equality. 
Genetic risk factors – ARHI Heritability   
Multiple studies have reported ARHI heritability estimates in different population 
samples. The estimates range between 0-79%, with the majority of estimates published 
prior to this work falling between 20-60%100–105 (Table 1.3).  The heritability of a trait is 
classically defined as the ‘proportion of variation in a trait explained by inherited genetic 
variants.’ Therefore, these estimates are evidence that genetic risk factors contribute to 
the variance in ARHI phenotypes observed in the population. The variation between the 
ARHI estimates is likely to be due to the heterogeneity between studies38,92,106–114 (as 
discussed below), and indicates that a comprehensive, widely applicable estimate is yet 
to be determined.   
There are three types of heritability estimates that capture the proportion of trait 
variance that is explained by inherited genetic variants. These are termed broad-sense 
heritability, narrow-sense heritability and SNP heritability. Broad-sense heritability (H2) 
encompasses additive, dominant, epistatic and maternal/paternal effects on trait 
variance. Narrow-sense heritability (h2) encompasses additive genetic effects only, and 
is the traditional method used for calculating heritability. For some time, twin studies 
were the main resource for calculating heritability. Monozygotic (MZ) and dizygotic (DZ) 
twins likely share the same environment, yet only monozygotic twins share the same 
genetic risk (excluding sporadic mutations and epigenetic modifications). Therefore, 
when comparing the trait prevalence between MZ and DZ twins, if the correlation is 
higher within MZ twins, the observed variation is more likely due to genetic factors.  
Thirdly, SNP heritability (h2g) includes the additive effects of all SNPs specified in a 
model. However, the additive effects of all SNPs are not known and so two methods are 
generally used to calculate this term; genomic relatedness matrix restricted maximum 
likelihood (GREML) and linkage disequilibrium (LD) score regression. These methods 
that test for the proportion of variance all assume a continuous distribution for the trait 
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of interest and so estimates for binary traits require further adjustment to the liability 
scale. 
The majority of ARHI heritability estimates calculated prior to this work were on twin or 
family samples and so most used a classical twin model to derive an estimate.  However, 
there has been much speculation as to whether this model, which assumes equal 
environmental exposures, results in inflated estimates of narrow-sense heritability115,116. 
In some instances this has been disproven; a study on ECG traits compared the estimate 
from the classical twin model and the GREML method (which overcomes this limitation) 
and no inflation was observed115. For other traits however, such as neuroticism, a modest 
inflation has been detected; when similarity in environment was controlled for, a lower 
estimate was calculated117. As of yet, there are no equivalent ARHI studies that have 
compared the different methods, and so it is unclear whether the estimates in Table 1.3 
are inflated due to this limitation. 
The age range of each sample also ought to be taken into account when assessing the 
estimates listed in Table 1.3. Over an individual’s lifetime, effects from environmental 
exposures accumulate. For some common complex traits this results in a decrease in the 
proportion of variance determined by genetic risk factors (thus a decrease in heritability 
with increasing age). However, this is universal for all traits, and the extent to which this 
applies to age-related traits such as ARHI, is not clear. To date, many ARHI study samples 
have been too small in size to stratify by age.  
One longitudinal study however, assessed the hearing ability of participants in a Swedish 
male twin registry at two time points, 20 years apart, and estimated the heritability of 
hearing loss at each timepoint. They found no difference in the magnitude of the genetic 
effect between the two time points, and rather  predicted that the rate of deterioration 
over the time period was affected by individual-environmental exposures103. A further 
study, conducted as part of the Nord-Trøndelag Health Study, also explored genetic 
effects on PTA thresholds, and used sibling pair correlations to estimate the heritability 
of hearing loss118. Here, the sibling correlation increased with age when calculated for 
sample subsets, consisting of 10-year age group samples from 20-71+ years, with the 
highest heritability estimate reaching 0.36118. Further work is required to address the 
reason for the wide range of heritability estimates, such as exploring the effects of age 
and environmental factors on the estimates.  
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ARHI Heritability Study N Hearing measure 
Age of sample 
(years) 
0-50%100 
4 Italian isolated 
populations 
N = 1,682 
(231, 329, 
429, 693) 
PTA (split 
low/med/high freq.) 
≥40 
40%119 Danish Twin 
Registry 
N>2,000 Self-report 70-102 
40% (unadj. for age) 
25% (adj. for age)101 
TwinsUK N = 2,076 Speech in noise 18-87 
56-70%102 TwinsUK N = 1,033 PTA (PC1-PC2, PC2) 41-86 
58% (aged 56-65) 
47% (aged 65+)103 
Swedish Twin 
Registry 
N =288 
N = 295 
PTA (high freq) 34-99 
75%104 Finnish Twin 
Study 
N = 217 PTA 63-76 
36-79%105 European 
population 
N = 952 PTA 50-75 
Table 1.3.  Summary of studies that report heritability estimates for ARHI 
 
 
A large number of environmental exposures are also associated with ARHI, and are 
discussed further in a later section entitled Environmental risk factors, p.38. These 
exposures can impact the heritability estimate, and possibly create heterogeneity 
between the studies that account for exposures and those that do not. Genes can interact 
with these risk factors via either increasing the risk of an exposure or influencing the 
response to an exposure (such as genes involved in damage repair mechanisms).  The 
environmental exposures, and any genetic susceptibility to these exposures, can 
therefore influence the development and progression of ARHI.  
To account for these effects, a number of the studies in Table 1.3 have adjusted for 
additional risk factors. For example, the study on the 4 isolated Italian populations 
excluded individuals aged <40 years, and, or that are diabetic or that have a history of 
including occupational noise exposure, ototoxic drug exposure, chromic otitis and 
acoustic damage. The heritability estimates were then calculated adjusting for age, sex 
and hypertension. Likewise, the study conducted on the European population, where 
heritability estimates ranged from 36-79%105, excluded individuals that had known 
otologic conditions.  
In addition to the adjustment or un-adjustment for environmental risk factors, and 
exclusion or inclusion based on medical conditions, heterogeneity between the study 
samples is also present in the form of the methods used to assess hearing ability. Five of 
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the seven studies listed in Table 1.3 used PTA thresholds to determine hearing ability. 
How the thresholds were averaged and thus how the hearing loss was classified varies. 
Firstly, three of the four Italian subpopulations studied had data available to calculate 
heritability estimates based on PTA thresholds, averaging ‘high’, ‘medium’ and ‘low’ 
scores. Across the three subpopulations, and across the three PTA frequencies, the 
(resulting 9) estimates ranged from 0-53%, yet only the ‘high’ PTA frequency, heritability 
estimate in Campara, was significant; 53% p<0.05100.  
Secondly, the four further studies listed in Table 1.3 that used PTA thresholds, either 
included only thresholds at the high frequencies103, or derived PTA-based principle 
components that reflect the shape of an individual’s audiogram102. The remaining two 
studies used either SNR scores from speech in noise testing, or self-report measures. 
Evidence of this heterogeneity being caused by different phenotyping methods, is 
demonstrated by the two estimates from the TwinsUK cohort. One study estimated 25-
45% using SNR as the phenotype101, and a second estimated 56-70% using a selection of 
PTA thresholds102. Although different subsets of the TwinsUK sample were used, and thus 
the age range of the two studies differed, subsequent work on the TwinsUK sample 
estimated a genetic correlation between SNR and PTA as -0.67. This is evidence that PTA 
thresholds and SNR scores do share genetic variance attributable to additive factors102, 
yet also capture variance due to distinct genetic risk factors.  
While there is variation between these estimates, and a number of studies that are 
limited by sample size (and thus statistical power), individually they indicate that ARHI 
has a heritable component, and highlight the possible effects of study-specific 
parameters. In order to comprehensively determine the genetic risk of ARHI on a 
population level, a large sample that is representative of the general population will need 
to be collected and an estimate calculated, possibly with adjustments for additional risk 
factors. These risk factors can be challenging to distinguish, especially where gene x 
environment interactions are present. Furthermore, the genetic risk on a population 
level ought not to be applied to individual patients, as the individual’s risk of ARHI will 
be further determined by additional factors. 
Environmental risk factors  
Numerous environmental risk factors have been associated with ARHI, such as smoking, 
diet, chemical exposures, education, alcohol intake and noise exposure120–124. The 
relationships between environmental exposures and ARHI risk are summarised in 
Figure 1.14120. The effect of each exposure on an individual’s risk of ARHI is poorly 
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understood, as are the interactions between the different exposures. The disparities 
between studies (displayed in Figure 1.14, column 2) regarding the effect of an exposure 
on ARHI risk, may be due to the heterogeneous nature of ARHI and, or the variability 
between the populations studied. It may also be due to the methods by which 
environmental factors were assessed or indeed how hearing ability itself is assessed. For 
example, associations with age, BMI, education and smoking have been seen to differ 
between men and women, at different frequencies of hearing loss121.  
 
Figure 1.14. Environmental factors associated with ARHI, from Van Eyken et al. 2007120 
 
Three of the most well-studied environmental risk factors for ARHI are noise exposure, 
chemical exposure and smoking. Noise-induced hearing loss is a distinct form of hearing 
loss but also an established risk factor for developing ARHI. Following exposure to 
intense and, or prolonged sound, it is common to experience a temporary threshold shift. 
For repeated or extreme exposures, a permanent threshold shift can occur which 
signifies permanent damage to sensory cells, synapses and cochlea neurons125.  
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Noise damage is detected when an elevation of auditory thresholds (a ‘notch’) at ~4kHz 
is observed (yet work by Nondhal, 2009126 contests this classification). Both human 
population  studies and studies with animal models have observed links between noise 
exposure  and an elevated risk of developing ARHI127,128, but as is evident from Figure 
1.14, a number of these findings are inconsistent. One study only observed a marked 
increased risk of ARHI when noise exposure had occurred in conjunction with other 
otologic issues128.  
Furthermore, a WHO systematic review on the subject highlighted the methodological 
heterogeneity between studies129. Strict criteria meant that only five studies were 
included in the work, two that focused on the correlation between HL and the use of 
personal listening devices, two that focused on the correlation between tinnitus 
symptoms and use of such devises and one study that assessed both. All three studies 
found a positive correlation between use of personal listening devices and hearing loss, 
one of which displayed a positive correlation between the amount of use and HL. None 
of the studies displayed a positive correlation between use and tinnitus symptoms. The 
authors however did conclude that all evidence was ‘low quality GRADE evidence’, and 
that the data were inadequate; the combined sample was made up of n=1551 young 
adults and teenagers and thus difficult to measure prolonged exposure and, or persistent 
HL129. In the general population it is very challenging to quantify levels of noise exposure 
and the extent to which it increases ARHI risk for each individual.  
Chemical exposures such as ototoxic drugs or aromatic solvents can also induce hearing 
loss. A common example are platinum-based drugs prescribed as chemotherapy to treat 
certain forms of cancer. The most frequently prescribed but also most ototoxic, is 
Cisplatin, which can cause sensorineural hearing loss, tinnitus and vertigo. Cisplatin 
forms part of a reactive aqua complex that binds DNA, inhibiting DNA replication and 
thus cell proliferation130. Cisplatin-induced damage in the cochlea, however, affects non-
proliferating cells and so must induce damage via an alternative mechanism. It is thought 
that this mechanism is via Cisplatin binding to mtDNA which induces an increase in the 
production of reactive oxygen species (ROS)76, ultimately resulting in cell apoptosis. As 
the cochlea is a metabolically active site, levels of mtDNA are high, and as mtDNA is 
histone-free, it is particularly vulnerable to Cisplatin.  
Aminoglycosides are commonly prescribed antibiotics and represent another form of 
ototoxic drug that induces an increase in the production of ROS in the cochlea. 
Aminoglycosides enter the cochlea via the stria vascularis and can remain in situ long 
after treatment is completed131,132. Here aminoglycoside-ion complexes form, which lead 
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to the breakdown of membranes that are in situ. This permits the release of reactive 
oxygen species, to which OHCs are particularly vulnerable133. In the case of exposure to 
aromatic solvents, the molecular mechanisms that lead to a HL are less well defined, yet 
in population samples the risk of developing a hearing loss has been found to increase in 
workers that are exposed to solvents. Furthermore, this hearing loss was shown to be 
exacerbated when the solvent exposure is experienced in conjunction with workplace 
noise exposure6. This dual exposure was labelled as an emerging risk in the European 
Agency for Safety and Health at Work134.  
The link between ROS exposure and sensorineural hearing loss has been further 
identified in animal models and human populations. For example, uncoupling protein 
(UCP) genes that are expressed in the central nervous system and work as 
neuroprotective proteins against ROS, have been linked to ARHI. In an elderly Japanese 
cohort, a variant upstream of UCP1 was associated with ARHI development135. 
Additionally, a variant in SOD2 (that codes for a mitochondria protein that has a role in 
hydrogen peroxide and diatomic oxygen production) has been associated with ARHI in a 
British cohort136. These associations identified in human populations are putatively 
supported by in vivo studies; when subjected to caloric restriction and thus lower levels 
of ROS, mice displayed reduced apoptosis and decelerated cochlear degeneration137–139.  
Lastly, smoking has been an established risk factor for ARHI for decades; a study on a 
Beaver Dam cohort in 1998 reported that pack-years of smoking is significantly 
associated with hearing impairment (defined by audiometric thresholds). The study also 
reported that passive smokers, (defined as individuals with a household member that 
smokes), were more likely to have a hearing impairment than those without household 
members that smoke140. The findings have recently been replicated in the UKBB sample; 
Dawes et al. identified a dose-response effect of increased hearing impairment in both 
passive and active smokers141. Again, this is a link that has been observed but is not 
comprehensively understood; nicotine exposure may affect OHC function or the 
neuronal transmission of auditory signals142. Alternatively, exposure to cigarette smoke 
may lead to a vascular insufficiency of the cochlea143. Further hypothesis to explain the 
link is that smoking is negatively associated with a healthy lifestyle, which encompasses 
multiple factors that may directly impact auditory function143.  
The focus of this thesis is the genetic risk of ARHI, yet in the future it will be important 
to assess these in the context of all risk factors as they are not independent and the 
relationships between each of the factors (including genetic risk) have not been 
comprehensively defined.  Furthermore, the work in Chapter 3 of this thesis 
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comprehensively assesses multiple hearing-related UKBB data fields for their suitability 
as surrogate measures for ARHI to use in genetic association analysis. Findings in 
Chapter 3 relating to the UKBB SIN test, which was used in multiple studies described in 
this section and the following section, challenge whether it is a reliable, stable measure 
and whether it really is a suitable surrogate phenotype for ARHI.  
1.3.3 Associated conditions 
Numerous traits have been linked to ARHI, including tinnitus, dementia, depression and 
medical conditions such as cardiovascular disease and diabetes144–152. Epidemiological 
studies frequently report linear relationships between the prevalence of multiple traits, 
which is suggestive of an association. Such associations may be due to ARHI being a risk 
factor for these conditions (or vice versa), common genetic and environmental risk 
factors or that they are independent traits of ageing.  
Cognitive decline and dementia  
Multiple studies conducted over the past 2 decades have reported an association 
between cognitive decline and hearing ability in old age148–152, and  in 2017, HL was 
defined as a modifiable risk factor for dementia in the Lancet Commission on Dementia 
prevention, intervention and care153. There are five hypotheses for the observed hearing-
cognition relationship; (1) over diagnosis, where the assessment of one condition is 
impacted by the presence of another condition such as a cognitively-demanding hearing 
test; (2) widespread neural degeneration, which affects distinct areas involved in 
cognition and auditory processing; (3) sensory degradation and deprivation, where a 
hearing loss causing neuronal inactivity can result in neuronal loss and subsequent 
cognitive degradation; (4) cognitive resource re-allocation of neurons from cognitive 
functions to auditory function, resulting in a depletion in cognitive resources,  and (5) 
social isolation/depression due to impaired hearing, which accelerates general cognitive 
decline154.  
The leading hypotheses is a re-allocation of cognitive load; if the input from the 
peripheral auditory system (outside the brainstem and auditory cortex) is degraded, 
more effort is required to process the signal as it reaches higher processing structures. 
Under this model, memory function is impaired as resources are reallocated to process 
the degraded auditory stimuli. The model was first proposed by Rabbitt in 1968155 and 
subsequent findings have supported this hypothesis, using multiple samples under 
multiple methodologies156–159.  
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As both hearing loss and impaired cognition are complex traits with mixed pathologies, 
defining phenotypes that are consistent and suitable to study in large sample sizes, is 
challenging. Ronnberg et al. studied the UKBB cohort and observed negative 
relationships between hearing loss and multiple visuospatial memory function tests, 
along with a small positive effect of hearing aid use on short-term working memory160. 
The large sample size (N=138,098), combination of hearing measures and cognitive tests 
performed, meant that the group could analyse subtypes of cognitive function in relation 
to hearing loss.  
Much of this analysis supported conclusions previously published by Ronnberg in 2011, 
who highlighted the importance of incorporating cognitive covariates when diagnosing 
and treating ARHI. A study by Heinrich et al. in 2016 also subset phenotypes of both 
conditions. A number of cognitive and speech perception measures were used to identify 
different relationships between the specific tests 161. Further to this, a recent systematic 
review on the hearing-cognition relationship concluded that hearing loss was a 
significant risk factor for incident dementia, but not for Alzheimers or vascular 
dementia159. Collectively, these findings imply varied relationships based on how the two 
conditions are measured and classified.  
Multiple studies have shown hearing aid use to be positively associated with cognitive 
ability162–164, indicating that hearing aid treatment may be a protective factor against 
cognitive decline. However, not all studies report a significant effect164 and while the 
effect has been observed in studies looking at short-term use of such devices, there is 
currently little evidence of hearing aid use having a long-term protective effect on 
cognition. Furthermore, these observations may reflect the fact that more cognitively 
able individuals are more likely to seek and frequently use hearing aid devices. As the 
size of the ageing population increases, so does the burden of HL and cognitive decline. 
Understanding the pathology of each, and the link between the two traits, will aid in the 
management of both conditions.  
Tinnitus  
Tinnitus and hearing loss are both symptoms of a malfunctioning auditory system. A 
relationship between tinnitus and hearing loss has been identified123,165, and the two 
traits share common risk factors including age166,167 and depressive symptoms168,169. 
Tinnitus is the perception of sound when there is no external sound source present, and 
is a relatively common condition, affecting 10-15% of the population146. Tinnitus differs 
between patients by the type of sound that is perceived, the level of distress that it causes 
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and whether the symptoms are acute or chronic. To add to the complexity, chronic 
tinnitus is a symptom of a number of monogenic disorders170. 
Multiple models hypothesising how subjective tinnitus develops have been proposed. In 
a subset of tinnitus patients with a HL, the frequency of the sound perceived is the same 
frequency as their HL171,172. It has subsequently been hypothesised that subjective 
tinnitus may be a result of molecular mechanisms that increase neuron excitability to 
compensate for a HL173. Examples of these theorised models include altered lateral 
inhibition173 (dysregulated inhibition of spontaneous activity at frequencies adjacent to 
the damaged frequency), homeostatic plasticity (an increase in neuronal gain at the 
damaged frequency) and stochastic resonance174 (increased spontaneous activity via a 
feedback loop at the dorsal cochlear nucleus175, to reach the neuron arousal 
suprathreshold).  
Work to understand the relationship between tinnitus and HL is still in its infancy and is 
largely limited to epidemiological studies. Population studies for tinnitus, like ARHI, 
suffer from a key limitation; there is no objective way to measure or quantify subjective 
tinnitus beyond self-report symptoms and subsequent distress. Heritability estimates 
for tinnitus vary from 11%176 in the first population study, to 68% in the male subset of 
a Swedish twin cohort177, to the most recent estimate of 40%178.  Identifying common 
and distinct risk factors such as genomic risk loci for both traits would progress the 
current knowledge of how the traits develop individually and in conjunction with one 
another.  
Depression 
A recent, systematic review and meta-analysis using the literature on the relationship 
between hearing loss and depression, concluded that there was a small but significant 
association between hearing loss and greater odds of depression140. Of the 44 studies 
included in the meta-analysis, 40 observed a positive association between hearing and 
depressive symptoms. Such studies have reported associations between depression and 
anxiety with hearing loss at high frequencies179, a higher incidence of depression among 
hearing loss sufferers, and also a lower incidence of depressive symptoms in hearing aid 
users180,181. 
A lower incidence of one condition, depressive symptoms, following the treatment of 
another condition, ARHI, with hearing aids, is suggestive of the latter being a risk factor 
for developing the former. If this hypothesis could be proven by identifying an 
underlying biological mechanism, improving treatments and prevention strategies for 
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ARHI could reduce the burden of depression on public health and subsequent economic 
resources. 
Conversely, another theory to explain the relationship between the two traits, is that HL 
hinders social interactions, and that this could lead to an onset of depressive symptoms. 
A recent study however has shown that psychosocial factors, such as participation in, 
and access to, social activities may not be responsible for the association, as adjustment 
for these factors did not attenuate the association182. Consistent with this finding, a 
second study in 2018 reported a possible common neural degradation that is in-part 
causal to both hearing loss and depression, based on neuroimaging of the limbic system, 
frontal cortex and auditory cortext182.  
Approaches to disentangle relationships between ARHI and associated traits 
The relationship between any of these traits and ARHI can be disentangled by a number 
of methods. Longitudinal analysis can reveal epidemiological trends of disease onset, 
progression and association between traits, though longitudinal studies require decades 
of foresight and rely on participant retention. Studies to identify common biological 
mechanisms can be more informative and efficient to conduct. For example, common 
biological mechanisms can be discovered by establishing whether two traits share 
common genetic risk factors. Techniques such as genetic correlation analysis are 
therefore a more practical approach to disentangling these relationships. 
Genetic correlation analysis between traits can assess the level of common genetic 
variance and can be performed with distinct trait-specific cohorts, thereby omitting the 
need for novel large-scale longitudinal data collection. Mendelian randomisation can be 
used to explore whether one trait is likely to be a modifiable risk factor for another, based 
on the nature of the shared genetic variance183. These techniques are especially valuable 
as they reduce the effects of confounding factors, which are difficult to omit in 
observational longitudinal studies184. Prior to this work, these techniques have not been 
used to disentangle the relationship between hearing and cognitive decline, tinnitus or 
depression.  
1.3.4 Strategies for defining ARHI in human populations 
Valid epidemiological and genetic analysis of complex traits relies on defining and 
ascertaining a robust phenotype. In quantitative traits this often consists of a measure 
by which an individual is classified by trait severity. Qualitative traits are assessed with 
a case control design with respect to the trait of interest. Pure tone audiometry (PTA), 
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signal to noise ratio (SNR) testing and self-report measures have all been used to define 
population prevalence and severity of ARHI.  
Assessing hearing ability: Pure Tone Audiometry 
PTA tests, as discussed in Section 1.2, are the gold standard measure of hearing 
impairment; an individual’s ability to hear at a range of frequencies and pitches is 
assessed and presented in the form of an audiogram. ARHI generally presents as a 
bilateral deterioration of hearing function that originates in the higher frequencies, as 
depicted by the downward sloping audiogram in Figure 1.15. To date, PTA testing is the 
most common ARHI phenotype used in most epidemiological and genetic studies of 
ARHI. However, PTA tests are not optimal or indeed practical for large-scale population 
studies as they require expensive, specialist equipment and trained staff. In addition, the 
test does not encompass a measure for distinguishing and interpreting sounds which are 
presented alongside background noise, sometimes termed ‘hidden hearing loss’, a 
common symptom of ARHI28,185.  
 
Figure 1.15. Example audiogram for a patient with age-related hearing loss.  
A hallmark of ARHI is a downward sloping audiogram for both the left right ears as it signifies a deterioration 
in hearing in the high frequencies and that the deterioration is bilateral. Hearing loss is classed as 
asymmetrical where there is greater than a 10dB difference between ears at the same frequency. 
Annotations on the right-hand side of the audiogram depict levels at which hearing abilities are described 
as normal, mild, moderate, severe and profound. Not all cases of ARHI will exhibit this downward sloping 
audiogram and there is no consensus to define ARHI by individual or grouped thresholds. The number of 
frequency thresholds that are tested can also differ between clinics. 
 
47 
 
Assessing hearing ability: Speech in noise testing 
Speech in noise (SIN) testing determines an individual’s ability to detect and process 
sounds at different frequencies with varying levels of background noise. The test 
produces a speech reception threshold (SRT) for each individual, indicating the level at 
which they can correctly interpret 50% of the speech presented to them. The SIN test has 
been proven as a useful surrogate for a PTA measure in the study of ARHI102 and is likely 
to be a more realistic measure of how ARHI impacts an individual’s ability to hear in daily 
life due to the incorporation of background noise. It is also amenable to genetic studies 
with large cohorts as it can be completed online or via telephone without additional 
expensive equipment or trained staff present. Different tests use either sentences, words 
or numbers as speech material. Currently, however, there is a lack of large cohorts with 
both SIN and genetic data available and testing protocols vary between studies102,113,186. 
The UKBB however, has recently released SIN and genetic data on a sample of >160,000 
individuals; magnitudes larger than other samples with SIN and genetic data.  
SIN tests were initially developed to provide an accessible, objective measure of hearing 
impairment, with the aim to increasing the diagnosis of hearing impairment and the 
subsequent uptake of amplification devices. SIN tests are a more accurate measure of 
‘real world hearing impairment’ as they mimic real-life situations more accurately than 
PTA. The standard speech in noise test was devised by Plomp, 1976187 and consists of a 
series of sentences played against a background noise. Participants then relay the 
sentence to be best of their comprehension. The test has an adaptive procedure; if the 
participant relays the sentence correctly, the dB ratio of the speech to background noise 
is altered such that the background noise level is increased. This continues until the 
intelligibility of the sentence reaches 50%. The ratio of speech to background noise at 
this 50% threshold level is the participant’s ‘speech reception threshold’ (SRT). 
The test has since been adapted for use via different platforms in multiple countries. In 
2004, the first digit-triplet test (DTT) for use by telephone was devised by Smits188. This 
differs to the SIN test devised by Plomp, as numbers (digits) are used in place of 
sentences or words. While the DTT has its advantages, it is less sensitive to cognitive 
function than alternative forms of SIN testing122,189,190. Triple digit SIN tests vary in the 
numbers selected to use, speaker that is employed, concatenation method, noise 
employed, scoring method and the tracking rule191–194. The UKBB SIN was based on the 
original Dutch online SIN test, first adapted for use in the UK by Action on Hearing Loss 
and further adapted for use in UKBB. The three key differences between these three tests 
(except the language used Dutch/English) are: (1) the tracking rule, (2) the number of 
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digit-triplets presented during the test and (3) the number of SNR measures used for the 
final SRT calculation (Table 1.4).  
Speech in noise (SIN) test Triplets played 
No. of triplets for 
SRT  
Tracking rule 
Dutch online Speech-in-
noise 
23 23 
1-up 1-down (2dB) 
Action on hearing loss (used 
by TwinsUK) 
26 26 
1-up 1-down (2dB) 
UKBB Speech in noise test 15 8 
1 up 1 down (4dB) for 
triplets 1-7, 1 up 1 down 
(2dB) for triplets 8-15 
Table 1.4 Summary of the adaptations to the original Dutch SIN test firstly for use by 
AoHL and secondly for UKBB.   
No. of triplets for SRT, the number of SNR ratios used to calculate the SRT value. The SRT is 
the mean SNR of these triplets.  
 
The SIN-PTA relationship 
Cohorts with both SIN and PTA data have been used to test whether the SIN test is an 
adequate surrogate for PTA as a measure of hearing ability. In the first study N=39 
(78 ears), correlations were calculated between SRTn and PTA thresholds 0.5,1,2 
(r2 = 0.732) and SRTn and PTA thresholds 0.5,1,2,4 (r2 =0.770). The sensitivity and 
specificity of the SRTn test to PTA measures were also calculated as 0.75 and 0.91 
respectively for PTA thresholds 0.5,1,2 and 0.79 and 1 for PTA thresholds 0.5,1,2,4188. 
The validation of the SIN test has also been tested in the TwinsUK cohort; N=351 female 
northern-European participants have completed both SIN and PTA tests. The correlation 
between SIN scores and PTA was r = 0.62, while the sensitivity and specificity calculated 
to be 89% and 80% respectively for a threshold of -9.25dB SNR when compared to 
PTA102. Furthermore, the genetic correlation (representing shared genetic variance 
attributable to additive factors) between the two traits in the TwinsUK cohort was 
calculated as -0.67102.  
The two studies used slightly different SIN tests (Dutch telephone test and Action on 
Hearing Loss web-based test), yet both demonstrate high correlations, sensitivity and 
specificity to PTA measures and thus support the use of SIN as a surrogate measure. In 
addition, the difference seen between the two tests (such that the sensitivity and 
specificity is not 100%) is not necessarily a limitation. Unlike the PTA test, the SIN test 
assesses a participant’s ability to process speech; patients that have difficulty 
deciphering speech can present with a normal audiogram. So, while validating the SIN 
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test against the PTA test is important, the differences between the two tests may have 
equal or even more importance when assessing ARHI. 
Self-report hearing measures 
Self-report measures are an increasingly common and practical method for the collection 
of data for a number of traits, on a large scale. In the analysis of complex traits, a larger 
sample size generally increases the statistical power. Although self-report measures can 
be subjective, genetic associations with ARHI have been found using this approach113.  
Self-report hearing measures may be simple questions regarding an individual’s hearing 
ability under different conditions, use of hearing amplification devices or any previous 
diagnoses of hearing-related problems and related symptoms.  
Several studies have reported the prevalence of hearing loss as measured by self-report 
status. These are summarised in a systematic review which was conducted with the aim 
of estimating the prevalence of presbycusis in the European population aged >60 years. 
The review reported on seven studies with self-report data (in addition to studies with 
PTA data)195. Prevalence estimates in the seven studies ranged from 8.1% (>60 years, 
Italian population)196 to 40.3% (>= 75 years, UK population)197. The variation in these 
estimates may be due to the different questionnaire measures used and may also reflect 
the varied demographics of the population samples.  
Two publications have reported on self-reported hearing aid use. The first summarises 
the correlation between frequent hearing aid use and SRT score123 and the second 
explores whether the use of hearing aids is associated with better cognition162.  The first 
study reported that only 21.5% of adults that had ‘poor’ hearing as defined by the UK 
Biobank (UKBB, introduced in section 1.4 and used extensively in this thesis) SIN test 
wore a hearing aid ‘most of the time’. The emphasis of the study was the relatively low 
uptake of hearing aids by those with a hearing impairment123. The second study reported 
a positive association between hearing aid use and cognition, independent of social 
isolation and depression162.  
The relationship between self-reported hearing ability and PTA and SIN 
measured hearing ability  
Four studies have collected both self-report and PTA data, and the prevalence estimates 
within studies differed by 7-16%198–201. A further study in 2016 reported similar 
findings; a cohort of 1669 participants aged >70, self-report measures and PTA scores 
were assessed. The self-report was not found to be truly representative of hearing 
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impairment as measured by PTA, indicating that the two measures may represent 
different forms of hearing impairment in this cohort, and possibly in cohorts that have 
been studied previously202.  
A study in 2015 describing the relationship of functional hearing and depression in the 
UKBB cohort reported a small (0.65dB) but significant difference between SRTB scores 
of those that reported self-reported hearing difficulty and those that did not. The study 
also reported a small but significant difference in SRTB score (0.51dB) for those reporting 
difficulty and no difficulty hearing in background noise195. However, a further study 
reported inconsistencies between participant perception of hearing ability and SIN 
measured hearing ability; 25-30% of participants that measured poor hearing (based on 
their UKBB SIN score) reported no difficulty with their hearing, and 25-30% that 
measured normal hearing reported hearing difficulties195.  
Based on the studies discussed in this section 1.3.4, it is clear that there are different 
ways to measure hearing impairment in population samples, each with individual merits 
and limitations. It would be informative to assess the prevalence of hearing impairment 
as measured by questionnaires, PTA thresholds and by SIN scores to determine which 
phenotype is most representative of ARHI, and to better interpret previous studies that 
have used each method of assessment.  
1.4 ARHI genetic risk 
ARHI is predicted to be genetically heterogeneous, indicated both by ARHI genetic 
studies to date38 and the fact that 150 genomic loci are associated with non-syndromic 
hereditary hearing loss alone (https://hereditaryhearingloss.org/). Identifying genetic risk factors 
for this trait would aid the understanding of its pathology and ultimately enable targeted 
treatments and prevention strategies. ARHI heritability estimates range between 30-
70%100,101,103–105,119 (as discussed previously in Genetic risk factors – ARHI Heritability, 
page 35) but to date there is little understanding of which genetic loci have a role in 
pathogenesis, and what their roles are. ARHI has been studied in human population 
studies, primarily with GWAS and candidate gene approaches, yet only five genomic loci 
have been significantly associated with ARHI, of which two have been replicated in 
independent samples109,111–113.   
1.4.1 Identifying genetic risk variants   
Several methods are commonly used to detect trait-specific genetic risk variants. In 
terms of ARHI, a number of these methods have been used to estimate genetic risk 
factors and variant associations with the phenotypes discussed previously. To determine 
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the variance in phenotypes that is explained based on genetic factors, a measure of 
heritability can be calculated (section 1.3.2). To identify individual genetic regions that 
likely cause this variance, techniques such as linkage analysis, candidate gene studies, 
genome-wide association studies and genome sequencing are applied, as discussed 
below.  
Linkage analysis  
Linkage analysis is a traditional approach used to identify chromosomal regions that 
harbor genetic disease markers. The technique makes use of the laws of genetic 
recombination; markers in close proximity on chromosomal regions are more likely to 
be inherited together. Family pedigrees are therefore used to identify chromosomal 
regions that cosegregate with a disease or trait of interest. Logarithm of odds scores are 
calculated to assess the probability that the observation is due to linkage rather than 
chance. Prior to the development of methods such as GWAS, linkage analysis was the 
optimal method to discover regions of the genome that are implicated in disease.  
A linkage analysis study was conducted on a group of ARHI cases presenting with high 
frequency hearing loss. The DFNA5 gene had been identified in non-syndromic 
sensorineural, progressive hearing loss in multiple  families of different genetic 
backgrounds203–205 and was therefore a strong candidate gene for ARHI. Analysis was 
conducted using a number of microsatellite regions on DFNA5 but no evidence of linkage 
was observed93. Following this, a genome-wide linkage study for ARHI was performed 
with a sample of 1789 individuals from the Framingham study, derived from 328 
extended pedigrees206. At the time, heritability of ARHI had been estimated as 40% in a 
classical twin study from the Danish twin register 119, while the linkage study provided 
broadly similar results with heritability estimates of 31% and 38% for age-adjusted low- 
and medium pure tone average frequencies respectively. Six chromosomal regions were 
identified as having suggestive evidence of linkage, four of which contained genes known 
to be involved in forms of deafness, three of which being implicated in Usher syndrome. 
However, while this study may indicate the role of congenital deafness genes in adult 
progressive hearing loss, no truly statistically significant findings were reported.  
Linkage analysis has also been performed with the self-report hearing measures. One 
study used a cohort of elderly male twin US military veterans. Four hundred markers 
were studied, and a region of suggestive linkage was identified on chromosome 3, in the 
same region that DFNA18 is located. This provides the first evidence to suggest that 
DFNA18 has a role in general hearing impairment in the ageing population207. A further 
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linkage study was performed, and although no significant associations were identified, 
variation in a region on chromosome 8 was correlated with a concave audiogram 
shape208.  
In keeping with many other common complex traits, there has been limited success in 
identifying ARHI susceptibility loci via linkage analysis, due to its’ inherent limitations.  
The power to detect linkage via pedigree analysis relies on the presence of highly 
penetrant, rare variants such as those in Mendelian or oligogenic disorders209 yet 
common, polygenic traits such as ARHI are caused by multiple, lower penetrance 
variants; the ‘common trait common variant hypothesis’ (Figure 1.16). A second 
limitation of linkage analysis is its limited power of resolution; the regions denoted by 
the widely spaced markers - usually microsatellites - are large and may contain hundreds 
of possible candidate genes. Where a region is significantly associated with the trait of 
interest, further analysis is then necessary to narrow down the genomic region of 
interest and identify the functional genetic variant or alteration.  
Candidate gene analysis 
A second method, candidate gene analysis, tests for association between a trait and a 
gene of interest. This approach may be used to identify a causal SNP or genome variant 
when there is prior knowledge that a gene, biological mechanism or pathway is 
associated with the trait of interest210. When genotyping costs were relatively high, in the 
early 2000s, this was the most cost-effective approach to use, as it only necessary to 
genotype the genome region of interest.    
As noted earlier, DFNA5 was considered a strong candidate gene for ARHI as it causes 
some forms of familial deafness. With the same data as used in the linkage analysis study, 
a case-control association study was conducted with satellite markers from the DFNA5 
candidate gene region, yet no evidence of association was found93. Another candidate 
gene study used samples from 7 different populations and tested for association between 
ARHI and GSTT1, GSTM1 and NAT2. These genes were selected on the basis that they 
have a role in defence against reactive oxygen species, a putative pathogenic mechanism 
in ARHI. In the combined European samples a significant association was observed with  
NAT2*6A, while associations with GSTT1 and GSTM1 were observed in the Finnish 
subsample211.  In 2008 a more comprehensive candidate gene study of ARHI was 
performed using 768 SNPs across 70 genes. The 70 genes were selected as they are genes 
known to cause monogenic forms of hearing loss genes in both mice and men. Here, 
GRHL2 was found to be associated with ARHI; one SNP reached the multiple-testing p 
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value threshold of association and surrounding SNPs showed suggested association, with 
a concordant direction of effect in all nine contributing cohorts212.   
 
 
Figure 1.16. Diagram to demonstrate the common variant common trait hypothesis.  
Spectrum of Disease Allele Effects. Disease associations are often conceptualized in two dimensions: allele 
frequency and effect size. Highly penetrant alleles for Mendelian disorders are extremely rare with large 
effect sizes (upper left), while most GWAS findings are associations of common SNPs with small effect sizes 
(lower right). The bulk of discovered genetic associations lie on the diagonal denoted by the dashed lines. 
Figure and Legend from Bush & Moore 2012213. 
 
The most comprehensive, ARHI-specific, large-scale candidate gene study to date on 
normal hearing was conducted using a multistep approach203. Nineteen candidate genes 
that had previously been reported in ARHI association analyses (yet were not genome-
wide significant), were examined for gene expression in mouse cochlear tissue. Gene 
expression in the cochlea was observed for 12 of the 19 candidate genes. Of the 12, 9 
were then replicated in independent samples. A relationship was also identified between 
specific audiometric patterns and variants in 7 of the replicated genes; CDH13, GRM8, 
ANK2, SLC16A6, ARSG, RIMBP2 and DCLK1. 
The gene GRM7 contained the first variant to be identified by association analysis, in 
2009, in a population sample comprising cases and controls collected in 8 centres from 
6 European countries (n=1700 total). Replication was attempted for the most highly 
associated variants, in a sample n=138, and the variant in GRM7 variant was 
replicated109.  GRM7 has been the focus of several subsequent candidate gene studies. 
The first study which aimed to replicate this finding was performed on a European-
American population (n=687), and used a range of hearing measures in an attempt to 
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better define different pathologies underlying a ARHI phenotype106.  Six phenotypes 
were defined and tested for association with three variants of interest from GRM7; 
rs11928865, Haplotype 6 and Haplotype 7. The study confirmed an association between 
variation in GRM7, PTA frequencies and SRT scores.  
A later study assessed whether GRM7 variants were associated with ARHI risk in a Han 
Chinese population sample108. Individuals were assigned to phenotype groups based on 
the shape of their audiograms, using K-cluster analysis, following Schuknecht’s model of 
the four audiogram patterns of ARHI26,214 subtypes.  Significant associations were 
identified for rs11928865, a SNP in intron 1 of GRM7 for the audiogram phenotypes 
‘abrupt loss’ and ‘sloping shape’, but not for ‘flat shape’ and ‘8kHz dip’. This work was 
another indication that different risk genetic factors may associate with distinct 
audiogram shapes. The latest study to assess GRM7 risk variants in an ARHI population 
sample tested 4 SNPs for association, and found one to associate in a dominant pattern215. 
Two studies have analysed GRM7 risk variants in relation to traits linked to ARHI; noise-
induced hearing loss in a Han Chinese sample216 and tinnitus and ARHI in a Portuguese 
sample217. Furthermore, a number of subsequent GWAS reported summary statistics for 
GRM7 SNPs included in their analysis38,107.  
The multiple findings of an ARHI-GRM7 association are promising, however further 
validation is required for multiple reasons. Firstly, associated SNPs are located in 
different regions of the GRM7 gene and were identified using differing phenotype 
measures in diverse ethnic samples. Secondly, the initial GWAS study did not report a 
significant association and the latest association studies, with greater statistical power, 
have failed to support an association with GRM7113.  
Interpreting these findings is complex, and a pathogenic mechanism of GRM7 in ARHI is 
yet to be established. Furthermore, as the candidate-gene approach is hypothesis-driven, 
it is susceptible to false positive results. Evidence based on work in other traits indicates 
that candidate gene association studies have provided many false positive results, 
demonstrated by more recent, highly powered GWAS218. The recent development of very 
large population samples could lead to a rapid expansion in studies of ARHI. Due to the 
falling costs of genotyping and the advent of the GWAS-era and thus hypothesis-free 
methods, candidate gene analysis is now a less favourable method to use for discovering 
novel genetic associations with traits of interest.  
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Genome-wide association studies 
The last decade has seen a rapid increase in the number and complexity of methods to 
uncover genetic risk variants associated with common complex traits. The falling cost of 
genotyping, the increase in large-cohort data collection and the development of high-
powered analysis platforms has led to wide-scale usage of GWAS to uncover genetic 
determinants of polygenic traits. The hypothesis-free approach tests for association 
between a trait of interest and up to billions of common genetic polymorphisms. Over 
the past decade, GWAS has enabled the discovery of genetic risk variants for a whole host 
of polygenic traits. For ARHI however, there are still very few genes that are known to 
be involved in pathogenesis, and heritability estimates, as noted, vary greatly depending 
on the characterisation of the condition, cohort demographics and analysis method.  
For an individual trait, the success of GWAS is determined by four main factors; the 
number of trait-associated loci that segregate in the population, the genetic architecture 
of these loci (including effect size and frequency), the size of the study sample and the 
heterogeneity of the trait219. For ARHI, prior to the work presented in this thesis, the 
number of trait-associated loci segregating in the population, and the architecture of 
these loci was largely unknown.  
The initial GWAS studies on ARHI used cohorts in the hundreds of individuals while 
studies in the past ten years have featured samples in the thousands and have increased 
genome array densities and utilised vast imputation panels. Although this has improved 
the power to identify associations, there is still a distinct lack of replicated associations 
from ARHI GWAS. This is likely due to the polygenic and multi-factorial nature of the 
trait, and the differing cohorts and study designs; previous ARHI GWAS differ in sample 
size, study population, SNP coverage and phenotype definition (Table 1.5).  
The first GWAS on ARHI was published in 2009. The sample included 1,692 participants, 
classified either case-control based on Z-scores derived from PTA frequency 
thresholds109. The study did not report any genome-wide significant associations, yet the 
lead suggestive association, as noted in the section above, was a SNP in the GRM7 gene 
transcript. The association replicated in an independent sample and subsequent gene 
expression analysis and immunohistochemistry of its protein product, metabotropic 
glutamate receptor 7, was observed in mice cochlea and in a single human cochlear 
sample. 
The following year, a second GWAS was published, and defined ARHI , using principal 
components (PCs) derived from PTA thresholds107, resulting in a quantitative phenotype. 
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Again, no significant associations were identified in the sample (n=352), but the most 
highly associated SNP was reported in the gene IQGAP2. A further GWAS also used 
quantitative phenotype, based on PCs derived from PTA thresholds. This study meta-
analysis of samples from across Europe and so had larger sample size (n=3,417). No 
significant associations were identified, but authors highlighted four candidate genes; 
DCLK1, PTPRD, CIMP and GRM8114. Replication was not conducted in the original study 
but the association with GRM8 was later supported in a subsequent GWAS38.  
In 2013, Nolan et al. studied three cohorts (n=3,900) using a quantitative phenotype 
derived from logistic regression analysis of PTA thresholds. The focus of the study was 
ESRRG and identified an association in females but not in males, in two of the three study 
cohorts92. The link was supported by functional work that was conducted in ESRRG 
knock out mice. A year later Fransen et al. performed a GWAS and attempted replication 
of all previous associations, with a phenotype derived from PCs of PTA thresholds (N = 
2,161)38. None of the previous findings were replicated and no new significant 
associations were found. At this stage, none of the five ARHI association studies had 
revealed any significant associations with risk variants, and there was little replication 
of suggestive findings between studies. The authors highlighted suggestive associations 
with ACVR1B and CCBE1 and concluded that ARHI is likely to be ‘highly polygenic in 
nature’ and that the trait is caused by multiple variants of small effect sizes, which are 
‘undetectable in a modestly powered GWAS’38. 
Later in 2014 two studies published the first genome-wide significant associations 
between genetic risk variants and ARHI. Firstly, a SNP in the salt-inducible kinase 3 
(SIK3) gene transcript was identified in a meta-analysis of samples (overall n=4,939), 
where the phenotypes were derived PC analysis on PTA thresholds. This finding is yet to 
be replicated in an independent sample, yet Sik3 expression was observed in the stria, 
hair cells and spiral ganglion neurons in P0-P5 mice111. The second study identified 
significant associations near to the SLC28A3 and PCDH20 gene transcripts, and reported 
replications at nominal levels of significance112. In 2015, Fransen et al. published a 
second GWAS with a cohort that had been used previously in a candidate gene study. No 
significant novel associations were identified, and replication was not achieved for any 
previous findings of ARHI-associated genes38.  
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Study Phenotype 
Genotyping array / no. of 
SNPs 
Sample size 
(analytical method) 
Ancestry of samples 
Genes identified 
P<5E-08 
Friedman et al., 
2009109 
Z-scores derived from PTA thresholds 2,4,8 
kHz (high frequency, most affected in the 
elderly). Use only the ‘best ear. 
Affymetrix 500K GeneChip® / 
506,627 
N = 846 cases and N = 
846 controls 
European  - 
Van Laer et al., 
2010107 
PC analysis of PTA thresholds. PCs 103 
captured 80% of the variation. PC1 
correlated with all frequencies. PC2-3 are 
‘shape’ variables. PC2 is a measure of the 
slope of the audiogram, PC3 measures the 
concavity of the audiogram. 
Affymetrix GeneChip Human 
Mapping 100 K array pair 
(Santa Clara, CA, USA) / 
83,381 
N=347  
(quantitative) 
Finnish Saami - 
Girotto et al., 2011114 (1) PTA low, medium and high 
(2) 7 different thresholds 250-8k Hz 
(3) PTA threshold PCs 1-3 (shapes as in Van 
Laer et al.) 
Illumina 370 k platform or 
Affymetrix 500K. Imputed to 
the 2.5M HapMap CEU SNP set 
v22 / ~2,200,000* 
N = 3417 
(meta-analysis) 
European - 
Nolan et al., 201392 PTA at 1kHz and 4 kHz 
0.25-4 kHz 
ABI TaqMan SNP genotyping 
assay, Illumina Infinium 
Human Hap550 array / 
555,164a 
N = 3900 
(quantitative) 
 - 
Wolber et al., 2014111 PC analysis of PTA thresholds (shapes as in 
Van Laer et al.) 
Illumina 370k chip, Affymetrix 
500k array, Illumina 
HumanHap300 Bead Chip, 
Illumina HumanHap610 Quad 
Chip / >2,300,000* 
N = 4939 (meta-
analysis) 
European, Silk Road SIK3 
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Vuckovic et al., 
2015112 
PTA 0.25, 0.5, 1 ,2, 4, 8 kHz 
PT averages for low, medium and high 
frequency groups 
Illumina 370 K, Affymetrix 500 
K, Illumina 700 K, Illumina 
Hap550, HumanExome Chip 
 / 8,455,987* (INGI-FVG), 
6,490,547* (INGI-CARL), 
38,020,975* (TALANA), 
6,302,431* (CILENTO), 
6,664,949* (SR). 
N = 2636 (meta-
analysis) 
European, Silk Road PCDH20, SLC28A3 
Fransen et al., 201538 PC scores from: 
Air conduction 0.25,0.5,1,2,3,4,6,8 kHz 
Bone conduction 0.5,1,2,4 kHz. 
Illumina CNV370 quad chip, 
Illumina HumanOmniExpress 
BeadChip / 
11,626,570* (before QC). 
N = 2161 
(quantitative) 
Belgian  - 
Hoffman et al., 
2016113 
Electronic health records – ICD coding 
Self-report measures and SRT scores 
Affymetrix Axiom arrays 
(optimised for population 
subgroups) / 
9,469,183*(EUR), 
8,090,486*(LAT), 
6,517,021*(EAS), 
7,829,026*(AFR) 
N = 6527 cases, N = 
45,882 controls 
White, non-Hispanic 
American 
ISG20, TRIOBP 
Table 1.5. Summary table of ARHI GWAS samples and phenotype methods to date.  
Study, first author and publication year; Phenotype, the phenotype used for association analysis; Genotyping array / no. of SNPs; genotyping array used to genotype discovery sample 
and the number of SNPs included in discovery analysis. *denotes the number of SNPs following imputation. a denotes number of SNPs prior to QC in the 1958 British birth cohort sample; 
Ancestry of samples, ancestry of sample used in discovery analysis; Genes identified P<5E-08, genes that contain SNPs or are in close proximity to SNPs that reached genome-wide 
significance in association analysis.  
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A study published in 2016 used self-report and SRT data obtained from electronic health 
records. This permitted a high powered GWAS of >6,500 ARHI cases and >45,000 
controls, where association was identified with two novel SNPs at genome wide 
significance. This discovery sample comprised of a subset of the GERA cohort (included 
only non-Hispanic whites). The most highly associated SNPs were further investigated 
in the remaining ethnic groups within the sample, and under different ARHI phenotype 
classifications (SRT and speech discrimination score, SDS and self-report measures). 
Two novel SNPs were identified in ISG20 and TRIOBP, and the associations were 
replicated. The authors also then took a candidate gene approach and identified two 
novel SNPs in ILDR1 and EYA4113. Prior to this study, no previous ARHI GWAS had 
identified and replicated multiple genome-wide significant risk variants. Table 1.5 
provides an overview of all previous ARHI GWAS study samples and phenotype 
classifications.  
A limitation of current GWAS published on a broad range of traits is that findings only 
explain <20-30% of the trait variance220. ARHI is thus far no exception to the missing 
heritability problem, in that the current genetic variants identified via GWAS largely do 
not account for trait heritability estimates. For complex traits, this is thought to be in part 
due to the way heritability is measured; inconsistencies in methodologies, the samples 
used and inflated measures due to most methodologies taking into account only additive 
genetic components resulting in ‘phantom heritability’220, a term used to describe the 
disparity between heritability estimates and the effect sizes of known pathogenic 
variants. Epigenetic factors are also likely to account in part for the missing heritability 
of complex traits221 such as ARHI222. Some epigenetic marks are inherited while some are 
acquired and are more dynamic. They play a role in all traits, predominantly in gene 
regulation, an important factor to study in ageing traits. 
In terms of ARHI, there have been a limited number of significant associations identified, 
and all with relatively small effect sizes. Therefore, it may be that the current ‘missing 
heritability’ in ARHI is due to a combination of phantom heritability, a number of rare 
SNPs with larger effect sizes which are not currently on GWAS arrays, or common SNPs 
with small effect sizes which can only be identified with much larger sample sizes than 
previous ARHI GWAS have used. The latter is likely under the common disease, common 
variants hypothesis. With the advent of large-scale datasets with which to perform 
GWAS, this hypothesis that ARHI genetic risk comprises of multiple common SNPs with 
small effect sizes, can now be tested (as detailed below), and forms the basis of the work 
in this thesis.   
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The UK Biobank cohort 
Over the past five years there has been a marked change in the size of cohorts that are 
available for GWAS analysis. Previously, substantial sample sizes were only attenable via 
meta-analyses, but biobank-style cohorts are now being created, which is collecting data 
on hundreds of thousands of participants. The UKBB was a leader in this movement and 
is the main dataset studied in this thesis. The UKBB was created as an international 
health resource, comprising of data on over 500,000 volunteers living in the UK and aged 
between 40-69 at the time of recruitment in 2009. Volunteers were invited to participate 
in the UKBB based on their postcode proximity to an assessment centre within the UK, 
and their age. This means that for all measured traits, there was an unbiased recruitment 
strategy; something which is difficult and not practical to achieve in a more traditional 
research recruitment strategy.  
The UKBB resource is being extensively used for epidemiological and genetic research 
internationally; over 700 papers that used data from the resource, have been published. 
A large proportion of these publications are GWAS studies, including a number on 
sensory disorders, cognitive function and ageing traits223–225. UKBB is the first and largest 
multi-trait resource with which high powered GWAS can be performed. The resource 
therefore provides an opportunity for epidemiological and genetic research into multiple 
complex traits such as ARHI.  
The size of the UKBB means that the statistical power of genetic analysis is elevated such 
that SNP associations with polygenic complex traits can be identified. As the main 
limitation of ARHI GWAS prior to this work was the limited statistical power, alongside 
the hypothesis that ARHI is highly polygenic, this dataset creates a unique opportunity 
to conduct the first substantially powered ARHI GWAS. During the ‘GWAS era’ multiple 
methods have been devised to perform association analysis. Analytical methods have 
been adapted for the large-scale datasets as they present new challenges. For example, 
due to its size of over 500,000 samples, the UK Biobank dataset poses new challenges 
such as computational efficiency and within-sample population structure. Previous 
GWAS had not featured samples of this magnitude without taking a meta-analysis 
approach.  
The methods are continually evolving and did so rapidly while the work outlined in this 
thesis was undertaken. The development of such methods is determined in-part by the 
type of data that is available. In the case of this study, the following parameters were 
considered when identifying a suitable method to use for association analysis: 
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phenotype data format (binary or quantitative), computational efficiency and 
practicality, and accountability for population structure and relatedness (effects that are 
commonly present in datasets of a substantial size226).  
At the time of analysis, PLINK 2.0227, BOLT-LMM228, SAIGE229 and SNPTEST230 were all 
available and considered for use. While all four methods could accommodate a binary 
phenotype, only BOLT-LMM and SAIGE could account for within-sample relatedness. 
BOLT-LMM was favourable as the relationship matrix was computed in conjunction with 
the association analysis. SAIGE, however, required this step to be conducted prior to 
association analysis. At the time of analysis, this was computationally demanding and 
was not a practical approach with the means available. In addition, PLINK 2.0 and BOLT-
LMM had the quickest analysis speed. BOLT-LMM was therefore selected as it was 
suitable for the binary phenotype, accounted for within-sample-relatedness, was 
computationally efficient and relatively fast. PLINK 2.0 and GEMMA were used for 
association analysis on the replication samples, due to sample-specific constraints, as 
described in Methods 2.1.   
Post-GWAS analysis  
Since the advent of GWAS, much progress has been made in discovering genetic variants 
that are associated with complex traits. However, much of the true progress from GWAS 
findings will be in the accurate diagnosis, treatment and prevention of such conditions. 
This is only possible if GWAS associations are translated into biological and clinically 
relevant information. The aim of identifying these genetic variants is ultimately to 
discover which pathways and mechanisms are involved in a pathology. For many 
conditions, these pathways and mechanisms are more viable targets for diagnosis, 
prevention and treatments than single SNP variants. Post-GWAS analysis is therefore a 
crucial stage in a GWAS study protocol.  
Post-GWAS analysis is a multi-step process tailored for the individual study, based on the 
number and nature of SNP associations, a priori work on the gene variants and the 
specific trait of interest. Generally, the first step is to validate the associations in order to 
eliminate false positive results and study-specific effects. Most commonly, a replication 
of the discovery association analysis is sought in an independent sample. Where possible, 
tests are performed on the same genetic markers under the same analytical methods and 
with a phenotype definition consistent with that used in the discovery analysis231.  
Moreover, the causal SNP at any one locus may not have been included in the GWAS 
analysis as only a subset of SNPs in the genome feature on genotyping arrays and 
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imputation reference panels. SNPs in close proximity to the causal SNP (whether it was 
included in the analysis or not) will have inflated test statistics due to LD between the 
SNPs. Identifying the number of causal SNPs at a locus can therefore be a challenge. 
Methods have been devised that can predict the number of causal SNPs at reach region 
of association, and which SNP best captures the variance. The estimate also predicts 
whether the test statistics for this SNP likely either inflates or diminishes the true effect 
size for a region232. For example, if multiple SNPs at a locus influence a trait but act in 
opposite directions, the reported effect size is therefore reduced when only one SNP is 
used to define the association within an LD region. Further methods can then be used to 
identify the most likely causal SNP.  
As single SNP associations alone do not yield a great amount of biologically relevant 
information, the combined effects of multiple SNPs can be studied via gene-based or 
gene-set analysis. Here, genes in close proximity to lead SNPs (identified in association 
analysis) are grouped based on either genomic position, known biological functions, 
states and processes or by expression signatures. The analysis identifies pathways or 
biological processes that show enrichment for these gene sets. Hypotheses can then be 
devised, regarding links between these pathways and processes, and the trait of interest. 
Furthermore, identifying biological mechanisms and pathologies common to multiple 
complex traits can advance the understanding of each trait individually, and the 
interactions between traits.  
There are several tools that can be used for in silico functional annotation. Those that 
perform gene-set analysis and pathway analysis such as FUMA233 (containing 
MAGMA234), DEPICT235, DAVID236 and GARFIELD237, are commonly used following 
association analysis. Selecting which tool to use can be based on several criteria, 
including: (i) the type of input data; either summary statistics from an association study 
or a pre-defined gene list, (ii) the reference datasets that the tool uses;  some datasets 
are more comprehensive than others and can include tissue-specific expression data that 
is relevant to the trait of interest, and (iii) what the output will be used for; whether 
comparisons will be made with complimentary data or if independent conclusions will 
be drawn. A discussion of a suitable tool to use for this study is presented in section 2.3.1. 
Following in silico functional analysis, it is common to employ in vitro and in vivo methods 
to investigate the biological function of genetic risk loci on the tissue or organ of interest. 
In terms of ARHI, the human auditory system is anatomically difficult to obtain, including 
post-mortem, as it is encased by the temporal bone. Therefore, in order to conduct 
histological and molecular work, a suitable animal model is required with which to study 
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auditory function, damage and dysregulation. Furthermore, the use of animal models 
permits in vivo analysis and genetic modification techniques. 
The mouse is the model organism of choice for ARHI genetics. The mouse auditory 
system has a similar physiology and structure to that of humans238 and protocols for 
assessing hearing function in mice are well established, such as auditory brain response 
(ABR) testing239 or the less informative startle response239. Furthermore, a substantial 
proportion of genetic information is conserved between the two species; humans and 
mice share 85% of their protein-coding genome. While there is a substantial divergence 
in functions such as chromatin organisation and transcriptional regulation221, an 
extensive toolkit is available for the genetic manipulation of mice239, which is not 
possible in humans. This includes but is not limited to, conditional knockouts, knock-ins, 
insertion of reporter transgenes and CRISPR transgenics (this relatively new gene 
editing technique has already been used in auditory research, such as for preventing 
deafness in Beethoven mice by disrupting the mutant allele of the Tmc1 gene)240.   
ARHI genetic studies with mice predominantly comprise three broad methods239: (1) the 
identification of pathogenic variants in mouse strains that have a genetic predisposition 
to express a hearing phenotype (2) large-scale mutagenesis screens, and assess the 
progeny for hearing phenotypes with the aim to identify potential HL risk loci. and (3) 
engineer mouse strains to express mutations in candidate HL genes and evaluate the 
resulting pathology. ARHI candidate genes that have been tested in human populations 
were first identified in mice, via methods (1) and (2).  
Firstly, several mouse inbred strains carry genetic variants that predispose them to 
develop ARHI. Distinct risk variants in the different strains, result in distinct pathologies.  
For example, the C57BL/6J-Tyrc-2J strain does not produce strial melanin and has a 
reduced endocochlear potential, indicative of a role of reactive oxygen species in the 
pathology of ARHI238. The C57BL/6J strain (which carries the Cdh23ahl allele) displays a 
progressive loss of inner and outer hair cells and the loss of spiral ganglion cells at the 
basal turn, by seven months of age 238,241. This is the most commonly used strain in 
transgenic studies, and so the accelerated HL in knock-out models must be accounted for 
in HL study conception and the interpretation of any subsequent findings. In recent 
work, the gene defect in C57BL/6J mice has been rescued in a subset of the strain, by 
CRISPR/Cas9-mediated homology directed repair 238. GWAS can also be conducted in 
animal models; a study identified nine significant loci in a GWAS conduced on 99 inbred 
strains of mice, with phenotypes classified by ABR thresholds242. Identifying the risk 
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variants in strains that are pre-disposed to developing deafness, or via mouse GWAS, 
gives rise to human ARHI risk gene candidates.  
Secondly, mutagenesis screens have proved to be a successful alternative to identifying 
novel hearing loss genes. Most recently, a mutagenesis screen performed on 3006 
knockout mouse strains identified 67 hearing gene candidates, 52 of which were 
novel243. In addition, findings from some mutagenesis screens have already been 
validated in human populations. In 2016, a group observed an association between the 
stdf SNP in the S1pr2 receptor and with a decrease in endocochlear potential and 
increased stria vascularis degeneration. The association was replicated in the 1958 
British Birth Cohort sample via candidate gene analysis244. While this study has been 
successful in applying the finding to a human population, without having determined the 
extent and nature of the human ARHI genetic risk, it is difficult to establish the extent to 
which mice are a suitable model to study human ARHI genetic risk and thus how 
applicable these findings are.  
Thirdly, for the reasons listed above, by using mice, there is an opportunity to engineer 
strains to display genetic variants identified in population GWAS or human candidate 
gene studies. The type of pathology which is then observed in the mouse can give rise to 
a hypothesis of the corresponding human pathology present in the GWAS population 
sample. However, we first need to identify risk variants in human populations as the 
genes identified prior to the work in this study are sparse, and account for a small 
proportion of the genetic variance of the trait.  
1.5 Thesis aims 
ARHI is the most common sensory impairment in the ageing population, and a major risk 
factor for dementia, yet little is known about the underlying biological determinants. Due 
to the location of the auditory system, encased in the temporal bone and as part of the 
brain, histological analysis is challenging. Genetic analysis is an alternative route by 
which to identify and investigate such biological determinants. However, prior to this 
study, little was known about the genetic component of ARHI, or whether genetic risk 
factors contribute to ARHI in the general population.  
This is mainly because previous ARHI studies have lacked the necessary statistical power 
due to limited sample sizes and the absence of a comprehensive, consistent definition of 
ARHI. ARHI is a polygenic, heterogeneous trait and, under the common trait common 
variant hypothesis, large, highly powered studies are required to identify genetic 
variants underlying such traits. It is challenging to develop diagnostics, treatments or 
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prevention strategies for ARHI without a comprehensive understanding of the biological 
determinants of the trait. 
The overall aim of this thesis is to develop current knowledge of ARHI pathogenesis by 
identifying genetic risk variants and further investigate putative mechanisms and 
pathways involved in ARHI. The UKBB resource contains phenotypic and genetic data on 
half a million volunteers from the UK, aged 40-69 and therefore provides a unique 
opportunity to investigate the genetic risk of multiple conditions, including ARHI, with 
unparalleled statistical power. With this motivation, I set out to address three specific 
aims:  
1. Use the UKBB data resource to derive phenotypes that best describe age-
related hearing loss in the population sample, and that are suitable for genetic 
association analysis 
Previous ARHI GWAS phenotypes have predominantly been derived from PTA 
thresholds. However, such data (i) is not practical to collect the large scale that is 
required (ii) does not encompass a key symptom of ARHI; difficulty interpreting speech 
in the presence of background noise. Therefore, in the UKBB, alternative data fields are 
investigated in order to identify a measure that best describes ARHI and that is suitable 
to use in genetic association analysis.   
2. Perform genetic association analysis with surrogate ARHI phenotypes derived 
from UKBB data fields, with the aim to identify putative ARHI risk loci.  
The genetic risk factors of ARHI are largely unknown. By identifying associations with 
SNP variants, genetic risk factors can be identified, and their biological functions 
investigated. GWAS has yet to be proven as an adequate method to ARHI genetic risk loci. 
Although hypothesised to be a polygenic trait comprising multiple risk variants of small 
effect size, a population study is yet to prove this theory. The UKBB resource can be used 
to test the theory that ARHI genetic risk variants can be detected with sufficient 
statistical power, and that there are multiple such variants with small effect sizes.  
3.  Investigate the putative functions of genetic risk variants identified in 
association analysis, in the development of ARHI 
The nature of ARHI risk loci is largely unknown; genes implicated in ARHI risk may be 
common to other forms of hearing loss, and variants may result in similar defects as seen 
in congenital HL but at a later onset, or, alternatively, ARHI may be caused by distinct 
genes and biological mechanisms, only observed in cases of ARHI. Investigating putative 
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functions of the identified risk loci will give rise to new hypotheses of how ARHI develops 
and which auditory structures are affected. 
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Chapter 2 - Methods  
2.1 Population study samples used in Chapters 3 and 4   
The UKBB is the primary population sample that is used in Chapters 3 and 4. Two further 
samples, TwinsUK and the English Longitudinal Study of Ageing, are used in Chapter 4 
for GWAS replication analysis. The following sections contain details on data that is 
available on each sample, the recruitment method and cohort demographics.  
2.1.1 UK Biobank  
The UKBB is an international health resource which is following the health and wellbeing 
of over 500,000 volunteers who were recruited in the UK and were aged between 40-69 
years during the time period 2006-2010. The Biobank was conceived to collect data with 
the aim to ‘improve the prevention, diagnosis and treatment of a wide range of serious 
and life-threatening illnesses’ (https://www.ukbiobank.ac.uk/). Data collection 
consisted of a number of physical measurements, questionnaire data and biological 
samples including blood, saliva and urine245. A subset of the sample, consisting of 20,000 
participants residing in north east England, were invited for a repeat visit in 2012-2013. 
The data collected by UKBB is available for use by researchers, subject to a successful 
application. This work presented in this thesis is associated with the UKBB project 
numbered 11516.   
2.1.1.1 UKBB non-genetic data   
The phenotype measures collected by UKBB that are specifically relevant to this thesis 
are explored in detail in Chapter 3. These consist of a speech in noise hearing test and 
three hearing-related questionnaire measures that were included in the health and 
lifestyle questionnaire. In Chapter 3, UKBB data is assessed for use as a surrogate 
phenotype measure for ARHI in the population sample, to be used for genetic association 
analysis. A description of the approaches used to study the UKBB speech in noise test 
and hearing- related questionnaire measures are described alongside the results 
presented in Chapter 3. The work in Chapter 3 is predominantly conducted with R 
versions R 3.2.0 – R 3.6.1. 
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Table 2.1 displays the description, instance and Field ID for all non-genetic data fields 
used in this work. For example, where the speech in noise (SIN) test baseline data is 
studied in Chapter 3, (section 3.2) the following two data fields are used: ‘Mean signal-
to-noise ratio (SNR), (left)’ Field ID 4230 and ‘Mean signal-to-noise ratio (SNR), (right)’ 
Field ID 4233. In Chapter 3 these are referred to as ‘SRTL’ and ‘SRTR’ respectively. In 
addition to the baseline data collection, a subset of participants competed the SIN test at 
the Cheadle assessment centre. For all longitudinal or repeat SIN data, the following 
additional data fields are used: ‘Mean signal-to-noise ratio (SNR), (left)’ at the first repeat 
assessment visit (2012-2013) Field ID 4230.1.0 and ‘Mean signal-to-noise ratio (SNR), 
(right)’ at the first repeat assessment visit Field ID 4233.1.0.  
 
2.1.1.2 UKBB phenotype definitions   
The aim of Chapter 3 is to assess various hearing-related data fields in the UKBB data 
resource and establish whether they sufficiently measure ARHI in the cohort, and 
whether they are suitable measures to use as phenotypes for GWAS. Therefore, much of 
Description  Instance Field ID 
Speech-reception-threshold (SRT) estimate (Left) T0 20019.0.0 
Speech-reception-threshold (SRT) estimate (Right) T0 20021.0.0 
Speech-reception-threshold (SRT) estimate (Left) T1 20019.1.0 
Speech-reception-threshold (SRT) estimate (Right) T1 20021.1.0 
Hearing difficulty/problems  T0 2247.0.0 
Hearing difficulty/problems  T1 2247.1.0 
Hearing difficulty/problems with background noise T0 2257.0.0 
Hearing difficulty/problems with background noise T1 2257.1.0 
Hearing aid user  T0 3393.0.0 
Hearing aid user  T1 3393.1.0 
Age when attended assessment centre  T0 21003.0.0 
Age when attended assessment centre T1 21003.1.0 
Sex T0 31.0.0 
Date of attending assessment centre  T0 53.0.0 
Date of attending assessment centre  T1 53.1.0 
UKBB assessment centre  T0  54.0.0 
UKBB assessment centre  T1 54.1.0 
Table 2.1. UK Biobank data fields and data field IDs.  
Description, description of data field, as on UKBB data showcase; Instance, instance of assessment, 
‘T0’ indicates baseline assessment and ‘T1’ indicates the first repeat assessment visit (2012-2013); Field 
ID, UKBB unique field ID. 
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the methodology of how the two phenotypes describe hearing difficulty (HDiff) and 
frequent hearing aid use (HAid) were derived, is presented alongside the results in in 
Chapter 3 and at the beginning of Chapter 4. The HDiff and HAid phenotype definitions 
are the same for the UKBB discovery and UKBB replication samples. Participants are 
assigned case/control status based on their responses to questionnaire measures 
regarding hearing difficulty and hearing aid use. HDiff cases responded “Yes” to both 
questions “Do you have any difficulty with your hearing” (UKBB Field ID 2247) and “Do 
you find it difficult to follow a conversation if there is background noise (such as TV, 
radio, children playing)?”  (UKBB Field ID 2257) HDiff controls were selected if their 
response to both questions was “No”. Participants with any other combination of 
responses are removed. In addition, HDiff controls aged <50 are removed from analysis, 
as were any controls that responded “Yes” to the question “Do you use a hearing aid most 
of the time?”  
HAid cases responded “Yes” to “Do you use a hearing aid most of the time?” (UKBB Field 
ID 3393) and controls responded “No”. If participants answered the questionnaire twice, 
i.e. attended an assessment centre for a repeat visit, the answer at the second time point 
was used in analysis, in order to increase the mean age of the sample. To reduce the 
likelihood of including congenital forms of deafness, participants who selected ‘I am 
completely deaf’ in the UKBB questionnaire were excluded from analysis.  
2.1.1.3 Study sample used for genetic association analysis 
The majority of UKBB participants are of self-reported white ethnicity (94.6%). As the 
largest population group, the northern European sample was therefore used in Chapter 
4 for genetic association analysis as this would provide the greatest statistical power. 
The sample used in the discovery association analysis was selected based on having 
‘white British’ ancestry, a classification derived from both principle component (PC) 
analysis and self-declared ethnicity246. The subset of the UKBB sample that is used in the 
replication meta-analysis is the remaining subset of samples with northern European 
ancestry.  
Maxim Freidin kindly assigned participants into discrete ancestry clusters in the UKBB, 
using the 1st and 2nd PC vectors provided by UKBB. A k-means clustering algorithm was 
applied to generate clusters for each PC. The cluster indices were combined for the PCs 
(1.1, 1.2, …, 5.5), and compared against self-reported ancestry and ancestry groups 
assigned accordingly. If contradictory, the pairwise clusters take precedence over the 
self-report grouping. 
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2.1.1.4 UKBB genotyping and imputation  
The ~500,000 samples in UKBB were genotyped on one of two arrays; 50,000 samples 
were genotyped on the Affymetrix UK BiLEVE Axiom array while the remaining 
~450,000 were genotyped on the Affymetrix UK Biobank Axiom® array. The two arrays 
shared 95% coverage resulting in >800,000 genotyped SNPs. Imputation was carried out 
centrally by UKBB, primarily using the HRC reference panel and IMPUTE2247. SNPs which 
do not feature on this panel were imputed with the UK 10K and 1000G panel. Analysis in 
this study was conducted with version 3 of the UKBB imputed data with 487,409 samples 
imputed and available for analysis following UKBB centrally performed SNP and sample 
quality control (QC).  
In addition to QC performed centrally by UKBB, for this study samples with excess 
heterozygosity, excess relatedness and sex discrepancies were identified (using a QC file 
centrally provided by UKBB) and removed prior to association analysis. Where samples 
show excess heterozygosity and sex discrepancies (with the participant’s self-report 
status), samples are removed as these can signify sample contamination or incorrect 
sample IDs. ‘Excess relatedness’ in this context refers to samples which have more than 
10 putative third-degree relatives in the kinship table. Such samples were removed to 
reduce effects from population stratification within the sample.  
2.1.1.5 Genetic association analysis with the UKBB sample  
For both the discovery and replication association analysis with the UKBB sample 
subsets, a linear mixed-effects model approach to test for association between imputed 
SNP dosages and the two traits. BOLT-LMM v.2.3.2226 was used for the association 
analysis, and corrects for population stratification and family structure mean that it is an 
optimal program to use for a dataset of this size.   
The analysis was also adjusted for age, sex, UKBB genotyping platform and UKBB PCs1-
10. For QC SNPs were filtered based on two thresholds: (1) minor allele frequency (MAF) 
> 0.01; and (2) imputation INFO score > 0.7. By implementing an MAF cut-off of 0.01, the 
likelihood of including participants with forms of congenital deafness was reduced; only 
variants that occur at least in 1/100 participants were detected, which is a higher 
frequency of variants than the frequency of congenital deafness. Individuals with < 98% 
genotype call rate were removed. UKBB PCs 1-10 were included as covariates to further 
reduce effects of population stratification and underlying population or sample structure 
within the dataset. Likewise, the UKBB genotyping platform was included as a covariate 
to reduce the effect of platform-specific genotype calls. Age and sex were included as 
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covariates due to the relationships between these factors and the two phenotypes, as 
explored in Chapter 3. A standard threshold was implemented for SNP INFO score, a 
measure that resembles the imputation certainty of an individual SNP; an INFO score of 
1 signifies complete certainty, while an INFO score of 0 signifies complete uncertainty.   
2.1.2 TwinsUK  
The TwinsUK cohort is used for replication analysis in Chapter 4. TwinsUK is the largest 
adult twin registry in the UK and comprises over 13,000 healthy twin volunteers aged 
18-103. The cohort is predominantly female (>80%) with a balance of monozygotic and 
dizygotic twin pairs248. Collection of data and biological materials commenced in 1992 
and is currently ongoing. During study participation, twins regularly complete health and 
lifestyle questionnaires and attend the study centre for clinical evaluation. 
2.1.2.1 TwinsUK study sample  
TwinsUK was selected as a suitable cohort to use for replication analysis as the study 
volunteers predominantly have Northern European ancestry and data collection 
included relevant questionnaire data on hearing status. From the main cohort, 
participants that were included in the HDiff study were those that had responded to the 
question ‘Do you suffer from hearing loss?’ in one of the TwinsUK study questionnaires. 
Participants that were included in the HAid analysis, were those that had responded to 
the question ‘Do you wear a hearing aid?’ or have confirmed ‘Wearing a hearing aid’. Only 
twins aged >40 were included in the analysis, to be comparable to the UKBB sample.   
2.1.2.2 TwinsUK phenotype definition 
The TwinsUK phenotypes were likewise derived from responses to questions. HDiff 
cases responded either “Yes, diagnosed by doctor or health professional” or “Yes, not 
diagnosed by health professional” to the question “Do you suffer from hearing loss?” 
while controls responded “No”. HAid cases responded or indicated “Yes” to either of “Do 
you wear a hearing aid?” and ‘Wearing a hearing aid’. HAid controls responded “No”.  
As TwinsUK is a longitudinal study, several participants gave responses to the same 
questions on multiple occasions. The most recent response was included in analysis, 
unless the latest response indicated that hearing had improved. In this scenario, the 
participant was excluded. If the individual’s response to any of the questions was the 
same as the previous response or indicates hearing has worsened, the second response 
and response date was taken. If response indicated hearing has improved, the sample 
was removed.  
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2.1.2.3 TwinsUK genotyping and Imputation  
Genotyping of TwinsUK was conducted with the following combination of Illumina 
arrays: HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1M. The imputation 
reference was 1000G Phase3 v5 (GRCh37). 
2.1.2.4 Genetic association analysis with the TwinsUK sample 
Due to the nature and size of the TwinsUK cohort, the association analysis was conducted 
using a linear mixed-effects model regression adjusting for age and sex with GEMMA249. 
GEMMA is a tool that can powerfully account for family structure present in cohorts such 
as TwinsUK. Maxim Freidin kindly ran the association analysis on the TwinsUK cohort 
with the phenotypes that I derived from the TwinsUK questionnaires. 
2.1.3 English Longitudinal Study of Ageing 
2.1.3.1 ELSA study sample  
Data from the ELSA cohort was utilised in the replication analysis presented in Chapter 
4. Similar to TwinsUK, ELSA was selected as a suitable cohort to use for replication 
analysis as the study volunteers predominantly have Northern European ancestry and 
data collection included relevant questionnaire data on hearing status. ELSA is a 
longitudinal study, consisting of around 12,000 respondents from the Health Survey for 
England250. The study began recruitment in 2002 and participants have been followed-
up every two years. Eight waves of data collection have been completed since 2002. The 
sample consists of men and women residing in the UK and that are ≥50 years of age.  
2.1.3.2 ELSA phenotype definition  
For the ELSA sample, phenotypes were derived from responses to questionnaire 
measures collected during study Wave 7. This wave was selected as the questions best 
matched those collected on the UKBB sample, and it provides the largest sample with a 
consistent questionnaire and with genotype data.  
The ELSA HDiff phenotype was derived using responses from two questions; “Do you 
ever have any difficulties with your hearing?” and “Do you find it difficult to follow a 
conversation if there is background noise, such as TV, radio or children playing (using a 
hearing aid as usual)?” Cases were defined as participants who responded “Yes” to both 
questions, and controls who responded “No” to both questions. As in the UKBB analysis, 
controls who reported hearing aid use or age <50 were removed, as were any cochlear 
implant users in the case or control samples. The HAid phenotype was derived using the 
question “Whether ever wears a hearing aid”; cases responded “Yes most of the time”, or 
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“Yes some of the time” while controls responded “No”. During ELSA data processing, age 
was capped at 90 years, and thus individuals aged > 90 were reported to be 90 years of 
age. 
2.1.3.3 ELSA genotyping and Imputation 
ELSA samples were genotyped at UCL Genomics in two batches using the Illumina 
HumanOmni 2.5M platform. Imputation was carried out centrally by ELSA with 
IMPUTE2, using the 1000 Genomes phase I data set 
(https://www.elsaproject.ac.uk/uploads/elsa/elsa_analysis.pdf). Prior to association 
analysis, centrally at ELSA before data release, sample relatedness was estimated in 
PLINK 1.934 and subsequently one of each pair of related individuals was excluded. 
2.1.3.4 Genetic association analysis with the ELSA sample  
The ELSA sample sizes for HDiff and HAid analysis are <5,000. BOLT-LMM authors advise 
alternative methods for samples that are n<5,000 due to BOLT-LMM being unreliable 
when used on samples of this size (https://data.broadinstitute.org/alkesgroup/BOLT-
LMM/). Therefore, PLINK2 was used to carry out logistic regression to test for 
association in the ELSA sample, adjusting for age and sex, as in the UKBB analysis.    
2.2 Post-GWAS statistical analysis 
2.2.1 Linkage Disequilibrium Score Regression  
A common quality control step post-GWAS is to calculate the genomic inflation factor 
(λGC) which estimates the inflation of the test statistics. Inflation can be a sign of 
confounding in the analysis, caused by factors such as cryptic relatedness or population 
stratification present in the sample. However, in more recent GWAS that use large 
sample sizes to study polygenic traits, the λGC cannot distinguish between the inflation 
caused by these confounding factors and inflation that is caused by polygenic effects. In 
these cases, alternative methods can be used to estimate the proportion of the observed 
inflation in the χ2 statistic that the intercept attributes to factors other than polygenic 
effects, such as confounding from cryptic relatedness. In Chapter 4, the univariate linkage 
disequilibrium score regression (LDSC) method is applied for this purpose, which 
regresses SNP LD scores against the SNP test statistics. The online tool used for this 
analysis is described in detail elsewhere251,252.  
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2.2.2 Conditional and Joint analysis 
As noted above to linkage disequilibrium (LD), SNPs that are in LD with a pathogenic 
variant will have inflated summary statistics. This means that it can be difficult to 
determine whether there are secondary associations at a region of association, or 
whether the test statistics of SNPs within a region represent one signal and are inflated 
because they are in LD with the functional variant. Methods have been devised which can 
determine whether there are secondary associations at a locus, and whether the lead 
SNP (SNP with the lowest P-value in the association analysis) captures the effect of the 
association at the locus. Conditional and joint SNP analysis was used in Chapter 4 to 
identify independent signals within the highly associated regions, using GCTA-COJO232. 
This analysis requires the LD reference sample, which was obtained by random selection 
of 10,000 individuals from the UKBB cohort with White British ancestry. The reference 
sample size of n=10,000 was selected to maximise power based on previous data 
simulations232. 
2.2.3 Heritability calculation  
SNP heritability (h2g) was estimated independently for the HDiff and HAid traits. The 
estimate was calculated with BOLT-LMM using restricted maximum likelihood variance 
analysis. As the two traits are not quantitative measures, the estimates were recalculated 
to the liability scale. The prevalence is required in order to re-calculate the estimate.  The 
trait prevalence specified in this calculation was the case prevalence in the analysed 
sample, and therefore was 0.35 for HDiff and 0.052 for HAid.  
2.2.4 Replication association analysis  
Independent replication of the association was conducted via a meta-analysis of the non-
British White UKBB subsample, the TwinsUK sample and the ELSA sample. A meta-
analysis was conducted to increase the statistical power of the replication analysis by 
increasing the total sample size.  
2.2.4.1 Association analysis and meta-analysis 
Due to the different nature of the three samples, three different methods were used to 
conduct association analyses, as discussed in the section above. Firstly, PLINK2.0 logistic 
regression was used to test for association between the HDiff and HAid phenotypes and 
genetic data in the ELSA sample. PLINK2.0 was selected as the samples are n<5,000 and 
therefore not suitable for analysis under the BOLT-LMM method. Secondly, association 
analysis on the TwinsUK HDiff and HAid samples was performed with a linear mixed-
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effects model regression with GEMMA. This method is suitable for the relatively small 
size of the sample, and the relatedness present within the sample. Lastly, BOLT-LMM was 
used to test for association with the candidate loci in the UKBB white non-British 
replication sample, as described for the discovery association analysis.  
The lead SNPs identified with conditional analysis on the UKBB discovery sample 
association analysis were tested for association with HDiff and HAid phenotypes in a 
fixed-effect inverse-variance weighted meta-analysis using METAL253 version 2011-03-
25, with the White non-British UKBB, ELSA and TwinsUK samples. BOLT-LMM does not 
report analysed sample size per SNP, so to obtain the weight of the UKBB replication 
sample per SNP, the sample size reported is from the sample sizes from PLINK linear 
regression. Bonferroni significance thresholds were calculated for the two traits as 
0.05/41, p=0.0012 for HDiff and 0.05/7, p=0.00714 for HAid based on the number of 
statistically significant independent associations in the discovery.  
2.2.4.2 Replication study power calculations 
A power calculation was performed to estimate the power of the meta-analysis 
replication for each independent locus analysed in the replication analysis at nominal 
significance (p<0.05) for both traits and at Bonferroni-corrected significance. (p<0.0012 
for HDiff and p<0.00714 for HAid).  
The following R code was applied: 
           chi<-qchisq(1-alpha/nl,1) # χ2 for significance threshold for the number of loci to 
replicate (nl) 
           t2<-(b/se)^2 # test-statistic for a SNP in discovery; b and se are effect size and 
corresponding standard error 
           q2<-t2/nd # proportion of variance explained by a SNP; nd is sample size in 
discovery 
           ncp<-nr*q2/(1-q2) # non-centrality parameter; nr is sample size in replication 
           pchisq(chi,1,ncp=ncp,lower.tail = F) # power of replication 
nl=1 was used to estimate the power to replicate at nominal significance; nl=7 and nl=41 
were used to estimate power to replicate SNPs at a Bonferroni-corrected significance 
threshold for HAid and HDiff respectively. 
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2.3 In silico functional analysis  
2.3.1 Gene-set analysis  
Gene-set analysis was one of the post-GWAS methods used in this work. The results are 
presented in Chapter 4. The goal of gene-set analysis is to provide functional context for 
multiple genetic associations and can be performed using multiple methods and 
datasets. In this work, gene-set analysis was performed via the online tool FUMA233. 
There are two distinct parts to the analysis: SNP2GENE and GENE2FUNC. SNP2GENE 
assigns lead SNPs based on the LD structures of associated regions and assigns lead SNPs 
to genes within a distance of 10kb based on positional mapping, eQTL information and 
3D chromatin interactions. The degree of association is calculated for each gene within 
10kb of a lead SNP.  
GENE2FUNC (gene enrichment analysis) is then performed by testing whether any genes 
are overrepresented in specified pre-defined gene sets. The gene sets and gene ontology 
(GO) terms that are used in this analysis to classify the gene sets are from MSigDB v5.2 
(http://software.broadinstitute.org/gsea/index.jsp). GO annotations include three groups: 
molecular function, cellular component and biological process. 
FUMA233 was selected as an appropriate tool as the two-step approach permits an input 
of summary statistics from association analysis, rather than a pre-defined gene list. For 
gene-set analysis, it deploys MAGMA234, which has been shown to be statistically robust 
by comparison to alternative methods254 and draws on the comprehensive MSigDB 
database (as noted above, v5.2 was used for these analyses). As of yet, there are no tools 
that can perform this analysis on data derived from cochlear tissue samples, as would be 
relevant for this study. Further, the same tool was used by colleagues and collaborators 
who were studying the shared genetic risk of Alzheimer’s and ARHI. Obtaining a 
comparable output was advantageous when comparing enriched gene sets and for 
identifying common biological processes.   
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Figure 2.1. Flow diagram of the FUMA 
method for gene-set analysis 
 
2.3.2 Genetic correlation analysis  
Genetic correlation analysis was performed between the HDiff trait and 765 traits that 
have publicly available data for correlation analysis on LD hub251,255. Two traits that used 
similar phenotypes to that used in this study were removed; the summary statistics 
contributed by the Neale lab which utilised two self-report hearing traits from UKBB 
data. Summary statistics were only included in the input to LD hub where the SNPs were 
included in the recommended list (SNPs imputed to Hapmap 3 and removal of the MHC 
region on CHR6 26MB-34MB).  A conservative significance threshold was calculated with 
a multiple-test correction (0.05/764, p = 6.5E-5). Due to the large number of significant 
findings, the results were further filtered based on the correlation size (rg). Traits with 
an rg >0.3 or < -0.3 were categorised into five groups based on trait symptom similarities: 
(1) breathing difficulties (2) health report/subjective wellbeing (3) hearing (4) low 
mood/depression and (5) pain.  
 
2.4 Prioritisation of gene candidates for functional follow-up 
Multiple methods were used in order to prioritise gene candidates for functional follow 
up analysis presented in Chapter 5. 
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2.4.1 Visualisation of genome regions of interest and LD calculations 
Locus plots generated with LocusZoom256 are useful for visualising SNP associations in 
the context of the genomic region at each lead SNP. It ought to be noted that a reference 
panel from the UK Biobank population (used in the genome-wide association analysis) 
is not available for this tool. It instead uses LD reference data from the hg/1000 Genomes 
Nov 2014 which is from the sample population group (EUR) and genome build (hg19). 
Similarly, LDlink257 which was used to determine the LD between significant SNPs at loci 
in close proximity to the lead SNP, LDlink tool uses 1000 Genomes Project as reference. 
Here the British in England and Scotland (GBR) population subset from the 1000G 
project data were selected. 
2.4.2 Predicating effect of variants on protein function using in-silico 
analysis  
In chapters 4 and 5, VEP was used to interpret the results of the joint and conditional 
analysis. For chapter 4, lead SNPs were mapped to the nearest protein coding genes with 
a maximum distance of 10kb using VEP258 GRCh37.  In chapter 5, the genomic context of 
the lead SNPs was determined using VEP; whether the SNP was in a gene transcript, the 
presence and distance from gene transcripts and the predicted consequence of the 
variant.  The predicted pathogenicity of missense variants was calculated with the Rare 
Exome Variant Ensemble Learner259. 
2.4.3 Data resources used in chapter 5 to gather data relating to primary 
gene candidates 
In chapter 5, the criteria used to define a ‘known’ hearing gene that had a previous link 
to hearing impairment at the time of analysis was evidence of a link with the PubMed 
search terms ‘gene name, hearing’ and ‘gene name, deafness’ or when cross-referenced 
with the list of genes reported to underlie deafness in either humans or mice (2018)260. 
Genes were cross-referenced with the Jackson laboratory to determine availability of 
mouse models and hearing phenotype observations (https://www.jax.org/). 
The gEAR database (https://umgear.org/) was also utilised to determine the expression 
level of candidate genes in mouse cochlear tissue. Data from an RNA-seq screen of 
cochlear hair cells and non-sensory cells in P0 mice was collected and used as evidence 
for gene prioritisation in chapter 5261. The data is presented in reads per kilo base per 
million mapped reads (RPKM). 
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2.5 Protein localisation analysis  
Adult mouse cochlear tissue samples were prepared and stained with antibodies against 
genes of interest.  
2.5.1 C57BL/6J mice 
Mouse cochlear explants were obtained from C57BL/6J mice for use in 
Immunohistochemistry. The results are presented in Chapter 5. The C57BL/6J mouse 
strain are genetically predisposed to develop sensorineural HL. Mice were euthanised at 
P28-P30 in order to study the location of protein targets in an adult, fully developed 
auditory system, but before strain-specific deterioration of auditory structures are 
observed. The Cdh23ahl allele in the C57BL/6J strain causes an accelerated HL, with a 
progressive loss of inner and outer HCs and loss of the SG cells at the basal turn of the 
cochlea by seven months of age238,241, which progresses to a profound hearing loss or 
deafness at 18-24 months of age.  
Sensory IHC loss and OHC loss is observed at the base of the cochlea in C57BL/6J mice 
as early as 3 months of age. As the degeneration progresses, OHC loss is observed 
throughout the cochlea at 26 months. At this age, a complete loss of IHCs can be observed 
at the base of the cochlea, while a 20% loss of IHCs is observed at the apex of the 
cochlea262. For these reasons, the mice used in this study were aged ~1 month (P28-P30). 
P28-P30 was selected because if using C57BL/6J mice at an older age, the loss of HC and 
SG cells would be occurring, and thus gene expression in these structures cannot be 
observed.  
2.5.2 Mouse cochlear tissue preparation 
The C57BL/6J mice used in this work were bred in an in-house facility. Mice were 
euthanised according to Schedule 1 procedures as described in United Kingdom 
legislation outlined in the Animals (Scientific Procedures) Act 1986.  
The dissected inner ears were fixed in 4% paraformaldehyde diluted in phosphate 
buffered saline (PBS) for 1 hour at room temperature before being washed several times 
in PBS (3x 10 minutes at room temperature). The inner ear samples were then 
decalcified in 10% EDTA overnight at 4oC before cochlear and vestibular system 
separation. Cochlea were mounted in 4% low-melting point agarose and sectioned on a 
Vibratome (1000 plus system, Intracel) at 200-µm intervals.  
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2.5.3 Immunofluorescence  
The immunofluorescence protocol used in this work is summarised in Figure 2.2 and in 
the two sections below, 2.5.3.1 and 2.5.3.2. 
2.5.3.1 Antibodies used to test for protein localisation 
Antibodies used to identify protein localisation in the organ of Corti were: anti-nidogen-
2 (NID2) at a 1:750 dilution (Ab14513, Abcam), anti-clarin-2 (CLRN2) at 1:1000 
(HPA042407, Atlas Antibodies) and anti-rho guanine nucleotide exchange factor 28 
(ARHGEF28) at 1:1000 (HPA037602, Atlas Antibodies). All were detected using of an 
isotype-specific Alexa Fluor 488 goat anti-rabbit secondary antibody (Santa Cruz 
Biotechnology). All antibodies were tested at various dilutions, in organ of Corti cell line 
number 2 (OC2) cells prior to tissue staining, in order to test and optimize the protocol. 
2.5.3.2 Immunofluorescence and sample imaging 
Antibodies were diluted in a goat blocking solution (4% triton, 8% goat serum, 1g BSA, 
50ml PHEM buffer) and sections were stained with primary antibodies overnight at 4oC. 
Following PBS washes, sections were incubated with the secondary antibody at 1:1000 
in darkness at room temperature for 2 hours. Phalloidin-Atto 647N to f-actin (Sigma-
Aldrich, Gillingham, UK) and DAPI were added to the secondary antibody incubations at 
1:1000 to stain hair cell stereocilia and DNA respectively. The samples were imaged 
using a Zeiss LSM 880 Airyscan 20x and 40x objectives.  
 
Figure 2.2. Diagram to summarise the immunohistochemistry method used in 
Chapter 5. 
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Chapter 3 - Defining a phenotype for association 
analysis  
3.1 Introduction  
As discussed in chapter 1, there is no standardised method with which to 
comprehensively classify ARHI in population studies. In order to conduct a valid GWAS 
however, the trait of interest ought to be unambiguously defined in the population. The 
aim of this chapter is therefore to identify a phenotype that best represents common, 
adult hearing impairment in the UKBB cohort and that is suitable to use in a GWAS. 
Some traits are quantitative or qualitative by nature, while others are defined as such by 
the criteria used for measurement. Most traits or conditions that are quantitative are 
however classified into qualitative categories based on defined thresholds within the 
quantitative range. This classification aids diagnoses, treatments and epidemiological 
analysis. For example, BMI is a quantitative trait, but patients are subset into qualitative 
categories for clinical use (underweight, healthy, overweight, obese) based on pre-
defined thresholds (<18.5, 18.5-24.9, 25-29.9, 30-39.9)263.  
In epidemiological studies, the prevalence of a condition is often reported, which 
requires the sample to be divided into ‘affected’ or ‘unaffected’ groups. In order to limit 
any bias that may be introduced by doing so, statistical definitions are commonly applied. 
A standard for defining a ‘normal’ (unaffected group) in a sample, is the selection of 
datapoints that are within 2 standard deviations from the sample mean264. However, this 
does not always reflect trait-specific clinical definitions such as symptom frequency. In 
these cases, arbitrary definitions of ‘normal’ are set, based on parameters from clinical, 
prognostic or operational definitions.  
As far as possible, a definition for ‘affected’ cases in a population sample must be stable, 
unambiguous and precise. Likewise, bias must be minimalised in the definition and 
subsequent selection of ‘unaffected’ controls. To achieve this, where possible, controls 
are selected from the sample population sample as cases, will have been exposed to the 
same risk factors, and have had these factors measured in the same manner as the case 
sample265.  
As discussed in chapter 1, ARHI is a sensorineural, bilateral hearing loss that begins in 
the high frequencies and progresses with increasing age266. In the context of a GWAS on 
adult hearing loss, a phenotype would therefore depict a common adult hearing loss that 
progresses with increasing age. Results from PTA tests are commonly used where 
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available in population studies, as this is a clinical method used to diagnose a hearing 
impairment. The type of hearing loss that a patient presents with can be implied by the 
shape of the audiogram from the PTA test. A right-hand sloping audiogram for both ears 
signifies sensorineural, bilateral hearing loss; as expected in ARHI.  
However, as discussed previously, while PTA testing is the standard and most widely 
used hearing test, it does not measure an individual’s ability of speech perception (and 
thus possible hidden hearing loss), a common symptom of ARHI. PTA testing is also 
impractical to conduct on a large scale such as that necessary for genetic association 
analysis; the test requires specialist equipment, a quiet environment, a trained 
professional and can take up to thirty minutes. An alternative test, the speech in noise 
(SIN) test187, can also be used to classify an individual’s hearing status; it measures the 
subject’s ability to correctly decipher speech in the presence of varying levels of 
background noise28,185. SIN testing therefore assesses a common symptom of ARHI 
(deciphering speech in the presence of background noise) and can be completed in the 
absence of a trained professional either online or on the telephone. Consequently, this 
test may be a more appropriate measure of ARHI in the general population and a more 
practical method for gathering phenotype data on the scale required for genetic 
association analysis. 
Lastly, self-report questionnaire measures are increasingly used to define phenotypes 
for use in GWAS. Questionnaires permit large-scale data collection and can result in both 
quantitative and qualitative phenotype definitions depending on whether the question 
responses are graded or binary. Questionnaires can assess numerous details of a trait 
such as severity and persistence, which can be combined to derive phenotypes that 
capture details from more than one questionnaire measure alone. These are also not 
without limitations however such as the incorporation of subjective or emotional 
responses.  
Of the previous eight GWAS conducted on ARHI, seven used phenotypes derived from 
PTA thresholds, as discussed in chapter 1. Individual studies have assessed hearing at 
different frequency ranges and used either a z-score or PC analysis to derive the 
phenotype for analysis38,92,107,109,111,112. Collectively, three loci were significantly 
associated with ARHI-related phenotypes in these studies. The most recent ARHI GWAS 
study used electronic health records along with self-report measures and SRT scores113 
rather than a PTA-derived phenotype. The size of this study was a magnitude larger than 
any previous ARHI GWAS and doubled the number of significant associations found in a 
single study; two significant ARHI-associated loci were identified and replicated. The use 
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of electronic health records and questionnaires to define the phenotype permitted the 
increase in sample size and thus increase in study power. The main limitation of ARHI 
GWAS to date has been the relatively small sample sizes used for analysis; globally there 
are few cohorts that have hearing data, genetic data and are of a sufficient size for a 
highly powered association analysis.  
The work presented in this chapter makes use of data collected in the UKBB cohort245 
(summarised in - Methods, 2.1.1). Upon attendance at a UKBB assessment centre, 
participants donated biological samples for genotyping, completed lifestyle 
questionnaires, online tasks and had standard physical measurements taken. The 
collected data comprises multiple hearing-realted data fields, including those derived 
from the UKBB SIN hearing test which participants performed on a touch screen monitor 
while at an assessment centre. Secondly, hearing-related questionnaire measures were 
part of the health and lifestyle questionnaire that was also completed at the assessment 
centre on the touch screen monitors. In total, data were collected at 23 UKBB assessment 
centres across the UK, 21 of which were open during a period within the initial 
recruitment phase from 2007-2010. Cheadle and Newcastle assessment centres hosted 
the imaging and repeat assessments respectively (2012-13), see - Methods, 2.1.1.  
Currently, no single measure can encompass whether an individual’s hearing 
impairment is a sensorineural, bilateral hearing loss that begins in the high frequencies 
and is progressive with age266. Therefore, it is a challenge to comprehensively assess the 
prevalence of ARHI in a population sample, meaning that in this chapter, when assessing 
the UKBB hearing data for use as a phenotype that is an indicator of ARHI there are 
several limitations to consider. The SIN test and questionnaires do not assess the audio 
frequency of a participant’s hearing loss. Secondly, the majority of the data is taken at 
one time point and so the progressive nature of all individuals’ hearing abilities cannot 
be assessed. With the available UKBB data therefore, the phenotype that ‘best’ describes 
ARHI will not be based on these factors.   
As noted, any bias needs to be limited when defining a trait and its prevalence in a 
population sample264,265. By using the UKBB, some of these potential sources are 
eliminated already; cases and controls will be selected from the same sample (the whole 
UKBB sample) and the assessment of hearing impairment is the same for all individuals. 
In addition, participants were not selected to take part in the study based on hearing-
related factors; unselective recruitment was conducted.  
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Several studies have been conducted using the UKBB hearing-related data fields since 
the initial data release in 2014. The first study presented a ‘snapshot’ of the data; the 
report stated that 1/10 participants experience a ‘substantial’ hearing impairment based 
on the results from the SIN test and highlighted the underutilization of hearing aids123. 
Subsequent publications have studied the hearing data in relation to other traits such as 
vision267, cognition122 and depression195 along with factors such as socio-economic 
status268, ethnicity123 and education267. The initial report on hearing-related phenotypes 
in the UKBB used the hearing test score (SRT) for the best-performing ear to classify 
participants; ‘normal hearing’ (SRT < -5.5dB), ‘insufficient hearing’ (-5.5dB < SRT < -
3.5dB) and ‘poor hearing’ (SRT > -3.5dB). Unexpectedly, this study reported that males 
had a slightly reduced risk of ‘insufficient’ hearing impairment and there was no 
difference in risk for male or females in the ‘poor’ hearing category. Authors suggest that 
this either indicates that the increased male susceptibility to hearing loss reported in 
some studies is due to modifiable risk factors, or that this particular SIN test is not 
sensitive enough; speech recognition may be unaffected due to the high redundancy of 
the speech signal123.  
A later study on the relationship between functional hearing (SRT score) and four UKBB 
cognitive measures reported an unexpectedly high proportion of 40-50-year-olds within 
the UKBB sample with ‘normal’ hearing122. This study also refers to an internet-based 
SIN test which has since been developed that has a greater sensitivity to high frequency 
hearing loss than the UKBB SIN269,270. While some of the same UKBB data fields will be 
assessed, the analyses summarised above will not be directly replicated or expanded on 
in the work presented in this thesis. Here, the aim is to (1) identify a viable, reliable 
phenotype that is a suitable indicator of ARHI within the cohort and (2) that can be used 
as a phenotype for genetic association analysis. 
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3.2 Results 
In the following sections the UKBB SIN test scores (SRT scores) and hearing 
questionnaire responses are analysed as potential surrogate phenotypes for ARHI 
genetic association analysis.  
3.2.1 SIN test data in the UKBB sample 
SRT scores have not previously been used as a phenotype measure for association 
analysis and the UKBB speech in noise test is the first speech in noise test to be used on 
a population of this size. Therefore, prior to conducting association analysis, various 
methods were used to assess the validity of SRT as a surrogate phenotype for ARHI, the 
reliability of the data and, subsequently, its’ suitability for use as a phenotype in 
association analysis.  
The UKBB SIN test procedure  
The UKBB SIN test is a form of the ‘Digit Triplet Test’. The UKBB version was adapted for 
use from the original Smits Digit Triplet Test188 that is introduced in chapter 1, section 
1.3.4. Adaptations were made specifically for the UKBB study and are based on work 
conduced at the University of Southampton194 and are described in detail by Hall, 2006 
which can be accessed via http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=158561. It was 
then subsequently tested on a normative sample of 20 volunteers with normal hearing, 
aged 18-29 at the time of assessment 
(http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=138440).  
At the UKBB assessment centres, participants were provided with a touch screen 
monitor and Sennheiser HD-25 headphones with which to complete the SIN test. 
Participants completed the SIN test twice; once for each ear. Participants with even study 
ID numbers performed the test on their left ear first and right ear second, and vice versa 
for those with odd study IDs.  
The UKBB protocol for the SIN test can be accessed via 
http://biobank.ctsu.ox.ac.uk/crystal/docs/Hearing.pdf. Briefly, volunteers were asked to set 
a comfortable volume for each ear prior to beginning the test. They were then played a 
set of three digits, E.g. ‘1, 2, 3’ and were prompted to enter the digits that they heard, 
using the touch screen monitor. The test follows an adaptive procedure; the following 
triplet is played with either an increased or decreased level of background noise, 
depending on whether the participant correctly or incorrectly identified the digit triplet. 
After the participant has completed 15 trials of triplets for the first ear, the test for the 
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second ear begins. The volunteers were asked to set a comfortable volume for the second 
ear, and 15 trials of triplets were then played. 
For each of the 15 trials, the participant will have a ‘speech to noise ratio’. This describes 
the noise level ratio between the digits played and the background noise. The ratio of 
speech to noise at the first trial was either -2dB or +2dB. Originally, all participants began 
the test with a speech to noise ratio of -2dB at the first trial. Part-way through the 
recruitment period, the protocol of the test was changed such that the speech to noise 
ratio of the first trial is instead +2dB so that so that it was easier for individuals that are 
hard of hearing to begin the test. It is stated that the protocol was implemented from 
August 2009. 
Upon completion of the test, each participant will have 15 SNR values for each ear (a 
speech to noise ratio for each of the 15 trials). By convention, the final score for the 
hearing test is the mean of the SNR values for the final 8 trials and is called the ‘Speech 
reception threshold’ (SRT). Each participant thus has one SRT score for each ear. The 
‘highest’ possible score for this test is -12dB (very good hearing) and the ‘lowest’ possible 
score is +8dB (very poor hearing). Also by convention, the ‘best ear’ SRT score per 
participant is used for analysis. This minimises the possibility of observing effects due to 
significant environmental exposures (such as past trauma or infection) that have 
affected the function of just one ear. Thus, for each individual, the ‘best ear’ SRT score 
(SRTB) was the lowest score for either the right SRT, (SRTR) or left SRT (SRTL), UKBB data 
fields as listed in - Methods 2.1.1.1. The SRTR and SRTL scores are however useful 
measures to assess the prevalence of bilateral hearing deterioration in the sample and, 
or the reliability of the measure within each participant. 
SIN test score Definition  
SNR Speech to noise ratio 
This describes the noise level ratio between the digits 
played and the background noise Each individual has 30 
SNR values. 15 for each ear, for each trial in the SIN test.  
SRTL 
Speech reception threshold, 
left ear 
Mean value of the final 8 SNR values for the left ear. Each 
participant has one SRTL 
SRTR 
Speech reception threshold, 
right ear 
Mean value of the final 8 SNR values for the right ear. 
Each participant has one SRTR 
SRTB 
‘Best’ Speech reception 
threshold 
For each individual, the SRTL or SRTR is used as the SRTB 
value, depending on which had the best score. (-12 best 
possible score, +8 worst possible score) 
 
Table 3.1. Definitions for the acronyms used to describe types of SIN test scores. The 
UKBB data field IDs corresponding to these scores are listed in Section 2.1.1.1. 
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Assessing the normality of the SRT distribution for a quantitative distribution 
The SRT score is a quantitative measure. Genetic association analysis of quantitative 
measures is performed using a linear mixed models approach and so is constrained by 
the assumption that a quantitative trait is normally distributed. Therefore, to assess 
whether the raw SRT scores were a suitable phenotype for association analysis, the SRT 
scores for each participant were plotted in Figure 3.1 and assessed for normality 
(distribution skewness, Table 3.2). It is not possible to perform the standard Shapiro-
Wilk test as it is not suitable for data samples with n>5000 (the greater the number of 
data samples used in the calculation, the greater the chance of a rejection of the null 
hypothesis). In the absence of a Shapiro-Wilk test, the normality of the data can be 
estimated based on the distribution skewness. Skewness that is greater than twice the 
standard error of the skewness signifies a non-normal distribution. 
A distribution with a skew >1 is determined ‘highly skewed’; all three of the SRTR/L/B 
distributions are highly skewed (Table 3.2) and can be visualised in the histograms in 
Figure 3.1, which display the distributions of SRTL, SRTR and SRTB for the whole sample. 
Poorer hearing is represented by greater SRT scores i.e. positive SRT scores. All three 
distributions are non-normal; the skewness is greater than twice the standard error of 
the skewness (Table 3.2). As raw SRTB distribution is highly skewed (>1) it is not a 
suitable quantitative measure for genetic association analysis in the current format. In 
order to use the SRT scores for association analysis, a strong transformation would be 
required, or categorisation of scores to create a binary trait of cases and controls.  
 
 
Figure 3.1. SRT distributions for the left ear, right ear and 'best' ear SRT scores in the 
UKBB sample.  
Lower scores signify greater hearing ability; an SRT score of +8 is the 'worst' possible score on the test and 
signifies a very poor hearing ability. A score of -12 signifies a very good hearing ability. All three distributions 
are highly skewed to the right; skewness >1 is classified ‘highly’ skewed. Left ear SRT distribution, SRTL; 
Right ear SRT distribution, SRTR; ‘Best ear’ SRT distribution, SRTB. 
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Defining SRT thresholds to create a qualitative phenotype  
Previous studies have used SRT score thresholds to categorise participant hearing ability 
as either good, insufficient or poor and are calculated such that ‘The ‘insufficient’ 
category is performance lower than -2 standard deviations with respect to the normative 
sample while the ‘poor’ category is defined by a further 2 dB step’123,188. This follows a 
standard statistical classification of ‘normal’ data points within a sample being within 2 
standard deviations of the sample mean264. Here the ‘normal’ proportion is denoted 
‘good’ hearing ability.  
Figure 3.2 displays a previous example of this for a different SIN test in a different 
sample. It displays a distribution of SRTTn scores (equivalent to the UKBB SRT scores) 
from the Smits Digit Triplet Test88 marked with classifications of hearing ability. The 
Smits test is the test that the UKBB SIN was adapted from. SRTTn scores from 39,968 
participants that completed the Dutch telephone SIN test are displayed. Based on these 
 
N 
Mean SRT 
(sd) 
Median 
SRT 
Skewness SE IQR SRT Range 
SRTL 163296 -6.59 (2.10) -7 2.39 3.67E-05 2.5 -11.25 +8 
SRTR 163237 -6.55 (2.11) -7 2.36 3.68E-05 2.5 -11.5 +8 
SRTB 160942 -7.36 (1.70) -7.5 2.75 3.75E-05 2 -11.25 +8 
Table 3.2. Summary of SRT scores in the UKBB sample.  
SRTL; SRT scores for the left ear, SRTR; SRT scores for the right ear, SRTB; SRT scores for the ‘best’ ear, 
calculated as the lowest SRT score for each individual. Skewness, distribution skewness; SE, standard error 
of the distribution skewness; IQR, interquartile range of the SRT score distribution. All three distributions are 
highly skewed to the right.  
 
 
Figure 3.2. SRT distribution from Smits 200588 in an elderly Dutch sample.  
This figure displays a ‘histogram and a cumulative histogram of SRTTns in 0.2-dB intervals. Vertical dotted 
lines depict borders between the different test results in terms of good, insufficient, and poor.’ The SRTTn 
measure for this Smits Digit Triplet telephone screening test is equivalent to the UKBB SIN test SRT. The 
sample includes individuals aged >18, with 75% of the sample >44 years of age.  Marked on the histogram 
are the classifications of hearing ability determined by SRT score thresholds; good SRT <4.1 dB, insufficient 
SRT -4.1dB <= -1.4dB and poor SRT > -1.4dB.  
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classifications, 67% of the Smits sample have ‘good’ hearing, 26% have ‘insufficient’ 
hearing and 6% have ‘poor’ hearing.  
This method can also be used to categorise the UKBB SRT data. A normative sample 
consisting of 20 volunteers (aged 18-29 years with normal hearing) was used to derive 
classification thresholds devised for the UKBB data; ‘normal hearing’ SRT < -5.5dB, 
‘insufficient’ hearing SRT -5.5dB to -3.5dB and ‘poor’ hearing SRT > -3.5dB. Figure 3.3 
displays the distribution of the SRTB scores from the UKBB sample, with the UKBB 
classification thresholds123,271 overlaid in purple. According to the UKBB classification 
thresholds, 11.92% of the UKBB SRTB scores are here ‘insufficient’ or ‘poor’. Based on 
these classifications, the prevalence of insufficient or poor hearing in the UKBB sample 
is <12% (Figure 3.3). This is in contrast to the Smits sample, where 32% had poor or 
insufficient hearing based on the corresponding thresholds (Figure 3.2).   
An explanation for the difference in prevalence (12% in UKBB and 32% in the Smits 
sample) is that different SIN tests vary; as discussed previously the UKBB test has been 
adapted from the original Smits Digit Triplet Test. For example, the Smits Digit Triplet 
test was conducted via telephone in a different language to the UKBB test, and different 
adaptive procedures are used for each of the two tests.  
 
Figure 3.3. Histogram presenting the SRTB distribution for the UKBB sample. 
The histogram distribution is the same as presented for SRTB in Figure 3.1. Classifications of hearing 
ability according to the UKBB classification thresholds Dawes 2014123are marked below the histogram. 
The proportions of the UKBB sample that falls into each of these categories are represented by 
percentage values in the bar shaded purple. Vertical purple lines indicate these proportions on the 
histogram distribution.  
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The population samples also vary, making comparisons between the studies difficult. 
The age distributions in the Smits and the UKBB samples differ; the Smits sample consists 
of participants aged >40, of which 75% are >44 years old. The UKBB sample participants 
are aged 40-69. Taking this into account, we may expect the prevalence to be lower in 
the Smits sample as there are younger participants in this sample, yet this is the opposite 
of what is observed with these threshold categories. This indicates that the UKBB SIN 
test is either not as sensitive as the Smits Digit Triplet test, that the prevalence of hearing 
impairment is genuinely 20% greater in the Smits sample, or that classification method 
used, incorrectly defines the true prevalence for at least one of the two samples.  
3.2.1.1 Is SRTB a valid indicator for ARHI in the UKBB sample? 
As the prevalence of hearing impairment in the UKBB sample is lower than expected, 
analysis was conducted to assess whether the SRT accurately measures ARHI in the 
sample (a progressive hearing loss with increasing age, higher prevalence in male 
subjects and presents as a bilateral HL266). The sample was studied to determine whether 
the prevalence of poor SRT scores increases with age and whether the test scores 
indicate a bilateral hearing deterioration. 
The relationship between SRTB and age and sex 
To assess the relationship between the SRT score and age, a Spearman's rank correlation 
between SRTB and age in years was calculated; r2s = 0.238, p<2.2e-16 (Figure 3.4). The 
correlations between age in years and each ear individually were 0.216 (SRTL) and 0.217 
(SRTR).  This indicates that there is a positive correlation with age; as age in years 
increases the SRT score increases, yet the correlation is modest; 0.238, Figure 3.4. A 
study conducted in 2017 on a group of participants aged >50 years observed correlations 
of age r2=0.317 for men and r2=0.354 for women, where hearing ability was tested with 
PTA using the WHO classification thresholds96.  
As these previous correlations were based on PTA data, they are not directly comparable 
to the UKBB SIN data. No previous study has reported an SRT score correlation with age. 
Therefore, the SRT scores were plotted by age group and sex, alongside data from the 
Smits Digit Triplet test (Figure 3.5). 
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Figure 3.4. Scatter plot of SRTB scores (dB) by participant 
age (years). 
The correlation of SRTB and age is marked on the graph; r2s = 0.238, 
p<2.2e-16. The regression line is marked in blue. 
 
 
 
 
Figure 3.5 is presented as a line graph that displays the mean SRT scores between 
different age groups for the two study samples, split by sex. The red and green lines on 
Figure 3.5 are plotted with the mean SRTB values for the female and male samples in the 
UKBB sample. The blue and purple lines are plotted with the mean SRTTn values from a 
Smits Digit Triplet Test sample272. Table 3.3 displays the raw data for Figure 3.5. Both 
Figure 3.5 and Table 3.3 demonstrate that the variability between SRT scores and age 
and sex is greater in the Smits Digit Triplet Test273 than the UKBB SIN Test. In the UKBB 
sample, there is no significant difference between male and female SRTB distributions (p-
value = 0.065). 
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Figure 3.5. Line graph displaying the mean SRT value by age group split by sex for the 
UKBB sample and Smits  Digit Triplet Test sample273. 
The UKBB recruited volunteers aged >39 and so there is no data for the age groups 25-29 and 30-34 for 
the UKBB sample. There was no data available for some of the age groups in the Smits sample; males aged 
40-59 or females aged 30-34 and females aged 55-59. 
 
   
 UKBB SIN Test Smits Digit Triplet Test 
Female  Male Female Male 
Age group 
(years) 
Median Mean Median Mean Median Mean Median Mean 
25-29 NA NA NA NA -8.3 -8.2 -7.6 -7.3 
30-34 NA NA NA NA -7.6 -7.5 -8.0 -7.6 
40-44 -8 -7.31 -8 -7.28 -9.2 -9.2 NA NA 
45-49 -8 -7.74 -8 -7.78 NA NA NA NA 
50-54 -8 -7.61 -8 -7.70 -8.4 -8.4 NA NA 
55-59 -7.5 -7.43 -7.5 -7.46 NA NA NA NA 
60-64 -7.5 -7.19 -7.5 -7.19 -7.2 -6.4 -6.2 -6.0 
65-70 -7 -6.85 -7 -6.74 -6.8 -6.4 -6.2 -5.7 
 
Table 3.3. Median and mean SRT scores for age groups, split by sex for both the 
UKBB SIN test sample and the Smits Digit Triplet Test.  
These scores correspond to the pot in Figure 3.5. The two studies did not use all of the same age groups 
for analysis. ‘NA’ is noted where there is no data available for an age group in a particular sample.  
 
 
Do the SRT scores report bilateral hearing impairment? 
ARHI is understood to present as a bilateral hearing deterioration266. If the SRT scores 
accurately represent ARHI, an individual’s SRTL and SRTR would therefore be highly 
correlated. Across the sample, the spearman’s rank correlation coefficient of SRTL and 
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SRTR is r2s=0.358, p-value< 2.2e-16, visualised in Figure 3.6a. Few studies report on the 
symmetry of hearing loss in a study sample. In a recent study however, 14.8% of males 
and 13.3% females exhibited asymmetry defined as an interaural difference of more than 
10 dB in hearing levels averaged over 0.5, 1, 2, and 4 kHz96.  As a different type of hearing 
test was used to assess participant hearing ability, the asymmetry cannot be directly 
compared between this sample and the UKBB sample. However, the work96 could 
support a theory that the unilateral hearing loss observed here in the UKBB SRT scores 
may reflect unilateral hearing deterioration rather than the low test re-test performance.   
Within the whole sample, the median difference between SRTL and SRTR was 1dB, and 
the mean difference was 1.55dB, yet the range was 0-18dB. Figure 3.6b is a second 
scatter plot of the same data (SRTL vs SRTR), but where the colouring denotes the density 
of points at specific score combinations. The plot enables a greater interpretation of the 
average differences between SRTL and SRTR, the range and the correlation. The majority 
of individuals cluster around the mean SRT scores ~7dB for both ears (Figure 3.6b) 
which may be a marker that the test lacks sensitivity. The range of difference between 
SRTL and SRTR for some participants (marked on Figure 3.6 (b), by blue shading and 
black points) may indicate that either the SIN test was not performed accurately for these 
participants or that there is a greater prevalence of unilateral hearing deterioration in 
ARHI sufferers than is currently understood.   
 
Figure 3.6. Scatter plots of SRTL and SRTR scores for all participants that have an SRT 
score for both ears.  
(a) is a scatter plot of SRTL by SRTR r2s=0.358, p< 2.2e-16, with a regression line marked in red. (b) is a density 
scatter plot of SRTL and SRTR. The density of participants with specific score combinations is denoted by 
colours red to blue and black. This scatter pot demonstrates both the cluster of individuals that have SRTL and 
SRTR scores clustered around the mean values and also the range difference between SRTL and SRTR; 0-
18dB.   
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Is a learning effect observed when performing the test on the second ear? 
89% of the sample have a different SRTR score to their SRTL. While this could be due to 
genuine differences in hearing abilities between participants’ ears or the measurement 
error on the test, it may be caused by a learning effect from the SIN test. If a learning 
effect was observed, it would be more likely that the second ear to be tested would be 
the ‘best’ SRT score. This would indicate that an individual is more likely to achieve a 
‘better’ score on the test having completed and ‘learnt’ how to perform the test, resulting 
in a disparity between the SRTL and SRTR scores.  
In the UKBB SIN test, the order of testing for left and right ears was determined by 
whether the participant study ID was an odd or even number.  ~50% of participants 
performed the test on their left ear first, followed by the right, and vice versa. Those with 
an even study ID number tested the left ear first and those with an odd study ID number 
tested the right ear first. Table 3.4 displays the number of participants that had the ‘best’ 
ear score for left/right ears and which ear was tested first. The proportion of left and 
right SRT scores that were the ‘best’ SRT score is not dependent upon which ear was 
tested. Interestingly, for both groups there is a slight preference for SRTL = SRTB. 
 
 SRTL = SRTB 
(n) 
% 
SRTR = SRTB 
(n) 
% 
SRTL = SRTR 
(n) 
% 
Left tested first 
(even study ID) 
36492 45.56 35253 43.39 8946 11.05 
Right tested first 
(odd ID) 
36559 45.22 34821 43.69 8871 11.09 
 
Table 3.4. Comparison of SRTL and SRTR scores in relation to the order of testing.  
 
The table displays the number of participants that that achieved a ‘better’ (lower) SRT score for their left 
ear (SRTL = SRTB), a ‘better’ score for their right ear (SRTR = SRTB) or the same SRT score for both 
ears (SRTL = SRTR). The proportion of each of these combinations are reported as percentage of the 
sample that either had the right or left ear tested first.  
 
 
3.2.1.2 Assessing the reproducibility of the SRT score  
Results in the previous section indicate a higher prevalence of unilateral HL than would 
be expected. While this may be the case, it contests the understanding that ARHI presents 
as a bilateral deterioration. Here I present work to explore whether these results are due 
to the insensitivity of the test and the reliability of the measure. The test re-test 
reproducibility of a measure indicates its validity and stability. The UKBB SIN was not 
95 
 
included in a pilot study and so the reproducibility of the measure has not previously 
been determined. 
Due to the way that the UKBB data were collected, there are two possible ways to study 
the reliability of the SRT test. Firstly, 10 UKBB assessment centres conducted the SIN test 
during the initial phase of recruitment (Birmingham, Bristol, Croydon, Middlesbrough, 
Nottingham, Sheffield, Liverpool, Hounslow, Swansea and Wrexham). To determine 
whether the test was reproducible in these different environments, i.e. the SRT 
distributions were consistent across different assessment centres, samples from each 
assessment centre are analysed based on (1) SRT distribution and (2) SRT correlation 
with age.  
Furthermore, a subset of individuals (n=4544) attended the Cheadle assessment centre 
for a repeat visit 2-4 years after their initial visit, and there completed a SIN test. With 
this sample, it is possible to test the reliability of the SRT score over time. A reliable 
measure would have a high correlation of scores between the first and second 
assessment over this short time period.  
Are the SRT distributions uniform across the different UKBB assessment 
centres? 
The SIN test was conducted at 10 of the UKBB assessment centres during the main phase 
of recruitment. Table 3.5 contains summary figures of the SRTB scores (and age of 
participants) at each of the 10 centres and Figure 3.7 displays the individual SRTB 
distributions. A Kruskal-Wallis rank sum test confirms that the distributions of best SRT 
scores are significantly different between centres, Kruskal-Wallis chi-squared = 7254.3, 
df = 9, p-value < 2.2e-16, (critical value of 16.9190 for 9df and alpha 0.05), indicating that 
it may not be a reproducible measure. However, it is challenging to discount external 
factors impacting SRT scores at each centre or inherent differences between the sub 
cohorts such as age distributions. 
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Assessment centre N Mean SRTB Median SRTB Mean Age Median age 
Birmingham 23370 -7.23 -7.5 56.29 57 
Bristol 11241 -7.14 -7.5 55.54 57 
Croydon 25956 -7.03 -7 56.51 58 
Hounslow 26379 -7.45 -7.5 56.15 57 
Liverpool 19418 -7.51 -7.5 57.68 59 
Middlesbrough 17936 -7.67 -8 56.67 58 
Nottingham 4602 -6.88 -7 57.22 59 
Sheffield 29240 -7.70 -8 57.18 59 
Swansea 2185 -6.04 -6 57.45 59 
Wrexham 615 -6.06 -6.5 56.89 58 
Table 3.5. Summary table of the number of participants that completed the SIN test at 
each UKBB assessment centre during the main phase of recruitment.  
 
The table also displays the mean and median SRTB scores at each UKBB assessment centre, and the 
mean and median ages of the participants that completed the SIN test at each centre. A Kruskal-Wallis 
rank sum test confirmed that the distributions of best SRT scores are significantly different between 
centres, Kruskal-Wallis chi-squared = 7254.3, df = 9, p-value < 2.2e-16, (critical value of 16.9190 for 9df 
and alpha 0.05). 
 
 
 
To explore the individual SRTB distributions with respect to age in each sample, box plots 
are presented in Figure 3.8. These plots display SRTB scores subset by assessment centre 
and participant age groups. As expected, all centres display a trend of increasing SRTB 
score with increased age. Nottingham, Swansea and Wrexham assessment centres 
visibly have a higher median SRT score for all age groups than the remaining centres. 
However, from Table 3.5, it is clear that the sample size in these centres are relatively 
low (<4,603) compared to all other centres (>17,936). The outliers that are present in 
these three centres may therefore likely have a greater effect on the median SRTB for 
these centres (median denoted by the mid-line of the box plot) and therefore could 
explain the observed shift.  
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In addition, Figure 3.8 demonstrates that while there is a trend for the SRTB score to 
increase as age increases (corresponding to the expected hearing deterioration with 
increasing age) within each centre, the median score may not be comparable between 
centres. For example, while the median SRTB score increases with age in both the 
Wrexham and Sheffield samples, the lower interquartile range of the Sheffield SRTB 65-
70 age group is the same as the SRTB median in the Wrexham <45 age group. This is 
another indicator of irreproducibility at different sites, or intrinsic differences between 
samples which impact the SRTB scores. This could be due to the effects of a number of 
hypothesised ARHI-related risk factors. Without determining these factors and the 
effects on the SRT score, they cannot be accounted for and it may not be suitable to 
analyse the data as one sample. 
 
Figure 3.7. Histograms of SRTB distributions plotted individually for the ten UKBB 
assessment centres.  
 
Distributions are for samples from the ten centres that ran the SIN test during the main phase of recruitment. 
The frequency (y-axis) scale differs between the plots as the sample size for each centre differs (Table 3.5). 
X-axis is labelled SRTB. 
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Figure 3.8. SRTB scores displayed as boxplots according to UKBB assessment 
centre and age group. 
The boxplots display the median SRTB for each age group (split by assessment centre) and the 
interquartile range (25th percentile, Q1 and 75th percentile, Q3). The maximum (Q1-1.5*IQR) and 
minimum values (Q3+q.5*IQR) are denoted by the whiskers and the outliers are presented as black 
dots outside of these minimum and maximum values. 
 
Did the protocol alteration affect the SRT distributions?  
A protocol alteration during recruitment consisted of changing the speech to noise ratio 
(SNR) at the first trial to +2dB, instead of -2dB. This was so that participants who were 
hard of hearing would more easily be able to begin the test procedure (see link to the 
UKBB protocol, p.85). The SIN test was carried out over different time periods in each 
assessment centre. Therefore, the protocol change in August 2009 will have had a 
different impact on different assessment centres, depending on when the hearing test 
was running at each centre. This could therefore be an external source of the variation 
that is observed in SRT scores between assessment centres demonstrated in Figure 3.8. 
In total, 49,686 participants completed the SIN test with the original protocol and 
116,642 completed the SIN test with the adapted protocol. Figure 3.9 displays the dates 
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of SIN testing at each assessment centre and the colour denotes which protocol was in 
use.  
An analysis of the raw UKBB SIN data shown in Figure 3.9 did not meet the expectation 
that the SIN test protocol change occurred in August 2009, as stated in the UKBB 
protocols (see link to UKBB protocol p.85). This discrepancy was discovered by plotting 
a visualisation of the SIN ratio at the first trial for each participant (either +2dB or -2dB) 
and subsetting the data by assessment centre and by date of assessment, Figure 3.9. It is 
apparent that not all the assessment centres adapted the new protocol on the intended 
date of August 2009. The Nottingham, Middlesbrough and Bristol assessment centres did 
not adapt the new protocol at all, while Sheffield, Liverpool and Hounslow adopted the 
protocol at different time points. Four assessment centres began SIN testing after August 
2009. Of these, Wrexham, Swansea and Birmingham all used the new protocol only, 
while 230 participants at Croydon performed the SIN test with the old protocol before 
the new version was implemented. Due to the very small number of participants (230), 
this is difficult to visualise in Figure 3.9.   
 
Figure 3.9. Graph displaying the dates that the SIN test was conducted at each 
assessment centre and which protocol was being used. 
Orange represents the testing period with the original protocol (first trial SIN -2dB) and turquoise represents 
the new protocol (first trial SIN +2dB). From this graph, it is apparent that not all of the assessment centres 
adopted the protocol change at the same time, August 2009 as the UKBB protocol states. 
 
Table 5 displays the number of participants at each of the assessment centres and the 
exact dates that testing commenced and was completed. A Man-Whitney-Wilcoxon test 
(Old protocol)  
(New protocol) 
100 
 
indicates that the SRT distributions are significantly different under the two protocols; 
W = 2.751+09, p-value < 2.2E-16. However, this significant difference could be due to the 
underlying significant difference between the assessment centres (identified in section 
1.1.3), rather than solely the protocol change.  
To explore whether this is due to the protocol change rather than the differences 
between assessment centres, the calculation was performed individually on the centres 
that used both protocols: Sheffield, Liverpool, Hounslow and Croydon. This removes the 
effect of the factors that cause variability between assessment centres. The SRTB 
distributions of the two protocols were significantly different in Sheffield, Liverpool and 
Croydon (p<0.05) but not in Hounslow. 
Assessment centre 
N for each protocol 
Mann Whitney test for SRTB between 
protocols 
-2 +2  
Bristol 11604 0 - 
Nottingham 4719 0 - 
Sheffield 3815 25928 W = 50334000, p-value = 8.107E-11 
Liverpool 3317 16439 W = 24670000, p-value = 7.268E-06 
Middlesbrough 19796 0 - 
Hounslow 6206 21054 W = 58770000, p-value = 0.01622 
Croydon 230 26243 W = 2307600, p-value = 1.939E-06 
Birmingham 0 24138 - 
Swansea 0 2212 - 
Wrexham 0 630 - 
 
Table 3.6.  A comparison of SRTB scores within assessment centres under different SIN 
protocols.  
Table listing the number of participants that completed the SIN test under each protocol, at each assessment 
centre, and the results of Mann Whitney test for difference between the SRTB distributions under different 
protocols, within the four centres that ran both of the protocols.  
 
Are participant SRT scores consistent over time? 
Having assessed the reproducibility of the test between different centres, the 
reproducibility was also tested over a period of time. 4529 individuals completed the 
SNR test twice; once during the initial recruitment phase (2006-2010) and again during 
the first repeat assessment (2012-2013). This subset can be used to calculate the test-
re-test correlation. The period of time between the first (T0) and second (T1) 
assessments differed between participants; the range in time between first and second 
visits was 2.11-3.88 years (770-1417 days). The mean and median number of days 
between tests were 1103.98 and 1100 respectively.  
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For a reliable test, SRTB difference between the two assessments would be negligible for 
the vast majority of participants over this short time period.  The correlation of SRTB 
scores between the first and second visits was r2=0.27, p<2.2E-16, graphically displayed 
in Figure 3.10 (SRTL r2=0.25, p<2.2E-16 and SRTR r2= 0.23 p<2.2E-16). There was a 
significant difference between the T0 and T1 scores; p=7.26E-11 with a mean difference 
of 0.17dB (sd.=1.65) between T0 and T1, unadjusted for the time elapsed between T0 
and T1. The distribution of SRTB scores at T0 and T1 is displayed in the density plot in 
Figure 3.11, a shift of SRT scores to the right on the distribution is visible for T1.  
 
Figure 3.10. Scatter plot for SRTB scores at T0 and T1.  
The correlation is 0.27, the regression line is marked in blue with the standard error shaded in grey. T0, 
SRTB score at baseline; T1, SRTB score at the repeat visit. The black dots on the graph do not 
comprehensively depict the density of data points. One black dot can represent multiple datapoints at each 
score combination. This means that without the regression line present, the points alone indicate a 
correlation closer to 1.  
 
 
This relatively low correction and significant difference between T0 and T1 scores could 
be explained by the natural deterioration of participants’ hearing over time. If the natural 
deterioration of hearing is the cause of the low correlation, there would be a correlation 
observed between the SRT change over time and the length of time between 
assessments; the greater amount of time that has elapsed, the greater the expected 
change in SRT. The mean difference in SRTB score per year elapsed was 0.05dB, (sd=0.56) 
and the Pearson’s product-moment correlation between time elapsed between 
assessments and SRTB is 0.06 p<2.2E-16. Both estimates indicate that there is a slight 
deterioration in hearing over time within the sample. The low correlation could also 
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signify the alternative sources of variation or poor test-re-test reliability, as discussed 
further in the discussion section of this chapter.   
 UKBB  Smits  
Age group at 
T0 
Predicted mean SRT difference over 5 years 
in dB (sd) 
Mean SRTTn difference over 5 years in 
dB (sd) 
40-49 0.25 (2.73) 0.23 (1.98) 
50-59 0.32 (2.68) 0.27 (2.10) 
60-70 0.22 (2.90) 0.39 (2.68) 
Table 3.7. Predicted SRT score differences over a five-year period. 
Mean predicted change in SRTB score over five years calculated for the UKBB sample (n=4529), and the 
mean change in SRTTn over five years with a sample that took the Dutch Triplet Digit test, n=427. The 
prediction of change in SRT over 5 years was calculated from the SRT change relative to the time elapsed 
between T0 and T1 per participant. The mean changes are displayed by participant age range at T0, the 
time point of the first measurement.  
 
 
Figure 3.12 graphically displays this difference in SRTB between the first and second 
assessments, and the amount of time elapsed between assessments. Figure 3.12 displays 
a scatter plot of the difference between SRTB at T0 and T1 in dB (y-axis), and the time 
elapsed in days between T1 and T0 (x-axis). The histograms represent the frequency 
distributions for the difference in SRTB over time, and the time that between T0 and T1.  
This scatter plot does not display a strong relationship between the SRTB difference 
between visits and the time elapsed between visits (r2=0.06, p<4.94E-05), though the 
relative SRTB change over time is in the range of the change in time seen in the Dutch 
Triplet Test (Table 3.7). The scatter and histogram on the y-axis visually display the 
 
Figure 3.11. Density plot of SRTB scores for T0 and T1 for the subset of individuals that 
completed the test twice. n=4529 
The black line marks the density distribution of SRTB scores at T0 and the blue line marks the density 
distribution for SRTB scores at T1. Here the shift (mean difference of 0.17dB) between T0 and T1 scores is 
visible; a shift to the right indicates a shift toward greater SRT scores and thus poorer hearing. 
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difference between the first and second SRTB scores (which in turn displays the 
variability within individuals on the performance on the test).  
 
Figure 3.12. Scatter plot of SRTB difference (dB) between first and second assessments 
and time between the two assessments (days). 
The marginal plots (histograms, grey) display the distribution of time between the two assessments in days 
(top) and the difference between SRTB scores for the first and second assessments.  The scatter plot 
visualises both the difference between SRTB scores between the first and second assessments (right) and 
the length of time between assessments (top). The scatter plot does not display a strong correlation between 
time elapsed and increase in SRTB, r2=0.06, p<4.94E-05. 
 
3.2.2 Hearing questionnaire measures in the UKBB sample  
In addition to the SIN test, participant hearing ability was assessed via questionnaires. 
The participants completed the questionnaires on touch screen monitors during the 
assessment centre visit.  The three hearing-related questions and the possible responses 
are listed below in Table 3.8, the UKBB Field IDs are listed in - Methods 2.1.1.1.  
 
Question Possible responses 
“Do you have any 
difficulty with your 
hearing?” 
Yes No Prefer not to 
answer  
Do not 
know  
I am 
completely 
Deaf 
- - 
-“Do you find it difficult 
to follow a conversation 
if there is background 
noise (such as TV, radio, 
children playing)?” 
Yes No Prefer not to 
answer  
Do not 
know  
- - - 
“Do you use a hearing aid 
most of the time?” 
Yes  No  Prefer not to 
answer 
- - - - 
 Table 3.8 Three hearing-related questions and possible responses that were included in 
the UKBB questionnaire. 
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All three of these questions were included in the questionnaires during the initial 
recruitment period 2007-2010 and in the pilot study. If participants responded, “I am 
completely deaf” to “Do you have any difficulty with your hearing?” they were not asked 
either of the two subsequent questions and they did not take part in the SIN test. Until 
2009, the question “Do you use a hearing aid most of the time?” was only presented to 
participants that had answered “Yes” to one of the two questions regarding hearing 
difficulty. In 2009, when the hearing test was integrated into the assessment day, all 
participants were asked “Do you use a hearing aid most of the time?” except from those 
that had responded “I am completely deaf” to “Do you have difficulty with your hearing?” 
Therefore, due to the restrictions on the question from 2007-2009, only ~3/5 of the 
sample were asked “Do you use a hearing aid most of the time”. 
3.2.2.1 Is the hearing aid use questionnaire a suitable indicator for ARHI? 
N=307,724 participants responded to the question “Do you use a hearing aid most of the 
time”, UKBB Field IDs are listed in - Methods 2.1.1.1. 4.9% of the sample responded “Yes” 
to “Do you use a hearing aid most of the time?” while 95% responded “No” (Table 9). 
These results can be visualised in Figure 3.13, which depicts the differing age 
distributions between those that responded “Yes” and “No”. For both males and females, 
the age distribution is significantly different between those that responded “Yes” and 
“No” (t = 92.023, df = 17470, p-value < 2.2e-16). This indicates that the prevalence of 
frequent hearing aid use increases with increasing age. There are however a number of 
outliers (marked by dots below the whiskers). These are present in the younger age 
groups reporting “Yes”, and so may be individuals that have congenital or an early-onset, 
acquired, form of hearing loss. 
 
 
“Do you use a hearing aid most of the time?”  
Response Yes No Do not know Total 
N 14966 292192 566 307724 
Prevalence % 4.9 95 <1 - 
Mean Age 61.87 56.87 56.27 57.11 
Median Age 63 58 58 59 
Male % 55 48.39 48.59 48.7 
Table 3.9 Summary of participant responses to the question regarding hearing aid use. 
N, the number of participants with a specific response; Prevalence, the percentage of participants for each 
response from the total that were presented with the question; Male %, percentage of participants that gave 
that specific response and are male.  
 
105 
 
This question can be used to classify participants by hearing impairment; those that use 
a hearing aid most of the time will have been diagnosed with a hearing impairment and 
subsequently prescribed treatment in the form of a hearing aid device. 
 
Figure 3.13. Box plots displaying the age distributions of participants that responded 
“Yes” and “No” to question regarding frequent hearing use. 
The boxplots display the median age for each response (split by sex) and the interquartile range (25 th 
percentile, Q1 and 75th percentile, Q3). The maximum (Q1-1.5*IQR) and minimum values (Q3+q.5*IQR) are 
denoted by the whiskers and the outliers are presented as black dots outside of these minimum and 
maximum values. The mean age of participants that responded ‘Yes’ and ‘No’ was significantly different, 
the t-test p value are annotated on the plot. 
 
3.2.2.2 Are the hearing difficulty questionnaire measures suitable indicators of 
ARHI?  
The UKBB recruited participants aged >40, and so is a suitable population to use to study 
ageing traits. However, from these questionnaire measures, the age of hearing difficulty 
onset cannot be determined. Table 3.10 and Table 3.11 display the counts and 
percentage of each of the possible responses for the two questions. A quarter of the 
sample (24.5%) responded that ‘Yes’ they have difficulty with their hearing, while over 
a third (36.74%) responded that ‘Yes’ they have difficulty with their hearing in the 
presence of background noise. From Table 3.10 and Table 3.11 it is also possible to see 
that the mean and median ages are higher for ‘Yes’ respondents than ‘No’ respondents 
for both groups.  
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Do you find it difficult to follow a conversation if there is background noise (such as TV, radio, 
children playing)? 
Response Yes No Do not know Prefer not to answer 
N 184290 306683 9957 675 
Prevalence % 36.74 61.14 0.02 0.001 
Mean age 57.8 55.76 56.42 55.69 
Median age 59 57 58 56 
 
Table 3.11. Summary of participant responses to the first question regarding hearing 
difficulty when background noise is present.  
N, number of participants that selected each response; Prevalence %, the percentage of the sample that 
selected each response.  
 
 
3.2.2.3 Is there a positive relationship between age and self-reported hearing 
difficulty? 
The prevalence of hearing difficulty within the different age groups was investigated 
further, to establish whether these measures are likely capturing progressive, adult 
hearing loss such as ARHI, or congenital and early-onset hearing impairments. The age 
distributions for the individuals that responded “Yes” and “No” to the two questions 
regarding hearing difficulty can be visualised in the boxplots in Figure 3.14. The age 
distributions are significantly different (p-value < 2.2e-16) those that responded “Yes” 
and “No” to the question “Do you have any difficulty with your hearing?” There was also 
a significant difference between the age distributions of individuals that responded “Yes” 
and “No” to “Do you find it difficult to follow a conversation if there is background noise 
(such as TV, radio, children playing)?”  (t = 87.785, df = 401400, p-value < 2.2e-16). 
Participants that responded to “Prefer not to answer” and “Do not know” were excluded 
from these calculations.  
Do you have any difficulty with your hearing? 
Response Yes No Do not know Prefer not to 
answer 
I am completely deaf 
N 122075 355466 19772 516 130 
Prevalence % 24.5 71.39 3.97 0.001 0.00026 
Mean age 58.7 55.8 56.48 55.87 56.72 
Median age 60 57 58 57 58 
Table 3.10. Summary of participant responses to the first question regarding hearing 
difficulty.  
N, number of participants that selected each response; Prevalence %, the percentage of the sample that 
selected each response.  
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Figure 3.14. Box plots displaying the age distributions of participants that responded 
“Yes” and “No” to the two questions regarding hearing difficulty.  
The boxplots display the median age for each response (split by sex) and the interquartile range (25 th 
percentile, Q1 and 75th percentile, Q3). The maximum (Q1-1.5*IQR) and minimum values (Q3+q.5*IQR) are 
denoted by the whiskers. The mean age of participants that responded ‘Yes’ and ‘No’ was significantly 
different for both questions, t-test p values are annotated on the plot. 
 
Of the 130 individuals that responded, “I am completely deaf”, 65 were male and 65 were 
female. The mean age for the 130 individuals was 56.72, while the median age was 58, 
and the age distribution in this sample was not significantly different to the age 
distribution of the overall cohort, (t = 0.25618, df = 129.07, p-value = 0.7982). This 
indicates that the portion of the sample that reports being “completely deaf” is more 
likely to be made up of individuals with congenital or early onset forms of HL, as opposed 
to ARHI cases. Therefore, this response is likely not suitable to use as a classification of 
ARHI.  
Table 3.12 summarises the combination of “Yes” and “No” responses for the two 
questions regarding hearing difficulty (HD) and difficulty when background noise is 
present (HDBN). Responding “No” to both of the questions was the most common 
combination of responses; 59.62% of the sample responded “No” to both. The prevalence 
of responding “Yes” to both questions is 21.62%. Only 4.03% of participants experience 
hearing difficulty without any difficulty when background noise is present, while 15.1% 
report having difficulty when background noise is present but no general hearing 
difficulty. This indicates that experiencing hearing difficulty when background noise is 
present, is more prevalent than general hearing difficulty and may, in some cases, 
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precede general hearing difficulty. This is of interest for this work as the most common 
symptom of ARHI is experiencing a difficulty hearing, in particular, deciphering speech 
when background noise is present. The prevalence of responding “Yes” to both questions 
is 21.62%, a prevalence that is expected for ARHI in a sample of this age range. In 
addition, 55.68% of the “Yes” and “Yes” respondents were male, representing a higher 
male prevalence, as expected in ARHI cases.   
 
3.2.2.4 UKBB hearing questionnaire responses over time  
During the repeat visit conducted at Cheadle, ~20,000 participants responded to the 
hearing-related questionnaires for a second time (T1), 2-4 years after their baseline 
assessment, T0 (as described in 3.2.1.2 for the participants that repeated the SIN test). 
For the HD question, 80.21% of participants (N=15,940 of N=19,873, Table 3.13) 
submitted the same response, either ‘Yes’ or ‘No’ to the question at both T1 and T0. 9,2% 
responded ‘No’ at T0 and ‘Yes’ at T1, indicative of a hearing deterioration, while 3.43% 
responded ‘Yes’ at T0 and ‘No’ at T1, indicative of an improved hearing ability. The latter 
may be due to a temporary hearing loss, uncertainty of own symptoms or an error in 
response.  
Similarly, for the HDBN question, 79% submitted the same response at both of the two 
timepoints while 10.67% responses indicated a deterioration between T0 and T1, and 
6.78% indicated an improvement in HDBN (or ambiguous responses) between T0 and 
T1. Lastly, 94.19% of the sample submitted the same response at T0 and T1 to the 
Question HD HDBN HD HDBN HD HDBN HD HDBN Total 
Response 
combination 
Yes Yes No No Yes No No Yes - 
N 101642 278509 18953 70970 470074 
Age mean 58.94 55.64 57.47 56.40 56.53 
Prevalence 
% 
21.62 59.25 4.03 15.1% - 
Age median 61 56 59 58 58 
% male  55.68 40.79 51.84 50.26 45.62 
Table 3.12. This table summarises the combinations of “Yes” and “No” responses from 
the two questions regarding participant hearing difficulty and difficulty in background 
noise.  
HD, “Do you have any difficulty with your hearing?”; HDBN, “Do you find it difficult to follow a conversation 
if there is background noise (such as TV, radio, children playing)?” The total number of participants that 
responded either “Yes” or “No” to both questions was 470,074. All other participants answered either “I am 
completely deaf”, “Prefer not to answer” or “Do not know” to at least one of the two questions. N, number of 
participants with specific response combination; prevalence %, percentage of participants with specific 
response combination from the total number of participants that gave one of these 4 response combinations.  
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hearing aid use question. 5.02% indicated that they had started using a hearing aid 
frequently since the baseline visit, while 0.63% indicated that they were no longer using 
a hearing aid most of the time, having previously responded that they were at T0. The 
summary totals that were used to derive these percentages are listed below in Table 
3.13.  
HD 
T0  
HDBN 
T0  
HAID 
T0 
Yes No Yes No Yes No 
T1 
Yes 4,292 681 
T1 
Yes 6,380 2,168 
T1 
Yes 568 573 
No 1,826 11,484 No 1,378 9,677 No 72 10,183 
 
Table 3.13. Table listing the number of “Yes” and “No” responses at T0 and T1.  
HD, UKBB question ‘Do you have any difficulty hearing’; HDBN, UKBB question “Do you find it difficult 
to follow a conversation if there is background noise (such as TV, radio, children playing)?”; HAID, UKBB 
question ‘Do you wear a hearing aid most of the time?”; Yes, “Yes” response to relevant question’; No, 
“No” response to relevant question; T0, baseline visit; T1, first repeat visit at Cheadle assessment centre. 
All values in the table represent numbers of participants with the corresponding two responses at T0 and 
T1. Participants that selected any other response for either question are not included in the totals listed 
in this table. 
 
3.2.2.5 A comparison between SRT scores and questionnaire measures  
In addition to using the questionnaire measures as surrogate phenotypes for ARHI, the 
questions could be used to validate the SRT data and vice versa. Anomalies or false 
readings could be detected by comparing participants SRT scores with questionnaire 
responses. For all three responses, it is expected that the SRTB mean and median for the 
subgroups that responded “Yes” would be greater than the mean and median for the 
subgroups that responded “No”. Table 3.14 displays the mean, median and range of the 
SRTB scores for Yes/No responses to each of the three hearing questions. The mean and 
median SRTB scores were higher for the “Yes” respondents than the “No” respondents 
for all three questions.  
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 SRTB mean SRTB median SRTB range N 
HD Yes -6.84 -7 -11.25   8.00 47,570 
HD No -7.48 -7.5 -11.5   8.00 123,238 
HDBN Yes -6.90 -7.5 -11.25   8.00 65,994 
HDBN No -7.49 -7.5 -11.5   8.00 110,401 
Hearing aid Yes -5.44 -6 -11   8 5,437 
Hearing aid No -7.36 -7.5 -11.5   8.0 17,5381 
 
Table 3.14  A comparison between SRTB scores and questionnaire responses.  
HD Yes; “Yes” response to the question ‘Do you have any difficulty hearing’, HD No; “No” response to the 
question ‘Do you have any difficultly with your hearing?’, HDBN Yes; “Yes” response to the question “Do 
you find it difficult to follow a conversation if there is background noise (such as TV, radio, children playing)?” 
HDBN No; “No” response to the question “Do you find it difficult to follow a conversation if there is 
background noise (such as TV, radio, children playing)?”, Hearing aid Yes; “Yes” response to ‘Do you wear 
a hearing aid most of the time?”, Hearing aid No; “No” response to ‘Do you wear a hearing aid most of the 
time”.  
 
 
 
Figure 3.15. Histograms of SRTB scores coloured by “Yes” and “No” responses to 
questionnaire measures. 
The distribution of (a) and subsequent colouring corresponds to the SRTB score of each participant and the 
response to the question ‘Do you have any difficulty with your hearing?’. The distributions and colouring of 
(b) and (c) correspond to the responses to the questions ‘Do you find it difficult to follow a conversation if 
there is background noise (such as TV, radio, children playing?)’ and ‘Do you wear a hearing aid most of the 
time?’. Light blue represents the distribution of SRT scores for “Yes” responses to the three questions and 
dark blue represents the distribution of SRT scores for “No” responses to the three questions. 
Figure 3.15 displays three histograms of SRTB scores. The histograms are coloured by 
participant response to each of the three UKBB hearing questions. Visually, the SRTB 
scores coloured in light blue are slightly shifted to the right for both HD and HDBN, 
consistent with the mean scores of “No” respondents being higher than “Yes” 
respondents. As the proportion of “Yes” responses is much smaller in the Hearing aid 
responses sample, it is not clear from the visualisation, but the mean score is almost 2dB 
> for “Yes” respondents than “No” respondents (Table 3.14).  Mann Whitney tests 
confirmed that the SRTB distributions are significantly different between “Yes” and “No” 
respondents for each question (p-value < 2.2e-16). This is evidence that overall in the 
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sample, on some level, the SRT scores reflect personal perception of hearing ability and 
also of common hearing aid use.  
The responses were also compared to the categorised UKBB scores; ‘normal hearing’ SRT 
< -5.5dB, ‘insufficient’ hearing SRT -5.5dB to -3.5dB and ‘poor’ hearing SRT > -3.5dB, as 
displayed in Table 3.15. The number of individuals with each classification (good, 
insufficient, poor), according to their SRTB score, is listed against the questionnaire 
responses. The percentage of each category for the responses is also noted. For all 
questions, the percent of individuals with ‘poor’ and ‘insufficient’ hearing was greater in 
the ‘Yes’ category, as expected. 
 
Question Resp. Normal 
% of 
response 
Insufficient 
% of 
response 
Poor 
% of 
response 
N total 
HD Yes 37,723 85.48 4,318 9.78 2,089 4.73 44,130 
HD No 111,096 94.26 5,488 4.66 1,279 1.09 117,863 
HDBN Yes 54,071 87.7 5,256 8.52 2,327 3.77 61,654 
HDBN No 99,622 94.31 4,893 4.6 1,116 1.06 105,631 
Hearing 
aid 
Yes 3,031 63 956 19.6 827 17.2 4,814 
Hearing 
aid 
No 154,547 92.74 9,443 5.67 2,660 1.60 166,650 
 
Table 3.15.  Comparison of SRTB scores and questionnaire responses. 
This table summarises the proportion of respondents to each question subset by SRTB score when classified 
‘Good’, ‘Insufficient’ and ‘Poor’. Resp. Response to question; HD, ‘Do you have any difficulty with you 
hearing?’; HDBN, ‘Do you find it difficult to follow a conversation if there is background noise (such as TV, 
radio, children playing?)’ and ‘Do you wear a hearing aid most of the time?’ and Hearing aid; ‘Do you use a 
hearing aid most of the time?’  
 
Perhaps surprisingly, 63% of participants that responded “Yes”, they do wear a “hearing 
aid most of the time” have ‘Normal’ hearing. Similarly, >54,000 individuals that respond 
“Yes” they do have difficulty hearing in background noise (87.7% of “Yes” respondents), 
have ‘normal’ hearing as determined by the SIN. These figures indicate that either the 
SIN test is not as sensitive as other SIN tests, as explored previously and, or that these 
SIN classifications are not an accurate description of hearing ability for this specific SIN 
test, as previously proposed. Or, alternatively, that individuals over-report hearing 
difficulties (though this assumingly does not apply to the response to hearing aid use). 
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3.2.3 Phenotypes derived for association analysis: HDiff and HAid  
It has been established in the previous sections that the combination of two “Yes” 
responses to the two questions regarding hearing difficulty results in a prevalence 
similar to the expected prevalence of ARHI in a sample of this age range; 21.62%. There 
is also a greater proportion of males reporting a hearing difficulty, as expected for ARHI. 
Findings from the SIN test data indicate that a number of limitations ought to be 
addressed prior to using the data as a surrogate ARHI phenotype in association analysis. 
In addition, the overall size of the sample that responded to the questions is three times 
the size of the sample that completed the SIN test, and so this data may provide greater 
power for association analysis.  
Therefore, for association analysis, the two questions regarding hearing difficulty were 
used to derive a qualitative phenotype. Participants were assigned case/control status 
based on their responses to the questions. A second phenotype was also derived using 
the responses to the question regarding hearing aid use. This derived phenotype depicts 
hearing loss that has been clinically diagnosed and for which treatment is likely resulting 
in some relief of symptoms.  
The first phenotype was derived from the two questions regarding hearing difficulty “Do 
you have any difficulty with your hearing?” and “Do you have any difficulty with your 
hearing” and “Do you find it difficult to follow a conversation if there is background noise 
(such as TV, radio, children playing)?” Participants that responded “Yes” to both 
questions were assigned as ‘cases’ while those that responded “No” to both of the two 
questions were assigned as ‘controls.’  
Participants with any other combination of responses were removed. In addition, 
controls aged <50 were removed from analysis in order to better age-match the case and 
control groups prior to analysis. To reduce the chance of false-positive controls due to 
an ambiguous combination of responses to the questions, controls that responded “Yes” 
to the question “Do you use a hearing aid most of the time?” were also removed. The 
resulting phenotype and will here-on be referred to as HDiff (Figure 3.17). 
The responses to the question regarding hearing aid use were used to derive the second 
trait representative of hearing impairment. Participants that responded “Yes” to the 
question “Do you use a hearing aid most of the time?” were classified as ‘cases’ and those 
that responded “No” were defined as ‘controls’. This phenotype will here-on be referred 
to as HAid (Figure 3.16). For both derived phenotypes (HDiff and HAid), if participants 
answered the questionnaire twice, i.e. attended an assessment centre for a repeat visit, 
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the answer at the second time point was used in analysis, in order to increase the mean 
age of the sample. The likelihood of including congenital forms of deafness was reduced 
as all participants that had selected ‘I am completely deaf’ in the UKBB questionnaire 
were excluded from analysis (based on the findings in Section 3.2.2.3) 
 
 
 
Figure 3.16. Flowchart describing how the phenotype based on self-
report hearing difficulty was derived. n, number of participants. 
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Figure 3.17.  Flowchart describing how a phenotype based on hearing 
aid use was derived.  n, number of participants. 
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3.3 Discussion  
The aim of this chapter was to identify or derive a surrogate phenotype for ARHI, using 
data from the UKBB sample. The SIN test data and hearing-related questionnaire 
responses were assessed as to whether the data (1) conforms to established ARHI 
characteristics; symptoms of hearing loss, especially in speech intelligibility, that show a 
positive correlation with age, increased prevalence in male subjects, and a bilateral 
deterioration and (2) their practicality for use in genetic association analysis; a stable, 
unambiguous qualitative or normalised quantitative measure.  
Firstly, the SRT scores were assessed to determine whether they are suitable as a 
quantitative phenotype for association analysis. The SRT distributions (Figure 1) are 
highly skewed (>1) to the right, a characteristic of SIN tests101. As a potential quantitative 
phenotype for association analysis however, this is a limitation; a normal distribution is 
one of the assumptions of regression models used in association analysis274. Although 
this is a large sample, a strong transformation is required which would result in a loss of 
sensitivity and thus a loss of power in the association analysis. 
An alternative way of using the SRT scores as a phenotype for association analysis is to 
create a qualitative phenotype where cases and controls are assigned by pre-defined SRT 
thresholds that define ‘poor/insufficient’ and ‘normal’ hearing. However, when these 
pre-defined classification thresholds are applied, the prevalence of hearing impairment 
(poor or insufficient) in the sample is <12%. While these thresholds are defined by the 
laboratory standard of ‘normal’ scores (being within 2 standard deviations from the 
mean264, here the mean of the normative sample), the subsequent prevalence is far lower 
than expected for ARHI in a cohort of this age range (40-69 year olds). Previous estimates 
predict that over 40% of the population aged 50 have hearing loss96.    
ARHI is understood to increase in prevalence with increasing age, is more prevalent and 
has an earlier onset in male subjects and presents as a bilateral hearing loss85–88. A 
suitable surrogate measure of ARHI would exhibit these three characteristics in the 
study sample. The UKBB SRTB does not however conform to these characteristics. Firstly, 
the SRTB correlation with age is r2s = 0.238, p<2.2e-16, indicative of a positive correlation 
with age but one that is relatively low for an age-related trait. In the UKBB sample SRTB 
scores are not significantly different between males and females (p= 0.065). This 
supports a previous report that the male UKBB sample does not have an increased risk 
of ‘poor’ hearing (SRTB > -3.5dB) and only had a slightly reduced risk of ‘insufficient’ 
hearing ( -3.5dB < SRTB > -5.5dB)123. Conversely, this conflicts with  reports of previous 
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measures of ARHI, including SIN tests, that display an increased prevalence and severity 
among male participants85–88.  
There are multiple possible explanations for these findings. Firstly, it could be speculated 
that these classification of ‘poor’ and ‘insufficient’ may not represent ARHI but define a 
more severe and less prevalent form of hearing loss. Secondly, an alternative 
explanation, is that the elevated male prevalence in other samples and from the self-
report measures, are due to elevated awareness rather than true hearing ability; this is 
the largest data sample that has not been selected based on perceived hearing ability. 
Furthermore, some cohorts that have been assessed via PTA testing are susceptible to a 
recruitment bias based on perceived hearing ability. A third explanation could be that 
the prevalence of genuine hearing impairment in the UKBB is slightly lower than the 
general population (and thus of previous estimates), due to its “healthy volunteer” 
selection bias that has been explored and reported elsewhere275.  
Analysis also challenges the understanding that ARHI generally presents as a bilateral 
hearing deterioration. The SRTL and SRTR correlation is 0.358, p-value< 2.2e-16 and the 
range of difference is 0-18dB. This either indicates that the prevalence of pronounced 
unilateral hearing deterioration is greater than is currently understood, or that a 
proportion of participants completed the test inconsistently due to modifiable external 
factors.   
The results presented in this chapter demonstrate that SIN test data is currently not 
suitable as either a qualitative or quantitative surrogate phenotype measure for ARHI. 
SRT scores in this cohort do not conform to expected characteristics of ARHI. In addition, 
the SRT distribution would require a strong transformation to achieve a normal 
distribution and the SRT thresholds for hearing impairment would need to be re-defined 
to accurately represent ARHI in the sample. This work has identified limitations to the 
SRT data that ought to be addressed prior to any further work being conducted on this 
data.  
In line with the findings presented here, a number of studies have also reported that this 
SIN test may be a less sensitive than alternative SIN tests122,162,189. The insensitivity of the 
test is apparent in the UKBB sample by the negligible difference between the 
interquartile range of the SRTB distribution (2dB) and the mean difference between 
participant SRTL and SRTR (1.55dB). These two measures demonstrate the redundancy 
of the SIN measure in this sample; the test does not discriminate between the hearing 
abilities for the majority of individuals.  
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The UKBB-specific adaptations that were made to the SIN test could be where the 
relative insensitivity arose. The two main adaptations were the number of trials 
presented to an individual, and the number of trial ratio scores used to calculate the SRT. 
Both were reduced in the UKBB version of the test compared to previous tests. In theory, 
reducing these can make the test more efficient as it takes less time for the participants 
to complete the test, yet this may in turn reduce the sensitivity of the test.  
Work that has been conducted since the implementation of the UKBB SIN test, has 
demonstrated that improving the test efficiency (reduce the number of trials from 25 to 
8.3) can be achieved, but when using a fixed-SNR procedure276 rather than the adaptive 
procedure (as used in the UKBB SIN test). The nature of the test procedure, fixed or 
adaptive, must be set prior to carrying out the test. Therefore, it is not a feasible 
retrospective alternation to make to the UKBB data.  
The number of trials completed by each participant must also be set prior to commencing 
the test. The number of trials used to calculate the SRT score can however be altered 
following the test; the maximum amount being the number of trials the participant 
completed. In this case, SNR scores from 8 trials were used to calculate the SRT, but SNR 
scores from all 15 trials were stored. Using all 15 SNR values to calculate the SRT may 
increase the sensitivity or reliability of the SRT score, as a greater number of data points 
will be used to calculate the mean value (the resulting SRTL or SRTR scores).  However, 
the UKBB sample has an additional, unique, limitation due to the protocol change. Either 
the sample would need to be split into two distinct groups for analysis, or the SRT value 
adjusted according to which protocol was used. 
Furthermore, the differences in SRT distributions between assessment centres and the 
difference in SRT measures over time in the same individuals, is suggestive of an unstable 
measure. A previous study reported a small numeric change in SRT scores over five years 
for different age groups (0.27dB for 40-49-year olds, 0.51dB for 50-59-year olds and 
0.41dB for 60-69-year olds)272. Another study that conducted longitudinal analysis for 
SIN testing and reported a test re-test correlation of 0.7 with a mean score difference of 
0.229277. The test re-test correlation was lower in the UKBB sample; 0.25 for SRTL and 
0.23 for SRTR.  
There are however clear limitations when making direct comparisons between these 
different datasets such as the age range, format of SIN tests and time elapsed between 
T0 and T1. Although the time period between tests was relatively short in the case of the 
UKBB test,  further sources of variation could be present such as environmental factors 
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or even the progression of associated traits that affect the progression of a HL at different 
rates between individuals. A sensitive and stable measure would have a proportionally 
greater interquartile range (less redundant) yet a greater consistency within 
participants (greater test re-test correlation), respectively. 
The power to detect genetic variants that are associated with a trait of interest is 
dependent on the amount of the variation in the trait that can be explained by genetic 
factors. Therefore, minimising non-genetic effects is required to maximise power. 
Potential modifiable environmental factors that affect the SRT score could be identified 
and quantified, and the SRT scores either adjusted or excluded accordingly. 
Speculatively, modifiable environmental effects between the assessment centres may be 
the differing noise levels present in the assessment centres, the frequency of headphone 
calibration, the maintenance of systems and additional instructions that are relayed to 
participants by assessment centre staff.  
In addition to the possible differences between the assessment centres themselves, there 
may be geographical differences in SRT scores that are due to lifestyle factors such as the 
prevalence of occupational noise-exposure or even the interpretation of the SIN test 
speech due to local accents.  Previous work has even demonstrated that factors such as 
participant computer literacy and education has an effect on the SRTB test score160. Here, 
the effect of individual assessment centres or participant computer literacy on the SRT 
score could be quantified and the data adjusted accordingly. By modelling the effect of 
each of these potential factors on the SRT score, it is possible to quantify the proportion 
of variance within the SRT distribution that is caused by each potential factor.  
Using this method, it may be possible to stratify participants based on assessment centre, 
protocol used or testing time period and use a meta-analysis approach. However, there 
would likely to be an element of collinearity which could result in an over-adjustment; 
computer literacy likely has a relationship with age and education. Similarly, 
demographics vary between assessment centres and so the varied SRT distributions may 
be a true reflection of hearing abilities rather than simply due to different testing 
practices at between assessment centres. 
To further investigate the SRT data, we shared our findings with Cas Smits, author of the 
original digits in noise test188. We visited the Smits lab in the Netherlands and presented 
the findings from the UKBB SRT data that is presented here in this chapter. Data from 
this original speech in noise test is used extensively in this chapter, in section 3.2 to 
compare to the data trends observed with the UKBB SRT data. Cas Smits was able to 
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identify further discrepancies between SRT score distributions between UKBB 
assessment centres, such that the scores are not directly comparable between centres. 
This finding supports the finding that SRT distributions were found to be significantly 
different between different UKBB assessment centres. Cas Smits subsequently published 
a study on the effects of a reduced number of triplets used in speech in noise tests and 
the resulting reduction in test sensitivity when an adaptive procedure is followed276. This 
is a possible factor contributing to the limitations identified in this chapter and could be 
further investigated with the UKBB data specifically. The findings presented in this thesis 
and subsequent concerns regarding the viability of the speech in noise data were also 
communicated with UKBB directly.  
In order to use the SRT data in future analysis, there are a number of ways that these 
limitations could be addressed. One way to quality-check the SRT data would be to cross-
reference the SRT scores with participant responses to the questionnaire measures. As 
presented in section 3.2.2.5, the questionnaire measures and SRT scores do have some 
level of consistency when comparing the mean and median SRTB values between “Yes” 
and “No” respondents to each of the questions. However, as can be deduced from the 
data in Table 3.15 where questionnaire responses are compared with the classifications 
of ‘normal’, ‘insufficient’ and ‘poor’ hearing, the data is conflicting. 63% of participants 
that claim to wear a hearing aid most of the time and 87% of respondents that have 
difficulty hearing in noise have ‘normal’ hearing according to their SRTB score 
classifications.  
The questionnaire data could even be used to re-define the classifications based on the 
prevalence of HL reported in the sample and the population. The authenticity of +ve dB 
SRT scores, especially +8dB SRT scores could also be checked via this method. 
Participants that reported ‘I am completely deaf’ did not take part in the SIN test, and 
therefore all participants that took part are expected to have some ability to hear in at 
least one ear. Therefore, a score of +8 may indicate that an individual did not perform 
the test correctly due to a misunderstanding or a malfunction of equipment. To reduce 
the likelihood of false +8dB scores, individuals that scored +dB for both ears and/or that 
did not report any hearing difficulties on the questionnaire, ought to be removed from 
further analysis.  
Following on from the SIN test analysis, the UKBB questionnaires and corresponding 
results were assessed for use as ARHI-surrogate phenotypes for genetic association 
analysis. Categorising participants based on “Yes” and “No” responses from the questions 
regarding hearing difficulty and hearing aid frequency, results in a qualitative 
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phenotype. “Yes” responses determine ‘cases’ and “No” determine ‘controls’. The 
questions regarding hearing difficulty resemble suitable surrogate measures for ARHI; 
reported hearing difficulty increases with age and a higher prevalence is observed in 
male subjects. The combination of two “Yes” responses to the hearing difficulty questions 
is the most accurate indication of ARHI in this sample based on the prevalence that is 
observed and increased proportion of males. The two hearing difficulty questions 
capture the main symptoms of ARHI; difficulty hearing and specifically, a difficulty 
hearing in the presence of background noise. The prevalence of the hearing difficulty 
measures and of hearing aid use are in line with both ARHI prevalence and hearing aid 
use for this age group, despite data demonstrating the under or over-estimation of 
hearing impairment by self-report measures278.   
Again, there are limitations that ought to be considered when using the questionnaire-
derived phenotypes. The main limitation is the bias that results from the subjective 
nature of the questions and possible responses. This limitation is not restricted to 
hearing phenotypes, but to many traits; the way in which individuals experience and thus 
classify symptoms is subjective. For example, two individuals may clinically have the 
same level of hearing impairment, but one is more aware of or more distressed by the 
symptoms than another; this individual is likely to report a greater hearing impairment. 
Due to this, there can be a disparity between an individuals’ true hearing impairments 
and their perceived (and thus self-reported) hearing impairment. This is difficult to 
adjust for within a sample, but one way to reduce this effect is to limit the use of questions 
that elicit an emotional response by altering the language that is used. A second method 
is to reduce the ambiguity of responses.  
The two questions regarding hearing difficulty are designed such that these effects are 
minimised. Firstly, the two questions directly ask, ‘do you have’ rather than ‘do you feel’ 
or ‘to what extent to do think you have’, and therefore evoke less of an ‘emotional’ 
response. Secondly, the possible answers are clearly defined; “Yes” and “No”, or “Prefer 
not to answer” or “Do not know”. This also reduces the effect of individuals’ self-
perceptions on the classification; a question asking participants to rank their hearing as 
‘very good/good/poor/’ would introduce further bias to the responses as there is more 
variation in individuals’ perceptions of ‘good’ vs. ‘very good’ than ‘yes’ and ‘no’. To 
further combat the issue of subjective responses to questionnaire measures, I have used 
a combination responses from more than one question to define the phenotype, which 
in turn increases the sensitivity and accuracy of the measure88,279.  
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There is a limitation in the way that the UKBB hearing difficulty questions are phrased 
however; no information is captured relating to the age of onset. Considering this, as the 
minimum age of participants is 40 years, a proportion of the control group may have the 
same genetic risk for developing the trait as participants in the case group but are yet to 
develop symptoms. For this reason, it is appropriate to age-match the two groups for 
association analysis, in this sample this was achieved by removing all controls aged <50 
years. In addition to the unknown age of onset, the cause of hearing impairment is also 
unknown. While the majority of the individuals that report a hearing difficulty are 
expected to be experiencing ARHI (as this is the most common form of hearing loss in 
the population), it is likely that there is a proportion of participants suffering from 
hearing loss by a separate cause. Again, using a combination of responses from both of 
the questions can reduce this effect. 
Similar to the hearing difficulty question responses, the responses to the hearing aid use 
question are “Yes”, “No”, “Prefer not to answer” and “Do not know” which again avoid 
bias from a possible ‘emotional’ response. The question is however more subjective; 
participants are asked whether they wear their hearing aid ‘most’ of the time. The 
amount of time that two individuals wear their hearing aids per week could be exactly 
same, but their response to this question may differ simply by their own interpretation 
of ‘most of the time’. Despite this limitation, this question is the closest measure in the 
UKBB to a clinical hearing loss diagnosis; frequent hearing aid uses will have been 
diagnosed with a hearing impairment and have subsequently been prescribed with a 
treatment device.  
This question can therefore serve as a quality control measure for both the accuracy of 
the derived phenotypes and the results from the genetic association analysis. As 
described earlier, this measure could be used to validate SRT scores and identify false-
positive cases or controls. In addition, the cases and controls defined with the hearing 
difficulty questions can be cross-checked with the responses to this question. 
Participants that answered “No” to the hearing difficulty questions and “Yes” to the 
hearing aid use question may have done so, if they do not have any difficulty with their 
hearing while using a hearing aid. In this study however, it is the participant’s hearing 
ability without the use of hearing aids that is of interest. Therefore, this question can be 
used to remove any participants that were falsely assigned ‘controls’ based on this 
interpretation of the hearing difficulty questions.   
The surrogate-ARHI phenotypes derived in this chapter (HDiff and HAid) display the 
hallmarks of ARHI that are possible to test; an increase in prevalence with increasing age 
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and in male subjects. However, as the possible responses are “Yes” and “No”, not further 
subjective classification is required to create a qualitative phenotype. The two qualitative 
were determined to be suitable for use in genetic association analysis. They also provide 
an opportunity to test the validity of phenotypes derived from questionnaire responses, 
in hearing genetic association analysis.  
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Chapter 4 - Genetic association analysis  
4.1 Introduction 
ARHI is understood to be a common complex trait, caused by multiple genetic and 
environmental risk factors. However, as discussed in chapter 1, little is understood about 
how these risk factors contribute to a pathology. GWAS is a method that can be used to 
identify trait-specific genetic risk variants, in the absence of any prior knowledge of trait-
specific mechanisms or biological pathways. Such genetic risk variants can subsequently 
be used to predict the biological underpinnings of a trait213. This method therefore 
provides an important opportunity for ARHI research. The last decade of common 
complex trait genetic research has been termed the ‘GWAS era’ as the method has led to 
the discovery of thousands of loci associated with multiple common complex traits219,280.  
Prior to the advent of GWAS, linkage analysis and candidate gene analysis were 
commonly used to identify novel risk loci for common complex traits such as ARHI. In 
linkage analysis, family pedigrees are studied to identify regions of chromosomes that 
are inherited in conjunction with a phenotype of interest. Linkage analysis was 
commonly used for complex traits prior to the development of SNP arrays and high-
density genotyping, as described in chapter 1 section 1.4.1. Several linkage studies have 
been used to identify genome regions implicated in hearing loss206,207, yet the method is 
most optimal for detecting highly penetrant pathogenic variants causal of Mendelian 
disorders. This is because the method generally lacks the power required to discover 
multiple variants of small effect sizes that cause complex traits such as ARHI.   
Candidate gene analysis is an alternative method used to test for association between a 
trait of interest and specific genome regions. It can be a more accessible approach than 
GWAS as it does not require genome-wide, high density genotyping, and so is less 
economically and computationally demanding. Candidate gene analysis is however 
dependant on prior knowledge of links to a genomic region or biological pathway of 
interest; a limitation for current ARHI studies. 
As described previously in section 1.4, GWAS is a hypothesis-free method where SNPs 
across the genome are tested for association with a trait of interest in a population 
sample. Current GWAS methods are a product of the rapid advances that have been made 
to the methodologies employed to uncover genetic components of common complex 
traits. As the success of GWAS has grown for numerous complex traits, so has the size of 
study samples, range of phenotypes studied and the number and complexity of the 
computational methods.  The optimal statistical method for association analysis depends 
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on the type of data that is used. Quantitative phenotypes are analysed by generalized 
mixed models, under various model assumptions. Qualitative traits are generally 
analysed with logistic regression analysis. Most commonly, an additive model is applied 
in GWAS, but an alternative model can be used, based on the assumption that there are 
alternative genetic effects are present such as dominant, recessive, multiplicative or 
additive SNP variants. During the GWAS era, models have been developed such that data 
with different structures and formats can be comparatively analysed.  
As described in Chapter 1 section 1.4.1, ARHI is in the infancy of its GWAS era. The first 
five ARHI GWAS did not identify any genome-wide significant loci. All five used PTA 
frequency thresholds to derive phenotypes for the association analysis; the studies used 
either selected PTA frequency thresholds, PC analysis or z-scores derived from 
frequency thresholds. The first ARHI GWAS study used population samples pooled from 
9 centres in 7 European countries, with a discovery sample totalling n=1692109. Although 
no genome-wide significant associations were found, authors reported rs11928865, in 
the GRM7 gene transcript, as the most highly associated SNP and replicated at their 
Bonferroni corrected threshold.  
The second study, on the Saami population (n=352), used PC analysis of PTA thresholds 
to define the phenotype and reported rs457717, in the intron of the IQGAP2 gene 
transcript, as the most highly suggestive association107. The third study was another 
meta-analysis of European samples and highlighted suggestive associations with the 
DCLK1, PTPRD, CIMP and GRM8 gene transcripts114. The fourth deployed a logistic 
regression analysis of PTA thresholds on a sample of 3,900 participants from the UK. 
Here the focus was on ESRRG, where an association was observed in females only92. In 
2015 Fransen performed an ARHI GWAS with the aim of replicating these previous 
findings. The authors of this study hypothesised ARHI to be a highly polygenic trait, with 
multiple causal genetic variants that have relatively small effect sizes that are not 
possible to detect with ‘modestly powered’ GWAS38. 
The first genome-wide significant associations in an ARHI GWAS were identified in 2014. 
A SNP in an intron region of the SIK3 gene transcript was identified using a phenotype 
derived from PTA thresholds by PC analysis, in a meta-analysis of European samples 
n=4939111. Later that year, a second study identified significant SNPs in close proximity 
to the  SLC28A3 and PCDH20112 gene transcripts. These two associations were identified 
in a meta-analysis of isolated populations in Italy and Central Asia and were further 
replicated in British and Finnish samples. Most recently, in 2016, the largest ARHI GWAS 
to date was performed using a variety of phenotypes derived from data stored in 
125 
 
electronic health records in the US. The size of the study sample was a magnitude larger 
than any previous ARHI GWAS, with n >6500 ARHI cases and n >45,000 controls. 
Significant associations were identified within and in close proximity to ISG20 and 
TRIOBP gene transcripts and the associations were further replicated in the independent 
UKBB sample113.  
Collectively, these studies reveal only a limited number of genetic variants to be 
significantly associated with ARHI via GWAS in population samples (see Table 1.5). The 
relatively few significant findings, combined with the multiple substantial heritability 
estimates, lead to a hypothesis that, like other complex traits, common adult hearing 
impairment is highly polygenic38. However, due to the recent availability of large-scale 
cohort data, namely the UKBB245, and improved genotyping and imputation coverage, 
there is now the potential for a more comprehensive association analysis to test the 
theory that ARHI has a highly polygenic nature, and to discover trait-associated variants.  
For many traits the GWAS era has permitted the identification of numerous trait-specific 
variant associations. The initial post-GWAS steps have been described in detail in 
Chapter 1, and commonly consist of (i) identifying the most the SNP(s) that best 
represent the association(s) at each region of association,231 (ii) validating the 
associations via replication analysis and (iii) exploring the biological relevance of the 
association, in the context of the trait of interest. Firstly, methods can be deployed that 
test for multiple associations at each locus and determine each lead SNP. Although the 
genome coverage of genotyping arrays and imputation reference panels have greatly 
increased, as described in Chapter 1 on page 62, the causal SNP may not feature on the 
array or panel and thus not be present in the association analysis. Where the data is 
available, the region of interest can even be sequenced, and the true functional variant 
can be identified. 
Secondly, it is custom to replicate the association analysis in an independent cohort to 
ensure that the findings are not study or cohort-specific and that the findings can be 
applied to a larger population. The replication analysis, where possible, ought to apply 
the same analytical method on the same genetic variants, using a comparable phenotype 
definition, in the independent sample231. Thirdly, the biological functions of associated 
SNPs can then be investigated either individually and, or collectively to hypothesise trait-
specific pathological mechanisms. A large number of in vitro and in vivo methods can be 
used to explore this. Further methods such as genetic correlation analysis281 can also be 
applied to draw hypotheses about how different traits are linked by common biological 
functions and pathologies, based on a shared genetic variance. Hypotheses could then 
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even be created with the aim to determine causality between traits, as discussed in 
Chapter 1, section 1.3.3.  
In this chapter genetic association analysis is performed with the aim of identifying 
genetic variants that are associated with the two phenotypes termed ‘HDiff’ and ‘HAid’ 
that were derived from UKBB questionnaire measures (Chapter 3). Secondly, replication 
analysis is performed, along with calculations to estimate the SNP heritability estimates 
for HDiff and HAid the two phenotypes in the UKBB sample. Lastly, gene-set analysis is 
conducted with the aim of identifying enriched biological pathways and mechanisms, 
and genetic correlation analysis conducted with the aim of identifying traits that share 
variance based on common genetic variants. 
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4.2 Results 
The results for this chapter are presented in three main sections as depicted below in 
Figure 4.1. 
 
Figure 4.1. Diagram to illustrate the layout of the results section for chapter 4.  
The three sections are (1) GWAS (2) Replication (3) In silico functional interpretation. 
 
4.2.1 Genome-wide association study  
4.2.1.1 UKBB phenotype definitions for GWAS 
In Chapter 3 two phenotypes were derived for use in genetic association analysis. UKBB 
participants were categorised using a case-control design based on responses to 
questions regarding hearing difficulty (HDiff, n=498,281) and hearing aid use (HAid, 
n=316,629). The description of how these two phenotypes were derived is detailed in 
Chapter 3, section 3.2.3 and - Methods, section 2.1.1.2.  
The samples were filtered based on genomic quality control criteria outlined in Chapter 
2. This was in addition to the genomic quality control that was conducted centrally by 
UKBB. Individuals were removed based on high levels of heterozygosity (indicative of 
sample contamination), any samples with excess relatedness (samples which have more 
than 10 putative third-degree relatives in the kinship table) and selected based on ‘white 
British’ status (samples who self-reported 'White British' and who have the 
corresponding genetic ancestry based on a PC analysis of the genotypes). Following the 
quality control filters, the final sample sizes used for the two association analyses are 
n=250,389 for HDiff (87,056 cases and 163,333 controls, Figure 4.2), n=253,918 for HAid 
(13,178 cases and 240,740 controls, Figure 4.3).  
128 
 
 
Figure 4.2. Flow chart describing case-control assignment for the hearing difficulty 
(HDiff) phenotype. 
Participants answered questions as part of the UKBB questionnaire that was administered at UKBB 
assessment centres. Participants who responded, ‘Prefer not to answer’, ‘I am completely deaf’ and ‘Do not 
know’ were removed from the analysis. Participants were removed from the control group if they responded 
“Yes” to “Do you use a hearing aid most of the time?” A lower age limit of 50 was implemented for controls 
to ensure age was consistent between the case and control groups due to the association of ageing with 
the trait. 
 
 
Figure 4.3. Flow chart describing case-control assignment for the hearing aid use (HAid) 
phenotype. 
Participants answered questions as part of the UKBB questionnaire that was administered at the UKBB 
assessment centres. No information was collected regarding age at hearing aid prescription or cause of 
hearing loss. 
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4.2.1.2 Genetic association analysis  
Two separate genetic association analyses were then conducted for HDiff and HAid,  as 
detailed in - Methods, section 2.1.1.4 - 2.1.1.5. For both analyses, a linear mixed-effects 
model was used to test for association between the two phenotypes  and 9,740,198 SNPs, 
using the analysis tool BOLT-LMM v.2.3.2226. The BOLT-LMM linear mixed effects model 
accounts for population stratification and cryptic relatedness present in large samples 
such as the UKBB, and jointly models all genotype markers. The two association analyses 
resulted in the identification of 2,080 SNPs associated with HDiff at genome-wide 
significance (P<5E-08) and 240 SNPs associated with HAid at genome-wide significance 
(P<5E-08), Figure 4.4. 
In certain datasets, it is common practice to assess the genomic inflation factor (λGC) to 
determine the amount of genomic inflation present and even to adjust the test statistics 
accordingly. However, when using large-scale datasets to analyse polygenic traits, this 
 
Figure 4.4. Manhattan plots displaying GWAS results for (a) HDiff, and (b) HAid 
phenotypes.  
The Manhattan plots display the P values of all SNPs tested in discovery analysis. The threshold for 
genome wide significance (p<5E-08) is indicated by a red dotted line. 
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can be an overly conservative approach. Therefore, an approach such as LDSC can be 
used to estimate the proportion of inflation in the χ2 statistic that the intercept 
attributes to alternative explanations than polygenicity, such as population 
stratification. Here, univariate linkage disequilibrium score regression (LDSC), (detailed 
in - Methods 2.2.1), was used to analyse the relationship between test statistic and LD251. 
Figure 4.5 displays quintile-quintile (Q-Q) plots for both HDiff and HAid analysis. The LD 
score regression intercepts for the two analyses are 1.032 for HDiff and 1.03 for HAid. 
The ratio (intercept-1)/(mean(χ2)-1) for HDiff was 8% and 5% for HAid. These represent 
the proportions of the inflation in the χ2 statistic that the intercept attributes to 
alternative explanations than polygenicity.  
4.2.1.3 Conditional and Joint analysis  
SNPs included in the analysis which are in proximity with the causal SNP at an associated 
locus, will likely have inflated test statistics due to LD. Therefore, not all significant SNPs 
represent individual associations, a cluster of SNPs in LD is likely representing only one 
or two causal variants. Rather than assuming that the SNP with the smallest P-value (and 
thus has the highest association) in each region of LD represents and captures the true 
effect of the variation at the locus, a conditional and joint analysis was conducted. The 
method tests for the presence of multiple causal variants at individual loci and whether 
the variation is accurately represented by a single SNP232.  
 
Figure 4.5. Q-Q plot of GWAS summary statistics, HDiff (left) and HAid (right).  
The plots display the quantile distribution of observed p-values (y-axis) vs the quantile distribution of expected p-
values (x-axis). 
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Here conditional and joint analysis using GCTA-COJO232, as described in - Methods 2.2.2, 
estimated that the 2,080 and 240 SNPs represent 41 and 7 independent loci to be 
associated with HDiff and HAid respectively, and identified a lead SNP at each locus. The 
method calculates a joint p-value for the region (pJ-value, Table 4.1, Table 4.2). Where 
this value is greater than the lead SNP p-value, this indicates that the true variance at 
that region is underestimated by the effect of the single SNP.  
4.2.1.4 Predicting the functional effects of variants using in-silico analysis 
Following the identification of the 48 lead SNPs, the Variant Effect Predictor (VEP)258 was 
used to establish the genomic context of each lead SNP. Each of the 48 SNPs was mapped 
to the nearest protein coding gene using the GRCh37 genomic reference. 27 of the HDiff 
lead SNPs and all seven of the HAid lead SNPs are located within gene transcripts. Of 41 
lead SNPs associated with HDiff, six variants lie in exons, four of which are predicted to 
result in missense mutations in the following genes transcripts: EYA4, CDH23, KLHDC7B 
and TRIOBP. 21 of the remaining HDiff lead SNPs lie within introns and the 14 remaining 
HDiff lead SNPs are intergenic (Table 4.1.1). Six of the lead SNPs associated with HAid 
reside in intronic regions and 1 lead SNP is intergenic. In Table 4.1and Table 4.2, the 
nearest protein coding gene to each SNP is named, along with the distance from the lead 
SNP to the gene transcript.   
Four gene loci feature lead SNPs in both HDiff and HAid: ARHGEF28, NID2, CTBP2 and 
EYA4. Furthermore, two highly significant independent associations with HDiff are 
within 100 kb of the ARHGEF28 gene (rs6453022, p-value=2.07E-12 and rs6890164, p-
value=4.15E-10), and the locus is also highly associated with the HAid phenotype 
(rs4597943, p-value=2.10E-11). The names of the genes in close proximity to the lead 
SNPs,  (Table 4.1 column 10 and Table 4.2 column 10) are annotated ‘a’ where the gene 
has previously been linked to a hearing phenotype or has a known function in the 
auditory system. Ten genes, a quarter of those listed, have previous links to hearing 
phenotypes or auditory function and are discussed in detail in Chapter 5. 
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HDiff results  
Chr SNP EA EAF INFO β SE p-value pJ-value Genes within 100kb 
Dist. To nearest 
gene (bp) 
22 rs36062310 G 0.96 1.000 -0.0315 0.003 1.90E-22 1.92E-22 
KLHDC7B, SYCE3, ADM2, ARSAa, CHKB, 
CPT1B, LMF2, MAPK8IP2, MIOX, NCAPH2, 
ODF3B, SBF1, SCO2, SYCE3, TYMP 
0 
5 rs6453022 C 0.50 1.000 -0.0126 0.001 1.70E-21 2.07E-12 ARHGEF28 0 
6 rs759016271 AGTAGTCCACTTTTC
TTCTTTGCCTG 0.39 0.997 -0.0127 0.001 6.10E-21 6.16E-21 
ZNF318, CRIP3, SLC22A7, CUL9, DNPH1, 
TTBK1 
0 
5 rs6890164 A 0.51 0.993 0.0119 0.001 3.30E-19 4.15E-10 ARHGEF28 6177 
11 rs7951935 G 0.62 0.996 -0.0114 0.001 7.80E-17 7.85E-17 TYR, NOX4 1472 
6 rs35186928 G 0.62 0.991 -0.0109 0.001 1.70E-15 1.69E-15 
HLA-DQA1, HLA-DRB1, HLA-DRB3, HLA-
DRB5, HLA-DRB6 
13352 
6 rs9493627 G 0.68 1.000 -0.0104 0.001 1.40E-13 1.41E-13 EYA4a  0 
22 rs132929 G 0.59 0.999 -0.0098 0.001 2.20E-13 4.61E-13 
BAIAP2L2a, SLC16A8, PICK1, PLA2G6, 
POLR2F 
0 
22 rs5756795 T 0.54 1.000 -0.0092 0.001 5.10E-12 1.09E-11 
TRIOBPa, GALR3, GCAT, GGA1a, H1F0, 
LGALS1, NOL12, PDXP, SH3BP1 
0 
14 rs1566129 T 0.41 1.000 0.0091 0.001 1.40E-11 1.37E-11 NID2, GNG2, RTRAF 0 
4 rs35414371 T 0.87 0.998 -0.0131 0.002 1.60E-11 1.64E-11 CLRN2a, LAP3, MED28, QDPR 1965 
3 
3:182069497_
TA_T 
TA 0.84 0.989 -0.0118 0.002 4.10E-11 4.07E-11 ATP11B  441791 
11 rs12225399 G 0.65 0.989 -0.009 0.001 8.60E-11 8.67E-11 
PHLDB1, ARCN1, IFT46, KMT2A, 
TMEM25, TREH, TTC36 
0 
11 rs55635402 A 0.81 0.996 0.0105 0.002 2.90E-10 2.94E-10 TUBa, EIF3F, NLRP10, OR10A3, RIC3 0 
16 rs62033400 A 0.61 0.999 0.0085 0.001 2.90E-10 2.95E-10 FTO, RPGRIP1L 0 
8 rs13277721 G 0.49 0.992 -0.0083 0.001 3.30E-10 3.35E-10 AGO2, PTK2 0 
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HDiff results  
Chr SNP EA EAF INFO β SE p-value pJ-value Genes within 100kb 
Dist. To nearest 
gene (bp) 
2 rs62188635 C 0.45 0.988 0.0083 0.001 4.70E-10 4.72E-10 KLF7 50519 
6 rs2236401 C 0.49 0.997 -0.0081 0.001 9.30E-10 9.38E-10 SYNJ2a, SERAC1a, GTF2H5 0 
7 rs4947828 T 0.23 0.999 -0.0096 0.002 1.00E-09 1.02E-09 GRB10 0 
10 rs6597883 T 0.84 0.989 0.0111 0.002 1.00E-09 1.05E-09 CTBP2 0 
5 rs34442808 T 0.49 0.992 -0.008 0.001 1.30E-09 1.32E-09 MCTP1, SLF1 0 
10 rs835267 A 0.53 0.996 0.008 0.001 1.60E-09 1.58E-09 EXOC6, CYP26A1, CYP26C1 0 
10 rs4948502 T 0.57 0.995 0.0081 0.001 1.70E-09 5.63E-10 ARID5B   0 
10 rs10824108 G 0.42 0.999 -0.0079 0.001 3.00E-09 1.24E-08 ADK, AP3M1, VCL 0 
1 rs12027345 G 0.57 0.995 0.0079 0.001 3.60E-09 3.64E-09 
MAST2, GPBP1L1, MAST2, TMEM69, 
TMA16P2, GPBP1L1 
12668 
6 rs217289 G 0.56 0.992 -0.0078 0.001 4.90E-09 4.92E-09 SNAP91 0 
3 rs13093972 A 0.55 0.992 -0.0078 0.001 5.50E-09 5.56E-09 ZBTB20 121137 
15 rs62015206 C 0.41 1.000 -0.0078 0.001 7.70E-09 7.76E-09 MAPK6, BCL2L10, GNB5 15613 
5 rs10475169 A 0.88 1.000 -0.0117 0.002 9.30E-09 9.37E-09 IRX2 190445 
17 rs17671352 T 0.38 0.999 0.0078 0.001 1.00E-08 1.43E-08 
ACADVL, DVL2a, DLG4, ASGR1, CLDN7, 
CTDNEP1, EIF5A, ELP5, GABARAP, GPS2, 
NEURL4, PHF23, SLC2A4, YBX2 
0 
1 rs7525101 C 0.56 1.000 -0.0075 0.001 1.50E-08 1.45E-08 LMX1Aa  61973 
17 rs12938775 G 0.50 1.000 0.0075 0.001 1.60E-08 2.25E-08 PAFAH1B1, CLUH, RAP1GAP2 0 
8 rs76837345 A 0.93 0.997 -0.0146 0.003 1.90E-08 1.95E-08 
CHMP4C, IMPA1, SLC10A5, SNX16, 
ZFAND1 
0 
6 rs9366417 G 0.26 0.993 0.0085 0.002 2.10E-08 2.12E-08 SOX4 291019 
8 rs3890736 G 0.63 0.993 -0.0077 0.001 2.20E-08 2.22E-08 GFRA2 15676 
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HDiff results  
Chr SNP EA EAF INFO β SE p-value pJ-value Genes within 100kb 
Dist. To nearest 
gene (bp) 
10 rs143282422 G 0.99 1.000 -0.0349 0.006 2.40E-08 3.02E-08 CDH23a, C10orf105 0 
7 rs9691831 A 0.42 0.995 -0.0074 0.001 3.10E-08 3.11E-08 TMEM213, ATP6V0A4a, KIAA1549 0 
11 rs141403654 A 0.98 0.878 -0.0313 0.006 3.50E-08 3.53E-08 
AGBL2, C1QTNF4, FNBP4, MTCH2, 
NUP160 
0 
18 rs4611552 T 0.78 0.995 -0.0089 0.002 3.60E-08 3.56E-08 CCDC68 9362 
13 rs12552 A 0.44 0.994 0.0073 0.001 4.80E-08 4.86E-08 OLFM4 0 
1 rs10927035 C 0.35 0.995 -0.0075 0.001 4.90E-08 4.89E-08 ATK3, SDCCAG8 0 
Table 4.1. Results output from BOLT-LMM and GCTA-COJO for HDiff association analysis.  
The table is continued on from the previous pages. Results output from BOLT-LMM and GCTA-COJO. Chr., chromosome; SNP, single nucleotide 
polymorphism; EA, effect allele; EAF, frequency of effect allele in BOLT-LMM; INFO, imputation quality metric, combination of imputation score and dosage 
confidence; β, effect size from BOLT-LMM approximation to infinitesimal mixed model; SE, standard error of the effect size; p-value, infinitesimal mixed-effects 
model association test p-value; pJ-value, p-value from a joint analysis of all the selected SNPs; Genes within 100kb, protein-coding genes that are within 100kb 
of the lead SNP. The gene in closest proximity to the SNP is emboldened; Dist. to gene (bp), distance in base pairs between SNP and nearest gene, a value of 
0 indicates the SNP lies within the gene. a denotes genes previously linked to hearing phenotypes in mice or humans. Two SNPs reached genome-wide 
significance that are in close proximity to HLA-DQA1 on Chr 6 (Figure 4.4) but were not present in conditional analysis results.    
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HAid results  
Chr SNP EA  EAF INFO β SE p-value pJ-value Genes within 100kb 
Dist. to nearest 
gene (bp) 
5 rs4597943 G 0.51 0.989 -0.0042 0.001 2.10E-11 2.09E-11 ARHGEF28 0 
2 rs9677089 A 0.75 0.989 -0.0046 0.001 2.00E-10 1.98E-10 SPTBN1a 0 
6 rs9321402 G 0.68 0.999 -0.0042 0.001 3.00E-10 3.02E-10 EYA4a 0 
14 rs1566129 T 0.41 1.000 0.0037 0.001 2.50E-09 2.53E-09 NID2, RTRAF 0 
3 rs3915060 C 0.27 0.983 0.004 0.001 9.70E-09 9.70E-09 ILDR1a, CD86, SLC15A2 0 
10 rs10901863 C 0.73 0.934 -0.004 0.001 2.60E-08 2.65E-08 CTBP2 0 
8 rs7823971 C 0.80 0.991 -0.0043 0.001 2.70E-08 2.68E-08 RP11-1102P16.1 0 
Table 4.2.   Results output from BOLT-LMM and GCTA-COJO for HAid association analysis.  
Results output from BOLT-LMM and GCTA-COJO. Chr., chromosome; SNP, single nucleotide polymorphism; EA, effect allele; EAF, 
frequency of effect allele in BOLT-LMM; INFO, quality metric, combination of imputation score and dosage confidence; β, effect size from 
BOLT-LMM approximation to infinitesimal mixed model; SE, standard error of the effect size; p-value, infinitesimal mixed-effects model 
association test p-value; pJ-value, p-value from a joint analysis of all the selected SNPs; Genes within 100kb, protein-coding genes that are 
within 100kb of the lead SNP. The gene in closest proximity to the SNP is emboldened; Dist. to nearest gene (bp), distance in base pairs 
between SNP and nearest gene, a value of 0 indicates the SNP lies within the gene. a denotes genes previously linked to hearing phenotypes 
in mice or humans; Two SNPs reached genome-wide significance that are in close proximity to HLA-DQA1 on Chr 6 (Figure 4.4) but were not 
present in conditional analysis results.    
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4.2.1.5 Heritability analysis of HDiff and HAid 
SNP heritability estimates (h2g) were calculated for HDiff and HAid with BOLT-LMM, as 
described in - Methods 2.2.3. The h2g was calculated as 0.117±0.001 HDiff for and h2g 
and 0.029±0.001 for HAid. BOLT-LMM is a tool for linear mixed models’ analysis and so 
this calculation assesses the variance under the assumption that the phenotype is a 
continuous trait. HDiff and HAid are qualitative phenotypes and so the estimates require 
a recalculation to the liability scale. The heritability estimates recalculated to the liability 
scale are 0.19 and 0.13 for HDiff and HAid respectively. 
4.2.2 Testing the replication of UKBB genetic associations in other 
samples 
An established method to validate GWAS associations is to replicate the association 
analysis in an independent study sample282. Here, replication was sought for the 41 lead 
SNPs in HDiff and the 7 lead SNPs in HAid by meta-analysing three independent samples; 
(i) the remaining northern-European population group in the UKBB cohort (white, non-
British Europeans), (ii) TwinsUK, and (iii) the English Longitudinal Study of Ageing 
(ELSA). Individually, each of these samples are relatively small in size and so a meta-
analysis approach was taken in order to increase the statistical power of the replication 
analysis.  
4.2.2.1 Samples and phenotypes used in replication analysis 
TwinsUK and the English Longitudinal Study of Ageing (ELSA) are two cohorts that were 
selected as replication samples. The cohorts were deemed suitable as the majority of the 
sample subjects are of northern European ancestry and both studies have collected 
hearing-related questionnaire data that is comparable to that collected by the UKBB. 
Further descriptions of the two samples are in - Methods 2.1.3 (ELSA) and - Methods 
2.1.2 (TwinsUK). The third sample comprised of subjects from the UKBB that are of 
northern European-ancestry and that were not used in the discovery association 
analysis,  as detailed in - Methods 2.1.1.2. Qualitative phenotypes were derived from 
questionnaire responses for both the ELSA and TwinsUK samples, as detailed in - 
Methods 2.1.2.2 and summarised below.  
Qualitative phenotypes were derived from questionnaire responses for both the ELSA 
and TwinsUK samples, as detailed in - Methods 2.1.2.2. In the ELSA sample, using data 
from wave 7 only, participants that responded “Yes” to both of the following questions; 
“Do you ever have any difficulties with your hearing?” and “Do you find it difficult to 
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follow a conversation if there is background noise, such as TV, radio or children playing 
(using a hearing aid as usual)?” were classified as HDiff cases, and participants that 
responded “No” to both, were classified as HDiff controls. As in the UKBB discovery 
analysis, controls who reported hearing aid use or age <50 were removed, as were any 
cochlear implant users in the case or control samples. Participants that responded, “Yes 
most of the time”, or “Yes some of the time” to “Whether ever wears a hearing aid” were 
classified as HAid cases and those that responded “No” were classified as HAid controls.  
In the TwinsUK sample, participants that responded either “Yes, diagnosed by doctor or 
health professional” or “Yes, not diagnosed by health professional” to the question “Do 
you suffer from hearing loss?” were classified as HDiff cases while those that responded 
“No” to any of the questions were classified as HDiff controls. Participants that responded 
or indicated “Yes” to either of “Do you wear a hearing aid?” and ‘Wearing a hearing aid’ 
were classified as HAid cases and those that responded no were classified as HAid 
controls. Twins aged <40 were removed from case and control groups prior to analysis 
so that the lower age limit was comparable to the UKBB cohort. In order to retain the size 
of the TwinsUK sample and thus optimise power, controls aged <50 were not removed 
(as in the discovery HDiff UKBB analysis). 
The same phenotype classification that was used for the discovery association analysis 
(described in Chapter 3) was used for the UKBB white non-British European sample, see 
- Methods 2.1.1.2. (here used for the replication analysis), resulting in HDiff n=23,582 
and HAid n=27,087. Resulting Twins UK samples sizes for association analysis of these 
traits were HDiff n = 3636 and HAid n = 3435 and for ELSA, samples sizes for association 
analysis of these traits were HDiff n = 3545 and HAid n = 4482. As noted previously, these 
samples are relatively small by comparison to the UKBB discovery sample and so a meta-
analysis approach was taken to increase statistical power to detect an association with 
the selected SNPs. The meta-analysis sample sizes totalled HDiff n = 30,765 and HAid n = 
35,004.  
4.2.2.2 Association analysis in replication samples  
Association analysis was conducted on each of the three samples individually, prior to 
the meta-analysis. Due to intrinsic differences between the samples and datasets, 
different models were used to test for association in each of the three samples. Genotype 
and imputation details for TwinsUK and ELSA are listed in are listed in - Methods 2.1.2.3 
and 2.1.3.3 respectively. A meta-analysis of all three association analyses was performed 
on the 48 lead SNPs identified in the two discovery GWAS (HDiff and HAid). A fixed-effect 
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inverse-variance weighted meta-analysis was conducted using METAL253 version 2011-
03-25.   
Replication was sought for all leading SNPs identified by conditional and joint analysis 
(41 for HDiff and 7 for HAid), and so Bonferroni corrections were applied in order to 
account for multiple testing. This resulted in the Bonferroni-corrected thresholds of 
significance being 0.05/41=0.0012 for HDiff and 0.05/7=0.00714 for HAid. Two intronic 
SNPs, rs759016271 in ZNF318 and rs1566129 in NID2, reached significance in the HDiff 
replication analysis (P<0.0012), and a further intronic SNP, rs4597943 in ARHGEF28 
replicated in HAid analysis at the significance threshold (P<0.00714). An additional 14 
SNPs reached nominal significance (Table 4.3and Table 4.4). 
Replication association analysis was conducted on the lead SNP at each locus. This was 
to avoid obtaining an over-conservative significance threshold; the greater the number 
of SNPs tested, the more conservative the Bonferroni level of significance. In both 
replication samples, all lead SNPs were present, i.e. genotyped, or imputed. It was 
therefore deduced that if the lead SNP was not the ‘causal’ SNP at the locus, the lead SNP 
would feature an inflated test statistic due to it being in LD with the causal SNP. This is 
because the two replication samples are of the same ancestral population subgroup as 
the discovery analysis and would therefore exhibit largely similar LD structures. This 
would remain the case if the ‘causal’ SNP did not feature on the genotyping platform or 
imputation panel in any of the samples.  
4.2.2.3 Estimating the statistical power of the replication analysis  
Power calculations were performed to assess the power of this replication sample to 
replicate the initial findings from the discovery association analysis282. Individual power 
calculations were performed for each of the 48 lead SNPs (for equation, see - Methods 
2.2.4.2). The significance value was Bonferroni corrected (0.05/41 and 0.05/7) for both 
traits and thus was set at p<0.0012 for HDiff and p<0.00714 for HAid.  
Based on these calculations, the meta-analysis sample is estimated to have >80% power 
to replicate 6 of the 41 HDiff lead SNPs at a Bonferroni-corrected significance level, 
p<0.0012. For 39 of the 41 SNPs, the sample was estimated to provide >80% to replicate 
the associations at a nominal level of significance, p<0.05. As for the replication of HAid 
lead SNPs, this sample was estimated to have <80% power to replicate all 8 lead SNPs at 
either Bonferroni-corrected or nominal thresholds of significance. The results of these 
power calculations are displayed alongside the replication summary statistics below, in 
Table 4.3 and Table 4.4.  
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SNP A1 A2 Weight Zscore P-value Dir. 
Rep. pwr. 
p<0.05 
Rep. pwr. 
p<0.0012 
rs759016271 a 
Agtagtcc 
Acttttctt 
ctttgcctg 
29866 4.556 5.20E-06 +++ 0.900 0.504 
rs1566129 t c 30894 3.534 0.00041 +++ 0.661 0.195 
rs36062310 a g 30868 2.974 0.002938 +-- 0.928 0.575 
rs143282422 a g 30274 2.652 0.007996 +-+ 0.492 0.098 
rs12225399 c g 29802 2.624 0.008688 +++ 0.610 0.160 
rs6597883 t c 30274 2.585 0.009748 ++- 0.564 0.133 
rs62033400 a g 30851 2.513 0.01198 +++ 0.600 0.153 
rs7951935 t g 29802 2.48 0.01312 ++- 0.820 0.360 
rs141403654 a t 29802 -2.392 0.01674 --- 0.477 0.091 
rs35186928 a g 29866 2.348 0.01885 +-+ 0.785 0.314 
rs17671352 t c 30852 2.228 0.02587 ++- 0.520 0.110 
rs217289 a g 29866 2.227 0.02597 +-+ 0.524 0.112 
rs62188635 t c 30377 -2.189 0.02859 --- 0.583 0.144 
rs76837345 a g 30318 -2.158 0.0309 --- 0.499 0.101 
rs55635402 a g 29802 2.132 0.03301 +++ 0.585 0.145 
rs10824108 t g 30274 1.982 0.04752 +-+ 0.541 0.120 
rs2236401 t c 29866 1.873 0.06102 ++- 0.561 0.131 
rs5756795 t c 30868 -1.696 0.08981 --+ 0.679 0.209 
rs7525101 t c 30389 1.636 0.1018 +++ 0.506 0.104 
rs10475169 a c 30356 -1.603 0.1088 -+- 0.516 0.108 
rs4948502 t c 30274 1.574 0.1155 +-+ 0.553 0.127 
rs9691831 a g 30717 -1.512 0.1305 -+- 0.492 0.098 
rs12938775 a g 30852 -1.481 0.1385 -+- 0.509 0.105 
rs4611552 t c 30753 -1.434 0.1515 --- 0.489 0.096 
rs13093972 a g 30098 -1.413 0.1577 --+ 0.525 0.113 
rs6453022 a c 30356 1.327 0.1846 +-- 0.912 0.532 
rs835267 a g 30274 1.17 0.242 ++- 0.555 0.128 
rs35414371 a t 30856 1.163 0.245 +-+ 0.657 0.192 
rs9493627 a g 29866 1.018 0.3086 +++ 0.724 0.248 
rs12027345 a g 30389 -0.986 0.3244 --+ 0.537 0.119 
rs3890736 a g 30318 -0.706 0.4805 +-- 0.495 0.099 
rs4947828 t g 30717 -0.562 0.574 +-- 0.571 0.137 
rs13277721 a g 30318 0.527 0.5983 +-- 0.590 0.147 
rs12552 a g 30676 0.489 0.6249 +-+ 0.480 0.093 
rs6890164 a g 30356 0.298 0.7658 +-- 0.877 0.455 
3:182069497_TA_T t ta 30098 0.298 0.766 ++- 0.629 0.172 
rs132929 a g 30868 0.234 0.815 ++- 0.731 0.256 
rs10927035 t c 30389 0.219 0.8268 +-+ 0.476 0.091 
rs34442808 t ta 30356 0.218 0.8277 -++ 0.560 0.131 
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SNP A1 A2 Weight Zscore P-value Dir. 
Rep. pwr. 
p<0.05 
Rep. pwr. 
p<0.0012 
rs9366417 a g 29866 0.137 0.8911 +-+ 0.490 0.097 
rs62015206 t c 30459 -0.071 0.9437 --+ 0.522 0.111 
Table 4.3. Summary statistics for HDiff phenotype from the replication meta-analysis of 
the white non-British UKBB sample, TwinsUK and ELSA.   
SNP, SNP ID; A1, the first allele for this marker in the first file where it occurs; A2, the second allele for this 
marker in the first file where it occurs; Weight, the sum of the individual study weights (N) for this marker; Z-
score, the combined z-statistic for the marker; P-value, meta-analysis p-value; Direction, direction of effect 
for each study ordered: white non-British UKBB sample, TwinsUK, ELSA; Replication power at p<0.05, 
estimated power to identify a replicated association at nominal significance; Rep. pwr. p<0.0012, estimated 
power to detect an association at significance threshold 0.05/41 = 0.0021, p<0.0012. 
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4.2.2.4 Replication of previously published ARHI GWAS findings  
In addition to the meta-analysis replication, it was investigated whether any associations 
that are highlighted by authors in previous ARHI GWAS, are replicated here in the HDiff 
or HAid discovery White British sample. Previous ARHI GWAS have identified significant 
associations between 5 gene loci (SIK3111, PCDH20112, SLC8A3112, ISG20113 and TRIOBP113) 
and ARHI phenotypes, while all other studies reported the most highly associated SNPs.  
Only two of the previously highlighted SNPs, located in close proximity to ISG20 and 
within TRIOBP, were significant in the HDiff analysis at a Bonferroni-corrected level of 
significance (p<7.50E-07). These two associations were originally identified in a GWAS 
that used phenotypes that were derived from electronic health records (Hoffman et al., 
2016113). No other lead variants from previous ARHI genetic studies were replicated at 
nominal level in this analysis, including the first reported ARHI associated gene variant 
in GRM7109. The summary statistics from HDiff and HAid for the SNPs highlighted in 
previous analysis are listed in Table 4.5. The legend for Table 4.5 is presented on the 
following page, is: 
Table 4.5. Summary statistics from HDiff and HAid GWAS analysis, at SNPs highlighted in 
previous adult hearing loss GWAS. 
Study, publication of previous finding; Gene, gene highlighted in the referenced publication as the lead SNP is 
either located in the gene region or in close proximity; SNP, single nucleotide polymorphism; CHR, 
Chromosome; BP, base position; A1, effect allele in analysis; A0, reference allele; INFO, quality metric, 
combination of imputation score and dosage confidence; UKBB pheno, phenotype used in this study; A1FREQ, 
frequency of effect allele in analysis sample; BETA, effect size from BOLT-LMM approximation to infinitesimal 
mixed model; SE, standard error of the effect size; p-value, infinitesimal mixed model association test p-value. 
*The SNP rs58389158 was not included in this analysis, but the SNP rs5756795, which is in complete LD with 
this SNP in the British population is listed here and referenced in the previous study. 
SNP A1 A2 Weight Zscore P-value Dir. 
Rep. pwr. 
p<0.05 
Rep. pwr. 
p<0.00714 
rs4597943 t g 34475 2.833 0.004608 +++ 0.695 0.413 
rs7823971 a c 34919 -1.886 0.05934 --- 0.541 0.265 
rs3915060 t c 34359 -1.664 0.09605 --+ 0.560 0.281 
rs1566129 t c 35139 0.784 0.4333 ++- 0.602 0.318 
rs10901863 t c 32251 0.638 0.5234 +-- 0.510 0.240 
rs9321402 a g 35101 0.58 0.5622 ++- 0.649 0.364 
rs9677089 a c 34727 -0.537 0.5915 --+ 0.653 0.368 
Table 4.4. Summary statistics for HDiff phenotype from the replication meta-analysis of 
the white non-British UKBB sample, TwinsUK and ELSA.   
SNP, SNP ID; A1, the first allele for this marker in the first file where it occurs; A2, the second allele for 
this marker in the first file where it occurs; Weight, the sum of the individual study weights (N) for this 
marker; Z-score, the combined z-statistic for the marker; P-value, meta-analysis p-value; Direction, 
direction of effect for each study ordered: white non-British UKBB sample, TwinsUK, ELSA; Replication 
power at p<0.05, estimated power to identify a replicated association at nominal significance; Rep. pwr. 
p<0.0012, estimated power to detect an association at significance threshold 0.05/7 = 0.00714, 
p<0.00714. 
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Variant highlighted in previous study Summary statistics from HDiff and HAid analysis in the UKBB cohort 
Citation Gene SNP CHR BP A1 A0 INFO 
UKBB 
pheno 
A1FREQ BETA SE p-value 
Friedman et al., 
2009109 
GRM7 rs11928865 3 7155702 T A 0.989 
HDiff 0.741 0.0016 0.0015 0.28 
HAid 0.742 -0.0014 0.0007 0.05 
Van Laer et al., 
2010107 
IQGAP2 rs457717 5 75920972 A G 0.986 
HDiff 0.326 0.0013 0.0014 0.34 
HAid 0.325 -0.0006 0.0007 0.37 
GRM7 rs161927 3 7838242 G A 0.988 
HDiff 0.134 0.0038 0.0019 0.05 
HAid 0.136 -0.0002 0.0009 0.86 
Girotto et al., 
2011114 
DCLK1 rs248626 5 141097725 A G 1.000 
HDiff 0.251 0.0018 0.0015 0.23 
HAid 0.252 -0.0003 0.0007 0.71 
KCNMB2 rs4603971 3 177902467 G A 0.992 
HDiff 0.934 -0.0015 0.0027 0.58 
HAid 0.934 0.0006 0.0012 0.63 
CMIP rs898967 16 81566780 C T 0.981 
HDiff 0.476 0.0010 0.0013 0.45 
HAid 0.476 0.0002 0.0006 0.76 
GRM8 rs2687481 7 125869122 G T 0.998 
HDiff 0.811 -0.0018 0.0017 0.28 
HAid 0.810 0.0012 0.0008 0.14 
Nolan et al., 
201392 
ESSRG rs2818964 1 216682448 G A 0.978 
HDiff 0.366 -0.0015 0.0014 0.27 
HAid 0.366 0.0004 0.0006 0.55 
Wolber et al., 
2014111 
SIK3 rs681524 11 116748314 T C 0.992 
HDiff 0.927 -0.0010 0.0026 0.71 
HAid 0.928 0.0018 0.0012 0.13 
Vuckovic et al., 
2015112 
PCDH20 rs78043697 13 62467039 T C 0.995 
HDiff 0.928 0.0000 0.0025 1.00 
HAid 0.928 0.0010 0.0012 0.38 
SLC28A3 rs7032430 9 86714002 C A 0.959 
HDiff 0.782 -0.0013 0.0016 0.43 
HAid 0.783 -0.0001 0.0008 0.91 
Fransen et al., 
201538 
ACVR1B rs2252518 12 52381026 C A 0.996 
HDiff 0.739 -0.0010 0.0015 0.50 
HAid 0.739 0.0001 0.0007 0.85 
CCBE1 rs34175168 18 57180682 G A 0.990 
HDiff 0.986 0.0112 0.0056 0.04 
HAid 0.986 -0.0009 0.0026 0.74 
Hoffman et al., 
2016113 
ISG20 rs4932196 15 89253268 T C 1.000 
HDiff 0.809 0.0085 0.0017 4.60E-07 
HAid 0.809 0.0039 0.0008 6.40E-07 
TRIOBP rs5756795* 22 38122122 T C 1 
HDiff 0.539 -0.0092 0.0013 5.10E-12 
HAid 0.538 -0.0027 0.0006 1.60E-05 
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4.2.3 In silico functional interpretation of genetic association analysis 
results 
The final sections of this chapter consist of in silico functional annotation of the results 
from the association analysis in section 4.2.1. In each of the following sections, methods 
are used to translate the SNP associations that were identified and validated in the 
previous sections, into putative findings relating to their biological relevance and multi-
trait effects. 
4.2.3.1 Gene-set analysis  
Gene-set analysis is a method that is commonly used for translating GWAS SNP 
associations into biologically relevant knowledge. Associated SNPs can be mapped to 
genes based on SNP location and function. These genes are then compared to pre-defined 
gene sets. Gene sets that show significant enrichment of the mapped genes, can thus be 
putatively linked to the trait of interest. Gene sets can allude to biological mechanisms as 
gene sets are defined by common functions and, or expression patterns.  
This is a particularly useful method in the analysis of polygenic traits because the 
combined effects of the associated variants (with individual small effect sizes) can be 
studied. In addition, by studying the combined effects, the threshold for significance is 
also lowered. The analysis was performed here using FUMA233, in two distinct steps; 
‘SNP2GENE’ and ‘GENE2FUNC’, where the results in the first step are used to calculate 
the latter. Firstly, gene association p-values are quantified based on associations of SNPs 
within 10kb of gene transcripts. Secondly, this group of genes are tested for enrichment 
in pre-defined gene sets, see - Methods 2.3.1. 
The gene sets and gene ontology (GO) terms that are used to classify the gene sets are 
from MSigDB v5.2 (http://software.broadinstitute.org/gsea/index.jsp). GO annotations 
include three groups; molecular function, cellular component and biological process. 
GENE2FUNC analysis was performed for both HDiff and HAid. In the SNP2GENE function, 
SNPs from the association analysis were mapped to 113 protein coding genes that were 
within 10kb of SNP location. For HDiff, significant gene sets are displayed in Figure 4.6; 
28 GO biological functions were significantly enriched with genes from the 113 
prioritised genes from HDiff analysis. As the number of genes within gene sets differ, and 
the number of genes that are enriched in each set are differ. The pink bar chart in Figure 
4.6 displays the proportion of overlapping genes per gene set, while the blue bar chart 
visualises the p-value for enrichment in each gene set. The yellow blocks on the graph 
demonstrate which genes (x-axis) are included in each gene set (y-axis). 
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The three GO biological functions with the most significant p-values are Dendritic spine 
organisation, Receptor clustering and Dendrite morphogenesis, all with an adjusted 
enrichment p-value of p=5.87e-3. All three of these processes are concerned with 
relaying or receiving information via either neuron or receptor structure and function. 
Based on the known structure of the auditory system, the function of associated genes 
can therefore be hypothesised. The biological processes that individual genes are 
associated with, and the interactions between genes within the same groups can be 
investigated further.  
4.2.3.2 Genetic correlation analysis between HDiff and >700 traits   
Genetic correlation analysis is a method that can be used to investigate relationships 
between traits, based on the proportion of their variance that is due to shared genetic 
variants.  Genetic correlations calculated via this method range from -1 rg to 1 rg, where 
0 indicates that the genetic causes of trait variance are entirely independent and 1 
indicates a complete correlation while a negative score indicates a negative correlation. 
Using publicly available summary statistics from several hundred GWAS analyses, and 
the summary statistics from HDiff association analysis, it has been possible to estimate 
the genetic correlation between HDiff and 764 different traits (publicly available GWAS 
summary statistics on LD hub251,255 see - Methods 2.3.2.). 
Following a Bonferroni correction (0.05/764, p< 6.54E-05), 153 traits display a 
significant correlation with HDiff.  The trait with the highest significant correlation to 
HDiff is ‘Tinnitus: Yes_ now most or all of the time’. This trait represents a sample that 
report experiencing tinnitus symptoms ‘now or most of the time’ that can be described 
as ‘noise (such as ringing or buzzing) in your head or in one or both of your ears that 
lasts for more than five minutes at a time?’ The data used in the correlation analysis with 
HDiff, consists of results from a GWAS run at the Neale lab that used UKBB tinnitus 
questionnaire responses as a phenotype (http://www.nealelab.is/)283.  
41 of the significant traits have an rg< -0.3 or rg> 0.3 and are listed in Table 4.6. These 
traits are grouped into five categories based on similarities between phenotype 
symptoms: breathing difficulties, health report/subject wellbeing, hearing, low 
mood/depression and pain. Dental pain (toothache and painful gums), frequency of 
tiredness/lethargy and other eye problems also had a significant rg>0.4 with HDiff. The 
majority of these traits have symptoms of depression and low mood, while three are 
related to breathing difficulties and seven relate to reporting the experience of different 
pain types.  
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Trait rg se p Group  
Wheeze or whistling in the chest in last year 0.3137 0.0306 1.35E-24 Breathing difficulties 
Shortness of breath walking on level ground 0.3228 0.0429 5.60E-14 Breathing difficulties 
Bring up phlegm/sputum/mucus on most days 0.342 0.0679 4.74E-07 Breathing difficulties 
Long-standing illness_ disability or infirmity 0.3763 0.0305 5.48E-35 Health report/Subjective wellbeing 
Overall health rating 0.3156 0.0266 2.09E-32 Health report/Subjective wellbeing 
Health satisfaction 0.3405 0.0374 8.47E-20 Health report/Subjective wellbeing 
Other serious medical condition/disability diagnosed by doctor 0.3203 0.0409 4.80E-15 Health report/Subjective wellbeing 
Subjective well being -0.3257 0.0421 1.06E-14 Health report/Subjective wellbeing 
Other eye problems 0.4311 0.0687 3.59E-10 Health report/Subjective wellbeing 
Had major operations 0.3196 0.06 9.84E-08 Health report/Subjective wellbeing 
Illnesses of siblings: None of the above (group 2) -0.3436 0.0702 9.94E-07 Health report/Subjective wellbeing 
Former alcohol drinker 0.3136 0.0701 7.56E-06 Health report/Subjective wellbeing  
Tinnitus: Yes_ now most or all of the time 0.6 0.0562 1.40E-26 Hearing  
Loud music exposure frequency 0.3224 0.0583 3.20E-08 Hearing 
Frequency of tiredness / lethargy in last 2 weeks 0.4089 0.029 2.79E-45 Low mood /depression 
Neuroticism score 0.315 0.0257 1.94E-34 Low mood /depression 
Miserableness 0.3283 0.0273 2.69E-33 Low mood /depression 
Seen doctor (GP) for nerves_ anxiety_ tension or depression 0.3447 0.0298 5.90E-31 Low mood /depression 
Frequency of depressed mood in last 2 weeks 0.3361 0.0318 4.30E-26 Low mood /depression 
Guilty feelings 0.3258 0.0309 4.98E-26 Low mood /depression 
Loneliness_ isolation  0.3233 0.0333 2.99E-22 Low mood /depression 
Frequency of unenthusiasm / disinterest in last 2 weeks 0.3239 0.0348 1.35E-20 Low mood /depression 
Frequency of tenseness / restlessness in last 2 weeks 0.3046 0.0336 1.26E-19 Low mood /depression 
Ever depressed for a whole week 0.371 0.041 1.45E-19 Low mood /depression 
Illness_ injury_ bereavement_ stress in last 2 years: Financial difficulties 0.3098 0.0368 3.70E-17 Low mood /depression 
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Trait rg se p Group  
Depressive symptoms 0.3314 0.0409 5.69E-16 Low mood /depression 
Ever unenthusiastic/disinterested for a whole week 0.3445 0.0432 1.53E-15 Low mood /depression 
Happiness 0.3148 0.0408 1.27E-14 Low mood /depression 
Financial situation satisfaction 0.3437 0.0473 3.87E-13 Low mood /depression 
Family relationship satisfaction 0.3118 0.0433 6.12E-13 Low mood /depression 
Ever highly irritable/argumentative for 2 days 0.3192 0.0457 2.78E-12 Low mood /depression 
Insomnia 0.3211 0.0484 3.31E-11 Low mood /depression 
Illness_ injury_ bereavement_ stress in last 2 years: Serious illness_ injury or 
assault to yourself 
0.3161 0.0485 7.36E-11 Low mood /depression 
Neuroticism 0.3125 0.0724 1.60E-05 Low mood /depression 
Chest pain or discomfort 0.3823 0.0341 3.60E-29 Pain 
Pain type(s) experienced in last month: None of the above -0.3225 0.0295 9.62E-28 Pain 
Pain type(s) experienced in last month: Neck or shoulder pain 0.3686 0.0367 9.34E-24 Pain 
Pain type(s) experienced in last month: Stomach or abdominal pain 0.3409 0.0418 3.73E-16 Pain 
Pain type(s) experienced in last month: Hip pain 0.3079 0.0394 5.25E-15 Pain 
Mouth/teeth dental problems: Toothache 0.428 0.0699 9.02E-10 Pain 
Mouth/teeth dental problems: Painful gums 0.4514 0.0749 1.71E-09 Pain 
Table 4.6. Genetic correlation results with HDiff phenotype. 
This table lists traits that had significant correlations with the HDiff phenotype and an rg < -0.3 or rg > 0.3.  The traits are ordered by group, and by p-value order within 
each group. Trait; trait as listed on LD hub, rg; genetic correlation, se; standard error of rg, p-value; p-value corresponding to rg, Group; traits were grouped based on 
common or similar symptoms and groups named according to common symptoms. 
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4.3 Discussion  
Phenotypes and association analysis  
The HDiff and HAid association analyses are the two largest hearing related GWAS to date. 
Over 2,320 genome-wide significant SNPs were identified, representing 44 independent 
associations with self-reported adult hearing difficulty in participants aged 40-69 years. The 
findings represent a nine-fold increase in independent, genome-wide significant genomic 
loci for ARHI-related phenotypes. A quarter of the loci identified have already been 
implicated in hearing conditions, while the remaining three quarters are novel associations 
with auditory function.   
The two studies demonstrate the utility of using self-report measures to successfully 
identify significant associations with hearing phenotypes in genetic population analysis. 
The studies demonstrate the scale that is required in order to achieve sufficient power to 
identify multiple variants of small effect sizes that cause complex traits. This work also 
provides the field with surrogate measures to assess common HL, that are practical to 
obtain on a large scale. There are some potential limitations to using questionnaires to 
assess hearing ability, as detailed in Chapter 3, meaning that the analysis may therefore 
have reduced power due to a bias in false-positive cases and, or false-negative controls. 
To reduce the likelihood of associations being driven by highly penetrant variants that cause 
forms of hearing impairment that are distinct to ARHI, rare variants were excluded from the 
analysis. A minor allele frequency threshold of >0.01 was implemented to exclude risk 
variants for forms of congenital hearing loss, as this is lower than the prevalence of 
congenital hearing loss in the UK population. Secondly, participants who selected ‘I am 
completely deaf’ in the UKBB questionnaire were excluded. As discussed in chapter 3, the 
age distribution of this subset of individuals that responded, ‘I am completely deaf’, was not 
significantly different from age distribution of the entire sample and so likely does not 
predominantly represent ARHI cases but rather individuals with other forms of hearing 
loss. 
Four loci were associated with both HDiff and HAid at genome-wide significance. Three 
further loci were associated with HAid yet not HDiff, and 37 were associated with HDiff yet 
not with HAid. The disparity in the number of findings is likely to be due in part to the 
reduced statistical power of HAid in comparison to HDiff. The case prevalence was 5% in 
HAid and 35% HDiff, and the overall sample sizes were n=253,918 and n=250,389 for HAid 
and HDiff respectively. This meant that the statistical power of HAid was much reduced 
compared to HDiff, due to the case: control ratio, a greater case: control ratios yield greater 
statistical power in association analyses. SAIGE228 provides an alternative to the BOLT-
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LMM226 model that can account for case: control imbalance in association analysis. However, 
BOLT-LMM was selected as it was the only available method that could compute a 
relationship matrix for a sample of this size. The matrix is necessary in order to account for 
the population structure within the UKBB, as discussed in ‘The UK Biobank cohort’ 
subsection of 1.4,.  
In addition to the disparity between the number of significant associations, there were 
multiple loci that were distinctly associated with either HAid or HDiff. This may indicate that 
the two phenotypes depict subtly distinct pathologies. Frequent hearing aid users likely 
experience a relief in symptoms with the use of the amplification device, indicative of an 
inner ear pathology. On the other hand, individuals that have trouble when listening to 
speech when background noise is present, may experience a pathology that affects both the 
peripheral and central auditory systems. HDiff may therefore depict a hearing impairment 
of mixed pathologies or one that at least encompasses the central auditory system, akin the 
hypothesis that most cases of ARHI present as a mixed pathology.  
Separately, GWAS are commonly adjusted for covariates where appropriate. The aim of 
these adjustments is to account for confounding, where variation in the outcome (trait) is 
due to the effect of the covariate. Confounding factors can either (i) predict the outcome in 
the absence of an exposure, (ii) be associated with but not act as a surrogate for the outcome 
or (iii) can interact with both the exposure and the outcome. An adjustment for these factors 
can increase the power to identify genetic variants that have a direct effect on the outcome 
(trait)284. Conversely, adjustment for covariates can reduce statistical power when the 
tested genetic variants have an effect on the covariate, or when a correlation between the 
trait and the covariate is not fully explained by the direct effect of the covariate on the trait. 
HDiff and HAid were adjusted for the following covariates: age, sex, UKBB genotyping 
platform and UKBB PCs 1-10. However, numerous social and lifestyle factors are also 
thought to contribute to hearing deterioration, as discussed in chapter 2), and which are 
likely to have an effect on the phenotypes used in this study. For example, hearing aid use 
in this sample has previously been shown to be significantly associated with Townsend 
score in the UKBB; those with ‘poor’ hearing and who wear hearing aids have a significantly 
lower Townsend score (less deprived) than those who do not123. Therefore, the statistical 
power may be increased by adjusting for covariates such as this. However, the relationship 
between Townsend score and HL or hearing aid use is not fully understood; it is likely that 
there are multiple factors encompassed in the Townsend score which have different effects 
on the risk of developing a hearing loss, the perception of symptoms and the prescription of 
hearing aids and the frequency of use. Here no further covariates were included, though 
factors that are associated with or hypothesised to interact with the HDiff and HAid ought 
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to be taken into consideration if results are used to estimate population prevalence or to 
inform future implementation of treatments and diagnostics.  
Heritability analysis of HDiff and HAid in the UKBB 
The SNP-based heritability estimates for HDiff ( h2 g =19%) and HAid (h2 g =13%), are at the 
mid-lower end of previous heritability estimates for ARHI100,103,285, see Table 1.3. This is not 
unexpected as h2g estimates are lower if not equal to h2 and H2, as h2g is an estimate only of 
the additive effects of the genotyped SNPs that are included in the analysis286. Secondly, 
phenotypes used to calculate these previous estimates are also predominantly derived from 
PTA scores, and as discussed, will likely have a different proportion of variance attributable 
to genetic causes, than the phenotypes used here.  
A previous estimate that was calculated with self-report measures however, was also higher 
than these two estimates, at 40% (95% CI=19-52%). The sample that was used to calculate 
this estimate was made of up of a subset of a Danish Twin Registry119, and the narrow-sense 
heritability estimate in theory assess additive effects of the entire genome, rather than just 
the genotyped SNPs in the model used here to calculate h2g. Furthermore, narrow sense 
heritability may be susceptible to inflation due to genotype and environmental factors 
within families that provide a commonality in addition to additive genetic effects287.   
The most recent study to calculate SNP heritability for an ARHI-related trait was the GWAS 
by Hoffman, 2016, which reported the estimated heritability for all genome-wide SNPs to 
be 8.7% (95% CI 2.9%-14.4%). Again this method differs to that used to calculate the 
estimates for HDiff and HAid, as the Hoffman calculation included additive effects only from 
SNPs that reached genome-wide significance, while HDiff and HAid estimates are based on 
additive effects of all SNPs in the GWAS analysis, regardless of the association p-value. 
Secondly, the prevalence that was stipulated in order to re-calculate the estimates to the 
liability scale, differed for each of these three estimates. The Hoffman sample stipulated a 
prevalence of 12.5% (the prevalence in the non-Hispanic whites in the sample cohort), 
while the prevalence for HDiff and HAid are 35% and 5% respectively. 
Future studies are likely to add context to the SNP heritability estimates presented in this 
chapter. This may be by including a greater number of variants and, or including rare 
variants not currently included in association analyses and which may have greater effect 
sizes. For this analysis, a SNP MAF of 0.01 was implemented and, following imputation and 
further QC, 9,740,198 SNPs were included in the HDiff and HAid analyses. Although this is a 
relatively large proportion of the SNPs in the genome in comparison to previous ARHI 
studies, a less conservative MAF and more dense genotyping and imputation will allow for 
a much larger number of SNPs to be tested for association. In time, it may also be possible 
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to accurately incorporate epigenetic and epistatic effects and to reduce the effects of 
confounding factors. As noted in the Introduction p.60, GWAS findings generally only 
explain 20-30% of the trait variance. Further work is therefore likely to result in an 
increased, and more accurate, heritability estimate than that presented here, which only 
compasses the effects of SNPs included in these GWAS.   
Replication of genetic association analysis of HDiff and HAid  
Associations at three of the lead SNPs were successfully replicated at a Bonferroni-
corrected level of significance, while an additional 15 SNPs reached nominal significance. 
Despite being a meta-analysis of three independent samples, the replication sample, was a 
magnitude smaller in size than the discovery sample. The replication sample therefore had 
less statistical power than the discovery sample, as is demonstrated by the power 
calculations.  The calculations predict the sample to have >80% power to replicate 6 SNPs 
at a Bonferroni-corrected level of significance, and 39 at nominal significance.  
The observed replication rate however, was half that of the predicted rate (based on these 
calculations). Assuming that the disparity is not due to false positive findings in the 
discovery sample, factors other than a reduction in statistical power may be causing the 
difference between predicted and observed replication rates. Two possible factors are the 
subtle differences in the questions used to derive the phenotypes in each of the three 
samples, along with the different models used to test for association may have reduced the 
power of analysis. The lack of replication currently observed across hearing genetic 
association studies does not invalidate the initial associations, but rather supports 
alternative methods of validation via functional analysis, such as by demonstrating a mode 
of action in auditory mechanisms or, even better, pathogenic consequences when the gene 
is dysregulated. 
Replication of previous ARHI GWAS findings  
In addition to the replication meta-analysis, it was investigated whether any SNPs that were 
highlighted in previous ARHI, are replicated in the HDiff or HAid sample. Two of the fifteen 
SNPs that were highlighted in previous studies are replicated in the HDiff sample at a 
Bonferroni-corrected level of significance; a variant that is in close proximity to ISG20, and 
a variant in the TRIOBP transcript. This is evidence to support these two previous findings, 
but does not however invalidate the remaining, previous significant findings. The 15 SNPs 
were selected from the 8 previous ARHI GWAS, 7 of which used phenotypes derived from 
PTA thresholds; only Hoffman (the study that identified the ISG20 and TRIOBP associations) 
used self-report measures to derive the phenotypes, see Table 1.5.  
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Disparities in findings were also present when different phenotype measures were used to 
test for association, even within the same population sample. Both Hoffman and Girotto 
used the Genetic Epidemiology Research on Adult Health and Ageing (GERA) cohort yet of 
the SNPs highlighted in Girotto114, none were replicated in the Hoffman analysis113. One used 
a PTA-derived phenotype while the other used electronic health records and self-report 
measures. Inconsistent phenotyping and the lack of large cohorts (data available for high-
powered analysis) is currently a general limitation of hearing research, both for the 
identification and replication (and thus validation) of genetic risk variants. As a result, 
validation methods rely heavily on functional analysis.   
Findings from genetic association analysis that are linked with forms of congenital 
deafness 
There has been speculation as to whether ARHI susceptibility variants lie within genes that 
are known to cause congenital deafness. If so, such variants would be expected to be less 
deleterious and expressed post-development, resulting in more mild forms of later-onset 
hearing impairment than as seen in forms of congenital deafness. The alternative hypothesis 
is that ARHI susceptibility genes are entirely novel to hearing and affect mechanisms 
distinct to those involved in congenital HL. These results indicate that both hypotheses are 
partially correct; a quarter of the lead SNPs in HDiff and HAid reside in or are in close 
proximity to known hearing genes. Only one of the lead SNPs is within a gene transcript that 
has previously been associated with ARHI (rs5756795, in TRIOBP) while nine loci have 
previously been linked to some form of hearing loss either in mouse models or humans 
(Table 4.1 and Table 4.2).  The remaining three quarters reside in loci that have no previous 
links to hearing function or pathologies. Within this group of novel associations however, 
there may be genetic variants that cause other forms of HL but have not yet been identified. 
Four significant gene loci are common to both HDiff and HAid analyses; EYA4, NID2, 
ARHGEF28 and CTBP2.  Variants within EYA4 have been reported in autosomal dominant 
non-syndromic hearing loss204,288,289, while NID2 and ARHGEF28 are novel associations with 
hearing phenotypes and auditory function. In addition to these, CDH23 and BAIAP2L2 have 
been linked to forms of syndromic deafness290,291 while EYA4204,288,289, TRIOBP, ILDR1 and 
LMX1A have been linked to non-syndromic HL16,113,292. Four further loci contain genes that 
have been implicated in hearing function, and these association results provide the first link 
between these genes (CTBP2, SYNJ2, SPTBN1 and TUB) and a human pathology.  
CTBP2 encodes C-terminal Binding Protein 2 a critical protein component of the inner ear 
hair cell pre-synaptic ribbon293. The function of the ribbon synapses is to facilitate the  
exocytosis function of synaptic vesicles, the organisation of which is highly specialised for 
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precise temporal neurotransmission along the organ of Corti294. SYNJ2 encodes 
Synaptojanin 2, an inositol phosphatase that is known to function in recycling 
neurotransmitter vesicles295. Its role in auditory function is yet to be established, though 
Synj2mozart mice display a progressive HL in conjunction with a deterioration of sensory HCs. 
SPTBN1 encodes βII-Spectrin, which has a role in anchoring HC rootlets in the cuticular 
plate, found at apex of sensory HCs, by providing mechanical support in conjunction with 
αII-Spectrin296.  
Tubtub mice exhibit progressive hearing loss and retinal degeneration in the absence of 
further neurological phenotypes, as observed in USH1297. Cochlea from Tubby-/- mice have 
an  accelerated outer and inner hair cell loss when compared to Tubby-/+ and Tubby+/+ mice 
and exhibit spiral ganglion cell loss298. The significance of identifying 10 known hearing loci 
is discussed in detail in chapter 5, along with further analysis of the associations with NID2 
and ARHGEF28. 
Gene-set analysis 
Gene-set analysis is a valuable tool for interpreting GWAS-derived SNP associations. In 
common complex traits, each variant that is associated with the trait has a relatively small 
effect size and often an ambiguous function. So, individually, SNP associations cannot 
generally reveal pathogenic pathways and mechanisms. By combining the effects and 
targets of associated SNPs, trait-relevant pathways can be identified, and pathogenic 
hypotheses can be derived, as discussed in section 1.4. Pathway analysis presented here 
resulted in significant findings with the HDiff phenotype and the results of GO Biological 
components are presented. A possible reason for the disparity in the number of significant 
GO processes, functions and components may be due to the quantity of significant 
associations in the original analysis. As the HDiff GWAS had greater power to identify 
significant associations (higher case: control ratio than HAid), there were a greater number 
of SNPs and thus genes included in MAGMA analysis; the MAGMA HDiff input used 113 genes 
while HAid input used only 67 genes based on the same inclusion threshold parameters. 
Therefore, when using the HAid data, fewer gene sets will have been included in the 
permutations and thus could not reach significance. 
The most significant GO biological process was dendritic spine organisation, while three 
additional significantly enriched relate to dendritic morphogenesis and development. This 
is in line with early theories of ARHI pathogenesis (sensory and neuronal) and where 
dendritic (and synaptic) density and morphology has been shown to change with age in the 
inferior colliculus (principal midbrain nucleus of the auditory pathway)299. The second most 
significant GO biological process was receptor clustering, one of a number of the significant 
GO biological terms that relate to properties of receptors or synapses. There are a number 
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of synaptic processes throughout the auditory pathway, from HCs to higher auditory 
structures. Furthermore, a recent study has shown that synapse degeneration is observed 
in the auditory cortex and hippocampus CA3 region in conjunction with hearing threshold 
increase and onset of profound hearing loss in C57BL/6J mice300. The results of gene-set 
enrichment analysis can vary widely based on the method selected, model parameters used 
and the selected reference dataset301. As the knowledge of gene sets is rapidly increasing, 
the composition of gene sets is continually evolving so these results are artificially limited 
to data that has been used to curate the gene sets. 
Significant genetic correlations between HDiff and multiple traits  
As discussed in Chapter 1 ‘Associated conditions’, epidemiological studies commonly report 
associations between different traits in population samples. However, these reports can be 
subject to reverse causation and a higher number of correlated cofounders184. Genetic 
correlation analysis is a method that can be used to identify shared genetic variance 
between traits, and that is less susceptible to reverse causation and the effects of correlated 
confounders. The correlation is an estimate for the proportion of variance that is shared 
between two traits, based on common genetic factors.  
It is therefore a useful ‘hypothesis generating tool’ that the correlation between two traits 
is due to pleiotropy or linkage. In the case of pleiotropy, the behaviour of one gene or genetic 
alteration may affect two distinct traits, or may affect one trait, but the expression of one 
trait has an effect on the expression of the second trait. Alternatively, the correlation may 
be caused by linkage if two distinct genes that affect one trait each, are in close proximity 
and thus in LD with one another. These two genes and thus the effect variants have on the 
two traits, will be inherited together and observed as a correlation. While numerous traits 
are likely to have a genetic correlation, it is not possible to conclude that the shared genetic 
variants have the same roles in the same mechanisms between the two traits. In addition, 
this particular method (cross-trait LD score regression) can be subject to bias from 
population stratification such as the impact of assertive mating on correlation estimates255.  
A trait representing persistent tinnitus had the greatest, significant genetic correlation with 
the HDiff phenotype, out of the traits that were tested (selected based on the publicly 
available data on LD hub). Therefore, this analysis provides a hypothesis that the two traits 
may be caused by common biological mechanisms. Tinnitus has been linked to hearing 
phenotypes in numerous cohorts yet a third of people with hearing loss do not have tinnitus. 
Understanding the relationship between these two traits could aid the development of 
either common diagnostics and treatments or the identification of distinct forms of either 
hearing loss or tinnitus. To date, only one GWAS has been performed on tinnitus 
independently of the multi-trait UKBB work by the Neale lab. The study was underpowered 
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(167 tinnitus cases and 749 controls) and thus no significant loci were identified yet 
suggestive associations allude to possible metabolic pathways that could be implicated in 
tinnitus pathology302. Identifying and understanding the genetic loci causal of the 
correlation observed between tinnitus and hearing loss in this genetic correlation analysis 
could allude to the pathology of subsets of tinnitus patients and thus strategies for managing 
either or both of the two traits. In order to achieve this, a high powered GWAS study of a 
robust tinnitus phenotype is required.  
Having grouped the traits into five broad categories, pain, breathing difficulties and 
depressive symptoms all have relatively high correlations with hearing loss. Again, like 
tinnitus, depressive symptoms have previously been associated with hearing loss195; a 
higher incidence of depressive symptoms has been reported for hearing loss sufferers, in 
addition to some studies reporting a reduced depressive symptoms in hearing aid 
users180,181. These links have been discussed in detail in Chapter 1. The association between 
auditory function and pain has been observed before, both in studies of hyperacusis and 
central nervous system functioning. Studies have also linked specific pain disorders with 
hearing traits; in the HUNT study sample, those with fibromyalgia and other forms of 
musculoskeletal pain had an increased likelihood of reporting hearing loss (OR 4.578, 95% 
CI 3.622-5.787 and OR 4.523, 95% CI 3.077-6.647 in women and men), an association which 
held true in individuals that had been clinically diagnosed with fibromyalgia303. The authors 
hypothesise that this may be due to common dysregulation of the central nervous system 
that affects both pain response and hearing ability. Migraines have also been studied in 
connection with auditory traits and disorders of the vestibular system303. 
There may however be an underlying bias due to collinearity in these results. Many of the 
41 traits that are highlighted here (significant p<, and a correlation of either <3 or >-3) are 
also based on self-report measures and thus an individual’s perceived overall health scores 
may result in correlation between these self-report measures. In addition, the genetic 
correlation analysis presented here is restricted to traits that have publicly available GWAS 
summary statistics on LD hub251 and the Bonferroni significance threshold determined by 
the number of traits included in the correlation analysis. While this is evidence of 
correlation between the traits that are tested in the samples that the original summary 
statistics are derived from, there are numerous other traits that are likely correlated and 
samples where these correlations may not be applicable. Currently, this method cannot be 
applied to recently admixed populations251 and so association analysis of multiple traits is 
required in these populations, independent on these northern-European decent genetic 
correlations. Despite this, the current methods for genetic correlation analysis provide are 
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crucial tools for identifying pleiotropy between common complex traits and disease and 
thus enhance our understanding of individual traits and interactions between them.304 
  
157 
 
Chapter 5 - Association to function  
5.1 Introduction 
The use of GWAS to identify phenotype-SNP associations in complex traits has advanced 
rapidly over the past 10 years. Conversely, the translation of these SNP associations into 
useful knowledge of functional biological mechanisms has severely lagged behind. Figure 
5.1 is from a review published in 2016 that demonstrates this point in terms of the number 
of publications; the number of functional follow-up studies from GWAS associations is a 
magnitude smaller than the number of GWAS published.  
 
Figure 5.1. Bar chart displaying the cumulative number of GWAS studies compared to the 
cumulative number of functional follow-up studies by year. 
The EBI GWAS catalog was used to determine the number of total GWASs reported from 2005 through the end 
of 2016, which are shown in blue. The number of post-GWAS functional studies reported each year were also 
identified (orange line) by (1) reviewing the titles, and in some cases, abstracts, of all research articles published 
in 23 relevant biomedical research journals∗, and (2) searching PubMed using the keywords “causal variant” or 
“functional variant.” Additional studies were identified through references from primary research or review 
articles found as described. Figure and Legend from Gallagher, 2018280.  
 
Performing follow-up analysis of GWAS findings is the only way to convert SNP associations 
into meaningful, biological information that can be used to understand multiple traits and 
to even diagnose, treat and manage conditions. There are several statistical, bioinformatic 
and bench-based approaches that can be used to translate SNP associations to functional 
biological knowledge. In chapter 4, imputed SNP data were used to test for association with 
two phenotypes. Over 2,200 SNPs are significantly associated with either HDiff or HAid.  
The initial post-GWAS steps are also presented in Chapter 4. Following association analysis, 
a statistical analysis approach called conditional (and sometimes joint) analysis was 
employed to isolate the lead SNP or SNPs at each locus to determine whether one or multiple 
variants are causing the association that is observed in each region305. In some cases, but 
not possible here, a region of association can then be fine mapped using via genome 
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sequencing, either of the region of the interest, or by using WGS or WES. Functional variants 
that were not included in the genotyped or imputed data can then also be tested for 
association305.  
The lead SNPs that were identified via conditional and joint analysis may be the functional 
variant at the locus or the SNP that best captures the variation. Replication analysis was 
then conducted with the aim to validate these findings. Only three of the lead SNP 
associations replicate at a Bonferroni-corrected level of significance. The relatively small 
size of the replication sample likely resulted in a lack of power to replicate a greater number 
of the associations. The work in chapter 4 also includes pathway analysis; a technique to 
identify gene and protein networks and thus hypothesise molecular and biological function 
of genes within associated regions. This method combines the effects of multiple genes to 
select networks and pathways that show significant enrichment with the phenotypes of 
interest.  
In previous hearing GWAS, a small number of approaches have been used to translate 
association to function as described in the ‘Genome-wide association studies’ subsection of 
1.4.1. The first ARHI GWAS (Friedman, 2009109) identified glutamate receptor, 
metabotropic 7 (GRM7) as the most highly associated gene candidate, performed 
histochemical studies in conjunction with the GWAS. Here just one SNP reached genome-
wide significance in the study. It is in close proximity to the GRM7 transcript and therefore 
GRM7 was identified as the primary gene candidate. The histochemical data revealed 
mGluR7 (encoded by the mouse homologue of GRM7) expression in sensory hair cells and 
in spiral ganglion neurons. The third GWAS (Girotto, 2011114) included bioinformatic 
analysis in the form of an in-silico gene network construction. In the fourth study, (Nolan, 
201392) knock-out mice for the primary gene candidate, estrogen-related receptor gamma 
(Esrrg), were tested for relevant phenotypes and used for histological analysis, similar to 
the fifth study where mice were used to test for SIK family kinase 3 (Sik3) protein 
expression in cochlear tissue at different stages of development; a SNP in intron 6 of the 
SIK3 transcript was the only genome-wide significant SNP identified111. Lastly, sequencing 
data were used to fine map regions of interest (Vuckovick, 2015112). The second (Van Laer, 
2010107), seventh (Fransen, 201538) and eighth (Hoffman, 2016113) ARHI GWAS were not 
published in conjunction with functional analysis.  
Three of the studies performed immunohistochemistry in conjunction with the GWAS; the 
focus was on the localisation of murine proteins coded by mouse homologues of GRM7109, 
ESSRG92 and SIK3111. All three of these studies confirmed expression of the candidate protein 
in cochlear tissue. In addition, Grm7 expression was observed in a cochlear tissue sample 
from an adult male (aged 83 with a PTA of 22dB), at the interdental cells of the spiral limbus, 
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IHCs, OHCs, Hensen’s cells, type II fibrocytes of the spiral ligament and at the spiral ganglion 
neurons109. These three studies demonstrate the use of immunohistochemistry to translate 
an associated genetic variant to a hypothesised site of pathology within cochlear tissue.  
For all previous ARHI GWAS it was clear which targets ought to be followed up; all studies 
that performed functional analysis detected only one significant locus or, in the absence of 
significance, selected the SNP with the highest association. Here, there are a high number of 
significant loci across the genome. Performing functional analysis on each of these 
candidates is not possible within this thesis due to practical and economical constraints. It 
is therefore necessary to prioritise a subset of candidates to investigate with functional 
analysis. Determining which gene is affected by the lead variant can be difficult; a number 
of the lead SNPs are not located within gene transcripts, and in gene dense regions, the 
associated SNPs may span multiple gene transcripts.  
Additionally, in this study, due to the lack of power to validate associations by replication, 
prioritisation and selection of viable candidates for prioritisation is essential to warrant 
functional follow up analysis.  To reduce bias in prioritisation and to not ‘cherry pick’ gene 
targets, where possible, a systemic evaluation ought to be followed for each of the loci. This 
framework is set out in 5.2.1 and is devised to prioritise gene candidates based on a number 
of criteria; the proximity of associated SNPs to the gene transcript, prior knowledge of gene 
function and function within the auditory system, strength of replication statistics, presence 
of a gene-specific mouse model, antibody availability and results from previous tissue-
specific gene expression screens. This framework is used to select candidates for 
immunohistochemistry on mouse inner ear tissue samples. The aim of this 
immunohistochemistry study is to contribute to the validation of individual gene 
associations and hypothesise their putative function in the inner ear. 
The concept of immunohistochemistry was first devised in the 1940s but it is still relevant 
for many current uses in research and diagnostics306. It exploits the binding properties of 
antibodies to specific protein domains (epitopes) and is means of detecting the presence of 
an epitope in a tissue sample. In this context, it can be utilised to determine whether a 
protein is expressed in the cochlea, and in which structure the protein is localised. The 
technique is of value in hearing research as the auditory system contains multiple structures 
that have distinct functions; there are over 26 different cell types in the cochlea alone. Each 
structure is highly specialised for specific functions and so determining the location of gene 
expression is a valuable means to explore putative functions.  
The majority of the bench-based functional approaches used in auditory research use mice 
as the model organism. The location of the auditory system, inside the temporal bone and 
in brain tissue, means that it is impossible to access tissue samples from human patients 
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and, as the cochlea is encased in the temporal bone, near-impossible post-mortem. This 
impedes bench-based research and results in a lack of tissue-specific expression data on 
databases available for in silico analysis. Animal models are therefore a valuable resource 
in the study of the auditory system. As discussed in a subsection of chapter 1, ‘Post-GWAS 
analysis’, the mouse is the most common model used in auditory research due to the 
common anatomy, physiology and conserved genomic functions between mice and 
humans238.   
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5.2 Results & Discussion 
The genetic loci significantly associated with HDiff and HAid phenotypes (Chapter 4) can be 
used to hypothesise mechanisms involved in auditory function and pathology. The first aim 
of this chapter is to prioritise genes within these loci as potential candidates for functional 
analysis. All lead SNPs identified by conditional and joint analysis in chapter 4 are subset 
into groups and assessed for prioritisation. The second aim is to select (based on this 
framework) a subset of these candidates and perform immunohistochemistry in adult 
mouse cochlear samples.  
The results of this chapter are presented in four sections, 5.2.1-5.2.4 (Figure 5.2). In section 
5.2.1 each of the 48 lead SNPs identified by conditional analysis is reviewed based on 
genomic location and a primary (protein-coding) candidate gene from each locus was 
selected for further investigation. As immunohistochemistry is the selected method, the 
focus is on protein-coding genes (rather than genomic features such as regulatory 
elements).  These primary gene candidates are then subset into two groups; (1) genes that 
already have an established role in hearing function and/or auditory pathologies and (2) 
those that are novel associations with hearing function and pathologies.  
Section 5.2.2 is a summary and discussion of primary gene candidate genes that are known 
to have a role in auditory function or that cause hearing phenotypes. The aim of section 5.2.2 
is to use previous knowledge of these known ‘hearing genes’ to speculate putative ARHI 
mechanisms. Section 5.2.3 is a report on the remaining the primary gene candidates that 
have not previously been linked to hearing function. The aim of section 5.2.3 is to assess 
each candidate gene for use in functional annotation, primarily for immunohistochemistry 
in the adult mouse, and also for future functional analysis. The results of the protein 
localisation analysis are presented in section 5.2.4.  
As a full review of 48 loci is not possible to report within this chapter, key data sources are 
selected, and the relevant literature is summarised. A number of assumptions are made in 
order to subset and rank the SNPs and subsequent loci. While this is a necessary part of the 
prioritisation process, there are limitations with these methods that ought to be considered 
when reviewing the subsequent data such as a literature bias for well characterised genes 
or those that were included on RNAseq screens in auditory tissue. As the categorisation of 
genes in each section dictates the content of the following section (Figure 5.2) critical 
discussions of each of the four results sections are included alongside the results, instead of 
a combined discussion at the end of the chapter.   
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5.2.1 Identification of primary gene candidates from HDiff and HAid genetic 
association analysis  
In this section primary gene candidates at each of the associated regions identified in the 
HDiff and HAid GWAS (presented in chapter 4) are selected and evaluated. At each locus a 
primary gene candidate is selected based on the proximity of the gene transcript to the lead 
SNP at the locus. Each locus is also assessed based on whether additional gene transcripts 
within the locus contained SNPs that were (1) in high LD (r2>0.6) with the lead SNP and (2) 
were significantly associated (P<E5-08) with the phenotype.  
The higher the number of gene transcripts that contain significant SNPs in the LD with the 
lead SNP, the lower the confidence in gene candidate selection. Conversely, at loci where 
only one gene transcript contains significant SNPs that are in high LD with the lead SNP, 
there is more confidence in the selection of the gene candidate. Locus plots that visualise 
each significant lead SNP and the flanking 1-200kb genome region, are included in the 
 
Figure 5.2. Workflow of results presented in Chapter 5. 
The results are divided into four sections and presented in 5.2.1-5.2.4. In section 5.2.2 and Section 5.2.3, 
each of the primary gene candidates is assessed based on the criteria listed in the corresponding boxes in 
this figure. 
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Appendix, locus plots (a-vv). The LDlink tool257 is used to test for LD scores between a lead 
SNPs and genome-wide significant SNPs in the same region see - Methods 2.4.1.   
For a number of the loci, more than one gene at the locus contains genome-wide significant 
SNPs that are in high LD with the lead SNP. Therefore, at these loci it is difficult to conclude 
which gene is the primary candidate. Here the primary candidate is selected based on either 
the proximity of the gene to the lead SNP (ZNF318, TYR, ATP11B, AGO2, ADK and SNAP91), 
prior knowledge regarding a known gene role in hearing function (CLRN2, based on 
knowledge of the role of clarin-1 in USH3 as reported in Section 1.2.1) or the presence of a 
second lead SNP in the same gene (ARHGEF28). While these assumptions aid in the selection 
of candidates to study, other genes in proximity ought to be considered in further analysis 
and when interpreting results from functional analysis.  
Following the selection of a primary gene candidate at each locus, each gene is evaluated 
with respect to whether it has previously been linked to a hearing pathology and, or has an 
established role in auditory function (Figure 5.2). To determine this, list of gene candidates 
is cross referenced with the published list of genes reported to underlie deafness in either 
humans or mice (2018)260, and with any report when using the PubMed search terms ‘<gene 
name>, hearing’ and ‘<gene name>, deafness’.  To present these data, the lead SNPs are 
divided into three tables based on whether they are in exon regions; Table 5.1, intronic; 
Table 5.2, or intergenic; Table 5.3.  
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5.2.1.1 Results & Discussion: Identification of primary gene candidates from HDiff and HAid genetic association analysis   
 
Table listing all lead SNPs from HDiff that are in gene exon regions  
Lead SNP Pheno P-value No. Gene names Primary candidate 
Aud. 
Func. 
Variant consequence (REVEL score) 
rs36062310 HDiff 1.90E-22 1 KLHDC7B KLHDC7B - Missense var. (0.088) 
rs6453022 HDiff 1.70E-21 1 ARHGEF28 ARHGEF28 - Missense var. (0.055) 
rs9493627 HDiff 1.40E-13 1 EYA4 EYA4 ✓ Missense var. (0.424) 
rs5756795 HDiff 5.10E-12 1 TRIOBP TRIOBP ✓ Missense var. (0.102) / 3’ UTR variant / NMD target 
rs143282422 HDiff 2.40E-08 1 CDH23 CDH23 ✓ Missense var. (0.198) / non-coding var. 
rs12552 HDiff 4.80E-08 1 OLFM4 OLFM4 - 3’ UTR variant 
 
Table 5.1. Lead SNPs from HDiff association analysis that reside in gene exons.  
Lead SNP; lead SNP in joint and conditional analysis performed in chapter 4, Pheno; phenotype used for GWAS, P-value; BOLT-LMM infinitesimal mixed model association test p-
value of the lead SNP in GWAS presented in chapter 4, No.; the number of genes at the locus that contained SNPs that had a genome-wide significant p-value and that are in high LD 
(r2>0.6) with the lead SNP, Gene names; gene names for the genes totalled in ‘No.’, Genomic position; genomic position of the lead SNP, Primary candidate; gene name of the nearest 
protein-coding gene to the position of the lead SNP, Aud. Func.; ✓ indicates that the proximity-based primary candidate has an established role in auditory function, Variant 
consequence; the VEP predicted consequence of the variant at the lead SNP position, NMD; non-mediated decay, UTR; untranslated region, NC; non-coding. REVEL prediction values 
for missense mutations are noted in brackets, scores range from 0-1 with higher scores reflecting greater likelihood that the variant is disease-causing307. As rs12552 is not a missense 
variant, no REVEL score is listed.  
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Table listing all lead SNPs from HDiff and HAid that are in gene intron regions 
Lead SNP Pheno P-value No. Gene names 
Primary 
candidate 
Aud. 
Func. 
Variant consequence 
rs4597943 HAid 2.10E-11 1 ARHGEF28 ARHGEF28 - Intron var. / Regulatory region var. 
rs759016271* HDiff 6.10E-21 2 CRIP3, ZNF318 ZNF318 - Intron var. / NMD target / NC transcript 
rs9321402 HAid 3.00E-10 1 EYA4 EYA4 ✓ Intron var. / NC transcript 
rs132929 HDiff 2.20E-13 1 BAIAP2L2 BAIAP2L2 ✓ Intron var. / NC transcript exon var. 
rs1566129 HDiff 1.40E-11 1 NID2 NID2 - Intron var. 
rs1566129 HAid 2.50E-09 1 NID2 NID2 - Intron var. / upstream gene var. 
rs12225399 HDiff 8.60E-11 1 PHLDB1 PHLDB1 - 
Intron var., NMD transcript var., NC transcript var., upstream gene var., 
regulatory region var. 
rs55635402 HDiff 2.90E-10 1 TUB TUB ✓ Intron var., downstream gene var., regulatory region var. 
rs9677089 HAid 2.00E-10 1 SPTBN1 SPTBN1 ✓ Intron var. 
rs62033400 HDiff 2.90E-10 1 FTO FTO - Intron var., NMD target, NC transcript var. 
rs13277721 HDiff 3.30E-10 2 AGO2, PTK2 AGO2 - Intron var., NC transcript var., NMD target 
rs2236401 HDiff 9.30E-10 1 SYNJ2 SYNJ2 ✓ Intron var. 
rs4947828 HDiff 1.00E-09 1 GRB10 GRB10 - Intron var., NC transcript var. 
rs6597883 HDiff 1.00E-09 1 CTBP2 CTBP2 ✓ Intron var., NC transcript var. 
rs10901863 HAid 2.60E-08 1 CTBP2 CTBP2 ✓ Intron var., NC transcript var. 
rs34442808 HDiff 1.30E-09 2 MCTP1 & ANKRD32 MCTP1 - Intron var., NC transcript var. 
rs835267 HDiff 1.60E-09 1 EXOC6 EXOC6 - Intron var., NMD target, regulatory region var. 
rs4948502 HDiff 1.70E-09 1 ARID5B ARID5B - Intron var. 
rs10824108 HDiff 3.00E-09 3 VCL, AP3M1, ADK ADK - Intron var., NC transcript var. 
rs217289 HDiff 4.90E-09 1 SNAP91 SNAP91 - Intron var., NMD target 
rs3915060 HAid 9.70E-09 1 ILDR1 ILDR1 ✓ Intron var., NC transcript var. 
rs17671352 HDiff 1.00E-08 6 
DLG4, ACADVL, DVL2, PHF23, 
CTDNEP1 
ACADVL - 
Down & upstream gene var., splice region var., intron var., NC transcript 
exon var., NMD target, regulatory region var. 
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Table listing all lead SNPs from HDiff and HAid that are in gene intron regions 
Lead SNP Pheno P-value No. Gene names 
Primary 
candidate 
Aud. 
Func. 
Variant consequence 
rs12938775 HDiff 1.60E-08 1 PAFAH1B1 PAFAH1B1 - Intron var., NC transcript var. 
rs76837345 HDiff 1.90E-08 1 CHMP4C CHMP4C - Intron var. 
rs9366417 HDiff 2.10E-08 1 SOX4 SOX4 - Intron var., NC transcript var. 
rs9691831 HDiff 3.10E-08 1 TMEM213 TMEM213 - Intron var. 
rs141403654 HDiff 3.50E-08 1 AGBL2 AGBL2 - Intron var. 
rs10927035 HDiff 4.90E-08 1 AKT3 AKT3 - Intron var. 
Table 5.2. Lead SNPs from HDiff and HAid association analyses that reside in gene introns. Legend as in Table 5.1. 
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Table listing all lead SNPs from HDiff and HAid that are in intergenic regions 
Lead SNP Pheno P-value No. Gene names Gen pos. 
Primary 
candidate 
Aud. 
Func. 
Variant consequence 
rs6890164 HDiff 3.30E-19 3 
ARHGEF28, ANKRA2, 
UTP15 
6177bp up ARHGEF28 - Intergenic var. 
rs7951935 HDiff 7.80E-17 2 TYR, NOX4 1472bp up TYR - Intergenic var. 
rs35186928 HDiff 1.70E-15 0 - 13352bp up HLA-DQA1 - Intergenic var., regulatory region var. 
rs35414371 HDiff 1.60E-11 2 QDPR, CLRN2 1965bp down CLRN2 - Downstream gene var. 
3:182069497_TA_T* HDiff 4.10E-11 0 ATP11B 441791bp ATP11B - - 
rs62188635 HDiff 4.70E-10 1 KLF7 50519bp up KLF7 - Intron var. in NC transcript 
rs12027345 HDiff 3.60E-09 1 MAST2 12668bp up MAST2 - Intergenic var. 
rs13093972 HDiff 5.50E-09 1 ZBTB20 121137bp up ZBTB20 - Intron var. in NC transcript 
rs62015206 HDiff 7.70E-09 2 MAPK6, BCL2L10 15613bp down MAPK6 - Upstream gene var., intron NC var. 
rs10475169 HDiff 9.30E-09 0 - 190445bp down IRX2 - Intergenic var. 
rs7525101 HDiff 1.50E-08 0 LMX1A 61973bp up LMX1A ✓ Intergenic var. 
rs3890736 HDiff 2.20E-08 1 GFRA2 15676bp down GFRA2 - Intergenic var., regulatory region var. 
rs7823971 HAid 2.70E-08 1 RP11-1102P16.1 - 
RP11-
1102P16.1 
- Intron var. in NC transcript 
rs4611552 HDiff 3.60E-08 1 CCD68 9362bp up CCD68 - Intergenic var., regulatory region var. 
 
Table 5.3. Lead SNPs from HDiff and HAid association analyses that reside in intergenic regions.  
Table legend as in Table 5.1. *denotes that the SNP is not in the Locuszoom reference and so the locus plot was created using a SNP (rs11280821) that in close proximity to 
3:182069497_TA_T.  
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This section evaluates 44 primary gene candidates for potential use in functional analysis. 
The results include an assessment of the confidence of the gene selections, based on the 
genomic context of the lead SNP. 34 of the lead SNPs reside within the gene transcript of the 
selected primary gene candidate, 6 in exon regions (Table 5.1) and 28 in intron regions 
(Table 5.2). For the majority of the primary gene candidates, the lead SNP resides in either 
an intron or exon of the gene and no other genes at the locus contain genome-wide 
significant SNPs in high LD with the lead SNP. This provides good confidence of the gene 
selection at these loci. However, 14 lead SNPs are in intergenic regions (Table 5.3) and 7 of 
the loci have genome-wide significant SNPs in high LD with the lead SNP, in more than one 
gene (Table 5.1, Table 5.2, Table 5.3 column titled ‘No.’ to represent the number of possible 
cis gene candidates under these assumptions). In these cases, there is greater ambiguity and 
thus less confidence when selecting the primary gene candidate. For example the region 
flanking the lead SNP rs62015206 in Figure 5.3 below, displays a region where a cluster of 
SNPs in high and in moderate LD with the lead SNP covers a region containing multiple gene 
transcripts. Here, the primary candidate is MAPK6, due to the SNPs in high LD (coloured in 
red) with the lead SNP (purple) are in the MAPK6 transcript.  
 
Figure 5.3. Locus plot displaying the genome region flanking the lead SNP rs62015206  
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. 
 
 
Secondly, the results include data from Ensembl Variant Effect Predictor (VEP), which 
predict the functional consequence of each variant. Five of the six lead SNPs that reside in 
exon regions are predicted to result in missense mutations. A missense mutation leads to 
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an amino acid substitution. REVEL scores which estimate the deleteriousness of such a 
change307, predict that the SNP rs9493627 (within an EYA4 exon region, REVEL score 
0.424), has the greatest likelihood, of the five, to be disease-causing.  
While a number of the lead SNPs may be the causal variant, it is likely that the variants listed 
are not the causal variant but are in high LD with the causal variant. However, this 
information can be used to identify possible regulatory regions and hypothesise variant 
consequences related to gene function. Most of the variants have multiple predicted 
consequences. This is largely due to the different transcripts and splice forms of genes in 
close proximity to the variant, but from this association analysis alone, it is not possible to 
conclude which transcript(s) relate to the variant association and thus which consequence 
is likely to be causal of the association with the phenotype.  
Thirdly, the results include a subset of 10 genes that are known to have a role in hearing 
function or pathology in either mouse or human subjects. Current knowledge of the function 
of these genes may reveal previously unknown ARHI mechanisms, that are already known 
to cause other forms of hearing impairment. These findings could also challenge the current 
knowledge of these specific genes. For example, a gene newly associated with ARHI that was 
previously known to cause an early-onset congenital defect (and thus had been determined 
as a developmental gene) could now be hypothesised to have a post-developmental role 
such as maintenance or stress response. In addition, the fact that almost a quarter of these 
gene candidates have previous links to hearing, can be interpreted as a validation of the 
association results, for using phenotypes derived from self-report measures. The loci 
containing known hearing genes are explored further in the next section (5.2.2). 
Primary gene candidates are selected based on the proximity to lead SNPs rather than any 
known genomic functions present within the region such as regulatory variants. While it 
necessary to focus on protein coding genes at each locus, especially when selecting 
candidates for immunohistochemistry, it is important to consider the fact that the true 
functional target gene or variant represented by the association may reside elsewhere at 
the locus or even at a different locus by either cis or trans interactions. To address this in 
future work, primary gene candidates could be determined using a combination of their 
proximity to lead SNPs and biological functionality and thus mapped to genes based on 
positional, eQTL and chromatin interaction data, possible with platforms such as FUMA233.  
For example, the lead SNP rs9366417 identified in HDiff is here reported to be in close 
proximity to the gene SOX4, but the SNP lies in the lncRNA transcript CASC15, which may be 
the true functional target represented by the variant association. A locus plot corresponding 
to this region is displayed in a following section, in Figure 5.6. 
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5.2.2 Loci associated in HDiff and HAid genetic association analysis that 
contain genes with a known role in hearing function or hearing conditions 
Ten of the 44 loci identified in Chapter 4 have previously been linked to auditory function 
(Table 5.1, Table 5.2, Table 5.3, column 9). The importance of some these findings is briefly 
discussed in a previous section; section 4.3 ‘Findings from genetic association analysis that 
are linked with forms of congenital deafness’. All ten loci contain genes that either (1) code 
for proteins that have an established role in the auditory pathway or (2) which have been 
implicated in hearing disorders and conditions. Only one locus (lead SNP rs5756795 in HDiff 
analysis) contains a gene that has been linked to AHRI; TRIOBP113. In this section each of 
these previous links to hearing loss are discussed, and the findings are discussed at the end 
of the section.  
5.2.2.1 Gene Function summaries 
EYA4 (DFNA10) 
Both HDiff and HAid analyses have lead SNPs that lie in the EYA4 gene; rs9493627 in exon 
10 (HDiff, p=1.40E-13) and rs9321402 in intron 10 (HAid, p=3.00E-10). Neither of the two 
SNPs replicated in the replication meta-analysis, yet variants in EYA4 have previously been 
linked to autosomal dominant non-syndromic hearing loss204,288,289. The EYA protein family 
is a class of protein tyrosine phosphatases and different EYA family members have distinct 
links to a number of conditions and diseases including multiple forms of hearing loss308.   
EYA4 specifically, codes for Transcriptional Coactivator and Phosphatase 4 and is located at 
the DFNA10 locus. The first direct link between EYA4 and human auditory function was 
identified in two families that present cases of late-onset hearing loss309. Since this initial 
finding, multiple other families with autosomal dominant non-syndromic hearing loss have 
been found to have insertions and variants in the EYA4 gene. The affected region differs 
between the families, but all variants result in premature stop codons in exon 14, exon 20, 
exon 13and intron 14289,310.  
The expression profile of EYA4 in the inner ear has been shown to differ between animals 
and it’s been hypothesised that this may reflect the different hearing phenotypes observed 
between mice and humans. In Eya4 mutant mice, hearing loss is early in onset and is caused 
by otitis media; Eya4–/– mice exhibit a phenotype indicative of middle ear effusion with 
tympanic membrane retraction. This is suggestive of Eya4 expression and function in the 
middle ear311.  This is in contrast to findings in non-human primates (marmosets), where 
EYA4 expression in adult inner ears is found in the hair cells, spiral ganglion and a range of 
supporting cells. The observed phenotype resulting from EYA4 mutations in humans is also 
different from that in rodents; diagnosed patients exhibit sensorineural hearing loss204. 
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From association analysis alone, it is not possible to confirm whether the pathology in the 
UKBB sample lies in the middle or inner ear. However, an inner ear pathology can be 
hypothesised. This is based on the observation of sensorineural defects in primate studies 
of EYA4 function, and because the GWAS the phenotypes were derived as surrogate 
measures for ARHI, a form of sensorineural hearing loss.  
SPTBN1 
The lead SNP (rs9677089, p=2.00E-10) resides in intron 2 of the SPTBN1 gene, which codes 
for βII Spectrin, a member of the beta-spectrin gene family. β II-Spectrin has been identified 
in the lateral wall of outer hair cells312 and at the apical region of inner hair cells in mouse 
cochlear tissue313. The most recent study on spectrin function in cochlear hair cells, found 
that β II-Spectrin, along with α II-Spectrin, provides mechanical support for HC rootlets. The 
work also revealed that βII spectrin was not required in the early development of HC 
stereocilia in mice; the spectrin rings form ~P14, at the time when mice acquire the ability 
to hear and are thus likely to have a role in HC function or maintenance. In aged mice, the 
authors found levels of spectrin ring disruption at OHCs correlates with ABR threshold 
deterioration296. In addition, Atoh1-Sptbn1−/− mice (lacking βII-spectrin in inner ear HCs by 
mating Atoh1-cre and Sptbn1flox/flox mice) display a severe deafness296. Despite this 
established role in the cochlea, prior to this study no link had been made between genetic 
variants in SPTBN1 and human hearing pathologies. Based on the previous work in mice, it 
could be hypothesised that the HDiff phenotype may in part be caused by defects in the 
support of HC rootlets.  
BAIAP2L2 
The lead SNP rs132929 (p=2.20E-13) in HDiff analysis is located in intron 7 of the BAIAP2L2 
gene which codes for Brain-specific angiogenesis inhibitor 1-associated protein 2-like 
protein 2. Baiap2l2 was a gene identified in the recent large-scale mutant mouse screen 
phenotypes243; BAIAP2L2 mutant mice were observed to have a mild hearing loss at all 
frequencies. The BAIAP2L2 gene transcript is also in a locus that is implicated in some cases 
of Waardenburg syndrome (WS). A WS patient with a full deletion of the locus (including 
the full BAIAP2L2 transcript), presents with profound bilateral sensorineural hearing 
loss290. Elsewhere, there are few reports of the general function and pathological impact of 
BAIAP2L2. These findings are evidence of BAIAP2L2 having a role in hearing function but 
do not reveal a biological cause for BAIAP2L2-linked pathology and thus do not provide an 
insight into the pathological mechanisms underlying the HDiff association at this locus.  
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TRIOBP 
The SNP rs5756795 had an association p-value of 5.10E-12 in the HDiff discovery analysis 
and lies in an exon of the TRIOBP gene transcript, which codes for TRIO and F-Actin Binding 
Protein. TRIOBP is the only gene that contains a lead SNP from either HDiff and HAid and 
that has previously been linked to ARHI. The previous link was also in a GWAS; a SNP in 
close proximity to the TRIOBP gene transcript reached genome-wide significance in the 
Hoffman 2016 ARHI GWAS113. The significant SNP in the Hoffman analysis is in high LD 
(r2=0.96) with a missense mutation in the TRIOBP transcript and is in complete LD with the 
lead SNP in HDiff analysis, rs5756795. 
In addition to ARHI, mutations in TRIOBP are known to cause recessive non-syndromic 
hearing loss DFNB2853 in 9 Palestinian families. 27 members from 7 of the families were 
shown to have homozygous nonsense mutations in the SH3 binding domain of TRIOBP, 
while 3 members from the remaining two families exhibited heterozygous mutations for 
two nonsense mutations. Following this finding, localisation of the protein products from 
different Triobp splice forms were studied in the mouse cochlea. Localisation was identified 
in inner ear hair cells, and localised with F-actin along the length of the stereocilia53. All 
previous TRIOBP variants that have been linked to familial cases of hearing loss are located 
in exon 6 of the isoforms TRIOBP4 or TRIOBP5314. The SNP that is here associated with HDiff 
lies in exon 7, and so may have a different impact on gene function at the stereocilia when 
compared to the functional effect of variants located in exon 6.  
TUB 
The lead SNP rs55635402 in HDiff analysis (p=2.90E-10) is located in an intron of the gene 
TUB, that codes for Tubby Bipartite Transcription Factor. This result provides the first 
evidence of a link between TUB and human hearing function. The Tub gene was initially 
studied in a mouse model of Usher Syndrome Type 1 (USH1) because Tubtub mice exhibit a 
progressive hearing loss and retinal degeneration in the absence of further neurological 
phenotypes as observed in USH1298. Tubby-like proteins are a unique family of bipartite 
transcription factors315, but the precise function of TUB in the mouse cochlea is not 
understood. It has since been observed that tub/tubC57 mice display an accelerated OHC and 
spiral ganglion cell loss at the basal end of the cochlea relative to tub/+ and +/+ C57 mice316. 
The hypothesised function of TUB in the auditory pathway is a modifying effect at synaptic 
junctions between sensory cells and neurons317. The association with HDiff therefore may 
be suggestive of pathologies that are present at synaptic junctions.    
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SYNJ2 
The lead SNP at the SYNJ2 locus in the HDiff analysis, rs2236401 (p=9.30E-10), resides in 
an intron region of SYNJ2. SYNJ2 codes for Synaptojanin 2, an inositol phosphatase that is 
known to function in recycling neurotransmitter vesicles295. This work provides the first 
link between SYNJ2 and a hearing pathology in humans. The finding linking SYNJ2 and 
hearing function was made in a mutant mouse mozart which displayed a progressive 
hearing loss caused by the deterioration of sensory cells, resulting in complete loss of hair 
cells318. This is suggestive of a role for Synj2 in hair cell maintenance and function and 
therefore a possible site of pathology in HDiff cases.  
Although not previously linked to hearing in a population cohort, SYNJ2 has also been 
associated with longevity and cognitive function in the elderly319; a trait closely related to 
ARHI. Further to this, a study in 2012 reported an association with SYNJ2 and cognitive 
abilities. Conserved longevity genes between yeast and nematode species320 were used as 
candidate genes to test for an association with cognitive ability in a human population meta-
analysis.  
ILDR1 (DFNB42) 
In the HAid analysis, the lead SNP rs3915060 (p=9.70E-09) lies in an intron of ILDR1, which 
codes for immunoglobulin-like domain-containing receptor 1. Variants in ILDR1 have been 
associated with multiple cases of autosomal recessive non-syndromic and syndromic 
sensorineural hearing loss321–324. Based on this, ILDR1 was also considered a candidate for 
common hearing impairment in the candidate gene analysis of the 2016 Hoffman study113, 
where common variants with in ILDR1 were found to be associated with the phenotype.  
The function of Ildr1 in the auditory system has been studied in mice; Ildr1(-/-) mice display 
a progressive degeneration of OHCs, and disruption to the tunnel of Corti is observed by 
p21325. Two further studies have identified roles for Ildr1 in tricellular tight junction 
formation326,327. In addition, protein up-regulation (fold change>1.5) and down-regulation 
(fold change<0.5) was shown to differ in over 800 proteins, between Ildr1(+/-) and Ildr1(-/-) 
mice at P21325. This indicates that ILDR1 may be a master regulator and, or have an 
upstream role in pathways in which these proteins are involved. The phenotype observed 
may therefore be caused by the modified expression of downstream targets.  
LMX1A 
The lead SNP from the HDiff analysis at the LMX1A locus, rs7525101 (p=1.50E-08) is in close 
proximity to the LMX1A gene transcript that codes for Lim homeobox transcription factor 
1. Mutations in LMX1A were discovered to cause to progressive sensorineural hearing loss 
in two Dutch families, and to severe cochlear and vestibular defects in mouse mutants(mtl 
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and bsd)328. In the two families, the phenotypes are varied in the age of onset, rate of 
progression and whether vestibular defects are observed. There are no apparent 
developmental pathologies however; the hearing loss is consistent between the two families 
in that it is progressive.  
The authors hypothesise that one copy of a functional LMX1A gene is sufficient for 
development of auditory and vestibular structures but not necessarily for the maintenance 
of function328. Although the lead SNP rs7525101 does not reside within the LMX1A 
transcript, the previous links to hearing phenotypes increase the likelihood that the target 
of the variant at this locus is in the function of LMX1A, either via a cis regulatory element or 
a SNP within the gene transcript that is in LD with this lead SNP.  
CDH23 
The lead SNP rs143282422, from HDiff analysis, lies in an exon of the CDH23 gene transcript 
which codes for cadherin-23, a protein that forms the majority of the stereocilia tip-link 
structure at the inner hair cells of the organ of Corti329. Multiple mouse strains have point 
mutations at the Cdh23 locus, which cause a variety of hearing phenotypes. A key example 
is the Cdh23ahl allele in the C57BL/6J strain, which is the most commonly used strain for 
transgenic analysis. The mutation causes an accelerated HL, with a progressive loss of inner 
and outer HCs and loss of the SG cells at the basal turn of the cochlea by seven months of 
age238,241. The locus containing Cdh23 is termed Ahl1 as it was one of the first loci found to 
be associated with ARHI in mice. The association with HDiff at this locus is the first link 
between CDH23 and ARHI to be found in a human population, however methylation levels 
at the CDH23 locus have been shown to have an association with ARHI risk in a sample of 
elderly women330. 
Homozygous mutations in CDH23 are known to cause Usher Syndrome Type 1D, symptoms 
of which include profound congenital sensorineural hearing loss vestibular areflexia, and 
adolescent-onset retinitis pigmentosa. It has also been identified in cases of non-syndromic 
hearing loss331,332 and is a candidate for common hearing impairment or presbycusis330. 
CDH23 was recently associated with non-syndromic hearing loss in a meta-analysis of four 
Asian population samples at the p.P240L variant333. The association between HDiff and 
CDH23 again suggests that the stereocilia may be some of the structures that cause HDiff 
when damaged or degenerated. The association with HDiff at this locus is therefore in part 
validated, as CDH23 is known to cause other forms of deafness (such as USH1D), along with 
the hearing defects observed in the C57BL/6J mouse strain.   
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CTBP2 
The lead SNP rs6597883 from HDiff  lies in an intron of CTBP2 which codes for the c-
terminal binding protein 2 and its’ alternative splice form that codes for ribeye, a major 
component of the hair cell ribbon synapse294,334. Anti-ctbp2 antibodies are commonly used 
as a marker for the ribbon synapse in protein localisation assays113. Although ribeye is an 
established component of the ribbon synapse, mutations in the coding transcript have not 
previously been associated with pathology in human hearing loss. At the ribbon synapse, 
multiple ribeye subunits interact via five distinct sites at A and B domains. Within the 
cochlea, these synapses are the site of rapid exocytosis of synaptic vesicles and thus have a 
specialised role in ‘speed vesicle trafficking’334.  Ribeye knock-down mice display a lack of 
IHC synaptic ribbons and diminished organisation of the IHC active zone topography 
(vesicle replenishment and Ca2+ channel regulation)335. These findings are the first to link 
CTBP2 (or ribeye) to a human pathology, and the established role of ribeye in the ribbon 
synapse is further evidence that suggests HDiff could be caused by a synaptopathy. 
Table 5.4 is a summary of the findings presented above, regarding the subset of gene 
candidates that have previous links to hearing loss or an established function in the auditory 
system. The legend for Table 5.4, which is on the following page, is:  
Table 5.4. Primary gene candidates with established links to hearing function and pathologies.  
Lead SNP; lead SNP in joint and conditional analysis performed in chapter 4, Geno position; genomic position of 
the lead SNP, Pheno; phenotype used for GWAS, Rep; ü indicates a nominal replication (P<0.05) in the replication 
meta-analysis presented in chapter 4, Known hearing gene; name of gene at locus that has an established link to 
hearing function or pathology, Mouse model with hearing phenotype; ü indicates that the mutant mouse model for 
the corresponding gene displays a hearing phenotype, Human HL; ü indicates that a variant in this gene has been 
linked to human hearing loss, Type of hearing loss; the type of hearing loss that individuals present due to a 
mutation in the corresponding gene,  Known function; understood function of the corresponding gene in the 
auditory system.
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Lead SNP Geno 
position 
Pheno Rep Gene Mouse 
pheno 
Human 
HL 
Type of human hearing 
loss 
Known function 
rs9493627 Exon HDiff - EYA4 ✓ ✓ Autosomal dominant 
non-syndromic hearing 
loss204,288,289 
Tympanic membrane hypervascularity, retraction of the 
tympanic membrane, and middle ear effusions336 rs9321402 Intron HAid - 
rs9677089 Intron HAid - SPTBN1 ✓ - Novel Anchoring complexes of HC stereocilia296 
rs132929 Intron HDiff - BAIAP2L2 ✓ ✓ Syndromic 
sensorineural hearing 
loss290 
- 
rs5756795 Exon HDiff - TRIOBP ✓ ✓ Non-syndromic 
recessive16 & ARHI113 
Provides durability and rigidity for normal 
mechanosensitivity of stereocilia53 
rs55635402 Intron HDiff ✓ TUB ✓ - Novel Neuronal cell synaptic function, via interactions with 
MTAP1A337 
rs2236401 Intron HDiff - SYNJ2 ✓ - Novel Hair cell maintenance possibly via  degradation of 
phosphoinositide signalling molecules318 
rs3915060 Intron HAid - ILDR1 ✓ ✓ Recessive Non-
syndromic Deafness, 
ARHI113 
OHC maintenance and function, possibly via modulating 
tricellulin expression338 
rs7525101 Intergeni
c 
HDiff - LMX1A ✓ ✓ Non-syndromic 
recessive hearing 
impairment292 
Formation of endolymphatic duct and HCs in the basal 
cochlear region, and interaction with LMO in cochlear 
structure formation339 
rs143282422 Exon HDiff ✓ CDH23 ✓ ✓ Syndromic Autosomal 
recessive291 
Cohesion of HC stereocilia with MYO7A and harmonin b55, 
and tip link function with PCDH15340 
rs6597883 Intron HDiff ✓ CTBP2 ✓ - Novel Component of the synaptic ribbon341 
rs10901863 Intron HAid - 
Table 5.4 Primary gene candidates with established links to hearing function and pathologies. 
177 
 
5.2.2.2 Discussion: Loci associated in HDiff and HAid genetic association analysis 
that contain genes with a known role in hearing function or hearing conditions 
Section 5.2.2 is a study into the subset of gene candidates that are already established as 
‘hearing’ genes; the genes that either have a known role in auditory function or that have 
been linked to a hearing pathology. For four of the genes; SPTBN1, TUB, SYNJ2 and CTBP2, 
this is the first report of evidence of a link to an auditory pathology in humans. Variants in 
each of these four genes are linked to hearing phenotypes in mutant mice, demonstrating 
conserved auditory functions between the two organisms and supporting the use of mice to 
identify pathogenic variants for human hearing function.  
Of the ten genes, only two have been linked to forms of common hearing loss; TRIOBP and 
ILDR1 were associated with common hearing impairment in a previous ARHI GWAS113. The 
remaining four genes that have previously been linked to human hearing loss; EYA4, 
BAIAP2L2, LMX1A and CDH23, cause rare or familial cases of severe, early or late-onset 
hearing impairment. As variants in these genes are here associated with a common hearing 
loss, the variants causing this pathology could be less deleterious than those observed in 
previous severe and rare cases. An example could be deleterious variants in a gene that 
codes for damage repair or damage resistance. If these variants resulted in an impeded or 
inhibited expression or function of the encoded protein, over time crucial structures may 
not be amply repaired, resulting in a progressive phenotype.  
Further to this, for several of the genes discussed in this section, the region harbouring the 
pathogenic variant in HDiff or HAid differs between the previous reported cases. This may 
reflect the difference between the phenotypes observed; rare, severe cases in contrast to 
common variants causing a common impairment as assessed here. The location of a variant 
within or in proximity to a gene transcript can affect the severity and onset of the 
phenotype. Distinct amino acid substitutions in Connexin 26 (GJB2) cause different 
functional changes which are correlated with the severity of some forms of congenital, non-
progressive sensorineural hearing impairment43.  
For example, pathogenic regions identified in the EYA4 transcript that presented as rare, 
severe cases have been variants that produce premature stop codons in exons 14289, exon 
20289, exon 13289 and intron 14310. In the association analysis here, lead SNPs are identified 
in intron 1 (HAid) and exon 1 (HDiff) in the EYA4 transcript. The subtle differences in clinical 
presentations for rarer, more severe cases as opposed to the more common hearing 
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phenotypes could be a result of variants in different functional regions of the gene resulting 
in a range of phenotypes.  
CDH23 is another example of a gene that causes varied phenotypes based the location of 
multiple mutations, ∼116 sites in CDH23 contain variants that cause auditory phenotypes. 
For example, some CDH23 USH1D patients present with both visual and auditory 
phenotypes while others have auditory phenotypes only. In addition, variation between 
phenotypes may be caused by variants that are involved in gene-gene interactions.  
With respect to using current knowledge of these genes to better understand ARHI, 
expression has been tested for six of these genes in the peripheral auditory system. The 
auditory structures in which these genes are expressed are therefore candidates as sites for 
biological mechanisms implicated in HDiff and HAid. Six have known roles in the cochlea, 
mainly in hair cell (HC) stereocilia function and maintenance: SPTBN1, HC stereocilia296; 
TRIOBP, HC stereocilia53; SYNJ2, HCs318; LMX1A, endolymphatic duct and basal HCs339; 
CDH23, HC stereocilia55; CTBP2, HCs341. TUB has a role in in the function of neuronal cell 
synapses337 while EYA4 is known to have a role at the tympanic membrane336. However, 
while six of the eight genes have a role in the cochlea, this does not necessarily indicate that 
the cochlea is the only site of pathology, or that expression is not altered under different 
conditions.  
Lastly, a number of these ten genes have been linked to other conditions that are associated 
with ARHI. SYNJ2 for example, has been linked to Alzheimer’s319,342 and depression343,344, 
and is known to have a functional role in neuronal cells. With this knowledge, it could be 
hypothesised that SYNJ2 function may be in higher auditory structures and that their 
degeneration leads to hair cell dysregulation and death. The hypothesis is further supported 
by the observation that the Synj1 knock-out mouse display neurological defects and die 
shortly after birth. SYNJ1 and SYNJ2 are two key proteins in the Synptojanin protein family.  
Although a Synj2 knock-out mouse has not yet been made, the hypothesis that a neurological 
defect is the underlying cause of HL was tested, in the mozart (Synj2 mutant mouse as 
described on p.154). the study performed nerve conductance tests on mozart mice yet found 
no abnormal neurological behaviour at age 12 weeks, by which time mozart mice were 
severely deaf318.This indicates that mozart mice do not display a neurological phenotype 
primary to hair cell degeneration and loss and that the underlying cause of HL in mozart 
may therefore be the inner ear defects. Phenotypes of the aged heterozygous mutant were 
not assessed beyond 12 weeks however, and authors note the multiple functional regions 
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in the gene that may have diverse functions318. Determining the role of associated genes in 
other conditions can improve knowledge of the gene role in hearing and the biological 
relationship between the two or between multiple traits.  
The associations observed at these loci are not ‘novel’ in respect to a link with hearing or 
auditory function. In addition, based on the data presented in this chapter, all of these 
targets have been previously characterised and therefore none was selected for use in 
immunohistochemistry analysis at this stage. For most of the genes however, this is the first 
link to common hearing impairment in a human population and so these are important 
findings for human ARHI genetic risk. The findings also support the use of mice to study 
human ARHI genetic risk, challenges current understanding of the function of these genes, 
and could be interpreted as a validation of the association analysis and reliability of 
phenotypes.   
5.2.3 Loci associated in HDiff and HAid genetic association analysis that 
contain genes that are novel associations with hearing function or hearing 
conditions 
In this section the 34 remaining loci are evaluated. These are the loci that have not 
previously been linked to auditory function or pathologies and I selected three candidates 
for protein localisation analysis in adult mouse cochlear tissue. As noted at the beginning of 
this chapter, in vitro and in vivo investigation of gene candidates requires multiple resources 
and can be a time-consuming process. Therefore, prioritisation of gene candidates is an 
essential step and ought to be thorough, with bias omitted where possible. For each locus, 
data gathered in section 5.2.1, (where the genomic context of lead SNPs and thus the 
confidence of gene candidate selection was reported), is extended using further criteria set 
out in Figure 5.2. The results are summarised in Table 5.5. 
Here the statistical strength and validity of the associations is summarised. Each candidate 
is assessed based on; the lead SNP p-value, whether the locus is significantly associated in 
both HDiff and HAid and whether the association is significant in the replication meta-
analysis, Table 5.5, columns 3, 6 & 7. Each candidate is also assessed based on the beta 
coefficient; the relative effect of allele copy number on the phenotype variation, Table 5.5 
column 4. As the association analysis uses qualitative data, the beta value is not accurate for 
assessing the exact ‘effect’ of the variant on phenotype variation but can be used for making 
comparisons between SNPs within this study.  
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In Table 5.5, column 12, it is noted whether any of the gene candidates had putative links to 
hearing pathologies or the auditory system. Data from the gEAR portal 
(https://umgear.org/) was also investigated in relation to the primary gene candidates. 
This data includes gene expression levels in hair cells and supporting cells from P0 mouse 
cochlear samples in recent RNA-seq screens345 (- Methods 2.4.3). These findings can be 
interpreted as a form of ‘validation’ of firstly the association at the locus, and secondly, 
confidence in the selection of the true functional candidate. 
Table 5.5 also includes information regarding the availability of mutant mouse models and 
whether these display a hearing phenotype (in cases where such a test had been performed, 
column 10). This data is included as, if the relevant mutant mouse displays a hearing 
phenotype, this provides evidence of the gene causing a hearing pathology and that this 
function is conserved across humans and mice. If the strain is available, the pathophysiology 
can be readily studied. It is also noted in Table 5.5 whether antibodies are commercially 
available against the primary candidate protein product, and if it has been reported in a 
peer-reviewed publication, Table 5.5, column 11. 
In order to summarise and rank information for each gene candidate, Table 5.5 is colour 
coded; dark blue signifies strong evidence to support gene prioritisation, pale blue signifies 
some evidence to support gene prioritisation and grey signifies relatively low evidence for 
gene prioritisation. To minimise the duplication of information within the table, if multiple 
SNPs were assigned the same primary candidate gene in section 5.2.1 (the three SNPs at the 
ARHGEF28 locus and the two SNPs at the NID2 locus) these SNPs are grouped together in 
the table within this section.   
The data in Table 5.5 is interpreted and discussed in the text that follows. Evaluation of the 
data is subset into four sections for ease of assessment. Gene candidates are subset into 
groups based on parameters within the table. Some of the candidates could be assigned to 
more than one group such as high statistical evidence from association and high expression 
in inner ear sequencing screens. In these instances, the candidate is listed in the first section 
to which it can be assigned.  
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Lead SNP 
Genomic 
position 
P-Value Beta (SE) 
Primary 
candidate 
Pheno. Rep. Mouse 
gEAR, NSC/HC 
(RPKM) 
Mouse 
pheno. 
Anti. Link to hearing 
rs36062310 Exon 1.90E-22 -0.0315 (0.003) KLHDC7B HDiff ✓ ✓ 20 / 8402.9 - ✓- - 
rs6453022 Exon 1.70E-21 -0.0126 (0.001) 
ARHGEF28 
HDiff - 
✓ No data - ✓- - rs6890164 Intergenic 3.30E-19 0.0119 (0.001) HDiff - 
rs4597943 Intron 2.09E-11 -0.0042 (0.001) HAid ✓✓ 
rs759016271 Intron 6.10E-21 -0.0127 (0.001) ZNF318 HDiff ✓✓ ✓ No data - ✓- - 
rs7951935 Intergenic 7.80E-17 -0.0114 (0.001) TYR HDiff ✓ ✓ 19420.4 / 331 ✓ ✓✓346 
Possible protective role via 
melanin347 
rs35186928 Intergenic 1.70E-15 -0.0109 (0.001) HLA-DQA1 HDiff ✓ ✓ No data - ✓- - 
rs1566129 Intron 1.40E-11 0.0091 (0.001) 
NID2 
HDiff ✓✓ 
✓ 
329277 / 
24934.7 
- ✓✓348 - 
rs1566129 Intron 2.50E-09 0.0037 (0.001) HAid - 
rs35414371 Intergenic 1.60E-11 -0.0131 (0.002) CLRN2 HDiff - ✓ 20 / 424.2 ✓-* ✓- Function at HC stereocilia349 
3:182069497
_TA_T 
Intergenic 4.10E-11 -0.0118 (0.002) ATP11B HDiff - ✓ 2649.9 / 5705.9 - ✓- - 
rs12225399 Intron 8.60E-11 -0.009 (0.001) PHLDB1 HDiff ✓ ✓ 31373.4 / 9133.8 - ✓- - 
rs62033400 Intron 2.90E-10 0.0085 (0.001) FTO HDiff ✓ ✓ 
11271.5 / 
26941.5 
- ✓✓350 - 
rs13277721 Intron 3.30E-10 -0.0083 (0.001) AGO2 HDiff - ✓ No data - ✓✓351 - 
rs62188635 Intergenic 4.70E-10 0.0083 (0.001) KLF7 HDiff ✓ ✓ 809.5 / 327.4 - ✓✓352 - 
rs4947828 Intron 1.00E-09 -0.0096 (0.002) GRB10 HDiff - ✓ 1214.1 / 482.6 - ✓- - 
rs34442808 Intron 1.30E-09 -0.008 (0.001) MCTP1 HDiff - ✓ 81 / 1475.3 ✓ ✓- 
Contains a cis-regulatory 
region for NR2F1 function in 
mouse inner ear 
development347 
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Lead SNP 
Genomic 
position 
P-Value Beta (SE) 
Primary 
candidate 
Pheno. Rep. Mouse 
gEAR, NSC/HC 
(RPKM) 
Mouse 
pheno. 
Anti. Link to hearing 
rs835267 Intron 1.60E-09 0.008 (0.001) EXOC6 HDiff - ✓ 256.4 / 2402.8 - ✓- - 
rs4948502 Intron 1.70E-09 0.0081 (0.001) ARID5B HDiff - ✓ 13534.1 / 2250.6 - ✓✓353 - 
rs10824108 Intron 3.00E-09 -0.0079 (0.001) ADK HDiff ✓ ✓ 3407.9 / 2317 - ✓✓354 - 
rs12027345 Intergenic 3.60E-09 0.0079 (0.001) MAST2 HDiff ✓ ✓ 20 / 20 - ✓✓355 - 
rs217289 Intron 4.90E-09 -0.0078 (0.001) SNAP91 HDiff ✓ ✓ 723.9 / 4711.6 - ✓- - 
rs13093972 Intergenic 5.50E-09 -0.0078 (0.001) ZBTB20 HDiff - ✓ 20 / 20 - ✓✓356 - 
rs62015206 Intergenic 7.70E-09 -0.0078 (0.001) MAPK6 HDiff - ✓ 20 / 33.3 - ✓✓357 - 
rs10475169 Intergenic 9.30E-09 -0.0117 (0.002) IRX2 HDiff - ✓ 1931.5 / 10284.9 - ✓- - 
rs17671352 Intron 1.00E-08 0.0078 (0.001) ACADVL HDiff ✓ ✓ 4967.8 / 5301.5 - ✓- - 
rs12938775 Intron 1.60E-08 0.0075 (0.001) PAFAH1B1 HDiff - ✓ 192.4 / 376.5 - ✓✓358 
Evidence of a role in HC 
planar polarity358 
rs76837345 Intron 1.90E-08 -0.0146 (0.003) CHMP4C HDiff - ✓ 82.1 / 297.4 - ✓ - 
rs9366417 Intron 2.10E-08 0.0085 (0.002) SOX4 HDiff - ✓ 
12907.2 / 
10772.7 
- ✓✓359 
SoxC gene family with role in 
HC production360 
rs3890736 Intergenic 2.20E-08 -0.0077 (0.001) GFRA2 HDiff - ✓ 24971.7 / 1987.8 - ✓✓361 
Expression in spiral neuron 
cell bodies362 
rs7823971 Intergenic 2.70E-08 -0.0043 (0.001) 
RP11-
1102P16.1 
HAid - - No data - ✓- - 
rs9691831 Intergenic 3.10E-08 -0.0074 (0.001) TMEM213 HDiff - ✓ 20 / 20 - ✓- - 
rs141403654 Intron 3.50E-08 -0.0313 (0.006) AGBL2 HDiff ✓ ✓ 154.6 / 718.3 - ✓- - 
rs4611552 Intergenic 3.60E-08 -0.0089 (0.002) CCDC68 HDiff - ✓ 23 / 541 - ✓- - 
rs12552 Exon 4.80E-08 0.0073 (0.001) OLFM4 HDiff - ✓ 67.3 / 82.5 - ✓✓363 - 
rs10927035 Intron 4.90E-08 -0.0075 (0.001) AKT3 HDiff - ✓ 3095.1 / 11550 - ✓- - 
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Lead SNP 
Genomic 
position 
P-Value Beta (SE) 
Primary 
candidate 
Pheno. Rep. Mouse 
gEAR, NSC/HC 
(RPKM) 
Mouse 
pheno. 
Anti. Link to hearing 
 
Table 5.5.  Summary table of data for primary gene candidates that are novel to hearing pathologies. 
Lead SNP; lead SNP at each region of association as defined by joint and conditional in chapter 4, Genomic position; genomic position of lead SNP, P-Value; BOLT-LMM infinitesimal mixed 
model association test p-value of the lead SNP in GWAS presented in chapter 4, Beta (SE); effect size from BOLT-LMM approximation to infinitesimal mixed model and (SE) standard error 
of the beta effect size, Primary candidate; gene in closest proximity to lead SNP, Pheno.; phenotype used for GWAS, Rep.; ✓ denotes a nominal p-value in the meta-analysis replication and 
✓✓ denotes a Bonferroni-corrected p-value in the meta-analysis replication, Mouse model; ✓ denotes that there is a mutant mouse model for this gene inc. archived strains, gEAR NSC/HC, 
RPKM; Results from RNAi screen of P0 mouse expression profile for non-sensory cells (NSC), Hair cells (HCs) Reads Per Kilobase of transcript, per Million mapped reads (RPKB), Mouse 
hearing phenotype; ✓ denotes that the mutant mouse model displays a hearing phenotype, Anti; ✓ denotes that there is a commercially available antibody for the protein of interest while ✓✓ 
denotes that the antibody has been used in a peer-reviewed publication, Link to hearing; details of any putative link to hearing in the current literature. Dark blue signifies strong evidence to 
support gene prioritisation, pale blue signifies some evidence to support gene prioritisation and grey signifies relatively low evidence for gene prioritisation. * denotes a finding that was not 
published when the work was conducted.  
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5.2.3.1 Gene candidates with strong statistical evidence based on association 
analysis 
Three primary candidates, ARHGEF28, ZNF318 and NID2, have strong statistical support for 
prioritisation, based on the association statistics from this study. Gene transcripts of all 
three candidates contain lead SNPs P<1.5E-11 in the discovery analysis, and all three 
replicate at a Bonferroni-corrected significance threshold in the replication meta-analysis. 
In addition, ARHGEF28 and NID2 are primary candidates that contain SNPs significantly 
associated (P<5E-08) with in both of the two phenotypes HDiff and HAid.  
In addition to this strong statistical evidence, gene family members of NID2 and ARHGEF28 
have been linked to hearing function or have been shown to be expressed in auditory 
structures.  ARHGEF6 is in the same guanine nucleotide exchange factor family as ARHGEF28 
and was recently studied in the context of its role in sensorineural hearing loss. ARHGEF6 
was hypothesised to have a role in sensorineural hearing loss as is also known as the gene 
which causes x-linked intellectual disability (as XLID46), a disorder where sensorineural 
hearing loss can present as a symptom364. A recent study identified expression of Arhgef6 
in the mouse cochlea and used a knock-down model to test for a functional role. The knock-
down mice displayed a significant threshold difference to wild-type siblings at P90 and by 
P60, exhibited abnormal morphology of IHC hair cell bundles and exhibited abnormal 
morphology of OHC bundles365. Being of the same gene family, it is possible that ARHGEF28 
has a similar role as, or site of action within the cochlea to, ARHGEF6.  
Expression of NID1 has been observed in cochlear structures366 and, as NID1 and NID2 are 
both components of the basement membrane structure, it could be hypothesised that NID2 
would also be present and have a function in the structure. The exact role of NID1 in the 
cochlea has not been determined, but expression was observed lining blood vessels, in the 
Reissner's membrane and the osseous spiral lamina. As the two proteins are expressed as 
components of the same basement membrane structures, it is likely that NID2 could also be 
expressed in the cochlea.  
5.2.3.2 Gene candidates with putative previous links to hearing function or hearing 
conditions 
Six of the candidates; TYR, CLRN2, MCTP1, PAFAH1B1, SOX4 and GFRA2, either have putative 
links to hearing reported in the literature that do not meet the criteria used in section 5.2.1 
or links that have subsequently been published. None of the six genes has been directly 
linked to auditory pathology in humans, though three have been linked to mouse hearing 
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phenotypes; Tyr, Clrn2 and Mctp1. Therefore, these is an interesting subset of potential 
candidates for further investigation. Below the individual merits and limitations of each 
candidate is discussed.  
Firstly, the lead SNP in close proximity to TYR (rs7951935) has a low p-value p=7.80E-17, 
and nominal replication in the replication meta-analysis. The lead SNP at this locus however 
is not within the TYR transcript, and although TYR is the nearest protein-coding gene 
transcript, there are multiple genome-wide associated SNPs that are in high LD with the 
lead SNP that reside in the NOX4 transcript, along with non-significant SNPs that are in 
moderate LD, in the GRM5 gene transcript. Figure 5.4. At this locus fine mapping is required 
to gain more confidence in gene candidate selection for functional analysis. 
Speculated links between tyrosinase (TYR) and hearing loss have been made, relating to the 
role of tyrosinase in the conversion of tyrosine to melanin. The production of melanin is 
thought to be a protective factor against hearing loss, specifically noise-induced hearing 
loss. To explore these observations, albino mice were studied in comparison to wild-type 
and to tyr-transgenic mice, where it was observed that melanin precursors had a protective 
effect against sensorineural hearing loss following noise exposure damage99. 
 
Figure 5.4. Locus plot displaying the genome region flanking the lead SNP rs7951935, in 
proximity to the TYR, NOX4 and GRM5 transcripts.  
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. 
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Secondly, a lead SNP in close proximity to CLRN2 has an association p-value of 1.60E-11 and 
is located 1956bp downstream of the CLRN2 gene transcript. Within the same LD block is 
the QDPR gene transcript. While QDPR has no previous link to hearing loss, CLRN2, which 
codes for clarin-2, is a strong candidate for two reasons. Firstly, CLRN2 is a paralogue of 
CLRN1, a gene which, when mutations are present, is known to cause autosomal recessive 
Usher syndrome Type-3 (sensorineural hearing loss is present from birth)367,368. Based on 
this, it could therefore be hypothesised that CLRN2 may also have a function in auditory 
structures.  
Furthermore, a recent study using Clrn2clarinet/clarinet mice generated via a large-scale forward 
genetic screen, demonstrated that Clrn2 is required for normal hair bundle integrity and 
functioning349; the mutant mice displayed a loss of mechano-electrical transduction 
followed by a gradual loss of HC stereocilia. Figure 5.5 depicts the loss of IHC and OHC 
stereocilia in p28 mice. Genetic association analysis that I performed using the HDiff 
phenotype (described in chapter 3 and 4), on 484 SNPs within 100kb of the CLRN2 
transcript, was also described in the study. The association in the UKBB cohort compliments 
the finding in the Clrn2clarinet/clarinet mice of CLRN2 function and demonstrates its relevance to 
human auditory function. However, protein localisation of CLRN2 in the cochlea has not yet 
been established via immunohistochemistry, so this would confirm the location of 
expression and support the evidence of this specialised function, and test whether the 
association here likely relates to the function of CLRN2 or QDPR.  
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Figure 5.5 Loss of the OHC and IHC hair bundle transducing stereocilia in Clrn2clarinet/clarinet 
mice.  
Pseudo-coloured scanning electron micrographs of individual OHC (top panels) and IHC (bottom panels) hair 
bundles from clarinet mice at P28. Clrn2clarinet/clarinet mutants have only two rows of OHC stereocilia, and the 
middle row of stereocilia is less uniform in height compared to controls. The middle and short rows of stereocilia 
in Clrn2clarinet/clarinet IHC bundles appear fewer in number, and heterogeneous in height. Scale bars, 2µm. Figure 
and legend reproduced and adapted with permission, L. Dunbar et al.369. 
 
Thirdly, the lead SNP that resides in MCTP1 is also highly associated with the HDiff p=1.30E-
09, but the association is not replicated in the meta-analysis. The lead SNP here resides in 
an intron region of MCTP1, indicating that this gene may be the functional target of the 
causal variant. However, there are also multiple SNPs at genome-wide significance that are 
in high LD with the lead SNP, that reside in the ANKRD23 gene transcript, downstream of 
MCTP1. MCTP1 does however have a putative link to auditory function as it is understood 
to contain a cis regulatory region that controls the activity of NR2F1, a gene that has a role 
in the development of the sensory hair cells and cochlear epithelium370. 
MCTP1 is therefore an example of a gene highly associated with a phenotype of interest but 
does not have a direct functional role in the auditory system. Instead, via a regulatory 
interaction, it affects the behaviour of a gene that is directly involved in cochlear 
development370. Therefore, protein localisation of MCTP1 in the cochlea would not be 
relevant to perform here. Secondly, fine mapping of this region is required to affirm the 
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assumption that MCTP1 is the target of the observed association at this locus rather than 
ANKRD23.  
The remaining three genes, GFRA2, PAFAH1B1 and SOX4 have been linked to auditory 
function by expression and, or function within critical auditory structures. By comparison 
to the other lead SNPs studied here, GFRA2 has a relatively lower significance level of 
association (p=2.20E-08) and is not replicated at nominal significance. Expression of GFRA2 
has been detected in adult human cochlear samples at spiral neuron cell bodies99, suggestive 
of a potential function in spiral ganglion neurons. This is evidence that GFRA2 is a strong 
candidate to pursue for determining a pathology, but as the location in the cochlea has 
already been established it is not prioritised for immunohistochemistry at this stage.  
Similar to GFRA2, the p-value for the lead SNP in the region of SOX4 is relatively low 
(p=2.10E-08) by comparison to the other lead SNPs in this analysis. SOX4 is a member of the 
SOXC transcription factor (TF) family which has been identified as potential targets for 
regeneration of supporting and hair cells in the mammalian inner ear360. This is a result of 
the finding that SOXC TFs (Sox4and Sox11) are strongly downregulated from E17.5 to P9 in 
the mouse inner ear. Further to this, proliferation of progenitor cells expressing Sox4 and 
Sox4 was observed in vivo in E16.5 mice360. In the same study, Sox4 expression was observed 
at hair cells via immunohistochemistry. Therefore, SOX4 is not a prioritised candidate for 
immunohistochemistry here, though expression could be present at additional structures 
in the cochlea in adult mice.  
In addition, the lead SNP at the SOX4 locus in this analysis may not actually represent a 
pathogenic function in the SOX4 gene. While SOX4 is the nearest protein-coding gene, the 
lead SNP is upstream of the SOX4 transcript and, as mentioned in section 5.2.1, is located in 
the RNA gene CASC15, in a different LD block to the SOX4 transcript (Figure 5.6). A fine 
mapping approach could be used to explore whether SOX4 is possibly the functional target 
of the pathogenic variant or the regulatory element CASC15.  
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Figure 5.6. Locus plot displaying the SOX4 protein-coding transcript and the CASC15 RNA-
coding transcript. 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. 
 
Lastly, the lead SNP that resides in an intron of PAFAH1B1 has an association p-value of 
1.60E-08, and while it does not reach nominal significance in the replication analysis, no 
other protein coding genes at the locus contain genome-wide associated SNPs in high LD 
with the lead SNP, giving confidence to the assertion that PAFAH1B1 is the functional target. 
PAFAH1B1 has been linked to hearing function firstly based on a hypothesis that it has a role 
in determining hair cell planar polarity. HC planar polarity is crucial to sensory cell function, 
as the precise organisation of stereocilia on the apical end of sensory cells affects their 
mechanostransduction. 
PAFAH1B1 (Lis1) is a microtubule regulator and thus was selected as a candidate regulatory 
gene for HC planar polarity. Based on the hypothesis, HC formation and maintenance has 
been studied in conditional Lis1 mutant mice. At the embryonic stage, the mutant mice 
display defective organisation of cells at the organ of Corti and of HC planar polarity. 
Maintenance of HC planar polarity was also affected in postnatal cochlear tissue in the 
mutants via the regulation of cytoplasmic dynein and organization of microtubules358. In 
this study too, immunohistochemistry was used to visualise structures within the cochlea 
and thus this candidate is not prioritised for immunohistochemistry here.  
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5.2.3.3 Gene candidates that are a novel association with hearing function or 
hearing conditions, yet display relatively high mRNA expression in the inner ear 
Of the remaining candidates, 12 have relatively high levels (>1000 RPKM) of gene 
expression in either NCS or HCs in P0 mouse inner ears, (Table 5.5, column 9). The data 
were collected from an RNA-seq screen of Atoh-1 expressing HCs. Within this group of gene 
candidates to have relatively high expression levels in this screen is KLHDC7B. The lead SNP 
at the KLHDC7B locus is rs36062310 and has the smallest p-value of all lead SNPs in the two 
association analyses P=1.90E-22. The lead SNP resides in an exon region of KLHDC7B, 
Figure 5.7.  
In addition to the relatively high expression in the RNAi screen, the protein products of 
Klhdc7b and Adk has been observed in a hair cell proteome screen using P4-P7 
Pou4f3/eGFP-transgenic mice. KLHDC7B is one of 934 proteins identified in the HC sample 
only (GFP + sample)371. Adk expression was also observed in the GFP + sample and was one 
in a group of 38 HC-only protein isoforms; a number of the genes studied have multiple 
isoforms which displayed differential expression in cochlear cell types examined. In 
contrast to this however, expression of Klhdc7b and Adk was not particularly high in the 
RNA-seq screen of Atoh1-expressing HCs in P0 mice. Table 5.5 displays the expression level 
of these transcripts in HCs in this screen as 2317 RPKM (Adk) and 8402.9 RPKM (Klhdc7b).  
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Figure 5.7. Locus plot of region containing the lead SNP rs36062310 p=1.90E-22 within an 
exon of KLHDC7B.  
The plot displays the region flanking the lead SNP (purple) by +/- 25kb. The colouring of remaining SNPs 
represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, SNPs are 
coloured grey. 
 
Within this group of 12 candidates, five have very high relative levels of expression in the 
RNA-seq screen261; Phldb1, Fto, Arid5b, Irx2 and Gfra2. Lead SNPs at PHLDB1, FTO, ARID5B 
loci lie within intron regions of respective genes, and no further SNPs at the loci reached 
genome-wide significance and are in high LD with the lead SNP. For these candidates, 
functional analysis could be justified, but will not be performed at this stage due to the 
stronger evidence of association and function for other candidates discussed previously. For 
IRX2 and GFRA2 however, there is less confidence in the selection of the primary candidate 
from the lead SNPs. The lead SNPs at the IRX2 and GFRA2 loci are >100kbp and >10kbp away 
from the gene transcripts respectively. Fine mapping would be required to confirm whether 
these are the most likely functional target of the associations at these loci. 
5.2.3.4 Gene candidates that are a novel association with hearing function or 
hearing conditions that display a relatively low mRNA expression in the inner ear  
Twelve candidates remain that are not in the top three loci with the strongest statistical 
evidence of association, have no other putative links to hearing function and have <1000  
RPKM in NSCs and/or HCs in RNA-seq screen261 (or were not included in this screen). For 
these candidates, further analysis is necessary before allocating resources to follow-up any 
of the targets in vivo. For example, this group contains the primary candidate RP11-
1102P16.1, an uncharacterised protein coding gene. 
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In addition, a number of these lead SNPs are some distance from the nearest gene transcript. 
An example is depicted in Figure 5.8, which displays the region flanking rs13093972, a SNP 
in proximity to the ZBTB20 gene transcript. This could be evidence that the functional 
variant has a regulatory role either upstream or downstream of the coding gene target; 
again a likely hypothesis in ARHI, as variants within the population collectively have an 
effect based on relatively small individual effects, such as observed when gene regulation is 
subtly altered. So, while there is not sufficiently strong evidence that these candidates and 
lead SNPs are suitable to prioritise for protein expression in the mouse cochlea at this time, 
these are important findings and ought to be evaluated again and may be suitable for follow-
up using alternative methods.  
 
Figure 5.8. Locus plot for the region containing the lead SNP rs13093972 p=5.50E-09 in 
proximity to ZBTB20.  
The colouring of remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information 
is not available, SNPs are coloured grey. The plot displays the region flanking the lead SNP (purple) by +/- 
400kb 
 
Based on the distance of lead SNPs from some of these primary candidates, the reported low 
expression in the P0 mouse inner ear RNA-seq screen and an absence of previous putative 
links with these candidates, these may not be the functional targets of the causal variant. 
Conversely, as these are novel to hearing loss, these could be the most progressive findings. 
Furthermore, the lack of expression in the RNA-seq screen could indicate that the genes are 
not expressed during development and therefore have a maintenance function, as expected 
in a progressive and heterogeneous trait such as ARHI.  
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5.2.4 Immunohistochemistry  
In the previous sections, gene candidates were evaluated with the aim of selecting a subset 
for protein localisation in adult cochlear tissue. In this final section, the selection of 
candidates and subsequent immunohistochemistry results are presented. The 
corresponding methods for protein localisation analysis are described in - Methods 2.5. The 
three loci selected contain the genes (1) NID2, (2) ARHGEF28 and (3) CLRN2, and are 
annotated on the Manhattan plots in Figure 5.9. 
 
Figure 5.9. Two Manhattan plots displaying GWAS results for HDiff (top) and HAid (bottom).  
The graphs are annotated with the position of the three genes that code for ARHGEF28, CLRN2 and NID2, 
which were selected for immunohistochemistry. The red dotted line marks genome-wide significance p<5E-08. 
The loci containing NID2 and ARHGEF28 contained SNPS that reached genome-wide significance in both HDiff 
and HAid. SNPs at the CLRN2 locus reached genome-wide significance in HDiff only.   
 
Expression of all three proteins is tested in n=3 adult mouse cochlear tissue (p28-p30), 
following the protocol set out in Chapter 2, section 2.5 ‘Protein localisation analysis’. In 
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addition to antibodies against the proteins of interest, phalloidin and DAPI are applied to 
samples to stain F-actin and AT regions of dsDNA respectively. F-actin is present in hair cell 
stereocilia and is therefore here used as a marker to locate the cochlear sensory hair cells. 
DAPI stains AT regions of dsDNA, mainly present in the nuclei, and thus can be used to 
visualise the structure of the sample from the composition of individual cells. 
5.2.4.1 Nidogen-2 (NID2) 
Nidogen-2, coded by NID2 was selected for protein localisation analysis. The same lead SNP 
rs1566129 reached genome-wide significance in both HDiff and HAid work and is located in 
intron 5 of NID2. The associated region can be observed in Figure 5.10 (HDiff) and Figure 
5.11 (HAid) with the lead SNP coloured purple. Within the loci, NID2 is the only gene 
transcript that contains SNPs that are within high LD (r2>0.6) at this locus. 
 
 
Figure 5.10 Locus plot of HDiff lead SNP and the NID2 gene transcript. 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. The plot displays 100kb +/- regions flanking the position of the lead SNP. 
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Figure 5.11 Locus plot of HAid lead SNP and the NID2 gene transcript 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. The plot displays 50kb +/- regions flanking the position of the lead SNP. 
 
Nidogen-2 is part of the nidogen glycoprotein family and is a component of the basement 
membrane complex, along with nidogen-1, the first isoform of the protein to be discovered. 
In the basement membrane complex, nidogen-2 binds to laminin-1 and to collagen I and 
IV372. Nidogen-2 is enriched in endothelial basement membranes and has a role in the 
formation and homeostasis of blood vessels. Work in Nid2-mutant mice has revealed that 
the two proteins may not have a structural role in the basement membrane as its formation 
was not affected373. Findings from another study that focused on Caenorhabditis elegans 
which possess one nidogen-coding gene, suggest that nidogens could have further roles, in 
addition to being part of the basement membrane complex. Nidogen mutants did not exhibit 
abnormal basement membranes but display affected axonal patterning such that the dorsal 
sub-lateral nerves are mispositioned to the dorsal midline374. 
The role of nidogens in auditory function has not previously been examined and there have 
been no previous associations with nidogens and auditory pathologies. The only  link that 
has been previously published has been the identification of nidogen-1 expression in the 
supporting cells of the organ of Corti, the Reissner’s membrane and the osseous spiral 
lamina 366. There are commercially available antibodies that have been successfully used in 
publications for protein localisation of nidogen-2 in multiple tissue types375.  
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Protein localisation of NID2 
 Here, anti-NID2 staining was observed in the lining of blood vessels, visible in Figure 5.12 
(c) bottom arrow, and (b) along the structure of the stria vascularis). This is evidence of 
antibody specificity in these samples, as nidogen-2 has previously been observed in blood 
vessel basement membranes in several tissue types372. Anti-NID2 staining is most 
prominent in a restricted region of the epithelial lining between the inner spiral sulcus and 
spiral limbus (Figure 5.12), with strong staining at the base of a cell in proximity to the inner 
hair cell (Figure 5.12 (c) top arrow and Figure 5.13). In the 40x images (Figure 5.13), anti-
NID2 staining is again observed in this region, appearing to be around the base of one cell 
at each plane of the z-stack. Anti-NID2 staining is not observed in any of the cell bodies of 
the sensory cells.  
 
 
 
(a) (c) (b) Anti-NID2 488 Phalloidin 565 Phalloidin 565 
Anti-NID2 488 
DAPI 605 
 Figure 5.12. Protein localisation of Anti-NID2 at the organ of Corti, 20x objective. 
Colour labelling in the composite image (c): Blue, DAPI; Magenta, phalloidin; Green, Anti-NID2. The white 
arrow directing downwards in (c) is to highlight prominent staining (anti-NID2, green) at a region of the epithelial 
lining between the inner spiral sulcus and spiral limbus. The white arrow pointing upwards is to highlight the 
blood vessel lining; the circular structure stained by anti-NID2 (green). The scale bar in (a) represents 100µm 
and is consistent for all three images in this figure. 
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Figure 5.13. Protein localisation of Anti-NID2 at the organ of 
Corti, 40x objective.  
Colour labelling in the composite image: Blue, DAPI; Magenta, 
phalloidin; Green, Anti-NID2. The white arrow in (c) points to prominent 
staining (anti-NID2, green) at a region of the epithelial lining between the 
inner spiral sulcus and spiral limbus. (c) also displays phalloidin staining 
in magenta, which highlights the apical ends of sensory hair cells. The 
scale bar in (a) represents 25µm and is consistent to all three panels in 
this figure.  
 
5.2.4.2 Rho Guanine Nucleotide Exchange Factor 28 (ARHGEF28)  
ARHGEF28 was selected for protein localisation and, similarly to NID2, contains lead SNPs 
that are genome-wide significant in both HDiff and HAid analysis. In addition, the in HDiff 
analysis, two ‘independent’ lead SNPs are at the ARHGEF28 locus and are in different ‘LD 
blocks’. In HDiff, rs6890164 and rs6453022 are the lead SNPs that reside in the ARHGEF28 
region, Figure 5.14 and Figure 5.16. rs6890164 lies 6177bp upstream of ARHGEF28 and 
rs6453022 resides in exon 7. In the HAid analysis the lead SNP rs4597943 lies in intron 7 of 
ARHGEF28 Figure 5.15 . The two SNPs rs6453022 and rs6890164 have an LD R2=0.7573 (p-
value <0.0001). 
(a) 
(c) 
(b) 
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Figure 5.14 Locus plot of HDiff lead SNP at the ARHGEF28 gene transcript 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. The plot displays 50kb +/- regions flanking the position of the lead SNP 
 
 
Figure 5.15 Locus plot of HAid lead SNP at the ARHGEF28 gene transcript 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. The plot displays 50kb +/- regions flanking the position of the lead SNP. 
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Figure 5.16 Locus plot of HDiff SNP in close proximity to the ARHGEF28 gene transcript 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. The plot displays 50kb +/- regions flanking the position of the lead SNP. 
 
ARHGEF28 codes for Rho Guanine Nucleotide Exchange Factor 28, a member of the Rho 
guanine nucleotide exchange factor family that activates the Ras-like family of Rho proteins. 
The exact function has not been established, but when over expressed in neuronal cells, 
ARHGEF28 has been shown to induce cell rounding and inhibit neurite outgrowth376. 
ARHGEF28 has not before been associated with auditory function or a pathology, but a 
number of studies have linked ARHGEF28 to amyotrophic lateral sclerosis (ALS) and motor 
neuron disease. ARHGEF28 is a neurofilament mRNA destabilising factor and prior to 
finding a link between ARHGEF28 and ALS patients, it was found to have a have a role in 
forming neuronal cytoplasmic inclusions in spinal motor neurons in mice (p190RhoGEF). 
The first link between ARHGEF28 and ALS was found  in sample of 7 familial ALS cases, 
where a frameshift mutation was identified, that is predicted to result in a truncated gene 
product377. Further work on the risk in this family revealed that the ARHGEF28 mutation 
may modify the risk via a C9orf72 expansion378. A second study to report a link with ALS 
identified a mutation in ARHGEF28 present in 0.52% of the 380 ALS cases in the Chinese 
cohort studied379. A second study in a Chinese cohort has, more recently, identified a 
number of variants at distinct locations within the ARHGEF28 gene which are hypothesised 
to confer or reduce risk of ALS development380. The latest link between ARHGEF28 and risk 
of neurodegenerative conditions was in two unrelated Charcot-Marie-Tooth/hereditary 
motor neuron disease cases381. Further to these links with neurodegenerative conditions, 
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ARHGEF28 has been linked with processes such as cell reorientation382, cell migration383 
and cell motility384 in addition to tumour morphology and behaviour385–387.  
Protein localisation of ARHGEF28 
At the organ of Corti (Figure 5.17), anti-ARHGEF28 localises at both inner and outer hair 
cells. Staining is also observed (less prominently) in the stria vascularis. This could be 
suggestive of a role in the sensory cells; both the inner and outer hair cells. In this section, 
the rows of outer hair cells have become displaced and so multiple rows are visible (cluster 
of inner hair cells rather than three, one from each row as seen previously). The 40x image 
of the organ of Corti(Figure 5.19)  also displays this anti-ARHGEF28 staining in the IHCs and 
OHCs, and staining does not appear to be present in the surrounding supporting cells. In 
addition to localising at the sensory cells, Anti-ARHGEF28 staining is localised at the spiral 
ganglion neurons, at the modiolus (Figure 5.18). Prominent staining of Anti-ARHGEF28 is 
not present however, in the unmyelinated nerve cells that originate from the hair cell 
synapses (Figure 5.17, Figure 5.19).  
 
 
 
Figure 5.17. Protein localisation of Anti-ARHGEF28 at the organ of Corti, 20x objective.  
Colour labelling in the composite image: Blue, DAPI; Magenta, phalloidin; Green, Anti-ARHGEF28. White 
arrow in (c) points out anti-ARHGEF28 staining (green) of the inner hair cell. The scale bar in (a) represents 
100µm and is consistent for all three images in this figure.  
(a) (c) (b) Phalloidin 565 
Anti-ARHEF28 488 
DAPI 605 
Anti-ARHGEF28 488 Phalloidin 565 
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Figure 5.19. Protein localisation of Anti-ARHGEF28 at the organ 
of Corti, 40x objective.  
Colour labelling in the composite image: Blue, DAPI; Magenta, phalloidin; 
Green, Anti-ARHGEF28. (c), the composite image, displays phalloidin 
staining in magenta, which highlights the apical ends of sensory hair cells. 
Anti-ARHGEF28 staining (green) is present in the cell bodies of the inner 
and outer hair cells. The scale bar in (a) represents 25µm and is consistent 
to all three panels in this figure. 
 
Figure 5.18. Protein localisation of Anti-ARHGEF28 at Spiral ganglion., 20x objective.  
Colour labelling in the composite image: Blue, DAPI; Magenta, phalloidin; Green, Anti-ARHGEF28. Anti-
ARHGEF28 staining is seen in white (b) and green (c) at the spiral ganglion neurons at the modiolus. The 
scale bar in (a) represents 100µm and is consistent for all three images in this figure. 
(a) 
(c) 
(b) 
ARHGEF2
8 488 
ARHGEF2Phalloid(a) (c) (b) Phalloidin 565 Anti-ARHEF28 488 
DAPI 605 
Phalloidin 565 Anti-ARHGEF28 488 
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5.2.4.3 Clarin-2 (CLRN2) 
The lead SNP in the locus containing the CLRN2 transcript is located 1965bp downstream 
of the CLRN2 gene. Within the same LD block as the lead SNP, is the QDPR gene transcript 
(Figure 5.20) CLRN2 codes for clarin-2, a membrane glycoprotein that is a paralog of CLRN1. 
Mutations in clarin-1 have been shown to cause autosomal recessive Usher syndrome Type-
3, a disorder where patients display a sensorineural hearing loss that is present from 
birth367,368.  Ush3a (CLRN1) expression has been observed in cochlear hair cells and spiral 
ganglion cells of mice at ages E16, P0, P5 and P10 and so it could be hypothesised that CLRN2 
is also expressed in these cell types.  
Additional work has established that the clarin-1 protein localises with microtubules and 
post-transgolgi vesicles of hair cells, suggestive of a role in neurosensoriepithelia388. Lastly, 
Clarin-1-/- mice exhibit disrupted stereocilia bundles and present an early onset, profound 
hearing loss389,390. Furthermore, as described in the previous section, recent work with 
Clrn2clarinet/clarinet mice has demonstrated an essential role of a functioning CLRN2 gene for 
hair bundle integrity and function349. As CLRN1 is expressed in the cochlea and, when 
mutated, can cause USH3A, CLRN2 was selected for protein localisation.  
 
 
Figure 5.20 Locus plot of the lead SNP in HDiff analysis in close proximity to the CLRN2 
gene transcript 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The colouring of 
remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD information is not available, 
SNPs are coloured grey. The plot displays 50kb +/- regions flanking the position of the lead SNP. 
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Protein localisation of CLRN2 
Under the 20x objective strong anti-CLRN2 staining is observed in outer and inner sensory 
hair cells and in the stria vascularis, Figure 5.21. Less prominent staining is observed in cells 
in the basilar membrane. In the 40x image (Figure 5.22), anti-CLRN2 staining at the outer 
hair cells appears more concentrated at the apical end of the cell.  
 
Figure 5.21. Protein localisation of Anti-CLRN2 at the organ of Corti, 20x objective.  
Colour labelling in the composite image: Blue, DAPI; Magenta, phalloidin; Green, Anti-CLRN2. The two 
arrows in (c) highlight anti-CLRN2 staining of the inner hair cell (arrow directed downward) and the outer hair 
cells (arrow directed towards the left of the image). The scale bar in (a) represents 100µm and is consistent 
for all three images in this figure.  
 
 
(a) (c) (b) Phalloidin 565 
Anti-CLRN2 488 
DAPI 605 
Phalloidin 565 Anti-CLRN2 488 
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5.2.4.4 Immunohistochemistry discussion 
The aim of this section (5.2.4) is to determine the location of protein expression within the 
cochlea for 3 of the primary gene candidates NID2, ARHGEF28 and CLRN2. By determining 
the location of the protein, a putative pathological site and mechanism can be hypothesised.   
Nidogen-2 
Nidogen-2 is an established component of the basement membrane complex. Therefore, in 
the cochlea, it could be hypothesised that nidogen-2 would localise to, and have a structural 
role, in the basilar membrane. Anti-NID2 staining is not visible at the basilar membrane but 
is observed at the epithelial lining between the inner spiral sulcus and spiral limbus. The 
role of this structure is not well established but based on its situation it may function to 
Figure 5.22. Protein localisation of Anti-
CLRN2 at the organ of Corti, 40x objective.  
Colour labelling in the composite image: Blue, DAPI; 
Magenta, phalloidin; Green, Anti-CLRN2. (c), the 
composite image, displays phalloidin staining in 
magenta, which highlights the apical ends of sensory 
hair cells. Anti-CLRN2 staining in green is present in 
the cell bodies of the inner and outer hair cells. The 
scale bar in (a) represents 25µm and is consistent for 
all three panels in this figure.  
 
(a) 
(c) 
(b) 
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support the position and movement of the tectorial membrane. The positioning, support 
and movement of the tectorial membrane is integral for HCs function; the tectorial 
membrane has a role in the synchronisation and regulation of feedback from the OHCs and 
exhibits specialised dynamic mechanics, which create the sub-tectorial space where IHC 
excitation occurs391. Therefore, dysregulation of this structure may lead to a hearing 
phenotype or damage of the sensory mechanisms. To further explore this hypothesis, 
tectorial membrane function could be assessed in a nidogen-2 mutant.   
At the end of this structure, the strong staining continues into the spike generator region of 
the cochlea, between the sensory cells and the modiolus of the inner ear. The pattern of this 
staining is clear in the 40x images of samples stained with anti-NID2 in Figure 5.13.  
nidogen-1 staining has also been observed in the Reissner’s membrane366 and the osseous 
spiral lamina yet staining of nidogen-2 was not observed in the samples used in this work. 
The staining of nidogen-2 is prominent in the lining of blood vessels (Figure 5.12) as 
hypothesised; previous immunohistochemistry has identified nidogen-2 staining around 
blood vessels in cardiac muscle and previous staining of nidogen-1 in the cochlea366  
Rho guanine nucleotide exchange factor 28 
No previous studies have tested for ARHGEF28 expression in the cochlea. ARHGEF28 is 
known to interact with the Ras-like family of Rho proteins and is a neurofilament mRNA 
destabilising factor. Here anti-ARHGEF28 staining localises to the sensory HCs (inner and 
outer) and seemingly lines the spiral ganglion nerve fibres. As a neurofilament mRNA 
destabilising factor, it could be hypothesised that the staining is present in the cytoplasm of 
the neurons and that the role of the protein may be in the formation or maintenance of the 
neuronal cytoskeleton.  
Based on the location of staining in these samples, it is possible that the location and thus 
function of ARHGEF28 may not be restricted to the cochlea. Furthermore, in these samples 
it is not possible to determine which of the anti-ARHGEF28-stained nerve fibres are type I 
or type II. The function and ARHGEF28-based pathology within this structure could be 
revealed further by confirming whether ARHGEF28 is expressed in both or in either of the 
nerve fibre types.  
Staining in the sensory cells is also present, yet it is not known whether the role of 
ARHGEF28 in these cells is distinct from its role in the spiral ganglion structure. There are 
multiple splice forms of the transcript and so it is even possible that the resulting protein 
isoforms could have distinct roles between auditory structures. There are two 
‘independent’ associations within the ARHGEF28 region in the HDiff analysis, represented 
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by two lead SNPs in distinct blocks of LD; this may even signify multiple functional regions 
within the transcript that contain variants with distinct roles. 
Clarin-2 
Clarin-2 (coded for by CLRN2) was selected as a candidate for protein localisation as 
mutations in its paralogue, CLRN1 are known to cause Ush3a syndrome368. In addition, more 
recently, the Clrn2clarinet/clarinet mouse was shown to display a progressive sensorineural 
hearing loss caused by the failure to maintain HC stereocilia bundle integrity and 
function349. Based on this mechanism, it is hypothesised that clarin-2 is expressed in the HCs 
and HC stereocilia.  
Staining of anti-CLRN2 is observed in the cochlear sensory HCs of p30 mice, as 
hypothesised. In these samples there is also staining in the stria vascularis, yet there is 
currently no hypothesised role for clarin-2 in this structure. The function of the stria 
vascularis is to generate the potassium-rich endolymph of the scala media392. The Clarin 
gene family are integral membrane glycoproteins68 and so could have a role in this epithelial 
function. To confirm whether Clarin-2 functions in the stria vascularis, expression could be 
tested in a Clrn2clarinet/clarinet using a consistent protocol and set of antibodies. If expression 
was not present, this would confirm that the clarin-2 protein is expressed in the stria 
vascularis structure. To understand the functional interaction between clarin-1 and clarin-
2, expression of clarin-2 could be repeated at the same developmental stage as has been 
tested with clarin-1. Based on the knowledge of Clarin-1 being critical for development of 
the sensory mechanisms and of clarin-2 maintaining this function, the timepoint at which 
clarin-1 function becomes redundant could be determined.  
Based on the location of the three proteins tested in the adult mouse cochlear tissue, the 
role of each protein in auditory function can be hypothesised. There are however some 
limitations to the methods that were used. Firstly, protein localisation is only assessed in 
the cochlea, one structure within the auditory system. Although staining is observed for all 
three proteins in this structure, the presence of the protein does not confirm the site of a 
pathology. Similarly, for all three proteins, the staining is not localised to just one cell type 
or one individual mechanism. Secondly, the location of the proteins within the structure is 
estimated based on the structure of the tissue as visualised with DAPI. Other than 
phalloidin, no other markers are used. To more accurately determine protein location 
within the structure, further cell-specific markers could be used such as Myosin 7a to mark 
the outline of the sensory hair cells or GFAP as a marker of glial cells.  
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Moreover, assays could be performed to confirm antibody specificity for anti-CLRN2 and 
anti-ARHGEF28 that were used here as these have not previously been used in published 
work. Alternatively, knock-out mouse models for these two genes could be used as a control 
model to test for non-specific binding. Lastly, the samples are from p28-p30 mice. At this 
stage adult mice have a fully developed auditory system and thus staining reveals an adult 
gene-expression profile (rather than a developmental or ageing profile). It would therefore 
be of value to evaluate gene-expression profiles in aged tissue as the phenotype of interest 
is of a late-onset, progressive nature. 
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Chapter 6 - Discussion  
Prior to this study, little was known about the genetic component of ARHI, or whether 
genetic risk factors contribute to ARHI in the general population.  The aim of this thesis was 
to contribute to the knowledge of ARHI genetic risk factors, and subsequently explore what 
these risk factors can tell us about the underlying biological factors that cause auditory 
dysfunction in the general population. This final chapter is a discussion of how the work 
presented in the results chapters has contributed towards answering some of the 
fundamental questions in this field, followed by a summary of three broad limitations of the 
study, and lastly some examples of how the findings could be used as a platform for future 
work.  
Summary of main findings 
Firstly, for many complex traits, GWAS has proven to be a valuable tool for successfully 
detecting associated genomic loci219. However, in the case of ARHI, previous GWAS had 
collectively resulted in a limited number of significant associations, and so it was 
undetermined as to whether GWAS is a suitable method for identifying ARHI risk variants. 
As a possible reason for these limited findings, Fransen, 2015 speculated that the ARHI 
‘phenotype depends on the aggregated effect of a large number of SNPs, of which the 
individual effects are undetectable in a modestly powered GWAS’38.  The work in this thesis 
is the first comprehensive study with the means to test this hypothesis, as this can only be 
tested using a sample with an adequate sample size (and thus statistical power), such as the 
UKBB.  
The principle finding in this thesis is that over 2,000 SNPs are significantly associated with 
the ARHI-related traits HDiff and HAid. This amounted to 44 independent genomic loci, 
increasing the number of known ARHI-associated loci 9-fold. Multiple common genetic 
variants (MAF>0.01) are associated with the two traits, resembling polygenic inheritance 
and a strong indication that ARHI has a heritable component. These findings establish the 
first evidence for the polygenic nature of common hearing impairment for older individuals 
in the British population.  
Secondly, the true heritable component of ARHI has been contested, as previous ARHI 
heritability estimates were performed using a variety of methods, cohorts and ARHI-
surrogate phenotypes, which has resulted in a range of estimates between 0-70%38,92,106–114. 
The range in these estimates, along with the limited number of significant associations 
identified in previous ARHI GWAS, lead to speculation as to whether ARHI heritability has 
largely been overestimated. The datasets used in Chapter 4 are the largest samples used to 
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calculate an ARHI heritability estimate, by an order of magnitude, and therefore has 
substantially greater statistical power and includes a greater proportion of the population 
than previous estimates. It therefore has the potential to provide a more comprehensive 
estimate for the proportion of variance in ARHI based on genetic risk.  
In this study SNP heritability (h2g) is estimated as 0.19 for HDiff and 0.13 for HAid. These 
estimates are lower than some previous estimates, such as those calculated based on PCs 
derived from PTA thresholds (70%102), but are in line with the TwinsUK estimate when SNR 
score-derived phenotype was used; 25% (adjusted for age)101. It could be argued that this 
SNR-derived phenotype is more consistent with the phenotype used in this study, as both 
measure hearing ability in background noise and both analyses were adjusted for age. These 
estimates are of great value to the field as (i) there are few large-scale estimates on the 
heritability of self-reported hearing ability and (ii) this sample was not recruited based on 
participant hearing ability.  
These HDiff and HAid heritability estimates and the genetic association analyses reveal that 
a sizeable proportion of the heritability, and thus the genetic risk of these two traits, is due 
to common variants. This is in contrast to single gene variants or alterations with large effect 
sizes, such as those seen in many congenital forms of HL as introduced in Chapter 1. As the 
estimates calculated in this work are ‘SNP heritability’ estimates, they reflect the proportion 
of variance based on the genotyped SNPs included in the association analysis model only. A 
minor allele frequency of >0.01 was implemented prior to the HDiff and HAid association 
analyses, and so this estimate is based on common variants rather than multiple higher 
effect rare alleles. SNP heritability only considers additive effects of the SNPs selected for 
input to the calculation and so SNP heritability estimates are generally lower by 
comparison, as less types of effect (for example, dominant or recessive effects) and the 
effects of less variants (only those specified in the model), are considered in the calculation. 
Furthermore, recent work has demonstrated that effect of rare variants, only identified by 
genome-sequencing, may actually account for much of this ‘missing heritability’393.  
A significant factor for ARHI GWAS being ‘modestly powered’ in work published prior to 
this study, is that seven of the eight ARHI-GWAS used audiometric data to assess hearing 
ability38,92,107,109,111,112,114. While PTA is the gold-standard method to assess hearing ability in 
clinic, it requires trained staff, expensive specialist equipment and is relatively time 
consuming. Collectively, these factors render it unsuitable for large-scale data collection 
that is required for high powered population studies.  One ARHI GWAS had made use of 
alternative phenotypes, (Hoffman, 2016), where two genetic loci were significantly 
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associated with phenotypes derived from ICD codes from electronic health records 
collected in the USA. The findings were replicated using a preliminary release of UKBB 
genetic data113.  
The work in this thesis is highly distinctive in that a key aim was to search for an alternative 
way to assess the ARHI status of participants on a large scale, focusing on the full release of 
the UKBB data. The aim was to determine whether the data could be used to derive a 
surrogate phenotype that both accurately represents ARHI in the sample and that was 
applicable for use as a phenotype for genetic association analysis. Work focused on the 
UKBB SIN test and the hearing-related questions included in the UKBB health and lifestyle 
questionnaire. As the largest collection of SIN data on one population cohort, the UKBB data 
also has a potential to set standards for future SIN testing. The data challenge previous 
standards for SIN testing and accepted characteristics of ARHI, which is the trait that most 
SIN tests are devised to assess.  
Firstly, the prevalence of hearing difficulty in the UKBB as assessed by SRT score categories 
defined by Smits et al88, is lower than expected for a sample of this age range. These findings 
contest the validity of either the previous population prevalence estimates, or the method 
of classification used to determine hearing ability based on UKBB SRT scores. Secondly, the 
results contest pre-established risk factors; no significant difference was observed between 
male and female SRT score distributions, contrary to previous data272,273 and the 
relationship between age and SRT score was modest (r2s = 0.238, p<2.2e-16) compared to 
previous reports96. In addition, the data suggest that bilateral hearing impairment is not as 
prevalent as previous estimates with PTA data have suggested; the correlation coefficient 
of SRTL and SRTR within the sample is r2s=0.358, p-value< 2.2e-16. Alternatively, this finding 
may reflect a low test-retest reliability within participants, as supported by the longitudinal 
data analysis. 
These results are especially valuable as they challenge current understanding of ARHI 
epidemiology and risk factors and bring into question whether previous measures of 
common adult hearing impairment, such as PTA scores or previous SIN tests, have 
accurately captured ARHI in the population. The results suggest that the correlation with 
age is not as high as previously estimated, that male sex may not be a significant risk factor 
and the prevalence of a bilateral deterioration is not as prevalent as previously thought. The 
work is also of importance to the field as it reveals a number of limitations of the UKBB SIN 
test; a low test-retest performance, significant differences in SRT score distributions 
between assessment centres and inconsistent protocol adaptations over time. Therefore, 
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while the data may challenge current understanding and progress knowledge of ARHI 
epidemiology, the limitations uncovered and supported by this work, regarding the 
reliability and sensitivity of the SIN test, ought to be recognised when establishing new 
standards for ARHI assessment. 
This is the first study to evaluate whether questionnaire data can be used to create a 
surrogate measure of ARHI for use in GWAS. No previous ARHI GWAS has used phenotypes 
derived from questionnaire responses, but in recent years this approach has been 
successfully used in genetic association studies for numerous complex traits225,394–396. This 
study has shown for the first time that by using a combination of responses from two 
questions regarding two key symptoms of ARHI; (i) hearing difficulty and (ii) difficulty in 
the presence of background noise, a qualitative phenotype measure can be derived that 
meets the expected population prevalence of ARHI and which displays expected trends such 
as progression with age and prevalence differences in male and female subjects85–88.  
These findings are an important contribution to the field of ARHI epidemiology as 
questionnaires are a quick and accessible way of collecting data. There is no requirement 
for expensive equipment, trained staff or for the individual to attend a clinic visit (a 
challenging task for some ageing patients). Therefore, a larger sample can be collected, and 
greater statistical power achieved, at a fraction of the cost of audiometric data collection. 
Similarly, collecting data on treatments such as hearing aids, negates the need to align 
clinical databases, a process which can be lengthy and complex due to ethical considerations 
and computational demands. In addition, longitudinal data can be collected remotely either 
online or by postal questionnaires.  
The two most recent and most successful (when defined by quantity of significant 
associations) ARHI GWAS attempts (Hoffman 2016113 and work presented in this thesis) 
use a combination of phenotypes that move away from the traditional approach of using 
phenotypes derived from audiometric data38,92,107,109,111,112,114 for GWAS. The results of both 
these studies support the use of large data samples that result in increased statistical power 
compared to smaller samples with more detailed phenotyping38,92,107,109,111,112,114.  These 
studies therefore pave the way for future work to use similar techniques, enabling progress 
which had not been feasible with the use of previous methods. 
Previous to this work, a number of traits had been associated with ARHI, mainly based on 
findings from epidemiological studies. Whether these associations are due to common risk 
factors, common biological pathologies and, or cause and effect relationships between 
traits, was largely undetermined123,140,165,179–181, as described in detail in section 1.3.3. The 
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genetic correlation analysis presented in Chapter 4 demonstrates for the first time that a 
number of these traits (such as tinnitus, depression and pain symptoms) have significant 
genetic correlations with the HDiff phenotype when using the LDSC251 method. Prior to this 
work, there was no evidence of a genetic correlation between these traits, or that there were 
any common biological underpinnings between the traits. By uncovering such correlations, 
we can better understand the biology of ARHI, the correlated traits, and the relationship 
between them. This work could be built upon by identifying common genetic risk factors 
and thus common pathological pathways. Ultimately, cause and effect relationships 
between traits can be investigated using techniques such as Mendelian randomisation397 or 
a recently developed latent causal variable (LCV) model398 that can infer causality.  
Perhaps most importantly, three quarters of the associated loci are novel associations with 
HL or hearing function. This represents a substantial increase in the number of ARHI risk 
gene candidates.  They also greatly progress the knowledge of the type of mechanisms and 
structures that are affected in common hearing impairment. Prior to this work, little was 
known of these mechanisms, yet together, these candidate genes have roles in all four 
structures implicated in Schuknecht’s subtypes, meaning that the pathology of common 
hearing impairment spans multiple cell types in the auditory system. This substantiates the 
hypothesis that ARHI likely has a mixed pathology within the population and possibly 
within individuals (due to the relatively small effects of individual variants). Numerous 
genes at associated loci are known to be expressed in sensory cells such as CLRN2, while 
others have predicted neuronal functions such as ARHGEF28, metabolic functions such as 
TYR, and possibly mechanical functions such as NID2.  
Three of the associations with novel hearing genes have been validated by expression 
analysis of ARHGEF28, NID2 and CLRN2 (Chapter 5). Further to this, work regarding CLRN2 
is a key example of how an association can be validated and further investigated by 
functional analysis. Alongside this study revealing a significant association with HDiff at the 
CLRN2 locus and subsequent protein localisation in sensory cells in adult mice, work from 
a forward genetic screen in mice uncovered a role of Clrn2 in hair cell stereocilia 
maintenance and function369. While a plausible ARHI gene candidate due to CLRN1 
mutations causing USH368,368,389,390, no previous links had been made between CLRN2 and 
function or pathologies. Collectively, the recent findings regarding CLRN2 are evidence that 
it likely has a role in maintenance rather than development, and so may well encode risk 
variants that contribute to ‘case’ phenotypes in HDiff.  
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The remaining quarter of candidate genes identified have been linked genes to human 
hearing pathologies that previously had known functions in the auditory system; CTBP2, 
TUB, SYNJ2 and SPTBN1. The link with CTBP2 is strong evidence of the reliability of this 
work; a splice variant of CTBP2 codes for ribeye, a main component of the HC synaptic 
ribbon. CTBP2 is a well-established component of this structure and antibodies against the 
protein are often used as a marker for HCs in localisation analysis. The association here 
between HDiff, HAid and CTBP2 variants also supports the theory of synaptopathy being a 
crucial step in the degradation of hearing in ARHI and noise-induced hearing loss something 
that was previously overlooked and, or unidentified36,399.  
At a number of these loci there is strong evidence to support the reliability of the association 
findings; six of the lead SNPs reside in, or in close proximity to, genes with links to different 
forms of hearing loss; EYA4, BAIAP2L2, TRIOBP, ILDR1, LMX1A and CDH23. Furthermore, 
two of these genes; TRIOBP and ILDR1, have previous links to ARHI-related phenotypes. 
This supports the authenticity of the findings, and even challenges current understanding 
of the specific function of certain genes within the auditory system. For example, LMX1A is 
a LIM homeodomain-containing transcription factor that has multiple roles in development 
and, specifically in the inner ear, has long been known to have a vital role in early 
development and structure formation400. The finding of an association between LMX1A and 
common, progressive HL traits, is suggestive of a maintenance role, beyond early 
development. This supports a recent study in mice where heterozygote mutations in the 
homeodomain of LMX1A do not result in severe developmental defects, but result in 
insufficient cochlear (and sometimes vestibular) function and maintenance401.  
Each candidate gene is of importance with respect to understanding the development of 
ARHI. For genes where the function is known, and even where the function in the auditory 
system is known, hypotheses of the meaning of these new associations can be readily 
proposed. However, for genes which have no previous link to hearing and where knowledge 
of gene function is limited, it is more difficult to derive such hypotheses. These associations 
may however be the most important as they could potentially provide the greatest 
advancements in our knowledge. ARHGEF28 for example, is highly associated with both 
HDiff and HAid yet there is no previous link to hearing function or a comprehensive 
understanding of how the gene functions in other tissues. By further exploring the function 
of such gene candidates, it may be possible to describe previously unknown biological 
mechanisms that are involved in auditory function or, more broadly, in multiple tissues 
affecting multiple conditions. Furthermore, the list of candidates that are novel to hearing 
function may actually be important findings in terms of other hearing conditions. This work 
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provides a list of possible candidates that could be used for screening to identify causes of 
other forms of hearing loss, where the pathology is currently unknown.  
Limitations and Future Work  
The work presented in this thesis has greatly improved our knowledge of the genetic risk of 
ARHI, and the suitability of multiple methods for studying the genetic risk of the condition. 
There are, however, a number of limitations that ought to be considered when interpreting 
the findings and also when performing work that builds on the results of this study.  As the 
analysis-specific limitations have been addressed in individual chapter discussions, three 
broad three limitations that relate to the findings collectively, are summarised below. 
Firstly, in GWAS studies, it is an established practice to replicate the association analysis in 
an independent population sample to eliminate the possibility of the findings being due to 
cohort or study-specific effects, as described in Chapter 1. A successful replication is a form 
of validation of the findings, and signifies that the results may be applicable to the wider 
population231. As discussed in Chapter 4, the replication meta-analysis resulted in three 
Bonferroni-corrected significant lead SNP replications, and just two of the leading SNPs 
highlighted in previous ARHI GWAS were replicated in the HDiff and HAid discovery 
analysis.  
The reason for this relatively low replication rate could be due to the heterogeneity between 
this study and those previous to it, and the relatively limited size of the replication sample. 
The replication meta-analysis and the Hoffman 2016113 GWAS sample (the only samples 
with significant replication statistics) were a magnitude smaller than the UKBB white 
British sample, and all other previous samples were two magnitudes smaller. As more large-
scale datasets become available, replication cohorts are more likely to have sufficient 
statistical power to replicate findings. For example, 23andMe (n>500,000 European 
descent402) includes questionnaire-derived hearing data.   
Until such data are analysed and, or become publicly available, the HDiff and HAid 
association results can be interpreted and assessed for reliability in other ways. Candidate 
genes from this work can be assessed for reliability by determining whether they have  
previously been implicated in other forms of human hearing loss, been identified as 
pathogenic markers in mouse screens, have a plausible biological mechanism such as 
confirmed expression in cochlear sensory structures, or have a role in neuronal 
maintenance and function. All of these situations would provide confidence for the relevant 
associations found in this work, as it suggests a role for the gene candidate in auditory 
function.   
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A second but related limitation of this work, is that by using the ‘white British’ and ‘white 
non-British’ populations, the findings are not necessarily applicable to the wider 
population. Population groups that were not within the PC components used to derive these 
population classifications may harbour distinct ARHI genetic risk loci, or distinct functional 
variants at the same loci as identified here. This limitation is common to the majority of 
published GWAS studies. There is a bias towards data collection on European samples and 
thus a bias as to whether results are applicable to diverse populations; in 2017, 88% of the 
published GWAS used samples of European Ancestry. Almost two thirds of these studies 
were from US, UK and Icelandic populations403. As a consequence of this ethnic bias, 
imputation reference maps and genotyping platforms that are accurate for samples of non-
European descent are far smaller in size and number than those for populations of European 
descent404, further limiting the diversity of studies and wider applicability of findings. 
As discussed in Chapter 1, differences in ARHI prevalence have been observed between 
different populations95–98, meaning that the limitation outlined above is likely to affect the 
applicability of these findings to the wider population. The imputed UKBB data used in this 
thesis, was imputed centrally by UKBB, using the HRC reference panel and the UK 10K and 
1000G reference panels. These were derived predominantly using European data and 
therefore are not suitable for multi-ethnic analysis, even though large subsets of other 
populations are present in the UKBB dataset. Imputation using appropriate reference maps 
and, or sequencing would be valuable to counteract this limitation and to explore whether 
differences in ARHI prevalence and progression between populations are based on genetic 
factors.   
A third limitation of the work presented in this thesis is the interaction of risk factors such 
as sex-specific effects and environmental exposures were not comprehensively explored 
due to time restrictions. As discussed in Chapter 1, multiple environmental risk factors have 
been associated with ARHI such as chemical exposures, alcohol intake, smoking and noise 
exposure120–124. The UKBB data does include a subset of data related to these exposures, but 
this was not explored here due to time limitations. The influence of these factors on ARHI 
development are important to understand, due to gene environment interactions in the 
context of an individual’s risk. To adjust for this, individuals’ genetic sex was included as a 
covariate in the genetic association analyses, but analysis was not stratified by sex. 
Stratifying the analysis by sex may have revealed sex-specific genetic risk factors, and thus 
progressed the knowledge of sex-specific risk factors, but it would have required halving 
the sample size of each analyses and thus vastly reduced the statistical power to identify 
significant associations.  
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The work described in this thesis provides a platform for future work to be carried out to 
furtherthe findings. Future work will also provide an opportunity to address the limitations 
that have been described above if certain data and, or analysis tools are accessible. The 
UKBB data resource offered a unique opportunity to achieve the aims set out in this thesis. 
The dataset is the largest, most comprehensive dataset to include hearing-related and 
genetic data fields and that is publicly available for research. This study has demonstrated 
the value of the UKBB dataset as it has substantially progressed the field of ARHI genetics, 
and it is likely that the potential of the resource to progress the field has not been fully 
realised, as discussed below.  
The broad and ongoing data collection at UKBB means that its potential for use in auditory 
research has not been exhausted. ARHI is understood to be a heterogeneous condition, 
pathological mechanisms and the genetic variants underlying such mechanisms are likely 
to vary within the population. This can result in a loss of power when using one method to 
define the condition. By subsetting the sample into groups based on hypothesised 
pathology, greater power may be gained in order to detect pathology-specific variants. For 
example, a comparison could be performed between individuals that have hearing difficulty 
in background noise but report no general difficulty (UKBB Field ID 2247.0.0), with those 
that have general hearing difficulties but not in the presence of background noise (UKBB 
Field ID 2257.0.0). This topic could be explored further by using several approaches. 
Firstly, by using the cognition data in conjunction with the hearing data, to subset 
participants by theorised pathologies. The UKBB data collection includes seven cognitive 
function tests; prospective memory (UKBB Field ID 20018), pairs matching (UKBB Field ID 
20197), fluid intelligence (UKBB Field ID 20016), reaction time (various Field IDs), symbol 
digit substitution (UKBB Field ID 20159), trail making A and B (various Field ID). Studies 
have already used these to search for links between cognition and hearing in the sample, 
but none has yet incorporated the effects of genetic risk122,162. In addition, the UKBB SIN 
results have been used to observe a relationship between poor SRTB score and increased 
levels of grey matter in whole brain and in predicted functional networks on a subset of the 
UKBB population (N=8,701, mean SRTB = -6dB, 61% showing normal hearing)238. This could 
be investigated further by incorporating genetic risk into the model, in an attempt to 
quantify the genetic interactions resulting in these changes.  
Secondly, non-genetic risk factors for ARHI can be explored with the UKBB data, as 
previously demonstrated by a number of epidemiological studies122,141,162.  These factors are 
also yet to be studied in conjunction with the UKBB genetic data. Data fields such as noise 
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exposure (Field IDs 4836 and 4825) and antibiotic use (various Field IDs) could be used in 
conjunction with hearing question response data to identify gene x environment 
interactions and identify variants that have a protective effect, such as those with roles in 
damage response mechanisms.  
Thirdly, the recruitment of participants was devised such that a recruitment bias and recall 
bias would be limited. The age of participants at recruitment means that longitudinal data 
can be collected as data is, and will continue to be, gathered regarding new diagnoses and 
the progression of numerous conditions. Therefore, the onset of hearing impairment for a 
number of participants will be recorded, as will the onset of other related conditions such 
as cognitive decline. This could increase statistical power to detect risk variants as 
participants can be subset not only based on symptoms, but also of age at symptom onset, 
permitting a better understanding of the interactions between different conditions. Current 
plans to link the UKBB resource to public health databases means that prospective analysis 
will also be permitted. 
In addition to phenotype data releases, future UKBB genetic data releases will provide an 
opportunity to further the work presented in this thesis. Currently, the UKBB is in the 
process of releasing WES data on a sample of 50k participants. As genotyped and imputed 
data included in the GWAS encompasses only a fraction of the genome, such data could be 
used to fine map and identify the true functional variant(s) in the six regions where the lead 
SNP here resides in a gene exon; rs36062310, KLHDC7B; rs6453022, ARHGEF28; 
rs9493627, EYA4; rs5756795, TRIOBP ; rs143282422, CDH23; rs12552, OLFM4. Following 
this, WES and WGS are to be released on samples from the whole UKBB cohort, which could 
be utilised for both fine mapping all regions of association and for detecting association 
between rare variants and the two traits studied here. Prior to this data release, WES from 
samples such as used in Girotto 2018(N=156)405 or from the TwinsUK sample (N=2000, 
UK10K;  N=2377, HLI next-gen sequenced data)406 could be used for fine mapping regions 
of interest. Identification of very rare alleles from WGS will however require samples that 
are magnitudes larger than these samples.  
Further to using the UKBB data to progress the findings in this work, there are many 
avenues to explore to continue the post-GWAS analysis. In much of the post-GWAS analysis 
presented here, the emphasis was on protein-coding genes as the aim of Chapter 5 was to 
select candidates for immunohistochemistry analysis. However, in the context of following 
up genetic variant associations, non-coding regions must also be included; ENCODE 
(https://www.encodeproject.org/) predicts that only 1% of the genome comprises of gene 
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transcripts and it is widely recognised that variants involved with complex traits are 
enriched in regulatory regions. Numerous tools are being developed and improved to study 
regulatory elements in this context such as transcription factor binding site databases such 
as ChIPBase (http://rna.sysu.edu.cn/chipbase/) or eQTL mapping via GTEx 
(https://www.gtexportal.org/home/). The GTEx v8 will make available expression data in 
a greater number of tissues including a number of distinct brain regions,  albeit not 
including the peripheral auditory system364. 
When studying regulatory elements, epigenetic features also ought to be assessed; GWAS 
findings currently only explain a fraction of trait heritability estimates, and epigenetic 
features are hypothesised to explain a proportion of this missing heritability for many 
complex traits293.  In addition, recent work has demonstrated that for traits such as BMI and 
cigarette consumption, studying epigenetic variation under a Bayesian statistical model 
proposed by Banos407, phenotype prediction is improved and novel associations can be 
identified. An epigenome-wide association scan (EWAS) exploring the association between 
DNA methylation levels in whole blood samples and ARHI identified and replicated high 
associations in promoter regions of TCF25 and POLE222. Further work could include EWAS 
on auditory tissue in a larger sample.   
A pathogenic variant detected via association analysis may act by influencing the behaviour 
or function of a downstream target. In this context, it is more likely that the downstream 
target will have a function in auditory mechanisms and therefore, pathway analysis is an 
important step in deciphering the biological relevance of associated genetic variants. There 
is however a relative lack of expression data from auditory tissue samples in publicly 
available annotation tools; between the two main data repositories for expression data in 
the inner ear, gEAR (https://umgear.org/, 13 datasets available) and SHIELD 
(https://shield.hms.harvard.edu/, 5 datasets available), there is only one study that 
contains expression data on aged samples (mice >P40222). The volume of relevant data is 
increasing however, for example the recent RNA-sequencing screen on adult mouse stria 
tissue408 increases the amount of relevant data, as it was performed on adult rather than 
pup samples and was not restricted to the inner ear sensory cells.  
While the main aim of identifying ARHI-risk loci is to gain insights into the pathology, 
methods are being devised that permit trait prediction based on genetic association results. 
For example, polygenic risk scores (PRS) can be calculated for individuals in a ‘target 
sample’ (such as clinic patients) based on genetic effects observed from a ‘training sample’ 
(here being the HDiff summary statistics)409. Although PRSs are predominantly not yet valid 
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for clinical use, the current methods are a step towards diagnosis and treatment for complex 
traits based on individual genetic risk and can be used to compare genetic risk of multiple 
traits. In the short-term, the understanding of ARHI pathology could benefit greatly from 
further analysis in this area due to the relatively little amount known about ARHI pathology 
and the great number of significantly correlated traits. A long-term goal of analysis such as 
this would be to contribute to multi-trait treatments or prevention strategies. 
In vitro and in vivo work will be an essential component of the post-GWAS analysis. The 
suitability of the mouse as a model for ARHI genetics means that much of this work could 
be conducted with mice. For example, further expression analysis such as presented in 
Chapter 5, but for a greater number of candidate genes. This would support findings from 
the association analysis, and indicate which structures are affected in gene-specific 
pathologies. Furthermore, as discussed in Chapter 5, expression profiles under different 
stress conditions and time points could lead to hypotheses of gene function.  
Forward genetic screens have already been used in this context, in the case of Clrn2, detailed 
above, and could be conducted with a number of the candidate genes presented in Chapter 
5. Where forward genetic screens are not feasible due to facilities or lethal effects of gene 
disruption or deletion in early development, alternative methods such as gene knock-down 
could be used to assess gene function in aged, wild-type mice. Using targeted editing 
techniques such as CRISPR-Cas9, it may be possible to deduce which functional gene regions 
correspond to varied phenotypes resulting from defects in the same gene. EYA4, as 
discussed in Chapter 5, is an example of this; multiple forms of hearing impairment are 
observed and are understood to be caused by variation at distinct regions within the 
gene204,288,289.   
In addition to forward genetic approaches, reverse genetic approaches could also be 
invaluable in the assessment of ARHI GWAS candidate genes. Reverse genetic approaches 
involve disrupting a gene, most commonly by knocking out or silencing the gene, and 
studying the subsequent phenotype. Where a phenotype relates to a trait of interest, 
hypotheses can be made about the function of the knocked-out or silenced gene. The 
International Mouse Phenotyping Consortium410 (IMPC) is a large-scale programme that 
aims to generate knock-out mouse models for each of the ~20,000 genes in the mouse 
genome. Aligning IMPC data with ARHI GWAS candidate genes could aid the validation of a 
genetic association, identification of a candidate gene within an associated region, and the 
function of a gene in the auditory system. 
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While several of the candidate genes in this study have been validated, there is a proportion 
of genes that are relatively under-studied and less well characterised. This leads to a bias 
towards functional annotation of well characterised genes as there is more, and indeed 
more relevant, data available. In the study of hearing function, the untargeted approach of 
the IMPC will provide an opportunity to validate and further explore the roles of genes that 
are less well characterised.  It is also worth noting that several of the associated regions may 
represent a gain of function variant. In these examples, a knock-out or silenced mouse 
model generated via the IMPC would not provide a suitable model to study the effects of the 
SNP on hearing function. However, if the gene is involved in normal hearing function, the 
mouse model will display a phenotype. The observation of a phenotype could therefore 
support the finding of an association with the candidate gene, and a validation that the 
candidate gene is the functional target of the associated SNP in the region.  
Concluding statements 
To conclude, the work presented in this thesis confirms for the first time the hypothesis that 
ARHI is a highly polygenic trait. The work demonstrates that the genetic risk of ARHI (in the 
UKBB population) consists of multiple common polymorphisms with relatively small effect 
sizes, and that GWAS is a valuable method by which to identify putative ARHI genetic risk 
loci. The work uncovered the value of self-report measures to classify hearing impairments 
in large cohort studies, and highlighted limitations of the UKBB SRT data in its current form.  
A quarter of the genetic risk loci identified in this study contain genes that are known to 
cause other forms of HL, and, or that have an established role in hearing function. The 
remaining risk loci identified resemble novel associations with HL, greatly expanding the 
knowledge of biological mechanisms involved in common hearing impairment. A better 
understanding of these mechanisms may lead to more comprehensive methods to diagnose, 
treat and even prevent forms of HL and associated conditions.  
  
221 
 
References  
1. Purves, D., Augustine, G.J., Fitzpatrick, D., Katz, L.C., LaMantia, A.-S., McNamara, J.O., and Williams, 
M.S. (2001). Neuroscience, 2nd edition (Sinauer Associates). 
2. Anthwal, N., and Thompson, H. (2016). The development of the mammalian outer and middle ear. 
J. Anat. 228, 217–232. 
3. Bartel-Friedrich, S., and Wulke, C. (2007). Classification and diagnosis of ear malformations. GMS 
Curr. Top. Otorhinolaryngol. Head Neck Surg. 6, Doc05. 
4. Mansour, S., Magnan, J., Nicolas, K., and Haidar, H. (2018). Otosclerosis. In Middle Ear Diseases, 
(Cham: Springer International Publishing), pp. 1–83. 
5. Pollak, A., Lechowicz, U., Kȩdra, A., Stawiński, P., Rydzanicz, M., Furmanek, M., Brzozowska, M., 
Mrówka, M., Skarzyński, H., Skarzyński, P.H., et al. (2016). Novel and De Novo mutations extend 
association of POU3F4 with distinct clinical and radiological phenotype of hearing loss. PLoS One 11, 
e0166618. 
6. Khan, S., and Chang, R. (2013). Anatomy of the vestibular system: A review. NeuroRehabilitation 
32, 437–443. 
7. Goutman, J.D., Elgoyhen, A.B., and Gómez-Casati, M.E. (2015). Cochlear hair cells: The sound-
sensing machines. FEBS Lett. 589, 3354–3361. 
8. Iwasa, K.H., Mizuta, K., Lim, D.J., Benos, D.J., and Tachibana, M. (1994). Amiloride-sensitive channels 
in marginal cells in the stria vascularis of the guinea pig cochlea. Neurosci. Lett. 172, 163–166. 
9. Chan, D.K., and Chang, K.W. (2014). GJB2-associated hearing loss: Systematic review of worldwide 
prevalence, genotype, and auditory phenotype. Laryngoscope 124, E34–E53. 
10. Gabriel, H., Kupsch, P., Sudendey, J., Winterhager, E., Jahnke, K., and Lautermann, J. (2001). 
Mutations in the connexin26/GJB2 gene are the most common event in non-syndromic hearing loss 
among the German population. Hum. Mutat. 17, 521–522. 
11. Wilcox, E.R., Burton, Q.L., Naz, S., Riazuddin, S., Smith, T.N., Ploplis, B., Belyantseva, I., Ben-Yosef, 
T., Liburd, N.A., Morell, R.J., et al. (2001). Mutations in the gene encoding tight junction claudin-14 
cause autosomal recessive deafness DFNB29. Cell 104, 165–172. 
12. Riazuddin, S., Ahmed, Z.M., Fanning, A.S., Lagziel, A., Kitajiri, S.I., Ramzan, K., Khan, S.N., Chattaraj, 
P., Friedman, P.L., Anderson, J.M., et al. (2006). Tricellulin is a tight-junction protein necessary for 
hearing. Am. J. Hum. Genet. 79, 1040–1051. 
13. Goutman, J.D., Elgoyhen, A.B., and Gómez-Casati, M.E. (2015). Cochlear hair cells: The sound-
sensing machines. FEBS Lett. 589, 3354–3361. 
222 
 
14. Musiek, F.E., and Baran, J.A. (2007). The auditory system : anatomy, physiology and clinical 
correlates. (Boston; Montreal : Pearson), p. 487. 
15. Davis, H., and Silverman, S.R. Hearing and deafness. (Rinehart & Winston of Canada Ltd;). 
16. Riazuddin, S., Khan, S.N., Ahmed, Z.M., Ghosh, M., Caution, K., Nazli, S., Kabra, M., Zafar, A.U., Chen, 
K., Naz, S., et al. (2006). Mutations in TRIOBP, which encodes a putative cytoskeletal-organizing 
protein, are associated with nonsyndromic recessive deafness. Am. J. Hum. Genet. 78, 137–143. 
17. Miyagawa, M., Nishio, S. ya, and Usami, S. ichi (2012). Prevalence and clinical features of hearing 
loss patients with cdh23 mutations: A large cohort study. PLoS One 7, e40366. 
18. Varga, R., Kelley, P.M., Keats, B.J., Starr, A., Leal, S.M., Cohn, E., and Kimberling, W.J. (2003). Non-
syndromic recessive auditory neuropathy is the result of mutations in the otoferlin (OTOF) gene [2]. 
J. Med. Genet. 40, 45–50. 
19. Iwasa, Y. ichiro, Nishio, S. ya, Sugaya, A., Kataoka, Y., Kanda, Y., Taniguchi, M., Nagai, K., Naito, Y., 
Ikezono, T., Horie, R., et al. (2019). OTOF mutation analysis with massively parallel DNA sequencing 
in 2,265 Japanese sensorineural hearing loss patients. PLoS One 14, e0215932. 
20. Nayagam, B.A., Muniak, M.A., and Ryugo, D.K. (2011). The spiral ganglion: Connecting the 
peripheral and central auditory systems. Hear. Res. 278, 2–20. 
21. Weisz, C., Glowatzki, E., and Fuchs, P. (2009). The postsynaptic function of type II cochlear 
afferents. Nature 461, 1126–1129. 
22. Brownell, W.E., Bader, C.R., Bertrand, D., and De Ribaupierre, Y. (1985). Evoked mechanical 
responses of isolated cochlear outer hair cells. Science (80-. ). 227, 194–196. 
23. Guinan, J.J. (2006). Olivocochlear efferents: Anatomy, physiology, function, and the measurement 
of efferent effects in humans. Ear Hear. 27, 589–607. 
24. Eybalin, M. (1993). Neurotransmitters and neuromodulators of the mammalian cochlea. Physiol. 
Rev. 73, 309–374. 
25. Webster, Douglas B; Fay, R.R. (2005). The Mammalian Auditory Pathway: Neurophysiology 
(Springer-Verlag). 
26. Schuknecht, H.F. (1964). Further Observations on the Pathology of Presbycusis. Arch. 
Otolaryngol. 80, 369–382. 
27. Landegger, L.D., Psaltis, D., and Stankovic, K.M. (2016). Human audiometric thresholds do not 
predict specific cellular damage in the inner ear. Hear. Res. 335, 83–93. 
28. Wu, P.Z., Liberman, L.D., Bennett, K., de Gruttola, V., O’Malley, J.T., and Liberman, M.C. (2019). 
Primary Neural Degeneration in the Human Cochlea: Evidence for Hidden Hearing Loss in the Aging 
Ear. Neuroscience 407, 8–20. 
223 
 
29. Liberman, M.C., and Kiang, N.Y.S. (1978). Acoustic trauma in cats. Cochlear pathology and 
auditory-nerve activity. Acta Otolaryngol. 86, 1–63. 
30. McGill, T.J.I., and Schuknecht, H.F. (1976). Human cochlear changes in noise induced hearing loss. 
Laryngoscope 86, 1293–1302. 
31. Schuknecht, H.F., and Gacek, M.R. (1993). Cochlear pathology in presbycusis. Ann. Otol. Rhinol. 
Laryngol. 102, 1–16. 
32. Fujioka, M., Okano, H., and Edge, A.S.B. (2015). Manipulating cell fate in the cochlea: A feasible 
therapy for hearing loss. Trends Neurosci. 38, 139–144. 
33. Johnsson, L.G. (1974). Sequence of degeneration of corti’s organ and its first-order neurons. Ann. 
Otol. Rhinol. Laryngol. 83, 294–303. 
34. Spoendlin, H. (1984). Factors inducing retrograde degeneration of the cochlear nerve. Ann. Otol. 
Rhinol. Laryngol. Suppl. 112, 76–82. 
35. Liberman, M.C., and Kujawa, S.G. (2017). Cochlear synaptopathy in acquired sensorineural 
hearing loss: Manifestations and mechanisms. Hear. Res. 349, 138–147. 
36. Liberman, M.C. (2017). Noise-induced and age-related hearing loss: New perspectives and 
potential therapies. F1000Research 6, 927. 
37. Suzuki, J., Corfas, G., and Liberman, M.C. (2016). Round-window delivery of neurotrophin 3 
regenerates cochlear synapses after acoustic overexposure. Sci. Rep. 6, srep24907. 
38. Fransen, E., Bonneux, S., Corneveaux, J.J., Schrauwen, I., Di Berardino, F., White, C.H., Ohmen, J.D., 
Van De Heyning, P., Ambrosetti, U., Huentelman, M.J., et al. (2015). Genome-wide association analysis 
demonstrates the highly polygenic character of age-related hearing impairment. Eur. J. Hum. Genet. 
23, 110–115. 
39. WHO (2016). WHO | Grades of hearing impairment. Who. 
40. Wallis, C., Ballo, R., Wallis, G., Beighton, P., and Goldblatt, J. (1988). X-linked mixed deafness with 
stapes fixation in a Mauritian kindred: Linkage to Xq probe pDP34. Genomics 3, 299–301. 
41. HGNC (2019). HUGO Gene Nomenclature - an overview | ScienceDirect Topics. 
42. Vona, B., Nanda, I., Hofrichter, M.A.H., Shehata-Dieler, W., and Haaf, T. (2015). Non-syndromic 
hearing loss gene identification: A brief history and glimpse into the future. Mol. Cell. Probes 29, 260–
270. 
43. Snoeckx, R.L., Huygen, P.L.M., Feldmann, D., Marlin, S., Denoyelle, F., Waligora, J., Mueller-
Malesinska, M., Pollak, A., Ploski, R., Murgia, A., et al. (2005). GJB2 mutations and degree of hearing 
loss: A multicenter study. Am. J. Hum. Genet. 77, 945–957. 
224 
 
44. Yu, Q., Wang, Y., Chang, Q., Wang, J., Gong, S., Li, H., and Lin, X. (2014). Virally expressed connexin26 
restores gap junction function in the cochlea of conditional Gjb2 knockout mice. Gene Ther. 21, 71–
80. 
45. Wilcox, S.A., Saunders, K., Osborn, A.H., Arnold, A., Wunderlich, J., Kelly, T., Collins, V., Wilcox, L.J., 
McKinlay Gardner, R.J., Kamarinos, M., et al. (2000). High frequency hearing loss correlated with 
mutations in the GJB2 gene. Hum. Genet. 106, 399–405. 
46. Wingard, J.C., and Zhao, H.B. (2015). Cellular and deafness mechanisms underlying connexin 
mutation-induced hearing loss – A common hereditary deafness. Front. Cell. Neurosci. 9, 202. 
47. Zhao, H.B., Yu, N., and Fleming, C.R. (2005). Gap junctional hemichannel-mediated ATP release 
and hearing controls in the inner ear. Proc. Natl. Acad. Sci. U. S. A. 102, 18724–18729. 
48. Wang, Y., Chang, Q., Tang, W., Sun, Y., Zhou, B., Li, H., and Lin, X. (2009). Targeted connexin26 
ablation arrests postnatal development of the organ of Corti. Biochem. Biophys. Res. Commun. 385, 
33–37. 
49. Chang, K.W. (2015). Genetics of Hearing Loss-Nonsyndromic. Otolaryngol. Clin. North Am. 48, 
1063–1072. 
50. Bykhovskaya, Y., Estivill, X., Taylor, K., Hang, T., Hamon, M., Casano, R.A.M.S., Yang, H., Rotter, J.I., 
Shohat, M., and Fischel-Ghodsian, N. (2000). Candidate locus for a nuclear modifier gene for 
maternally iherited deafness. Am. J. Hum. Genet. 66, 1905–1910. 
51. Rodriguez-Paris, J., and Schrijver, I. (2009). The digenic hypothesis unraveled: The GJB6 del(GJB6-
D13S1830) mutation causes allele-specific loss of GJB2 expression in cis. Biochem. Biophys. Res. 
Commun. 389, 354–359. 
52. Liu, X.Z., Yuan, Y., Yan, D., Ding, E.H., Ouyang, X.M., Fei, Y., Tang, W., Yuan, H., Chang, Q., Du, L.L., et 
al. (2009). Digenic inheritance of non-syndromic deafness caused by mutations at the gap junction 
proteins Cx26 and Cx31. Hum. Genet. 125, 53–62. 
53. Shahin, H., Walsh, T., Sobe, T., Abu Sa’ed, J., Abu Rayan, A., Lynch, E.D., Lee, M.K., Avraham, K.B., 
King, M.-C., and Kanaan, M. (2005). Mutations in a Novel Isoform of TRIOBP That Encodes a 
Filamentous-Actin Binding Protein Are Responsible for DFNB28 Recessive Nonsyndromic Hearing 
Loss. Am. J. Hum. Genet. 78, 144–152. 
54. Kitajiri, S., Sakamoto, T., Belyantseva, I.A., Goodyear, R.J., Stepanyan, R., Fujiwara, I., Bird, J.E., 
Riazuddin, S., Riazuddin, S., Ahmed, Z.M., et al. (2010). Actin-Bundling Protein TRIOBP Forms 
Resilient Rootlets of Hair Cell Stereocilia Essential for Hearing. Cell 141, 786–798. 
55. Boëda, B., El-Amraoui, A., Bahloul, A., Goodyear, R., Daviet, L., Blanchard, S., Perfettini, I., Fath, K.R., 
Shorte, S., Reiners, J., et al. (2002). Myosin VIIa, harmonin and cadherin 23, three Usher I gene 
products that cooperate to shape the sensory hair cell bundle. EMBO J. 21, 6689–6699. 
225 
 
56. Liu, X.Z., Walsh, J., Mburu, P., Kendrick-Jones, J., Cope, M.J.T.V., Steel, K.P., and Brown, S.D.M. 
(1997). Mutations in the myosin VIIA gene cause non-syndromic recessive deafness. Nat. Genet. 16, 
188–190. 
57. Puffenberger, E.G., Jinks, R.N., Sougnez, C., Cibulskis, K., Willert, R.A., Achilly, N.P., Cassidy, R.P., 
Fiorentini, C.J., Heiken, K.F., Lawrence, J.J., et al. (2012). Genetic mapping and exome sequencing 
identify variants associated with five novel diseases. PLoS One 7,. 
58. Riazuddin, S., Belyantseva, I.A., Giese, A.P.J., Lee, K., Indzhykulian, A.A., Nandamuri, S.P., Yousaf, R., 
Sinha, G.P., Lee, S., Terrell, D., et al. (2012). Alterations of the CIB2 calcium-and integrin-binding 
protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48. Nat. Genet. 44, 1265–
1271. 
59. Ebermann, I., Phillips, J.B., Liebau, M.C., Koenekoop, R.K., Schermer, B., Lopez, I., Schäfer, E., Roux, 
A.F., Dafinger, C., Bernd, A., et al. (2010). PDZD7 is a modifier of retinal disease and a contributor to 
digenic Usher syndrome. J. Clin. Invest. 120, 1812–1823. 
60. Mathur, P., and Yang, J. (2015). Usher syndrome: Hearing loss, retinal degeneration and 
associated abnormalities. Biochim. Biophys. Acta - Mol. Basis Dis. 1852, 406–420. 
61. Weil, D., Kussel, P., Blanchard, S., Levy, G., Levi-Acobas, F., Drira, M., Ayadi, H., and Petit, C. (1997). 
The autosomal recessive isolated deafness, DFNB2, and the Usher 1B syndrome are allelic defects of 
the myosin-VIIA gene. Nat. Genet. 16, 191–193. 
62. Ouyang, X.M., Xia, X.J., Verpy, E., Du, L.L., Pandya, A., Petit, C., Balkany, T., Nance, W.E., and Liu, X.Z. 
(2002). Mutations in the alternatively spliced exons of USH1C cause non-syndromic recessive 
deafness. Hum. Genet. 111, 26–30. 
63. Ahmed, Z.M., Smith, T.N., Riazuddin, S., Makishima, T., Ghosh, M., Bokhari, S., Menon, P.S.N., 
Deshmukh, D., Griffith, A.J., Riazuddin, S., et al. (2002). Nonsyndromic recessive deafness DFNB18 
and usher syndrome type IC are allelic mutations of USHIC. Hum. Genet. 110, 527–531. 
64. Bork, J.M., Peters, L.M., Riazuddin, S., Ahmed, Z.M., Li, X.C., Griffith, A.J., Wilcox, E.R., Friedman, T.B., 
Morell, R.J., Griffith, A.J., et al. (2001). Usher syndrome 1D and nonsyndromic autosomal recessive 
deafness DFNB12 are caused by allelic mutations of the novel cadherin-like gene CDH23. Am. J. Hum. 
Genet. 68, 26–37. 
65. Doucette, L., Merner, N.D., Cooke, S., Ives, E., Galutira, D., Walsh, V., Walsh, T., MacLaren, L., Cater, 
T., Fernandez, B., et al. (2009). Profound, prelingual nonsyndromic deafness maps to chromosome 
10q21 and is caused by a novel missense mutation in the Usher syndrome type IF gene PCDH15. Eur. 
J. Hum. Genet. 17, 554–564. 
66. Weil, D., El-Amraoui, A., Masmoudi, S., Mustapha, M., Kikkawa, Y., Lainé, S., Delmaghani, S., Adato, 
A., Nadifi, S., Zina, Z. Ben, et al. (2003). Usher syndrome type I G (USH1G) is caused by mutations in 
the gene encoding SANS, a protein that associates with the USH1C protein, harmonin. Hum. Mol. 
226 
 
Genet. 12, 463–471. 
67. Weston, M.D., Luijendijk, M.W.J., Humphrey, K.D., Möller, C., and Kimberling, W.J. (2004). 
Mutations in the VLGR1 Gene Implicate G-Protein Signaling in the Pathogenesis of Usher Syndrome 
Type II. Am. J. Hum. Genet. 74, 357–366. 
68. Adato, A., Vreugde, S., Joensuu, T., Avidan, N., Hamalainen, R., Belenkiy, O., Olender, T., Bonne-
Tamir, B., Ben-Asher, E., Espinos, C., et al. (2002). USH3A transcripts encode clarin-1, a four-
transmembrane-domain protein with a possible role in sensory synapses. Eur. J. Hum. Genet. 10, 339–
350. 
69. Booth, K.T., Kahrizi, K., Babanejad, M., Daghagh, H., Bademci, G., Arzhangi, S., Zareabdollahi, D., 
Duman, D., El-Amraoui, A., Tekin, M., et al. (2018). Variants in CIB2 cause DFNB48 and not USH1J. 
Clin. Genet. 93, 812–821. 
70. Song, J., Feng, Y., Acke, F.R., Coucke, P., Vleminckx, K., and Dhooge, I.J. (2016). Hearing loss in 
Waardenburg syndrome: A systematic review. Clin. Genet. 89, 416–425. 
71. Everett, L.A., Glaser, B., Beck, J.C., Idol, J.R., Buchs, A., Heyman, M., Adawi, F., Hazani, E., Nassir, E., 
Baxevanis, A.D., et al. (1997). Pendred syndrome is caused by mutations in a putative sulphate 
transporter gene (PDS). Nat. Genet. 17, 411–422. 
72. Sheffield, V.C., Kraiem, Z., Beck, J.C., Nishimura, D., Stone, E.M., Salameh, M., Sadeh, O., and Glaser, 
B. (1996). Pendred syndrome maps to chromosome 7q21-34 and is caused by an intrinsic defect in 
thyroid iodine organification. Nat. Genet. 12, 424–426. 
73. Wémeau, J.L., and Kopp, P. (2017). Pendred syndrome. Best Pract. Res. Clin. Endocrinol. Metab. 
31, 213–224. 
74. Bizhanova, A., and Kopp, P. (2010). Genetics and phenomics of Pendred syndrome. Mol. Cell. 
Endocrinol. 322, 83–90. 
75. Lilly, E., Bunick, C.G., Maley, A.M., Zhang, S., Spraker, M.K., Theos, A.J., Vivar, K.L., Seminario-Vidal, 
L., Bennett, A.E., Sidbury, R., et al. (2019). More than keratitis, ichthyosis, and deafness: Multisystem 
effects of lethal GJB2 mutations. J. Am. Acad. Dermatol. 80, 617–625. 
76. Fischer, N., Weber, B., and Riechelmann, H. (2016). Presbycusis - Age-related hearing loss. 
Laryngorhinootologie. 95, 497–510. 
77. Lin, F.R., Thorpe, R., Gordon-Salant, S., and Ferrucci, L. (2011). Hearing loss prevalence and risk 
factors among older adults in the United States. Journals Gerontol. - Ser. A Biol. Sci. Med. Sci. 66 A, 
582–590. 
78. Gates, G.A., Cooper, J.C., Kannel, W.B., and Miller, N.J. (1990). Hearing in the elderly: the 
Framingham cohort, 1983-1985. Part I. Basic audiometric test results. Ear Hear. 11, 247–256. 
227 
 
79. Helzner, E.P., Cauley, J.A., Pratt, S.R., Wisniewski, S.R., Zmuda, J.M., Talbott, E.O., De Rekeneire, N., 
Harris, T.B., Rubin, S.M., Simonsick, E.M., et al. (2005). Race and sex differences in age-related hearing 
loss: The health, aging and body composition study. J. Am. Geriatr. Soc. 53, 2119–2127. 
80. Cruickshanks, K.J., Tweed, T.S., Wiley, T.L., Klein, B.E.K., Klein, R., Chappell, R., Nondahl, D.M., and 
Dalton, D.S. (2003). The 5-year incidence and progression of hearing loss: The epidemiology of 
hearing loss study. Arch. Otolaryngol. - Head Neck Surg. 129, 1041–1046. 
81. Roth, T.N., Hanebuth, D., and Probst, R. (2011). Prevalence of age-related hearing loss in Europe: 
A review. Eur. Arch. Oto-Rhino-Laryngology 268, 1101–1107. 
82. Meyer, C., and Hickson, L. (2012). What factors influence help-seeking for hearing impairment 
and hearing aid adoption in older adults? Int. J. Audiol. 51, 66–74. 
83. Yamasoba, T., Lin, F.R., Someya, S., Kashio, A., Sakamoto, T., and Kondo, K. (2013). Current 
concepts in age-related hearing loss: Epidemiology and mechanistic pathways. Hear. Res. 303, 30–
38. 
84. Rosenhall, U. (2015). Epidemiology of age related hearing loss. Hear. Balanc. Commun. 13, 46–50. 
85. Agrawal, Y., Platz, E.A., and Niparko, J.K. (2008). Prevalence of hearing loss and differences by 
demographic characteristics among US adults: data from the National Health and Nutrition 
Examination Survey, 1999-2004. Arch. Intern. Med. 168, 1522–1530. 
86. Gopinath, B., Rochtchina, E., Wang, J.J., Schneider, J., Leeder, S.R., and Mitchell, P. (2009). 
Prevalence of Age-Related Hearing Loss in Older Adults: Blue Mountains Study. Arch. Intern. Med. 
169, 415. 
87. Pearson, J.D., Morrell, C.H., Gordon-Salant, S., Brant, L.J., Metter, E.J., Klein, L.L., and Fozard, J.L. 
(1995). Gender differences in a longitudinal study of age-associated hearing loss. J. Acoust. Soc. Am. 
97, 1196–1205. 
88. Smits, C., and Houtgast, T. (2005). Results from the Dutch speech-in-noise screening test by 
telephone. Ear Hear. 26, 89–95. 
89. Davis, A.C. (1989). The prevalence of hearing impairment and reported hearing disability among 
adults in Great Britain. Int. J. Epidemiol. 18, 911–917. 
90. Lee, J., Dhar, S., Abel, R., Banakis, R., Grolley, E., Lee, J., Zecker, S., and Siegel, J. (2012). Behavioral 
Hearing Thresholds between 0.125 and 20 kHz Using Depth-Compensated Ear Simulator Calibration. 
Ear Hear. 33, 315–329. 
91. Gopinath, B., Rochtchina, E., Wang, J.J., Schneider, J., Leeder, S.R., and Mitchell, P. (2009). 
Prevalence of Age-Related Hearing Loss in Older Adults: Blue Mountains Study. Arch. Intern. Med. 
169, 415. 
228 
 
92. Nolan, L.S., Maier, H., Hermans-Borgmeyer, I., Girotto, G., Ecob, R., Pirastu, N., Cadge, B.A., Hübner, 
C., Gasparini, P., Strachan, D.P., et al. (2013). Estrogen-related receptor gamma and hearing function: 
evidence of a role in humans and mice. Neurobiol. Aging 34, 2077.e1-2077.e9. 
93. Laer, L. Van, DeStefano, A.L., Myers, R.H., Flothmann, K., Thys, S., Fransen, E., Gates, G.A., Van Camp, 
G., and Baldwin, C.T. (2002). Is DFNA5 a susceptibility gene for age-related hearing impairment? Eur. 
J. Hum. Genet. 10, 883–886. 
94. Price, K., Zhu, X., Guimaraes, P.F., Vasilyeva, O.N., and Frisina, R.D. (2009). Hormone replacement 
therapy diminishes hearing in peri-menopausal mice. Hear. Res. 252, 29–36. 
95. Barrenäs, M.L., and Lindgren, F. (1991). The influence of eye colour on susceptibility to TTS in 
humans. Br. J. Audiol. 25, 303–307. 
96. Homans, N.C., Metselaar, R.M., Dingemanse, J.G., van der Schroeff, M.P., Brocaar, M.P., Wieringa, 
M.H., Baatenburg de Jong, R.J., Hofman, A., and Goedegebure, A. (2017). Prevalence of age-related 
hearing loss, including sex differences, in older adults in a large cohort study. Laryngoscope 127, 725–
730. 
97. Agrawal, Y., Platz, E.A., and Niparko, J.K. (2008). Prevalence of hearing loss and differences by 
demographic characteristics among US adults: data from the National Health and Nutrition 
Examination Survey, 1999-2004. Arch. Intern. Med. 168, 1522–1530. 
98. Gates, G.A., Cooper, J.C., Kannel, W.B., and Miller, N.J. (1990). Hearing in the elderly: the 
Framingham cohort, 1983-1985. Part I. Basic audiometric test results. Ear Hear. 11, 247–256. 
99. Murillo-Cuesta, S., Contreras, J., Zurita, E., Cediel, R., Cantero, M., Varela-Nieto, I., and Montoliu, L. 
(2010). Melanin precursors prevent premature age-related and noise-induced hearing loss in albino 
mice. Pigment Cell Melanoma Res. 23, 72–83. 
100. Bedin, E., Franzè, A., Zadro, C., Persico, M.G., Ciullo, M., Hladnik, U., Dolcetta, D., Grasso, D.L., 
Riccardi, P., Nutile, T., et al. (2009). Age-related hearing loss in four Italian genetic isolates: An 
epidemiological study. Int. J. Audiol. 48, 465–472. 
101. Momi, S.K., Wolber, L.E., Fabiane, S.M., MacGregor, A.J., and Williams, F.M.K. (2015). Genetic and 
Environmental Factors in Age-Related Hearing Impairment. Twin Res. Hum. Genet. 18, 383–392. 
102. Wolber, L.E., Steves, C.J., Spector, T.D., and Williams, F.M.K. (2012). Hearing ability with age in 
Northern European women: A new web-based approach to genetic studies. PLoS One 7, e35500. 
103. Bogo, R., Farah, A., Johnson, A.C., Karlsson, K.K., Pedersen, N.L., Svartengren, M., and Skjönsberg, 
Å. (2015). The Role of Genetic Factors for Hearing Deterioration Across 20 Years: A Twin Study. 
Journals Gerontol. - Ser. A Biol. Sci. Med. Sci. 70, 647–653. 
104. Viljanen, A., Kaprio, J., Pyykkö, I., Sorri, M., Kauppinen, M., Koskenvuo, M., and Rantanen, T. 
(2007). Genetic and environmental influences on hearing at different frequencies separately for the 
229 
 
better and worse hearing ear in older women. Int. J. Audiol. 46, 772–779. 
105. Hendrickx, J.J., Huyghe, J.R., Topsakal, V., Demeester, K., Wienker, T.F., Van Laer, L., Van Eyken, 
E., Fransen, E., Mäki-Torkko, E., Hannula, S., et al. (2013). Familial aggregation of pure tone hearing 
thresholds in an aging European population. Otol. Neurotol. 34, 838–844. 
106. Newman, D.L., Fisher, L.M., Ohmen, J., Parody, R., Fong, C.T., Frisina, S.T., Mapes, F., Eddins, D.A., 
Frisina, R.D., Frisina, R.D., et al. (2012). GRM7 variants associated with age-related hearing loss based 
on auditory perception. Hear. Res. 294, 125–132. 
107. Van Laer, L., Huyghe, J.R., Hannula, S., Van Eyken, E., Stephan, D.A., Mäki-Torkko, E., Aikio, P., 
Fransen, E., Lysholm-Bernacchi, A., Sorri, M., et al. (2010). A genome-wide association study for age-
related hearing impairment in the Saami. Eur. J. Hum. Genet. 18, 685–693. 
108. Luo, H., Yang, T., Jin, X., Pang, X., Li, J., Chai, Y., Li, L., Zhang, Y., Zhang, L., Zhang, Z., et al. (2013). 
Association of GRM7 Variants with Different Phenotype Patterns of Age-Related Hearing Impairment 
in an Elderly Male Han Chinese Population. PLoS One 8, e77153. 
109. Friedman, R.A., Van Laer, L., Huentelman, M.J., Sheth, S.S., Van Eyken, E., Corneveaux, J.J., Tembe, 
W.D., Halperin, R.F., Thorburn, A.Q., Thys, S., et al. (2009). GRM7 variants confer susceptibility to age-
related hearing impairment. Hum. Mol. Genet. 18, 785–796. 
110. Duijvestijn, J.A., Anteunis, L.J., Hendriks, J.J., and Manni, J.J. (1999). Definition of hearing 
impairment and its effect on prevalence figures. A survey among senior citizens. Acta Otolaryngol. 
119, 420–423. 
111. Wolber, L.E., Girotto, G., Buniello, A., Vuckovic, D., Pirastu, N., Lorente-Cánovas, B., Rudan, I., 
Hayward, C., Polasek, O., Ciullo, M., et al. (2014). Salt-inducible kinase 3, SIK3, is a new gene associated 
with hearing. Hum. Mol. Genet. 23, 6407–6418. 
112. Vuckovic, D., Dawson, S., Scheffer, D.I., Rantanen, T., Morgan, A., Di Stazio, M., Vozzi, D., Nutile, T., 
Concas, M.P., Biino, G., et al. (2015). Genome-wide association analysis on normal hearing function 
identifies PCDH20 and SLC28A3 as candidates for hearing function and loss. Hum. Mol. Genet. 24, 
5655–5664. 
113. Hoffmann, T.J., Keats, B.J., Yoshikawa, N., Schaefer, C., Risch, N., and Lustig, L.R. (2016). A Large 
Genome-Wide Association Study of Age-Related Hearing Impairment Using Electronic Health 
Records. PLoS Genet. 12, e1006371. 
114. Girotto, G., Pirastu, N., Sorice, R., Biino, G., Campbell, H., d’Adamo, A.P., Hastie, N.D., Nutile, T., 
Polasek, O., Portas, L., et al. (2011). Hearing function and thresholds: A genome-wide association 
study in European isolated populations identifies new loci and pathways. J. Med. Genet. 48, 369–374. 
115. Nolte, I.M., Jansweijer, J.A., Riese, H., Asselbergs, F.W., Van Der Harst, P., Spector, T.D., Pinto, Y.M., 
Snieder, H., and Jamshidi, Y. (2017). A Comparison of Heritability Estimates by Classical Twin 
230 
 
Modeling and Based on Genome-Wide Genetic Relatedness for Cardiac Conduction Traits. Twin Res. 
Hum. Genet. 20, 489–498. 
116. Young, A.I. (2019). Solving the missing heritability problem. PLoS Genet. 15, e1008222. 
117. Felson, J. (2014). What can we learn from twin studies? A comprehensive evaluation of the equal 
environments assumption. Soc. Sci. Res. 43, 184–199. 
118. Kvestad, E., Czajkowski, N., Krog, N.H., Engdahl, B., and Tambs, K. (2012). Heritability of hearing 
loss. Epidemiology 23, 328–331. 
119. Christensen, K., Frederiksen, H., and Hoffman, H.J. (2001). Genetic and environmental influences 
on self-reported reduced hearing in the old and oldest old. J. Am. Geriatr. Soc. 49, 1512–1517. 
120. Van Eyken, E., Van Camp, G., and Van Laer, L. (2007). The complexity of age-related hearing 
impairment: Contributing environmental and genetic factors. Audiol. Neurotol. 12, 345–358. 
121. Rigters, S.C., Metselaar, M., Wieringa, M.H., De Jong, R.J.B., Hofman, A., and Goedegebure, A. 
(2016). Contributing Determinants to Hearing Loss in Elderly Men and Women: Results from the 
Population-Based Rotterdam Study. Audiol. Neurotol. 21, 10–15. 
122. Moore, D.R., Edmondson-Jones, M., Dawes, P., Fortnum, H., McCormack, A., Pierzycki, R.H., and 
Munro, K.J. (2014). Relation between speech-in-noise threshold, hearing loss and cognition from 40-
69 years of age. PLoS One 9, e107720. 
123. Dawes, P., Fortnum, H., Moore, D.R., Emsley, R., Norman, P., Cruickshanks, K., Davis, A., 
Edmondson-Jones, M., McCormack, A., Lutman, M., et al. (2014). Hearing in middle age: A population 
snapshot of 40- to 69-year olds in the united kingdom. Ear Hear. 35, e44–e51. 
124. Cruickshanks, K.J., Nondahl, D.M., Dalton, D.S., Fischer, M.E., Klein, B.E.K., Klein, R., Nieto, F.J., 
Schubert, C.R., and Tweed, T.S. (2015). Smoking, central adiposity, and poor glycemic control increase 
risk of hearing impairment. J. Am. Geriatr. Soc. 63, 918–924. 
125. Ryan, A.F., Kujawa, S.G., Hammill, T., Le Prell, C., and Kil, J. (2016). Temporary and Permanent 
Noise-induced Threshold Shifts: A Review of Basic and Clinical Observations. Otol. Neurotol. 37, 
e271–e275. 
126. Nondahl, D.M., Shi, X., Cruickshanks, K.J., Dalton, D.S., Tweed, T.S., Wiley, T.L., and Carmichael, 
L.L. (2009). Notched audiograms and noise exposure history in older adults. Ear Hear. 30, 696–703. 
127. Gates, G.A., Schmid, P., Kujawa, S.G., Nam, B.H., and D’Agostino, R. (2000). Longitudinal threshold 
changes in older men with audiometric notches. Hear. Res. 141, 220–228. 
128. Kujawa, S.G., and Liberman, M.C. (2006). Acceleration of age-related hearing loss by early noise 
exposure: Evidence of a misspent youth. J. Neurosci. 26, 2115–2123. 
129. Śliwińska-Kowalska, M., and Zaborowski, K. (2017). WHO environmental noise guidelines for 
231 
 
the European region: A systematic review on environmental noise and permanent hearing loss and 
tinnitus. Int. J. Environ. Res. Public Health 14, 1139. 
130. Sheth, S., Mukherjea, D., Rybak, L.P., and Ramkumar, V. (2017). Mechanisms of Cisplatin-Induced 
Ototoxicity and Otoprotection. Front. Cell. Neurosci. 11, 338. 
131. Dulon, D., Hiel, H., Aurousseau, C., Erre, J.P., and Aran, J.M. (1993). Pharmacokinetics of 
gentamicin in the sensory hair cells of the organ of Corti: Rapid uptake and long term persistence. 
Comptes Rendus l’Academie Des Sci. - Ser. III 316, 682–687. 
132. Aran, J.M., Erre, J.P., Lima Da Costa, D., Debbarh, I., and Dulon, D. (1999). Acute and chronic effects 
of aminoglycosides on cochlear hair cells. Ann. N. Y. Acad. Sci. 884, 60–68. 
133. Campo, P., Morata, T.C., and Hong, O.S. (2013). Chemical exposure and hearing loss. Disease-a-
Month 59, 119–138. 
134. Campo P, Ma guin K, Gabriel S,  et al. (2009). Combined exposure to noise and ototoxic 
substances: European Agency for Safety and Health at Work (EU-OSHA). 
135. Sugiura, S., Uchida, Y., Nakashima, T., Ando, F., and Shimokata, H. (2010). The association 
between gene polymorphisms in uncoupling proteins and hearing impairment in Japanese elderly. 
Acta Otolaryngol. 130, 487–492. 
136. Nolan, L.S., Cadge, B.A., Gomez-Dorado, M., and Dawson, S.J. (2013). A functional and genetic 
analysis of SOD2 promoter variants and their contribution to age-related hearing loss. Mech. Ageing 
Dev. 134, 298–306. 
137. Seidman, M.D. (2000). Effects of dietary restriction and antioxidants on presbyacusis. 
Laryngoscope 110, 727–738. 
138. Henry, K.R. (1986). Effects of dietary restriction on presbyacusis in the mouse1. Int. J. Audiol. 
25, 329–337. 
139. Someya, S., Yamasoba, T., Weindruch, R., Prolla, T.A., and Tanokura, M. (2007). Caloric restriction 
suppresses apoptotic cell death in the mammalian cochlea and leads to prevention of presbycusis. 
Neurobiol. Aging 28, 1613–1622. 
140. Cruickshanks, K.J., Klein, R., Klein, B.E.K., Wiley, T.L., Nondahl, D.M., and Tweed, T.S. (1998). 
Cigarette smoking and hearing loss: The epidemiology of hearing loss study. J. Am. Med. Assoc. 279, 
1715–1719. 
141. Dawes, P., Cruickshanks, K.J., Moore, D.R., Edmondson-Jones, M., McCormack, A., Fortnum, H., 
and Munro, K.J. (2014). Cigarette smoking, passive smoking, alcohol consumption, and hearing loss. 
JARO - J. Assoc. Res. Otolaryngol. 15, 663–674. 
142. Harkrider, A.W., Champlin, C.A., and McFadden, D. (2001). Acute effect of nicotine on non-
232 
 
smokers: I. OAEs and ABRs. Hear. Res. 160, 73–88. 
143. Nakanishi, N., Okamoto, M., Nakamura, K., Suzuki, K., and Tatara, K. (2000). Cigarette smoking 
and risk for hearing impairment: A longitudinal study in Japanese male office workers. J. Occup. 
Environ. Med. 42, 1045–1049. 
144. Torre, P., Cruickshanks, K.J., Klein, B.E.K., Klein, R., and Nondahl, D.M. (2006). The Association 
Between Cardiovascular Disease and Cochlear Function in Older Adults. J. Speech, Lang. Hear. Res. 
48, 473–481. 
145. Brant, L.J., Gordon-Salant, S., Pearson, J.D., Klein, L.L., Morrell, C.H., Metter, E.J., and Fozard, J.L. 
(1996). Risk factors related to age-associated hearing loss in the speech frequencies. J. Am. Acad. 
Audiol. 7, 152–160. 
146. Gates, G.A., Cobb, J.L., D’Agostino, R.B., and Wolf, P.A. (1993). The relation of hearing in the 
elderly to the presence of cardiovascular disease and cardiovascular risk factors. Arch. Otolaryngol. 
Head. Neck Surg. 119, 156–161. 
147. Mitchell, P., Gopinath, B., McMahon, C.M., Rochtchina, E., Wang, J.J., Boyages, S.C., and Leeder, S.R. 
(2009). Relationship of Type 2 diabetes to the prevalence, incidence and progression of age-related 
hearing loss. Diabet. Med. 26, 483–488. 
148. Kiely, K.M., Gopinath, B., Mitchell, P., Luszcz, M., and Anstey, K.J. (2012). Cognitive, health, and 
sociodemographic predictors of longitudinal decline in hearing acuity among older adults. Journals 
Gerontol. - Ser. A Biol. Sci. Med. Sci. 67 A, 997–1003. 
149. Rönnberg, J., Hygge, S., Keidser, G., and Rudner, M. (2014). The effect of functional hearing loss 
and age on long- and short-term visuospatial memory: Evidence from the UK biobank resource. 
Front. Aging Neurosci. 6, 1–13. 
150. Rönnberg, J., Rudner, M., and Lunner, T. (2011). Cognitive Hearing Science: The Legacy of Stuart 
Gatehouse. Trends Amplif. 15, 140–148. 
151. Tay, T., Jie, J.W., Kifley, A., Lindley, R., Newall, P., and Mitchell, P. (2006). Sensory and cognitive 
association in older persons: Findings from an older Australian population. Gerontology 52, 386–394. 
152. Uhlmann, R.F., Larson, E.B., Rees, T.S., Koepsell, T.D., and Duckert, L.G. (1989). Relationship of 
hearing impairment to dementia and cognitive dysfunction in older adults. JAMA 261, 1916–1919. 
153. Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S.G., Huntley, J., Ames, D., Ballard, C., 
Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017). Dementia prevention, intervention, and care. 
Lancet 390, 2673–2734. 
154. Fulton, S.E., Lister, J.J., Bush, A.L.H., Edwards, J.D., and Andel, R. (2015). Mechanisms of the 
Hearing-Cognition Relationship. Semin. Hear. 36, 140–149. 
233 
 
155. Rabbitt, P.M. (1968). Channel-capacity, intelligibility and immediate memory. Q. J. Exp. Psychol. 
20, 241–248. 
156. Rabbitt, P. (1991). Mild hearing loss can cause apparent memory failures which increase with 
age and reduce with IQ. Acta Otolaryngol. 111, 167–176. 
157. McCoy, S.L., Tun, P.A., Cox, L.C., Colangelo, M., Stewart, R.A., and Wingfield, A. (2005). Hearing 
loss and perceptual effort: Downstream effects on older adults’ memory for speech. Q. J. Exp. Psychol. 
Sect. A Hum. Exp. Psychol. 58, 22–33. 
158. Tun, P.A., O’Kane, G., and Wingfield, A. (2002). Distraction by competing speech in young and 
older adult listeners. Psychol. Aging 17, 453–467. 
159. Boxtel, M.P.J. Van, Beijsterveldt, C.E.M. Van, Houx, P.J., and Anteunis, L.J.C. (2000). Mild Hearing 
Impairment Can Reduce Verbal Memory Per- formance in a Healthy Adult Population. J. Clin. Exp. 
Neuropsychol. 22, 147–154. 
160. Rönnberg, J., Hygge, S., Keidser, G., and Rudner, M. (2014). The effect of functional hearing loss 
and age on long- and short-term visuospatial memory: Evidence from the UK biobank resource. 
Front. Aging Neurosci. 6, 326. 
161. Heinrich, A., Henshaw, H., and Ferguson, M.A. (2016). Only behavioral but not self-report 
measures of speech perception correlate with cognitive abilities. Front. Psychol. 7, 1–16. 
162. Dawes, P., Emsley, R., Cruickshanks, K.J., Moore, D.R., Fortnum, H., Edmondson-Jones, M., 
McCormack, A., and Munro, K.J. (2015). Hearing loss and cognition: The role of hearing aids, social 
isolation and depression. PLoS One 10, e0119616. 
163. Young Choi, A., Shim, H.J., Lee, S.H., Yoon, S.W., and Joo, E.J. (2011). Is cognitive function in adults 
with hearing impairment improved by the use of hearing aids? Clin. Exp. Otorhinolaryngol. 4, 72–76. 
164. Acar, B., Yurekli, M.F., Babademez, M.A., Karabulut, H., and Karasen, R.M. (2011). Effects of 
hearing aids on cognitive functions and depressive signs in elderly people. Arch. Gerontol. Geriatr. 
52, 250–252. 
165. Nondahl, D.M., Cruickshanks, K.J., Huang, G.H., Klein, B.E.K., Klein, R., Javier Nieto, F., and Tweed, 
T.S. (2011). Tinnitus and its risk factors in the Beaver Dam Offspring Study. Int. J. Audiol. 50, 313–
320. 
166. Nondahl, D.M., Cruickshanks, K.J., Wiley, T.L., Klein, B.E.K., Klein, R., Chappell, R., and Tweed, T.S. 
(2010). The ten-year incidence of tinnitus among older adults. Int. J. Audiol. 49, 580–585. 
167. Bhatt, J.M., Lin, H.W., and Bhattacharyya, N. (2016). Tinnitus Epidemiology: Prevalence, Severity, 
Exposures And Treatment Patterns In The United States: Bhatt JM: Tinnitus in the United States HHS 
Public Access. JAMA Otolaryngol Head Neck Surg 142, 959–965. 
234 
 
168. Crocetti, A., Forti, S., Ambrosetti, U., and Bo, L. Del (2009). Questionnaires to evaluate anxiety 
and depressive levels in tinnitus patients. Otolaryngol. - Head Neck Surg. 140, 403–405. 
169. Krog, N.H., Engdahl, B., and Tambs, K. (2010). The association between tinnitus and mental 
health in a general population sample: Results from the HUNT Study. J. Psychosom. Res. 69, 289–298. 
170. Sand, P.G., Langguth, B., Kleinjung, T., and Eichhammer, P. (2007). Genetics of chronic tinnitus. 
Prog. Brain Res. 166, 159–168. 
171. Schecklmann, M., Vielsmeier, V., Steffens, T., Landgrebe, M., Langguth, B., and Kleinjung, T. 
(2012). Relationship between audiometric slope and tinnitus pitch in tinnitus patients: Insights into 
the mechanisms of tinnitus generation. PLoS One 7, e34878. 
172. Norena, A., Micheyl, C., Chéry-Croze, S., and Collet, L. (2002). Psychoacoustic characterization of 
the tinnitus spectrum: Implications for the underlying mechanisms of tinnitus. Audiol. Neuro-Otology 
7, 358–369. 
173. Krauss, P., Schilling, A., Tziridis, K., and Schulze, H. (2019). Models of tinnitus development: From 
cochlea to cortex. HNO 67, 172–177. 
174. Krauss, P., Tziridis, K., Metzner, C., Schilling, A., Hoppe, U., and Schulze, H. (2016). Stochastic 
resonance controlled upregulation of internal noise after hearing loss as a putative cause of tinnitus-
related neuronal hyperactivity. Front. Neurosci. 10, 597. 
175. Soussi, T., and Otto, S.R. (1994). Effects of electrical brainstem stimulation on tinnitus. Acta 
Otolaryngol. 114, 135–140. 
176. Kvestad, E., Czajkowski, N., Engdahl, B., Hoffman, H.J., and Tambs, K. (2010). Low heritability of 
tinnitus: Results from the second Nord-Trøndelag Health Study. Arch. Otolaryngol. - Head Neck Surg. 
136, 178–182. 
177. Maas, I.L., Brüggemann, P., Requena, T., Bulla, J., Edvall, N.K., Hjelmborg, J.V.B., Szczepek, A.J., 
Canlon, B., Mazurek, B., Lopez-Escamez, J.A., et al. (2017). Genetic susceptibility to bilateral tinnitus 
in a Swedish twin cohort. Genet. Med. 19, 1007–1012. 
178. Bogo, R., Farah, A., Karlsson, K.K., Pedersen, N.L., Svartengren, M., and Skjönsberg, Å. (2016). 
Prevalence, Incidence Proportion, and Heritability for Tinnitus. Ear Hear. 38, 292–300. 
179. Jayakody, D.M.P., Almeida, O.P., Speelman, C.P., Bennett, R.J., Moyle, T.C., Yiannos, J.M., and 
Friedland, P.L. (2018). Association between speech and high-frequency hearing loss and depression, 
anxiety and stress in older adults. Maturitas 110, 86–91. 
180. Lee, A.T.H., Tong, M.C.F., Yuen, K.C.P., Tang, P.S.O., and Van Hasselt, C.A. (2010). Hearing 
impairment and depressive symptoms in an older chinese population. J. Otolaryngol. - Head Neck 
Surg. 39, 498–503. 
235 
 
181. Gopinath, B., Wang, J.J., Schneider, J., Burlutsky, G., Snowdon, J., McMahon, C.M., Leeder, S.R., and 
Mitchell, P. (2009). Depressive symptoms in older adults with hearing impairments: The blue 
mountains study: Letters to the editor. J. Am. Geriatr. Soc. 57, 1306–1308. 
182. Cosh, S., von Hanno, T., Helmer, C., Bertelsen, G., Delcourt, C., and Schirmer, H. (2018). The 
association amongst visual, hearing, and dual sensory loss with depression and anxiety over 6 years: 
The Tromsø Study. Int. J. Geriatr. Psychiatry 33, 598–605. 
183. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R., Duncan, L., Perry, J.R.B., 
Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human diseases and 
traits. Nat. Genet. 47, 1236–1241. 
184. Smith, G.D. (2010). Mendelian randomization for strengthening causal inference in 
observational studies: Application to gene × environment interactions. Perspect. Psychol. Sci. 5, 527–
545. 
185. Schaette, R., and McAlpine, D. (2011). Tinnitus with a Normal Audiogram: Physiological 
Evidence for Hidden Hearing Loss and Computational Model. J. Neurosci. 31, 13452–13457. 
186. Smits, C., Theo Goverts, S., and Festen, J.M. (2013). The digits-in-noise test: Assessing auditory 
speech recognition abilities in noise. J. Acoust. Soc. Am. 133, 1693–1706. 
187. Plomp, R. (1976). Binaural and Monaural Speech Intelligibility of Connected Discourse in 
Reverberation as a Function of Azimuth of a Single Competing Sound Source (Speech or Noise). Acta 
Acust. United with Acust. 34, 200–211. 
188. Smits, C., Kapteyn, T.S., and Houtgast, T. (2004). Development and validation of an automatic 
speech-in-noise screening test by telephone. Int. J. Audiol. 43, 15–28. 
189. Jansen, S., Luts, H., Dejonckere, P., Van Wieringen, A., and Wouters, J. (2013). Efficient hearing 
screening in noise-exposed listeners using the digit triplet test. Ear Hear. 34, 773–778. 
190. Smits, C., Theo Goverts, S., and Festen, J.M. (2013). The digits-in-noise test: Assessing auditory 
speech recognition abilities in noise. J. Acoust. Soc. Am. 133, 1693–1706. 
191. Zokoll, M.A., Wagener, K.C., Brand, T., Buschermöhle, M., and Kollmeier, B. (2012). 
Internationally comparable screening tests for listening in noise in several European languages: The 
German digit triplet test as an optimization prototype. Int. J. Audiol. 51, 697–707. 
192. Ozimek, E., Kutzner, D., Sk, A., and Wicher, A. (2009). Polish sentence tests for measuring the 
intelligibility of speech in interfering noise. Int. J. Audiol. 48, 433–443. 
193. Jansen, S., Luts, H., Wagener, K.C., Frachet, B., and Wouters, J. (2010). The French digit triplet 
test: A hearing screening tool for speech intelligibility in noise. Int. J. Audiol. 49, 378–387. 
194. Hall, S. (2006). The Development of a New English Sentence in Noise Test and an English Number 
236 
 
Recognition Test. (Unpublished MSc Thesis). 
195. Keidser, G., Seeto, M., Rudner, M., Hygge, S., and Rönnberg, J. (2015). On the relationship between 
functional hearing and depression. Int. J. Audiol. 54, 653–664. 
196. Martini, A., Mazzoli, M., Rosignoli, M., Trevisi, P., Maggi, S., Enzi, G., and Crepaldi, G. (2008). 
Hearing in the Elderly: A Population Study: Audición en la senectud: Un estudio poblacional. Int. J. 
Audiol. 40, 285–291. 
197. Davis, A., Smith, P., Ferguson, M., and Stephens, D. (2007). Acceptability, benefit and costs of 
early screening for hearing disability. Health Technol. Assess. (Rockv). 11, 1–293. 
198. Davis, A.C. (1989). The prevalence of hearing impairment and reported hearing disability among 
adults in Great Britain. Int. J. Epidemiol. 18, 911–917. 
199. Hietanen, A., Era, P., Sorri, M., and Heikkinen, E. (2004). Changes in hearing in 80-year-old 
people: a 10-year follow-up study. Int. J. Audiol. 43, 126–135. 
200. Hietanen, A., Era, P., Henrichsen, J., Rosenhall, U., Sorri, M., and Heikkinen, E. (2005). Hearing 
among 75-year-old people in three Nordic localities: a comparative study. Int. J. Audiol. 44, 500–508. 
201. Rosenhall, U., Jönsson, R., and Söderlind, O. Self-assessed hearing problems in Sweden: a 
demographic study. Audiology 38, 328–334. 
202. Choi, J.S., Betz, J., Deal, J., Contrera, K.J., Genther, D.J., Chen, D.S., Gispen, F.E., and Lin, F.R. (2016). 
A Comparison of Self-Report and Audiometric Measures of Hearing and Their Associations with 
Functional Outcomes in Older Adults. J. Aging Health 28, 890–910. 
203. Girotto, G., Vuckovic, D., Buniello, A., Lorente-Cánovas, B., Lewis, M., Gasparini, P., and Steel, K.P. 
(2014). Expression and replication studies to identify new candidate genes involved in normal 
hearing function. PLoS One 9, e85352. 
204. Makishima, T., Madeo, A.C., Brewer, C.C., Zalewski, C.K., Butman, J.A., Sachdev, V., Arai, A.E., 
Holbrook, B.M., Rosing, D.R., and Griffith, A.J. (2007). Nonsyndromic hearing loss DFNA10 and a novel 
mutation of EYA4: Evidence for correlation of normal cardiac phenotype with truncating mutations 
of the Eya domain. Am. J. Med. Genet. Part A 143, 1592–1598. 
205. Yu, C., Meng, X., Zhang, S., Zhao, G., Hu, L., and Kong, X. (2003). A 3-nucleotide deletion in the 
polypyrimidine tract of intron 7 of the DFNA5 gene causes nonsyndromic hearing impairment in a 
Chinese family. Genomics 82, 575–579. 
206. DeStefano, A.L., Gates, G.A., Heard-Costa, N., Myers, R.H., and Baldwin, C.T. (2003). Genomewide 
linkage analysis to presbycusis in the Framingham Heart Study. Arch. Otolaryngol. Head. Neck Surg. 
129, 285–289. 
207. Garringer, H.J., Pankratz, N.D., Nichols, W.C., and Reed, T. (2006). Hearing impairment 
237 
 
susceptibility in elderly men and the DFNA18 locus. Arch. Otolaryngol. - Head Neck Surg. 132, 506–
510. 
208. Huyghe, J.R., Van Laer, L., Hendrickx, J.J., Fransen, E., Demeester, K., Topsakal, V., Kunst, S., 
Manninen, M., Jensen, M., Bonaconsa, A., et al. (2008). Genome-wide SNP-Based Linkage Scan 
Identifies a Locus on 8q24 for an Age-Related Hearing Impairment Trait. Am. J. Hum. Genet. 83, 401–
407. 
209. Hirschhorn, J.N., and Daly, M.J. (2005). Genome-wide association studies for common diseases 
and complex traits. Nat. Rev. Genet. 6, 95–108. 
210. Patnala, R., Clements, J., and Batra, J. (2013). Candidate gene association studies: A 
comprehensive guide to useful in silico tools. 
211. Van Eyken, E., Van Camp, G., Fransen, E., Topsakal, V., Hendrickx, J.J., Demeester, K., Van De 
Heyning, P., Mäki-Torkko, E., Hannula, S., Sorri, M., et al. (2007). Contribution of the N-
acetyltransferase 2 polymorphism NAT2*6A to age-related hearing impairment. J. Med. Genet. 44, 
570–578. 
212. Van Laer, L., Van Eyken, E., Fransen, E., Huyghe, J.R., Topsakal, V., Hendrickx, J.J., Hannula, S., 
Mäki-Torkko, E., Jensen, M., Demeester, K., et al. (2008). The grainyhead like 2 gene (GRHL2), alias 
TFCP2L3, is associated with age-related hearing impairment. Hum. Mol. Genet. 17, 159–169. 
213. Bush, W.S., and Moore, J.H. (2012). Chapter 11: Genome-Wide Association Studies. PLoS Comput. 
Biol. 8, e1002822. 
214. Gates, G.A., and Mills, J.H. (2005). Presbycusis. Lancet 366, 1111–1120. 
215. Chang, N.-C., Dai, C.-Y., Lin, W.-Y., Yang, H.-L., Wang, H.-M., Chien, C.-Y., Hsieh, M.-H., and Ho, K.-Y. 
(2018). The Association of GRM7 Single Nucleotide Polymorphisms with Age-Related Hearing 
Impairment in a Taiwanese Population. J. Int. Adv. Otol. 14, 170–175. 
216. Yu, P., Jiao, J., Chen, G., Zhou, W., Zhang, H., Wu, H., Li, Y., Gu, G., Zheng, Y., Yu, Y., et al. (2018). 
Effect of GRM7 polymorphisms on the development of noise-induced hearing loss in Chinese Han 
workers: A nested case-control study. BMC Med. Genet. 19, 4. 
217. Haider, H.F., Flook, M., Aparicio, M., Ribeiro, D., Antunes, M., Szczepek, A.J., Hoare, D.J., Fialho, G., 
Paço, J.C., and Caria, H. (2017). Biomarkers of presbycusis and tinnitus in a Portuguese older 
population. Front. Aging Neurosci. 9, 346. 
218. Richards, J.B., Kavvoura, F.K., Rivadeneira, F., Styrkársdóttir, U., Estrada, K., Halldórsson, B. V., 
Hsu, Y.H., Zillikens, M.C., Wilson, S.G., Mullin, B.H., et al. (2009). Collaborative meta-analysis: 
Associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann. Intern. Med. 
151, 528–537. 
219. Visscher, P.M., Wray, N.R., Zhang, Q., Sklar, P., McCarthy, M.I., Brown, M.A., and Yang, J. (2017). 
238 
 
10 Years of GWAS Discovery: Biology, Function, and Translation. Am. J. Hum. Genet. 101, 5–22. 
220. Zuk, O., Hechter, E., Sunyaev, S.R., and Lander, E.S. (2012). The mystery of missing heritability: 
Genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. 109, 1193–1198. 
221. Petronis, A. (2010). Epigenetics as a unifying principle in the aetiology of complex traits and 
diseases. Nature 465, 721–727. 
222. Wolber, L.E., Steves, C.J., Tsai, P.C., Deloukas, P., Spector, T.D., Bell, J.T., and Williams, F.M.K. 
(2014). Epigenome-wide DNA methylation in hearing ability: New mechanisms for an old problem. 
PLoS One 9, e105729. 
223. Gao, X.R., Huang, H., and Kim, H. (2019). Genome-wide association analyses identify 139 loci 
associated with macular thickness in the UK Biobank cohort. Hum. Mol. Genet. 28, 1162–1172. 
224. Khawaja, A.P., Cooke Bailey, J.N., Wareham, N.J., Scott, R.A., Simcoe, M., Igo, R.P., Song, Y.E., 
Wojciechowski, R., Cheng, C.Y., Khaw, P.T., et al. (2018). Genome-wide analyses identify 68 new loci 
associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. 
Nat. Genet. 50, 778–782. 
225. Marioni, R.E., Harris, S.E., Zhang, Q., McRae, A.F., Hagenaars, S.P., Hill, W.D., Davies, G., Ritchie, 
C.W., Gale, C.R., Starr, J.M., et al. (2018). GWAS on family history of Alzheimer’s disease. Transl. 
Psychiatry 8, 99. 
226. Loh, P.R., Tucker, G., Bulik-Sullivan, B.K., Vilhjálmsson, B.J., Finucane, H.K., Salem, R.M., Chasman, 
D.I., Ridker, P.M., Neale, B.M., Berger, B., et al. (2015). Efficient Bayesian mixed-model analysis 
increases association power in large cohorts. Nat. Genet. 47, 284–290. 
227. Chang, C.C., Chow, C.C., Tellier, L.C.A.M., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-
generation PLINK: Rising to the challenge of larger and richer datasets. Gigascience 4, 7. 
228. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A., and Price, A. (2017). Mixed model association for 
biobank-scale data sets. BioRxiv 194944. 
229. Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N., LeFaive, J., 
VandeHaar, P., Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling for case-control 
imbalance and sample relatedness in large-scale genetic association studies. Nat. Genet. 50, 1335–
1341. 
230. Marchini, J., Howie, B., Myers, S., McVean, G., and Donnelly, P. (2007). A new multipoint method 
for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913. 
231. Kraft, P., Zeggini, E., and Ioannidis, J.P.A. (2009). Replication in genome-wide association studies. 
Stat. Sci. 24, 561–573. 
232. Yang, J., Ferreira, T., Morris, A.P., Medland, S.E., Madden, P.A.F., Heath, A.C., Martin, N.G., 
239 
 
Montgomery, G.W., Weedon, M.N., Loos, R.J., et al. (2012). Conditional and joint multiple-SNP analysis 
of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 
369–375. 
233. Watanabe, K., Taskesen, E., Van Bochoven, A., and Posthuma, D. (2017). Functional mapping and 
annotation of genetic associations with FUMA. Nat. Commun. 8, 1826. 
234. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA: Generalized Gene-Set 
Analysis of GWAS Data. PLoS Comput. Biol. 11, e1004219. 
235. Pers, T.H., Karjalainen, J.M., Chan, Y., Westra, H.J., Wood, A.R., Yang, J., Lui, J.C., Vedantam, S., 
Gustafsson, S., Esko, T., et al. (2015). Biological interpretation of genome-wide association studies 
using predicted gene functions. Nat. Commun. 6, 1–9. 
236. Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57. 
237. Iotchkova, V., Ritchie, G.R.S., Geihs, M., Morganella, S., Min, J.L., Walter, K., Timpson, N.J., Dunham, 
I., Birney, E., and Soranzo, N. (2019). GARFIELD classifies disease-relevant genomic features through 
integration of functional annotations with association signals. Nat. Genet. 51, 343–353. 
238. Bowl, M.R., and Dawson, S.J. (2015). The mouse as a model for age-related hearing loss - A mini-
review. Gerontology 61, 149–157. 
239. Brown, S.D.M., Hardisty-Hughes, R.E., and Mburu, P. (2008). Quiet as a mouse: Dissecting the 
molecular and genetic basis of hearing. Nat. Rev. Genet. 9, 277–290. 
240. György, B., Nist-Lund, C., Pan, B., Asai, Y., Karavitaki, K.D., Kleinstiver, B.P., Garcia, S.P., 
Zaborowski, M.P., Solanes, P., Spataro, S., et al. (2019). Allele-specific gene editing prevents deafness 
in a model of dominant progressive hearing loss. Nat. Med. 25, 1123–1130. 
241. Kane, K.L., Longo-Guess, C.M., Gagnon, L.H., Ding, D., Salvi, R.J., and Johnson, K.R. (2012). Genetic 
background effects on age-related hearing loss associated with Cdh23 variants in mice. Hear. Res. 
283, 80–88. 
242. Crow, A.L., Ohmen, J., Wang, J., Lavinsky, J., Hartiala, J., Li, Q., Li, X., Salehide, P., Eskin, E., Pan, C., 
et al. (2015). The genetic architecture of hearing impairment in mice: Evidence for frequency-specific 
genetic determinants. G3 Genes, Genomes, Genet. 5, 2329–2339. 
243. Bowl, M.R., Simon, M.M., Ingham, N.J., Greenaway, S., Santos, L., Cater, H., Taylor, S., Mason, J., 
Kurbatova, N., Pearson, S., et al. (2017). A large scale hearing loss screen reveals an extensive 
unexplored genetic landscape for auditory dysfunction. Nat. Commun. 8, 886. 
244. Ingham, N.J., Carlisle, F., Pearson, S., Lewis, M.A., Buniello, A., Chen, J., Isaacson, R.L., Pass, J., 
White, J.K., Dawson, S.J., et al. (2016). S1PR2 variants associated with auditory function in humans 
and endocochlear potential decline in mouse. Sci. Rep. 6, 1–13. 
240 
 
245. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., 
Landray, M., et al. (2015). UK Biobank: An Open Access Resource for Identifying the Causes of a Wide 
Range of Complex Diseases of Middle and Old Age. PLoS Med. 12, e1001779. 
246. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., 
Delaneau, O., O’Connell, J., et al. (2017). Genome-wide genetic data on ~500,000 UK Biobank 
participants Supplementary Material. BioRxiv 166298. 
247. Marchini, J., O’Connell, J., Delaneau, O., Sharp, K., Kretzschmar, W., Band, G., McCarthy, S., Petkova, 
D., Bycroft, C., Freeman, C., et al. Genotype imputation and genetic association studies of UK Biobank. 
PDF access via: www.ukbiobank.ac.uk/scient. 
248. Moayyeri, A., Hammond, C.J., Hart, D.J., and Spector, T.D. (2013). The UK adult twin registry 
(twinsUK resource). Twin Res. Hum. Genet. 16, 144–149. 
249. Zhou, X., and Stephens, M. (2012). Genome-wide efficient mixed-model analysis for association 
studies. Nat. Genet. 44, 821–824. 
250. Steptoe, A., Breeze, E., Banks, J., and Nazroo, J. (2013). Cohort profile: The English Longitudinal 
Study of Ageing. Int. J. Epidemiol. 42, 1640–1648. 
251. Zheng, J., Erzurumluoglu, A.M., Elsworth, B.L., Kemp, J.P., Howe, L., Haycock, P.C., Hemani, G., 
Tansey, K., Laurin, C., Pourcain, B.S., et al. (2017). LD Hub: A centralized database and web interface 
to perform LD score regression that maximizes the potential of summary level GWAS data for SNP 
heritability and genetic correlation analysis. Bioinformatics 33, 272–279. 
252. Bulik-Sullivan, B., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price, A.L., 
Neale, B.M., Corvin, A., et al. (2015). LD score regression distinguishes confounding from polygenicity 
in genome-wide association studies. Nat. Genet. 47, 291–295. 
253. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: Fast and efficient meta-analysis of 
genomewide association scans. Bioinformatics 26, 2190–2191. 
254. De Leeuw, C.A., Neale, B.M., Heskes, T., and Posthuma, D. (2016). The statistical properties of 
gene-set analysis. Nat. Rev. Genet. 17, 353–364. 
255. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R., Duncan, L., Perry, J.R.B., 
Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human diseases and 
traits. Nat. Genet. 47, 1236–1241. 
256. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, M., Abecasis, 
G.R., Willer, C.J., and Frishman, D. (2011). LocusZoom: Regional visualization of genome-wide 
association scan results. Bioinformatics 27, 2336–2337. 
257. Machiela, M.J., and Chanock, S.J. (2015). LDlink: A web-based application for exploring 
population-specific haplotype structure and linking correlated alleles of possible functional variants. 
241 
 
Bioinformatics 31, 3555–3557. 
258. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek, P., and Cunningham, 
F. (2016). The Ensembl Variant Effect Predictor. Genome Biol. 17, 122. 
259. Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S., McDonnell, S.K., Baheti, S., Musolf, A., Li, 
Q., Holzinger, E., Karyadi, D., et al. (2016). REVEL: An Ensemble Method for Predicting the 
Pathogenicity of Rare Missense Variants. Am. J. Hum. Genet. 99, 877–885. 
260. Lewis, M.A., Nolan, L.S., Cadge, B.A., Matthews, L.J., Schulte, B.A., Dubno, J.R., Steel, K.P., and 
Dawson, S.J. (2018). Whole exome sequencing in adult-onset hearing loss reveals a high load of 
predicted pathogenic variants in known deafness-associated genes and identifies new candidate 
genes. BMC Med. Genomics 11, 77. 
261. Cai, T., Jen, H.I., Kang, H., Klisch, T.J., Zoghbi, H.Y., and Groves, A.K. (2015). Characterization of 
the transcriptome of nascent hair cells and identification of direct targets of the atoh1 transcription 
factor. J. Neurosci. 35, 5870–5883. 
262. Spongr, V.P., Flood, D.G., Frisina, R.D., and Salvi, R.J. (1997). Quantitative measures of hair cell 
loss in CBA and C57BL/6 mice throughout their life spans. J. Acoust. Soc. Am. 101, 3546–3553. 
263. NHS (2019). What is the body mass index (BMI)? - NHS. 
264. Coggon, D., Barker, D., and Rose, G. (2009). Chapter 2. Quantifying disease in populations. | The 
BMJ. 
265. Coggen, D., Rose, G., & Barker, D.J.P. (2012). Chapter 8. Case-control and cross sectional studies 
| The BMJ. 
266. Fischer, N., Weber, B., and Riechelmann, H. (2016). Presbyakusis. Laryngorhinootologie. 95, 
497–510. 
267. Keidser, G., Rudner, M., Seeto, M., Hygge, S., and Rönnberg, J. (2016). The effect of functional 
hearing and hearing aid usage on verbal reasoning in a large community-dwelling population. Ear 
Hear. 37, e26–e36. 
268. Dawes, P., Cruickshanks, K.J., Moore, D.R., Fortnum, H., Edmondson-Jones, M., McCormack, A., 
and Munro, K.J. (2015). The effect of prenatal and childhood development on hearing, vision and 
cognition in adulthood. PLoS One 10, e0136590. 
269. Vlaming, M.S.M.G., Mackinnon, R.C., Jansen, M., and Moore, D.R. (2014). Automated screening for 
high-frequency hearing loss. Ear Hear. 35, 667–679. 
270. Leensen, M.C.J., De Laat, J.A.P.M., Snik, A.F.M., and Dreschler, W.A. (2011). Speech-in-noise 
screening tests by internet, Part 2: Improving test sensitivity for noise-induced hearing loss. Int. J. 
Audiol. 50, 835–848. 
242 
 
271. Dawes, P. (2013). UK Biobank normative data for the Digit Triplet Test. Access via 
www.ukbiobank.ac.uk. 1–4. 
272. Stam, M., Smits, C., Twisk, J.W.R., Lemke, U., Festen, J.M., and Kramer, S.E. (2015). Deterioration 
of Speech Recognition Ability Over a Period of 5 Years in Adults Ages 18 to 70 Years. Ear Hear. 36, 
e129–e137. 
273. Smits, C., Kramer, S.E., and Houtgast, T. (2006). Speech reception thresholds in noise and self-
reported hearing disability in a general adult population. Ear Hear. 27, 538–549. 
274. Goh, L., and Yap, V.B. (2009). Effects of normalization on quantitative traits in association test. 
BMC Bioinformatics 10, 415. 
275. Fry, A., Littlejohns, T.J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., and Allen, 
N.E. (2017). Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank 
Participants with Those of the General Population. Am. J. Epidemiol. 186, 1026–1034. 
276. Smits, C. (2017). Improving the efficiency of speech-in-noise hearing screening tests. Ear Hear. 
38, e385–e388. 
277. Momi, S.K., Wolber, L.E., Fabiane, S.M., MacGregor, A.J., and Williams, F.M.K. (2015). Genetic and 
Environmental Factors in Age-Related Hearing Impairment. Twin Res. Hum. Genet. 18, 383–392. 
278. Kim, S.Y., Kim, H.J., Kim, M.S., Park, B., Kim, J.H., and Choi, H.G. (2017). Discrepancy between self-
assessed hearing status and measured audiometric evaluation. PLoS One 12, e0182718. 
279. Nondahl, D.M., Cruickshanks, K.J., Wiley, T.L., Tweed, T.S., Klein, R., and Klein, B.E. Accuracy of 
self-reported hearing loss. Audiology 37, 295–301. 
280. Gallagher, M.D., and Chen-Plotkin, A.S. (2018). The Post-GWAS Era: From Association to 
Function. Am. J. Hum. Genet. 102, 717–730. 
281. van Rheenen, W., Peyrot, W.J., Schork, A.J., Lee, S.H., and Wray, N.R. (2019). Genetic correlations 
of polygenic disease traits: from theory to practice. Nat. Rev. Genet. 20, 567–581. 
282. Kraft, P., Zeggini, E., and Ioannidis, J.P.A. (2009). Replication in genome-wide association studies. 
Stat. Sci. 24, 561–573. 
283. Churchhouse, C., and Neale, B. (2017). Rapid GWAS of thousands of phenotypes for 337,000 
samples in the UK Biobank. 
284. Aschard, H., Vilhjálmsson, B.J., Joshi, A.D., Price, A.L., and Kraft, P. (2015). Adjusting for heritable 
covariates can bias effect estimates in genome-wide association studies. Am. J. Hum. Genet. 96, 329–
339. 
285. Gates, G.A., Couropmitrcc, N.N., and Alycrs, R.H. (1999). Genetic associations in age-related 
hearing thresholds. Arch. Otolaryngol. - Head Neck Surg. 125, 654–659. 
243 
 
286. Zaitlen, N., and Kraft, P. (2012). Heritability in the genome-wide association era. Hum. Genet. 
131, 1655–1664. 
287. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., McCarthy, M.I., 
Ramos, E.M., Cardon, L.R., Chakravarti, A., et al. (2009). Finding the missing heritability of complex 
diseases. Nature 461, 747–753. 
288. Schönberger, J., Wang, L., Shin, J.T., Sang, D.K., Depreux, F.F.S., Zhu, H., Zon, L., Pizard, A., Kim, J.B., 
MacRae, C.A., et al. (2005). Mutation in the transcriptional coactivator EYA4 causes dilated 
cardiomyopathy and sensorineural hearing loss. Nat. Genet. 37, 418–422. 
289. Pfister, M., Tóth, T., Thiele, H., Haack, B., Blin, N., Zenner, H.-P., Sziklai, I., Nürnberg, P., and Kupka, 
S. (2002). A 4bp-Insertion in the eya-Homologous Region (eyaHR) of EYA4 Causes Hearing 
Impairment in a Hungarian Family Linked to DFNA10. Mol. Med. 8, 607–611. 
290. Bondurand, N., Dastot-Le Moal, F., Stanchina, L., Collot, N., Baral, V., Marlin, S., Attie-Bitach, T., 
Giurgea, I., Skopinski, L., Reardon, W., et al. (2007). Deletions at the SOX10 Gene Locus Cause 
Waardenburg Syndrome Types 2 and 4. Am. J. Hum. Genet. 81, 1169–1185. 
291. Bolz, H., Von Brederlow, B., Ramírez, A., Bryda, E.C., Kutsche, K., Nothwang, H.G., Seeliger, M., 
Cabrera, M.D.C.S., Vila, M.C., Molina, O.P., et al. (2001). Mutation of CDH23, encoding a new member 
of the cadherin gene family, causes Usher syndrome type 1D. Nat. Genet. 27, 108–112. 
292. Schrauwen, I., Chakchouk, I., Liaqat, K., Jan, A., Nasir, A., Hussain, S., Nickerson, D.A., Bamshad, 
M.J., Ullah, A., Ahmad, W., et al. (2018). A variant in LMX1A causes autosomal recessive severe-to-
profound hearing impairment. Hum. Genet. 137, 471–478. 
293. Sheets, L., Trapani, J.G., Mo, W., Obholzer, N., and Nicolson, T. (2011).  Ribeye is required for 
presynaptic Ca V 1.3a channel localization and afferent innervation of sensory hair cells . 
Development 138, 1309–1319. 
294. Uthaiah, R.C., and Hudspeth, A.J. (2010). Molecular Anatomy of the Hair Cell’s Ribbon Synapse. 
J. Neurosci. 30, 12387–12399. 
295. Planchart, A. (2013). Analysis of an intronic promoter within Synj2. Biochem. Biophys. Res. 
Commun. 440, 640–645. 
296. Liu, Y., Qi, J., Chen, X., Tang, M., Chu, C., Zhu, W., Li, H., Tian, C., Yang, G., Zhong, C., et al. (2019). 
Critical role of spectrin in hearing development and deafness. Sci. Adv. 5, eaav7803. 
297. Ohlemiller, K.K., Hughes, R.M., Mosinger-Ogilvie, J., Speck, J.D., Grosof, D.H., and Silverman, M.S. 
(1995). Cochlear and retinal degeneration in the Tubby mouse. Neuroreport 6, 845–849. 
298. Ohlemiller, K.K., Hughes, R.M., Lett, J.M., Ogilvie, J.M., Speck, J.D., Wright, J.S., and Faddis, B.T. 
(1997). Progression of cochlear and retinal degeneration in the tubby (rd5) mouse. Audiol. Neuro-
Otology 2, 175–185. 
244 
 
299. Helfert, R.H., Sommer, T.J., Meeks, J., Hofstetter, P., and Hughes, L.F. (1999). Age-related synaptic 
changes in the central nucleus of the inferior colliculus of Fischer-344 rats. J. Comp. Neurol. 406, 285–
298. 
300. Yu, Y.F., Zhai, F., Dai, C.F., and Hu, J.J. (2011). The relationship between age-related hearing loss 
and synaptic changes in the hippocampus of C57BL/6J mice. Exp. Gerontol. 46, 716–722. 
301. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., 
Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: A knowledge-
based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545–
15550. 
302. Gilles, A., Camp, G., Van de Heyning, P., and Fransen, E. (2017). A pilot genome-wide association 
study identifies potential metabolic pathways involved in tinnitus. Front. Neurosci. 11, 71. 
303. Stranden, M., Solvin, H., Fors, E.A., Getz, L., and Helvik, A.S. (2016). Are persons with fibromyalgia 
or other musculoskeletal pain more likely to report hearing loss? A HUNT study. BMC Musculoskelet. 
Disord. 17, 477. 
304. Solovieff, N., Cotsapas, C., Lee, P.H., Purcell, S.M., and Smoller, J.W. (2013). Pleiotropy in complex 
traits: Challenges and strategies. Nat. Rev. Genet. 14, 483–495. 
305. Pasaniuc, B., and Price, A.L. (2017). Dissecting the genetics of complex traits using summary 
association statistics. Nat. Rev. Genet. 18, 117–127. 
306. Coons, A.H., Creech, H.J., and Jones, R.N. (2013). Immunological Properties of an Antibody 
Containing a Fluorescent Group. Exp. Biol. Med. 47, 200–202. 
307. Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S., McDonnell, S.K., Baheti, S., Musolf, A., Li, 
Q., Holzinger, E., Karyadi, D., et al. (2016). REVEL: An Ensemble Method for Predicting the 
Pathogenicity of Rare Missense Variants. Am. J. Hum. Genet. 99, 877–885. 
308. Tadjuidje, E., and Hegde, R.S. (2013). The Eyes Absent proteins in development and disease. Cell. 
Mol. Life Sci. 70, 1897–1913. 
309. Wayne, S. (2001). Mutations in the transcriptional activator EYA4 cause late-onset deafness at 
the DFNA10 locus. Hum. Mol. Genet. 10, 195–200. 
310. Liu, F., Hu, J., Xia, W., Hao, L., Ma, J., Ma, D., and Ma, Z. (2015). Exome sequencing identifies a 
mutation in EYA4 as a novel cause of autosomal dominant non-syndromic hearing loss. PLoS One 10, 
e0126602. 
311. Matsuzaki, S., Hosoya, M., Okano, H., Fujioka, M., and Ogawa, K. (2018). Expression pattern of 
EYA4 in the common marmoset (Callithrix jacchus) cochlea. Neurosci. Lett. 662, 185–188. 
312. Legendre, K., Safieddine, S., Kussel-Andermann, P., Petit, C., and El-Amraoui, A. (2008).  II- V 
245 
 
spectrin bridges the plasma membrane and cortical lattice in the lateral wall of the auditory outer 
hair cells. J. Cell Sci. 121, 3347–3356. 
313. Cortese, M., Papal, S., Pisciottano, F., Elgoyhen, A.B., Hardelin, J.-P., Petit, C., Franchini, L.F., and 
El-Amraoui, A. (2017). Spectrin βV adaptive mutations and changes in subcellular location correlate 
with emergence of hair cell electromotility in mammalians. Proc. Natl. Acad. Sci. 114, 2054–2059. 
314. Kitajiri, S.I., Sakamoto, T., Belyantseva, I.A., Goodyear, R.J., Stepanyan, R., Fujiwara, I., Bird, J.E., 
Riazuddin, S., Riazuddin, S., Ahmed, Z.M., et al. (2010). Actin-bundling protein TRIOBP forms resilient 
rootlets of hair cell stereocilia essential for hearing. Cell 141, 786–798. 
315. Boggon, T.J., Shan, W.S., Santagata, S., Myers, S.C., and Shapiro, L. (1999). Implication of tubby 
proteins as transcription factors by structure-based functional analysis. Science 286, 2119–2125. 
316. Ohlemiller, K.K., Hughes, R.M., Lett, J.M., Ogilvie, J.M., Speck, J.D., Wright, J.S., and Faddis, B.T. 
(1997). Progression of cochlear and retinal degeneration in the tubby (rd5) mouse. Audiol. Neuro-
Otology 2, 175–185. 
317. Yousaf, R., Friedman, T.B., and Riazuddin, S. (2016). Genetic modifiers of hearing loss. In 
Monographs in Human Genetics, (Karger Publishers), pp. 73–83. 
318. Manji, S.S.M., Williams, L.H., Miller, K.A., Ooms, L.M., Bahlo, M., Mitchell, C.A., and Dahl, H.H.M. 
(2011). A mutation in synaptojanin 2 causes progressive hearing loss in the ENU-mutagenised mouse 
strain mozart. PLoS One 6, e17607. 
319. Gasparoni, G., Bultmann, S., Lutsik, P., Kraus, T.F.J., Sordon, S., Vlcek, J., Dietinger, V., Steinmaurer, 
M., Haider, M., Mulholland, C.B., et al. (2018). DNA methylation analysis on purified neurons and glia 
dissects age and Alzheimer’s disease-specific changes in the human cortex. Epigenetics and 
Chromatin 11, 41. 
320. Lopez, L.M., Harris, S.E., Luciano, M., Liewald, D., Davies, G., Gow, A.J., Tenesa, A., Payton, A., Ke, 
X., Whalley, L.J., et al. (2012). Evolutionary conserved longevity genes and human cognitive abilities 
in elderly cohorts. Eur. J. Hum. Genet. 20, 341–347. 
321. Talebi, F., Mardasi, F.G., Asl, J.M., and Sayahi, M. (2017). Next-generation sequencing identifies 
three novel missense variants in ILDR1 and MYO6 genes in an Iranian family with hearing loss with 
review of the literature. Int. J. Pediatr. Otorhinolaryngol. 103, 103–108. 
322. Wang, X., Wang, L., Peng, H., Yang, T., and Wu, H. (2018). A Novel p.G141R Mutation in ILDR1 
Leads to Recessive Nonsyndromic Deafness DFNB42 in Two Chinese Han Families. Neural Plast. 
2018, 1–6. 
323. Diaz-Horta, O., Duman, D., Foster, J., Sirmaci, A., Gonzalez, M., Mahdieh, N., Fotouhi, N., Bonyadi, 
M., Cengiz, F.B., Menendez, I., et al. (2012). Whole-Exome Sequencing Efficiently Detects Rare 
Mutations in Autosomal Recessive Nonsyndromic Hearing Loss. PLoS One 7, e50628. 
246 
 
324. Borck, G., Rehman, A.U., Lee, K., Pogoda, H.M., Kakar, N., Von Ameln, S., Grillet, N., Hildebrand, 
M.S., Ahmed, Z.M., Nürnberg, G., et al. (2011). Loss-of-function mutations of ILDR1 cause autosomal-
recessive hearing impairment DFNB42. Am. J. Hum. Genet. 88, 127–137. 
325. Sang, Q., Li, W., Xu, Y., Qu, R., Xu, Z., Feng, R., Jin, L., He, L., Li, H., and Wang, L. (2015). ILDR1 
deficiency causes degeneration of cochlear outer hair cells and disrupts the structure of the organ of 
Corti: a mouse model for human DFNB42. Biol. Open 4, 411–418. 
326. Kitajiri, S.I., and Katsuno, T. (2016). Tricellular Tight Junctions in the Inner Ear. Biomed Res. Int. 
2016, 1–5. 
327. Kim, N.K.D., Higashi, T., Lee, K.Y., Kim, A.R., Kitajiri, S., Kim, M.Y., Chang, M.Y., Kim, V., Oh, S.H., 
Kim, D., et al. (2015). Downsloping high-frequency hearing loss due to inner ear tricellular tight 
junction disruption by a novel ILDR1 mutation in the Ig-like domain. PLoS One 10, e0116931. 
328. Steffes, G., Lorente-Cánovas, B., Pearson, S., Brooker, R.H., Spiden, S., Kiernan, A.E., Guénet, J.L., 
and Steel, K.P. (2012). Mutanlallemand (mtl) and Belly Spot and Deafness (bsd) Are Two New 
Mutations of Lmx1a Causing Severe Cochlear and Vestibular Defects. PLoS One 7, e51065. 
329. Jaiganesh, A., De-la-Torre, P., Patel, A.A., Termine, D.J., Velez-Cortes, F., Chen, C., and Sotomayor, 
M. (2018). Zooming in on Cadherin-23: Structural Diversity and Potential Mechanisms of Inherited 
Deafness. Structure 26, 1210-1225.e4. 
330. Bouzid, A., Smeti, I., Chakroun, A., Loukil, S., Gibriel, A.A., Grati, M., Ghorbel, A., and Masmoudi, S. 
(2018). CDH23 methylation status and presbycusis risk in elderly women. Front. Aging Neurosci. 10, 
241. 
331. Liang, Y., Wang, K., Peng, Q., Zhu, P., Wu, C., Rao, C., Chang, J., Li, S., and Lu, X. (2018). A novel 
variant in the CDH23 gene is associated with non-syndromic hearing loss in a Chinese family. Int. J. 
Pediatr. Otorhinolaryngol. 104, 108–112. 
332. Ganapathy, A., Pandey, N., Srisailapathy, C.R.S., Jalvi, R., Malhotra, V., Venkatappa, M., Chatterjee, 
A., Sharma, M., Santhanam, R., Chadha, S., et al. (2014). Non-syndromic hearing impairment in India: 
High allelic heterogeneity among mutations in TMPRSS3, TMC1, USHIC, CDH23 and TMIE. PLoS One 
9, e84773. 
333. Xu, T., Zhu, W., and Wang, P. (2019). The p.P240L variant of CDH23 and the risk of nonsyndromic 
hearing loss: a meta-analysis. Eur. Arch. Oto-Rhino-Laryngology 276, 11–16. 
334. Magupalli, V.G., Schwarz, K., Alpadi, K., Natarajan, S., Seigel, G.M., and Schmitz, F. (2008). Multiple 
RIBEYE-RIBEYE Interactions Create a Dynamic Scaffold for the Formation of Synaptic Ribbons. J. 
Neurosci. 28, 7954–7967. 
335. Jean, P., de la Morena, D.L., Michanski, S., Tobón, L.M.J., Chakrabarti, R., Picher, M.M., Neef, J., Jung, 
S.Y., Gültas, M., Maxeiner, S., et al. (2018). The synaptic ribbon is critical for sound encoding at high 
247 
 
rates and with temporal precision. Elife 7, e29275. 
336. Depreux, F.F.S., Darrow, K., Conner, D.A., Eavey, R.D., Liberman, M.C., Seidman, C.E., and Seidman, 
J.G. (2008). Eya4-deficient mice are a model for heritable otitis media. J. Clin. Invest. 118, 651–658. 
337. Ikeda, A., Zheng, Q.Y., Zuberi, A.R., Johnson, K.R., Naggert, J.K., and Nishina, P.M. (2002). 
Microtubule-associated protein 1A is a modifier of tubby hearing (moth1). Nat. Genet. 30, 401–405. 
338. Sang, Q., Li, W., Xu, Y., Qu, R., Xu, Z., Feng, R., Jin, L., He, L., Li, H., and Wang, L. (2015). ILDR1 
deficiency causes degeneration of cochlear outer hair cells and disrupts the structure of the organ of 
Corti: a mouse model for human DFNB42. Biol. Open 4, 411–418. 
339. Huang, Y., Hill, J., Yatteau, A., Wong, L., Jiang, T., Petrovic, J., Gan, L., Dong, L., and Wu, D.K. (2018). 
Reciprocal Negative Regulation Between Lmx1a and Lmo4 Is Required for Inner Ear Formation. J. 
Neurosci. 38, 5429–5440. 
340. Kazmierczak, P., Sakaguchi, H., Tokita, J., Wilson-Kubalek, E.M., Milligan, R.A., Müller, U., and 
Kachar, B. (2007). Cadherin 23 and protocadherin 15 interact to form tip-link filaments in sensory 
hair cells. Nature 449, 87–91. 
341. Sheets, L., Trapani, J.G., Mo, W., Obholzer, N., and Nicolson, T. (2011).  Ribeye is required for 
presynaptic Ca V 1.3a channel localization and afferent innervation of sensory hair cells . 
Development 138, 1309–1319. 
342. Koran, M.E.I., Hohman, T.J., Meda, S.A., and Thornton-Wells, T.A. (2014). Genetic interactions 
within inositol-related pathways are associated with longitudinal changes in ventricle size. J. 
Alzheimer’s Dis. 38, 145–154. 
343. Tamási, V., Petschner, P., Adori, C., Kirilly, E., Ando, R.D., Tothfalusi, L., Juhasz, G., and Bagdy, G. 
(2014). Transcriptional evidence for the role of chronic venlafaxine treatment in neurotrophic 
signaling and neuroplasticity including also glutatmatergic- and insulin-mediated neuronal 
processes. PLoS One 9, e113662. 
344. Luciano, M., Lopez, L.M., De Moor, M.H.M., Harris, S.E., Davies, G., Nutile, T., Krueger, R.F., Esko, 
T., Schlessinger, D., Toshiko, T., et al. (2012). Longevity candidate genes and their association with 
personality traits in the elderly. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 159 B, 192–200. 
345. Scheffer, D.I., Shen, J., Corey, D.P., and Chen, Z.Y. (2015). Gene expression by mouse inner ear 
hair cells during development. J. Neurosci. 35, 6366–6380. 
346. Feng, H., Xia, X., Li, C., Song, Y., Qin, C., Zhang, Y., and Lan, X. (2015). TYR as a multifunctional 
reporter gene regulated by the Tet-on system for multimodality imaging: An in vitro study. Sci. Rep. 
5, 15502. 
347. Uehara, S., Izumi, Y., Kubo, Y., Wang, C.C., Mineta, K., Ikeo, K., Gojobori, T., Tachibana, M., Kikuchi, 
T., Kobayashi, T., et al. (2009). Specific expression of Gsta4 in mouse cochlear melanocytes: A novel 
248 
 
role for hearing and melanocyte differentiation. Pigment Cell Melanoma Res. 22, 111–119. 
348. Murphy, P.A., Begum, S., and Hynes, R.O. (2015). Tumor angiogenesis in the absence of 
fibronectin or its cognate integrin receptors. PLoS One 10, e0120872. 
349. Dunbar, L., Patni, P., Aguilar, C., Mburu, P. Corns, L., Wells, H.R.R., Delmaghani, S., Parker, A. 
Johnson, S., Chessum, L.,  et al. (2019). Clarin-2 is Required for Maintenance of Mechanotransducing 
Stereocilia and Essential for Hearing. In ARO Midwinter Meeting Abstract, p. 
https://cdn.ymaws.com/www.aro.org/resource/resmgr/. 
350. Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.G., et al. (2011). 
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. 
Biol. 7, 885–887. 
351. Pircs, K., Petri, R., Madsen, S., Brattås, P.L., Vuono, R., Ottosson, D.R., St-Amour, I., Hersbach, B.A., 
Matusiak-Brückner, M., Lundh, S.H., et al. (2018). Huntingtin Aggregation Impairs Autophagy, 
Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. Cell Rep. 24, 1397–1406. 
352. Gao, Y., Liu, X.F., Lu, X.C., Ma, C., Cao, J., and Fan, L. (2012). Protective effects of atorvastatin 
against oxidized LDL-induced downregulation of KLF expression in EA.hy926 cells. Int. J. Mol. Med. 
30, 330–336. 
353. Joshi, P., Greco, T.M., Guise, A.J., Luo, Y., Yu, F., Nesvizhskii, A.I., and Cristea, I.M. (2013). The 
functional interactome landscape of the human histone deacetylase family. Mol. Syst. Biol. 9, 672. 
354. Vlajkovic, S.M., Guo, C.X., Telang, R., Wong, A.C.Y., Paramananthasivam, V., Boison, D., Housley, 
G.D., and Thorne, P.R. (2011). Adenosine kinase inhibition in the cochlea delays the onset of age-
related hearing loss. Exp. Gerontol. 46, 905–914. 
355. Ren, A., Zhang, W., Yarlagadda, S., Sinha, C., Arora, K., Moon, C.S., and Naren, A.P. (2013). 
MAST205 competes with cystic fibrosis transmembrane conductance regulator (CFTR)-associated 
ligand for binding to CFTR to regulate CFTR-mediated fluid transport. J. Biol. Chem. 288, 12325–
12334. 
356. Nielsen, J. V., Nielsen, F.H., Ismail, R., Noraberg, J., and Jensen, N.A. (2007). Hippocampus-like 
corticoneurogenesis induced by two isoforms of the BTB-zinc finger gene Zbtb20 in mice. 
Development 134, 1133–1140. 
357. Tan, J., Yang, L., Liu, C., and Yan, Z. (2017). MicroRNA-26a targets MAPK6 to inhibit smooth 
muscle cell proliferation and vein graft neointimal hyperplasia. Sci. Rep. 7, 46602. 
358. Sipe, C.W., Liu, L., Lee, J., Grimsley-Myers, C., and Lu, X. (2013). Lis1 mediates planar polarity of 
auditory hair cells through regulation of microtubule organization. Dev. 140, 1785–1795. 
359. Lucas, M.E. (2006). The bHLH transcription factor hand2 is essential for noradrenergic 
differentiation of sympathetic neurons. Development 133, 4015–4024. 
249 
 
360. Gnedeva, K., and Hudspeth, A.J. (2015). SoxC transcription factors are essential for the 
development of the inner ear. Proc. Natl. Acad. Sci. U. S. A. 112, 14066–14071. 
361. Mathioudakis, N., Sundaresh, R., Larsen, A., Ruff, W., Schiller, J., Guerrero-Cázares, H., Burger, P., 
Salvatori, R., and Quiñones-Hinojosa, A. (2015). Expression of the pituitary stem/progenitor marker 
GFRα2 in human pituitary adenomas and normal pituitary. Pituitary 18, 31–41. 
362. Liu, W., and Rask-Andersen, H. (2014). Immunohistological analysis of neurturin and its 
receptors in human cochlea. Auris Nasus Larynx 41, 172–178. 
363. Liu, W., Li, H., Hong, S.H., Piszczek, G.P., Chen, W., and Rodgers, G.P. (2016). Olfactomedin 4 
deletion induces colon adenocarcinoma in ApcMin/+ mice. Oncogene 35, 5237–5247. 
364. Kutsche, K., Yntema, H., Brandt, A., Jantke, I., Nothwang, H.G., Orth, U., Boavida, M.G., David, D., 
Chelly, J., Fryns, J.P., et al. (2000). Mutations in ARHGEF6, encoding a guanine nucleotide exchange 
factor for Rho GTPases, in patients with X-linked mental retardation. Nat. Genet. 26, 247–250. 
365. Zhu, C., Cheng, C., Wang, Y., Muhammad, W., Liu, S., Zhu, W., Shao, B., Zhang, Z., Yan, X., He, Q., et 
al. (2018). Loss of ARHGEF6 Causes Hair Cell Stereocilia Deficits and Hearing Loss in Mice. Front. Mol. 
Neurosci. 11, 362. 
366. Ishiyama, A., Mowry, S.E., Lopez, I.A., and Ishiyama, G. (2009). Immunohistochemical 
distribution of basement membrane proteins in the human inner ear from older subjects. Hear. Res. 
254, 1–14. 
367. Fields, R.R., Zhou, G., Huang, D., Davis, J.R., Möller, C., Jacobson, S.G., Kimberling, W.J., and Sumegi, 
J. (2002). Usher Syndrome Type III: Revised Genomic Structure of the USH3 Gene and Identification 
of Novel Mutations. Am. J. Hum. Genet. 71, 607–617. 
368. Adato, A., Vreugde, S., Joensuu, T., Avidan, N., Hamalainen, R., Belenkiy, O., Olender, T., Bonne-
Tamir, B., Ben-Asher, E., Espinos, C., et al. (2002). USH3A transcripts encode clarin-1, a four-
transmembrane-domain protein with a possible role in sensory synapses. Eur. J. Hum. Genet. 10, 339–
350. 
369. Dunbar, L.A., Patni, P., Aguilar, C., Mburu, P., Corns, L., Wells, H.R., Delmaghani, S., Parker, A., 
Johnson, S., Williams, D., et al. (2019). Clarin‐2 is essential for hearing by maintaining stereocilia 
integrity and function. EMBO Mol. Med. 11, e10288. 
370. Tarchini, B., Longo-Guess, C., Tian, C., Tadenev, A.L.D., Devanney, N., and Johnson, K.R. (2018). A 
spontaneous mouse deletion in Mctp1 uncovers a long-range cis-regulatory region crucial for NR2F1 
function during inner ear development. Dev. Biol. 443, 153–164. 
371. Hickox, A.E., Wong, A.C.Y., Pak, K., Strojny, C., Ramirez, M., Yates, J.R., Ryan, A.F., and Savas, J.N. 
(2017). Global analysis of protein expression of inner ear hair cells. J. Neurosci. 37, 1320–1339. 
372. Kohfeldt, E., Sasaki, T., Göhring, W., and Timpl, R. (1998). Nidogen-2: A new basement membrane 
250 
 
protein with diverse binding properties. 
373. Schymeinsky, J., Nedbal, S., Miosge, N., Poschl, E., Rao, C., Beier, D.R., Skarnes, W.C., Timpl, R., and 
Bader, B.L. (2002). Gene Structure and Functional Analysis of the Mouse Nidogen-2 Gene: Nidogen-2 
Is Not Essential for Basement Membrane Formation in Mice. Mol. Cell. Biol. 22, 6820–6830. 
374. Seong Hoon Kang, and Kramer, J.M. (2000). Nidogen is nonessential and not required for normal 
type IV collagen localization in Caenorhabditis elegans. Mol. Biol. Cell 11, 3911–3923. 
375. Bader, B.L., Smyth, N., Nedbal, S., Miosge, N., Baranowsky, A., Mokkapati, S., Murshed, M., and 
Nischt, R. (2005). Compound Genetic Ablation of Nidogen 1 and 2 Causes Basement Membrane 
Defects and Perinatal Lethality in Mice. Mol. Cell. Biol. 25, 6846–6856. 
376. Van Horck, F.P.G., Ahmadian, M.R., Haeusler, L.C., Moolenaar, W.H., and Kranenburg, O. (2001). 
Characterization of p190RhoGEF, A RhoA-specific Guanine Nucleotide Exchange Factor That 
Interacts with Microtubules. J. Biol. Chem. 276, 4948–4956. 
377. Droppelmann, C.A., Wang, J., Campos-Melo, D., Keller, B., Volkening, K., Hegele, R.A., and Strong, 
M.J. (2013). Detection of a novel frameshift mutation and regions with homozygosis within 
ARHGEF28 gene in familial amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 
14, 444–451. 
378. Farhan, S.M.K., Gendron, T.F., Petrucelli, L., Hegele, R.A., and Strong, M.J. (2017). ARHGEF28 
P.LYS280METFS40TER in an amyotrophic lateral sclerosis family with a C9ORF72 expansion. Neurol. 
Genet. 3, e190. 
379. Ma, Y., Tang, L., Chen, L., Zhang, B., Deng, P., Wang, J., Yang, Y., Liu, R., Yang, Y., Ye, S., et al. (2014). 
ARHGEF28 gene exon 6/intron 6 junction mutations in Chinese amyotrophic lateral sclerosis cohort. 
Amyotroph. Lateral Scler. Front. Degener. 15, 309–311. 
380. Song, Y., Lin, F., Ye, C. hui, Huang, H., Li, X., Yao, X., Xu, Y., and Wang, C. (2019). Rare, low-
frequency and common coding variants of ARHGEF28 gene and their association with sporadic 
amyotrophic lateral sclerosis. Neurobiol. Aging. 
381. Previtali, S.C., Zhao, E., Lazarevic, D., Pipitone, G.B., Fabrizi, G.M., Manganelli, F., Mazzeo, A., 
Pareyson, D., Schenone, A., Taroni, F., et al. (2019). Expanding the spectrum of genes responsible for 
hereditary motor neuropathies. J. Neurol. Neurosurg. Psychiatry jnnp-2019-320717. 
382. Abiko, H., Fujiwara, S., Ohashi, K., Hiatari, R., Mashiko, T., Sakamoto, N., Sato, M., and Mizuno, K. 
(2015). Rho guanine nucleotide exchange factors involved in cyclic-stretch-induced reorientation of 
vascular endothelial cells. J. Cell Sci. 128, 1683–1695. 
383. Zaritsky, A., Tseng, Y.Y., Rabadán, M.A., Krishna, S., Overholtzer, M., Danuser, G., and Hall, A. 
(2017). Diverse roles of guanine nucleotide exchange factors in regulating collective cell migration. 
J. Cell Biol. 216, 1543–1556. 
251 
 
384. Miller, N.L.G., Kleinschmidt, E.G., and Schlaepfer, D.D. (2014). RhoGEFs in Cell Motility: Novel 
Links Between Rgnef and Focal Adhesion Kinase. Curr. Mol. Med. 14, 221–234. 
385. Pisamai, S., Roytrakul, S., Phaonakrop, N., Jaresitthikunchai, J., and Suriyaphol, G. (2018). 
Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel 
digestion coupled with mass spectrometry (GeLC MS/MS) approaches. PLoS One 13, e0200619. 
386. Kleinschmidt, E.G., Miller, N.L.G., Ozmadenci, D., Tancioni, I., Osterman, C.D., Barrie, A.M., Taylor, 
K.N., Ye, A., Jiang, S., Connolly, D.C., et al. (2019). Rgnef promotes ovarian tumor progression and 
confers protection from oxidative stress. Oncogene. 
387. Masià-Balagué, M., Izquierdo, I., Garrido, G., Cordomí, A., Pérez-Benito, L., Miller, N.L.G., 
Schlaepfer, D.D., Gigoux, V., and Aragay, A.M. (2015). Gastrin-stimulated Gα<inf>13</inf> activation 
of Rgnef protein (ArhGEF28) in DLD-1 colon carcinoma cells. J. Biol. Chem. 290, 15197–15209. 
388. Zallocchi, M., Meehan, D.T., Delimont, D., Askew, C., Garige, S., Gratton, M.A., Rothermund-
Franklin, C.A., and Cosgrove, D. (2009). Localization and expression of clarin-1, the Clrn1 gene 
product, in auditory hair cells and photoreceptors. Hear. Res. 255, 109–120. 
389. Geng, R., Geller, S.F., Hayashi, T., Ray, C.A., Reh, T.A., Bermingham-McDonogh, O., Jones, S.M., 
Wright, C.G., Melki, S., Imanishi, Y., et al. (2009). Usher syndrome IIIA gene clarin-1 is essential for 
hair cell function and associated neural activation. Hum. Mol. Genet. 18, 2748–2760. 
390. Geng, R., Melki, S., Chen, D.H.-C., Tian, G., Furness, D.N., Oshima-Takago, T., Neef, J., Moser, T., 
Askew, C., Horwitz, G., et al. (2012). The Mechanosensory Structure of the Hair Cell Requires Clarin-
1, a Protein Encoded by Usher Syndrome III Causative Gene. J. Neurosci. 32, 9485–9498. 
391. Lukashkin, A.N., Richardson, G.P., and Russell, I.J. (2010). Multiple roles for the tectorial 
membrane in the active cochlea. Hear. Res. 266, 26–35. 
392. Salt, A.N., Melichar, I., and Thalmann, R. (1987). Mechanisms of Endocochlear Potential 
Generation By Stria Vascularis. Laryngoscope 97, 984–991. 
393. Wainschtein, P., Jain, D.P., Yengo, L., Zheng, Z., TOPMed Anthropometry Working Group, Trans-
Omics for Precision Medicine Consortium, Cupples, L.A., Shadyab, A.H., McKnight, B., Shoemaker, 
B.M., et al. (2019). Recovery of trait heritability from whole genome sequence data. BioRxiv 588020. 
394. Deary, V., Hagenaars, S.P., Harris, S.E., Hill, W.D., Davies, G., Liewald, D.C.M., McIntosh, A.M., Gale, 
C.R., and Deary, I.J. (2018). Genetic contributions to self-reported tiredness. Mol. Psychiatry 23, 609–
620. 
395. Lane, J.M., Vlasac, I., Anderson, S.G., Kyle, S.D., Dixon, W.G., Bechtold, D.A., Gill, S., Little, M.A., Luik, 
A., Loudon, A., et al. (2016). Genome-wide association analysis identifies novel loci for chronotype in 
100,420 individuals from the UK Biobank. Nat. Commun. 7, 10889. 
396. Clarke, T.K., Adams, M.J., Davies, G., Howard, D.M., Hall, L.S., Padmanabhan, S., Murray, A.D., 
252 
 
Smith, B.H., Campbell, A., Hayward, C., et al. (2017). Genome-wide association study of alcohol 
consumption and genetic overlap with other health-related traits in UK biobank (N=112117). Mol. 
Psychiatry 22, 1376–1384. 
397. Davies, N.M., Holmes, M. V., and Davey Smith, G. (2018). Reading Mendelian randomisation 
studies: A guide, glossary, and checklist for clinicians. BMJ 362, k601. 
398. O’Connor, L.J., and Price, A.L. (2018). Distinguishing genetic correlation from causation across 
52 diseases and complex traits. Nat. Genet. 50, 1728–1734. 
399. Sergeyenko, Y., Lall, K., Charles Liberman, M., and Kujawa, S.G. (2013). Age-related cochlear 
synaptopathy: An early-onset contributor to auditory functional decline. J. Neurosci. 33, 13686–
13694. 
400. Koo, S.K., Hill, J.K., Hwang, C.H., Lin, Z.S., Millen, K.J., and Wu, D.K. (2009). Lmx1a maintains 
proper neurogenic, sensory, and non-sensory domains in the mammalian inner ear. Dev. Biol. 333, 
14–25. 
401. Wesdorp, M., de Koning Gans, P.A.M., Schraders, M., Oostrik, J., Huynen, M.A., Venselaar, H., 
Beynon, A.J., van Gaalen, J., Piai, V., Voermans, N., et al. (2018). Heterozygous missense variants of 
LMX1A lead to nonsyndromic hearing impairment and vestibular dysfunction. Hum. Genet. 137, 389–
400. 
402. Hyde, C.L., Nagle, M.W., Tian, C., Chen, X., Paciga, S.., Wendland, J.., Tung, J., Hinds, D.., Perlis, R.., 
and Winslow, A.. (2017). depression in individuals of European descent. Nat Genet 48, 1031–1036. 
403. Mills, M.C., and Rahal, C. (2019). A scientometric review of genome-wide association studies. 
Commun. Biol. 2, 9. 
404. Popejoy, A.B., and Fullerton, S.M. (2016). Genomics is failing on diversity. Nature 538, 161–164. 
405. Vuckovic, D., Mezzavilla, M., Cocca, M., Morgan, A., Brumat, M., Catamo, E., Concas, M.P., Biino, G., 
Franzè, A., Ambrosetti, U., et al. (2018). Whole-genome sequencing reveals new insights into age-
related hearing loss: cumulative effects, pleiotropy and the role of selection. Eur. J. Hum. Genet. 26, 
1167–1179. 
406. Verdi, S., Abbasian, G., Bowyer, R.C.E., Lachance, G., Yarand, D., Christofidou, P., Mangino, M., 
Menni, C., Bell, J.T., Falchi, M., et al. (2019). TwinsUK: The UK Adult Twin Registry Update. Twin Res. 
Hum. Genet. 1–7. 
407. Banos, D.T., McCartney, D.L., Battram, T., Hemani, G., Walker, R.M., Morris, S.W., Zhang, Q., 
Porteous, D.J., McRae, A.F., Wray, N.R., et al. (2018). Bayesian reassessment of the epigenetic 
architecture of complex traits. BioRxiv 450288. 
408. Korrapati, S., Taukulis, I., Olszewski, R., Pyle, M., Gu, S., Singh, R., Griffiths, C., Martin, D., Boger, 
E., Morell, R.J., et al. (2019). Single Cell and Single Nucleus RNA-Seq Reveal Cellular Heterogeneity 
253 
 
and Homeostatic Regulatory Networks in Adult Mouse Stria Vascularis. Front. Mol. Neurosci. 12, 316. 
409. Sugrue, L.P., and Desikan, R.S. (2019). What Are Polygenic Scores and Why Are They Important? 
JAMA - J. Am. Med. Assoc. 321, 1820–1821. 
410. Dickinson, M.E., Flenniken, A.M., Ji, X., Teboul, L., Wong, M.D., White, J.K., Meehan, T.F., Weninger, 
W.J., Westerberg, H., Adissu, H., et al. (2016). High-throughput discovery of novel developmental 
phenotypes. Nature 537, 508–514. 
 
  
254 
 
Appendix   
The following locus plots display genetic association results for SNPs located at genome regions 
flanking all lead SNPs from HDiff and HAid analysis. The following applies to all plots and so is not 
included in individual legends: 
Purple indicates lead independent SNP generated from GCTA-COJO conditional analysis. The 
colouring of remaining SNPs represents the correlation (r2) to the lead SNP (purple). Where LD 
information is not available, SNPs are coloured grey. The plots display 200kb +/- regions flanking 
the position of the lead SNP, except in gene-dense regions, where 100kb +/- is displayed. Two of the 
lead SNPs are not in the Locuszoom SNP reference database (rs759016271 and 
3:182069497_TA_T) and so SNPs in close proximity to these lead SNPs were used to create the 
locus plots.  
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Locus plots (Figure a-f) for lead SNPs that reside in exon regions 
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Figure a. Locus plot for genomic region flanking rs36062310 
 
Figure b. Locus plot for genome region flanking SNP rs6453022 
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Figure c. Locus plot for genome region flanking SNP rs9493627 
 
 
Figure d. Locus plot for region flanking SNP rs5756795 
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Figure e. Locus plot of genome region flanking rs143282422 
 
Figure f. Locus plot for genome region flanking SNP rs12552 
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Locus plots (g-hh) for lead SNPs that reside in intron regions 
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Figure g. Locus plot for genome region flanking SNP rs4597943 
 
Figure h. Genome region flanking SNP rs9296413 
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Figure i. Locus plot for genome region flanking rs9321402 
 
Figure j. Locus plot of genomic region flanking SNP rs132929 
 
Figure k. Locus plot of genome region flanking SNP rs1566129 
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Figure l. Locus plot of genome region flanking SNP rs1566129 
 
Figure m. Locus plot of genome region flanking rs12225399 
 
Figure n. Locus plot of genome region flanking SNP rs55635402 
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Figure o. Locus plot flanking genome region SNP rs9677089 
 
Figure p. Locus plot of genome region flanking SNP rs62033400 
 
Figure q. Locus plot of genome region flanking SNP rs13277721 
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Figure r. Locus plot of genome region flanking SNP rs2236401 
 
Figure s. Locus plot of genome region flanking SNP rs4947828 
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Figure t. Locus plot of genome region flanking SNP rs6597883 
 
Figure u. Locus plot of genome region flanking SNP rs10901863 
 
Figure v. Locus plot of genome region flanking SNP rs34442808 
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Figure w. Locus plot of genome region flanking SNP rs835267 
 
Figure x. Locus plot of genome region flanking SNP rs4948502 
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Figure y. Locus plot of genome region flanking SNP rs10824108 
 
Figure z. Locus plot of genome region flanking SNP rs217289 
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Figure aa.  Locus plot of genome region flanking SNP rs3915060 
 
Figure bb.  Locus plot of genome region flanking SNP rs17671352 
 
Figure cc. Locus plot of genome region flanking SNP rs12938775 
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Figure dd. Locus plot of genome region flanking SNP rs76837345 
 
Figure ee. Locus plot for genome region flanking SNP rs9691831 
 
Figure ff. Locus plot for genome region flanking SNP rs9366417 
270 
 
 
Figure gg. Locus plot for genome region flanking SNP rs141403654 
 
Figure hh. Locus plot for genome region flanking SNP rs10927035 
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Locus plots (ii-vv) for lead SNPs that reside in intergenic regions  
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Figure ii. Locus plot for genome region flanking SNP rs6890164 
 
Figure jj. Locus plot for genome region flanking SNP rs7951935 
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Figure kk. Locus plot for genome region flanking SNP rs35186928 
 
Figure ll. Locus plot for genome region flanking SNP rs3514371 
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Figure mm. Locus plot for genome region flanking SNP rs11280821. Proximity to 
3:182069497_TA_T 
 
Figure nn. Locus plot for genome region flanking SNP rs62188635 
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Figure oo. Locus plot for genome region flanking SNP rs12027345 
 
Figure pp. Locus plot of genome region flanking SNP rs13093972 
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Figure qq. Locus plot of genome region flanking SNP rs62015206 
 
Figure rr. Locus zoom plot for genome region flanking SNP rs10475169 
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Figure ss. Locus zoom plot for genome region flanking rs7525101 
 
Figure tt. Locus zoom plot for genome region flanking SNP rs3890736 
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Figure uu. Locus plot for genome region flanking SNP rs7823971 
 
Figure vv. Locus plot of genome region flanking SNP rs4611552 
 
